id	sid	tid	token	lemma	pos
dpc-4176	1	1	dermatology	dermatology	NOUN
dpc-4176	1	2	:	:	PUNCT
dpc-4176	1	3	practical	practical	ADJ
dpc-4176	1	4	and	and	CCONJ
dpc-4176	1	5	conceptual	conceptual	ADJ
dpc-4176	1	6	review	review	NOUN
dpc-4176	1	7	|	|	ADV
dpc-4176	1	8	dermatol	dermatol	ADJ
dpc-4176	1	9	pract	pract	NOUN
dpc-4176	1	10	concept	concept	NOUN
dpc-4176	1	11	.	.	PUNCT
dpc-4176	2	1	2024;14(3):e2024181	2024;14(3):e2024181	NUM
dpc-4176	2	2	1	1	NUM
dpc-4176	2	3	guselkumab	guselkumab	NOUN
dpc-4176	2	4	in	in	ADP
dpc-4176	2	5	psoriasis	psoriasis	NOUN
dpc-4176	2	6	and	and	CCONJ
dpc-4176	2	7	beyond	beyond	ADP
dpc-4176	2	8	aditya	aditya	PROPN
dpc-4176	2	9	kumar	kumar	PROPN
dpc-4176	2	10	bubna1	bubna1	PROPN
dpc-4176	2	11	,	,	PUNCT
dpc-4176	2	12	vinayak	vinayak	PROPN
dpc-4176	2	13	viplav1	viplav1	PROPN
dpc-4176	2	14	1	1	NUM
dpc-4176	2	15	department	department	NOUN
dpc-4176	2	16	of	of	ADP
dpc-4176	2	17	dermatology	dermatology	NOUN
dpc-4176	2	18	,	,	PUNCT
dpc-4176	2	19	katihar	katihar	VERB
dpc-4176	2	20	medical	medical	ADJ
dpc-4176	2	21	college	college	PROPN
dpc-4176	2	22	,	,	PUNCT
dpc-4176	2	23	karim	karim	PROPN
dpc-4176	2	24	bagh	bagh	PROPN
dpc-4176	2	25	,	,	PUNCT
dpc-4176	2	26	katihar	katihar	PROPN
dpc-4176	2	27	,	,	PUNCT
dpc-4176	2	28	bihar	bihar	PROPN
dpc-4176	2	29	,	,	PUNCT
dpc-4176	2	30	india	india	PROPN
dpc-4176	2	31	key	key	ADJ
dpc-4176	2	32	words	word	NOUN
dpc-4176	2	33	:	:	PUNCT
dpc-4176	2	34	guselkumab	guselkumab	NOUN
dpc-4176	2	35	,	,	PUNCT
dpc-4176	2	36	psoriasis	psoriasis	NOUN
dpc-4176	2	37	,	,	PUNCT
dpc-4176	2	38	hidradenitis	hidradenitis	PROPN
dpc-4176	2	39	suppurativa	suppurativa	PROPN
dpc-4176	2	40	,	,	PUNCT
dpc-4176	2	41	pyoderma	pyoderma	NOUN
dpc-4176	2	42	gangrenosum	gangrenosum	NOUN
dpc-4176	2	43	,	,	PUNCT
dpc-4176	2	44	pityriasis	pityriasis	NOUN
dpc-4176	2	45	rubra	rubra	NOUN
dpc-4176	2	46	pilaris	pilaris	NOUN
dpc-4176	2	47	citation	citation	NOUN
dpc-4176	2	48	:	:	PUNCT
dpc-4176	2	49	bubna	bubna	PROPN
dpc-4176	2	50	ak	ak	PROPN
dpc-4176	2	51	,	,	PUNCT
dpc-4176	2	52	viplav	viplav	NOUN
dpc-4176	2	53	v.	v.	ADP
dpc-4176	2	54	guselkumab	guselkumab	NOUN
dpc-4176	2	55	in	in	ADP
dpc-4176	2	56	psoriasis	psoriasis	NOUN
dpc-4176	2	57	and	and	CCONJ
dpc-4176	2	58	beyond	beyond	ADP
dpc-4176	2	59	.	.	PUNCT
dpc-4176	3	1	dermatol	dermatol	NOUN
dpc-4176	3	2	pract	pract	PROPN
dpc-4176	3	3	concept	concept	NOUN
dpc-4176	3	4	.	.	PUNCT
dpc-4176	4	1	2024;14(3):e2024181	2024;14(3):e2024181	X
dpc-4176	4	2	.	.	PUNCT
dpc-4176	5	1	doi	doi	PROPN
dpc-4176	5	2	:	:	PUNCT
dpc-4176	5	3	https://doi.org/10.5826/dpc.1403a181	https://doi.org/10.5826/dpc.1403a181	PROPN
dpc-4176	5	4	accepted	accept	VERB
dpc-4176	5	5	:	:	PUNCT
dpc-4176	5	6	march	march	PROPN
dpc-4176	5	7	15	15	NUM
dpc-4176	5	8	,	,	PUNCT
dpc-4176	5	9	2024	2024	NUM
dpc-4176	5	10	;	;	PUNCT
dpc-4176	5	11	published	publish	VERB
dpc-4176	5	12	:	:	PUNCT
dpc-4176	6	1	july	july	PROPN
dpc-4176	6	2	2024	2024	NUM
dpc-4176	6	3	copyright	copyright	NOUN
dpc-4176	6	4	:	:	PUNCT
dpc-4176	6	5	©	©	PROPN
dpc-4176	6	6	2024	2024	NUM
dpc-4176	6	7	bubna	bubna	NOUN
dpc-4176	6	8	et	et	PROPN
dpc-4176	6	9	al	al	PROPN
dpc-4176	6	10	.	.	PUNCT
dpc-4176	7	1	this	this	PRON
dpc-4176	7	2	is	be	AUX
dpc-4176	7	3	an	an	DET
dpc-4176	7	4	open	open	ADJ
dpc-4176	7	5	-	-	PUNCT
dpc-4176	7	6	access	access	NOUN
dpc-4176	7	7	article	article	NOUN
dpc-4176	7	8	distributed	distribute	VERB
dpc-4176	7	9	under	under	ADP
dpc-4176	7	10	the	the	DET
dpc-4176	7	11	terms	term	NOUN
dpc-4176	7	12	of	of	ADP
dpc-4176	7	13	the	the	DET
dpc-4176	7	14	creative	creative	ADJ
dpc-4176	7	15	commons	common	NOUN
dpc-4176	7	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4176	7	17	license	license	NOUN
dpc-4176	7	18	(	(	PUNCT
dpc-4176	7	19	by	by	ADP
dpc-4176	7	20	-	-	PUNCT
dpc-4176	7	21	nc-4.0	nc-4.0	NOUN
dpc-4176	7	22	)	)	PUNCT
dpc-4176	7	23	,	,	PUNCT
dpc-4176	7	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4176	7	25	,	,	PUNCT
dpc-4176	7	26	which	which	PRON
dpc-4176	7	27	permits	permit	VERB
dpc-4176	7	28	unrestricted	unrestricted	ADJ
dpc-4176	7	29	noncommercial	noncommercial	ADJ
dpc-4176	7	30	use	use	NOUN
dpc-4176	7	31	,	,	PUNCT
dpc-4176	7	32	distribution	distribution	NOUN
dpc-4176	7	33	,	,	PUNCT
dpc-4176	7	34	and	and	CCONJ
dpc-4176	7	35	reproduction	reproduction	NOUN
dpc-4176	7	36	in	in	ADP
dpc-4176	7	37	any	any	DET
dpc-4176	7	38	medium	medium	NOUN
dpc-4176	7	39	,	,	PUNCT
dpc-4176	7	40	provided	provide	VERB
dpc-4176	7	41	the	the	DET
dpc-4176	7	42	original	original	ADJ
dpc-4176	7	43	authors	author	NOUN
dpc-4176	7	44	and	and	CCONJ
dpc-4176	7	45	source	source	NOUN
dpc-4176	7	46	are	be	AUX
dpc-4176	7	47	credited	credit	VERB
dpc-4176	7	48	.	.	PUNCT
dpc-4176	8	1	funding	funding	NOUN
dpc-4176	8	2	:	:	PUNCT
dpc-4176	8	3	none	none	NOUN
dpc-4176	8	4	.	.	PUNCT
dpc-4176	9	1	competing	compete	VERB
dpc-4176	9	2	interests	interest	NOUN
dpc-4176	9	3	:	:	PUNCT
dpc-4176	9	4	none	none	NOUN
dpc-4176	9	5	.	.	PUNCT
dpc-4176	10	1	authorship	authorship	NOUN
dpc-4176	10	2	:	:	PUNCT
dpc-4176	10	3	all	all	DET
dpc-4176	10	4	authors	author	NOUN
dpc-4176	10	5	have	have	AUX
dpc-4176	10	6	contributed	contribute	VERB
dpc-4176	10	7	significantly	significantly	ADV
dpc-4176	10	8	to	to	ADP
dpc-4176	10	9	this	this	DET
dpc-4176	10	10	publication	publication	NOUN
dpc-4176	10	11	.	.	PUNCT
dpc-4176	11	1	corresponding	correspond	VERB
dpc-4176	11	2	author	author	NOUN
dpc-4176	11	3	:	:	PUNCT
dpc-4176	11	4	dr	dr	PROPN
dpc-4176	11	5	aditya	aditya	PROPN
dpc-4176	11	6	kumar	kumar	PROPN
dpc-4176	11	7	bubna	bubna	PROPN
dpc-4176	11	8	,	,	PUNCT
dpc-4176	11	9	mbbs	mbbs	PROPN
dpc-4176	11	10	,	,	PUNCT
dpc-4176	11	11	ddvl	ddvl	NOUN
dpc-4176	11	12	,	,	PUNCT
dpc-4176	11	13	dnb	dnb	PROPN
dpc-4176	11	14	,	,	PUNCT
dpc-4176	11	15	associate	associate	NOUN
dpc-4176	11	16	professor	professor	NOUN
dpc-4176	11	17	,	,	PUNCT
dpc-4176	11	18	department	department	NOUN
dpc-4176	11	19	of	of	ADP
dpc-4176	11	20	dermatology	dermatology	NOUN
dpc-4176	11	21	,	,	PUNCT
dpc-4176	11	22	katihar	katihar	VERB
dpc-4176	11	23	medical	medical	ADJ
dpc-4176	11	24	college	college	PROPN
dpc-4176	11	25	,	,	PUNCT
dpc-4176	11	26	karim	karim	PROPN
dpc-4176	11	27	bagh	bagh	PROPN
dpc-4176	11	28	,	,	PUNCT
dpc-4176	11	29	katihar	katihar	VERB
dpc-4176	11	30	854106	854106	NUM
dpc-4176	11	31	bihar	bihar	PROPN
dpc-4176	11	32	,	,	PUNCT
dpc-4176	11	33	india	india	PROPN
dpc-4176	11	34	.	.	PUNCT
dpc-4176	12	1	tel	tel	PROPN
dpc-4176	12	2	:	:	PUNCT
dpc-4176	12	3	+916452	+916452	NUM
dpc-4176	12	4	239202	239202	NUM
dpc-4176	12	5	email	email	NOUN
dpc-4176	12	6	:	:	PUNCT
dpc-4176	12	7	zimbabwa21@gmail.com	zimbabwa21@gmail.com	X
dpc-4176	12	8	introduction	introduction	NOUN
dpc-4176	12	9	guselkumab	guselkumab	NOUN
dpc-4176	12	10	is	be	AUX
dpc-4176	12	11	a	a	DET
dpc-4176	12	12	humanized	humanize	VERB
dpc-4176	12	13	monoclonal	monoclonal	NOUN
dpc-4176	12	14	igg1	igg1	NOUN
dpc-4176	12	15	lambda	lambda	NOUN
dpc-4176	12	16	il23p19	il23p19	PROPN
dpc-4176	12	17	antibody	antibody	NOUN
dpc-4176	12	18	,	,	PUNCT
dpc-4176	12	19	and	and	CCONJ
dpc-4176	12	20	the	the	DET
dpc-4176	12	21	first	first	ADJ
dpc-4176	12	22	in	in	ADP
dpc-4176	12	23	this	this	DET
dpc-4176	12	24	group	group	NOUN
dpc-4176	12	25	to	to	PART
dpc-4176	12	26	get	get	VERB
dpc-4176	12	27	approval	approval	NOUN
dpc-4176	12	28	by	by	ADP
dpc-4176	12	29	the	the	DET
dpc-4176	12	30	us	us	PROPN
dpc-4176	12	31	food	food	NOUN
dpc-4176	12	32	and	and	CCONJ
dpc-4176	12	33	drug	drug	NOUN
dpc-4176	12	34	administration	administration	NOUN
dpc-4176	12	35	for	for	ADP
dpc-4176	12	36	the	the	DET
dpc-4176	12	37	treatment	treatment	NOUN
dpc-4176	12	38	of	of	ADP
dpc-4176	12	39	moderate	moderate	ADJ
dpc-4176	12	40	-	-	PUNCT
dpc-4176	12	41	to	to	ADP
dpc-4176	12	42	-	-	PUNCT
dpc-4176	12	43	severe	severe	ADJ
dpc-4176	12	44	chronic	chronic	ADJ
dpc-4176	12	45	plaque	plaque	NOUN
dpc-4176	12	46	psoriasis	psoriasis	NOUN
dpc-4176	12	47	in	in	ADP
dpc-4176	12	48	adults	adult	NOUN
dpc-4176	12	49	,	,	PUNCT
dpc-4176	12	50	who	who	PRON
dpc-4176	12	51	are	be	AUX
dpc-4176	12	52	candidates	candidate	NOUN
dpc-4176	12	53	for	for	ADP
dpc-4176	12	54	systemic	systemic	ADJ
dpc-4176	12	55	therapy	therapy	NOUN
dpc-4176	12	56	/	/	SYM
dpc-4176	12	57	phototherapy	phototherapy	NOUN
dpc-4176	12	58	;	;	PUNCT
dpc-4176	12	59	and	and	CCONJ
dpc-4176	12	60	psoriatic	psoriatic	ADJ
dpc-4176	12	61	arthropathy	arthropathy	ADJ
dpc-4176	12	62	[	[	X
dpc-4176	12	63	1	1	NUM
dpc-4176	12	64	]	]	PUNCT
dpc-4176	12	65	.	.	PUNCT
dpc-4176	13	1	further	far	ADV
dpc-4176	13	2	,	,	PUNCT
dpc-4176	13	3	guselkumab	guselkumab	NOUN
dpc-4176	13	4	has	have	AUX
dpc-4176	13	5	found	find	VERB
dpc-4176	13	6	to	to	PART
dpc-4176	13	7	be	be	AUX
dpc-4176	13	8	of	of	ADP
dpc-4176	13	9	value	value	NOUN
dpc-4176	13	10	in	in	ADP
dpc-4176	13	11	treating	treat	VERB
dpc-4176	13	12	hidradenitis	hidradenitis	PROPN
dpc-4176	13	13	suppurativa	suppurativa	PROPN
dpc-4176	13	14	(	(	PUNCT
dpc-4176	13	15	hs	hs	PROPN
dpc-4176	13	16	)	)	PUNCT
dpc-4176	13	17	,	,	PUNCT
dpc-4176	13	18	pyoderma	pyoderma	NOUN
dpc-4176	13	19	gangrenosum	gangrenosum	NOUN
dpc-4176	13	20	(	(	PUNCT
dpc-4176	13	21	pg	pg	NOUN
dpc-4176	13	22	)	)	PUNCT
dpc-4176	13	23	,	,	PUNCT
dpc-4176	13	24	pityriasis	pityriasis	NOUN
dpc-4176	13	25	rubra	rubra	NOUN
dpc-4176	13	26	pilaris	pilaris	NOUN
dpc-4176	13	27	(	(	PUNCT
dpc-4176	13	28	prp	prp	PROPN
dpc-4176	13	29	)	)	PUNCT
dpc-4176	13	30	and	and	CCONJ
dpc-4176	13	31	lichen	lichen	NOUN
dpc-4176	13	32	planus	planus	NOUN
dpc-4176	13	33	(	(	PUNCT
dpc-4176	13	34	lp	lp	NOUN
dpc-4176	13	35	)	)	PUNCT
dpc-4176	13	36	.	.	PUNCT
dpc-4176	14	1	the	the	DET
dpc-4176	14	2	level	level	NOUN
dpc-4176	14	3	of	of	ADP
dpc-4176	14	4	evidence	evidence	NOUN
dpc-4176	14	5	for	for	ADP
dpc-4176	14	6	its	its	PRON
dpc-4176	14	7	utility	utility	NOUN
dpc-4176	14	8	in	in	ADP
dpc-4176	14	9	off	off	ADP
dpc-4176	14	10	-	-	PUNCT
dpc-4176	14	11	label	label	NOUN
dpc-4176	14	12	dermatologic	dermatologic	ADJ
dpc-4176	14	13	disorders	disorder	NOUN
dpc-4176	14	14	has	have	AUX
dpc-4176	14	15	been	be	AUX
dpc-4176	14	16	enumerated	enumerate	VERB
dpc-4176	14	17	in	in	ADP
dpc-4176	14	18	figure	figure	NOUN
dpc-4176	14	19	1	1	NUM
dpc-4176	14	20	.	.	PUNCT
dpc-4176	15	1	introduction	introduction	NOUN
dpc-4176	15	2	:	:	PUNCT
dpc-4176	15	3	guselkumab	guselkumab	NOUN
dpc-4176	15	4	is	be	AUX
dpc-4176	15	5	an	an	DET
dpc-4176	15	6	interleukin	interleukin	NOUN
dpc-4176	15	7	23p19	23p19	NUM
dpc-4176	15	8	inhibitor	inhibitor	NOUN
dpc-4176	15	9	,	,	PUNCT
dpc-4176	15	10	and	and	CCONJ
dpc-4176	15	11	the	the	DET
dpc-4176	15	12	first	first	ADJ
dpc-4176	15	13	in	in	ADP
dpc-4176	15	14	this	this	DET
dpc-4176	15	15	group	group	NOUN
dpc-4176	15	16	,	,	PUNCT
dpc-4176	15	17	to	to	PART
dpc-4176	15	18	be	be	AUX
dpc-4176	15	19	approved	approve	VERB
dpc-4176	15	20	by	by	ADP
dpc-4176	15	21	the	the	DET
dpc-4176	15	22	us	us	PROPN
dpc-4176	15	23	food	food	NOUN
dpc-4176	15	24	and	and	CCONJ
dpc-4176	15	25	drug	drug	NOUN
dpc-4176	15	26	administration	administration	NOUN
dpc-4176	15	27	for	for	ADP
dpc-4176	15	28	the	the	DET
dpc-4176	15	29	management	management	NOUN
dpc-4176	15	30	of	of	ADP
dpc-4176	15	31	moderate	moderate	ADJ
dpc-4176	15	32	to	to	ADP
dpc-4176	15	33	severe	severe	ADJ
dpc-4176	15	34	psoriasis	psoriasis	NOUN
dpc-4176	15	35	.	.	PUNCT
dpc-4176	16	1	apart	apart	ADV
dpc-4176	16	2	from	from	ADP
dpc-4176	16	3	its	its	PRON
dpc-4176	16	4	utility	utility	NOUN
dpc-4176	16	5	in	in	ADP
dpc-4176	16	6	psoriasis	psoriasis	NOUN
dpc-4176	16	7	,	,	PUNCT
dpc-4176	16	8	there	there	PRON
dpc-4176	16	9	are	be	VERB
dpc-4176	16	10	a	a	DET
dpc-4176	16	11	number	number	NOUN
dpc-4176	16	12	of	of	ADP
dpc-4176	16	13	other	other	ADJ
dpc-4176	16	14	dermatologic	dermatologic	ADJ
dpc-4176	16	15	conditions	condition	NOUN
dpc-4176	16	16	where	where	SCONJ
dpc-4176	16	17	guselkumab	guselkumab	NOUN
dpc-4176	16	18	has	have	AUX
dpc-4176	16	19	demonstrated	demonstrate	VERB
dpc-4176	16	20	value	value	NOUN
dpc-4176	16	21	.	.	PUNCT
dpc-4176	17	1	objectives	objective	NOUN
dpc-4176	17	2	:	:	PUNCT
dpc-4176	17	3	the	the	DET
dpc-4176	17	4	aim	aim	NOUN
dpc-4176	17	5	of	of	ADP
dpc-4176	17	6	this	this	DET
dpc-4176	17	7	narrative	narrative	NOUN
dpc-4176	17	8	review	review	NOUN
dpc-4176	17	9	is	be	AUX
dpc-4176	17	10	to	to	PART
dpc-4176	17	11	describe	describe	VERB
dpc-4176	17	12	the	the	DET
dpc-4176	17	13	utility	utility	NOUN
dpc-4176	17	14	of	of	ADP
dpc-4176	17	15	guselkumab	guselkumab	NOUN
dpc-4176	17	16	in	in	ADP
dpc-4176	17	17	psoriasis	psoriasis	NOUN
dpc-4176	17	18	as	as	ADV
dpc-4176	17	19	well	well	ADV
dpc-4176	17	20	as	as	ADP
dpc-4176	17	21	its	its	PRON
dpc-4176	17	22	implication	implication	NOUN
dpc-4176	17	23	in	in	ADP
dpc-4176	17	24	off	off	ADP
dpc-4176	17	25	-	-	PUNCT
dpc-4176	17	26	label	label	NOUN
dpc-4176	17	27	dermatologic	dermatologic	ADJ
dpc-4176	17	28	disorders	disorder	NOUN
dpc-4176	17	29	.	.	PUNCT
dpc-4176	18	1	methods	method	NOUN
dpc-4176	18	2	:	:	PUNCT
dpc-4176	18	3	pubmed	pubmed	PROPN
dpc-4176	18	4	,	,	PUNCT
dpc-4176	18	5	google	google	PROPN
dpc-4176	18	6	scholar	scholar	NOUN
dpc-4176	18	7	,	,	PUNCT
dpc-4176	18	8	scopus	scopus	NOUN
dpc-4176	18	9	and	and	CCONJ
dpc-4176	18	10	researchgate	researchgate	NOUN
dpc-4176	18	11	were	be	AUX
dpc-4176	18	12	searched	search	VERB
dpc-4176	18	13	for	for	ADP
dpc-4176	18	14	scholarly	scholarly	ADJ
dpc-4176	18	15	articles	article	NOUN
dpc-4176	18	16	related	relate	VERB
dpc-4176	18	17	to	to	ADP
dpc-4176	18	18	guselkumab	guselkumab	NOUN
dpc-4176	18	19	and	and	CCONJ
dpc-4176	18	20	its	its	PRON
dpc-4176	18	21	utility	utility	NOUN
dpc-4176	18	22	in	in	ADP
dpc-4176	18	23	dermatology	dermatology	NOUN
dpc-4176	18	24	using	use	VERB
dpc-4176	18	25	the	the	DET
dpc-4176	18	26	search	search	NOUN
dpc-4176	18	27	terms	term	NOUN
dpc-4176	18	28	“	"	PUNCT
dpc-4176	18	29	guselkumab	guselkumab	NOUN
dpc-4176	18	30	”	"	PUNCT
dpc-4176	18	31	and	and	CCONJ
dpc-4176	18	32	“	"	PUNCT
dpc-4176	18	33	psoriasis	psoriasis	NOUN
dpc-4176	18	34	”	"	PUNCT
dpc-4176	18	35	and	and	CCONJ
dpc-4176	18	36	“	"	PUNCT
dpc-4176	18	37	other	other	ADJ
dpc-4176	18	38	dermatological	dermatological	ADJ
dpc-4176	18	39	disorders	disorder	NOUN
dpc-4176	18	40	”	"	PUNCT
dpc-4176	18	41	.	.	PUNCT
dpc-4176	19	1	results	result	NOUN
dpc-4176	19	2	:	:	PUNCT
dpc-4176	19	3	guselkumab	guselkumab	NOUN
dpc-4176	19	4	is	be	AUX
dpc-4176	19	5	a	a	DET
dpc-4176	19	6	valuable	valuable	ADJ
dpc-4176	19	7	biologic	biologic	NOUN
dpc-4176	19	8	agent	agent	NOUN
dpc-4176	19	9	for	for	ADP
dpc-4176	19	10	the	the	DET
dpc-4176	19	11	management	management	NOUN
dpc-4176	19	12	of	of	ADP
dpc-4176	19	13	psoriasis	psoriasis	NOUN
dpc-4176	19	14	and	and	CCONJ
dpc-4176	19	15	psoriatic	psoriatic	ADJ
dpc-4176	19	16	arthropathy	arthropathy	ADJ
dpc-4176	19	17	.	.	PUNCT
dpc-4176	20	1	it	it	PRON
dpc-4176	20	2	has	have	AUX
dpc-4176	20	3	also	also	ADV
dpc-4176	20	4	been	be	AUX
dpc-4176	20	5	used	use	VERB
dpc-4176	20	6	successfully	successfully	ADV
dpc-4176	20	7	for	for	ADP
dpc-4176	20	8	other	other	ADJ
dpc-4176	20	9	dermatologic	dermatologic	ADJ
dpc-4176	20	10	disorders	disorder	NOUN
dpc-4176	20	11	like	like	ADP
dpc-4176	20	12	hidradenitis	hidradenitis	PROPN
dpc-4176	20	13	suppurativa	suppurativa	PROPN
dpc-4176	20	14	,	,	PUNCT
dpc-4176	20	15	lichen	lichen	NOUN
dpc-4176	20	16	planus	planus	NOUN
dpc-4176	20	17	,	,	PUNCT
dpc-4176	20	18	pityriasis	pityriasis	NOUN
dpc-4176	20	19	rubra	rubra	NOUN
dpc-4176	20	20	pilaris	pilaris	NOUN
dpc-4176	20	21	and	and	CCONJ
dpc-4176	20	22	pyoderma	pyoderma	NOUN
dpc-4176	20	23	gangrenosum	gangrenosum	NOUN
dpc-4176	20	24	.	.	PUNCT
dpc-4176	21	1	recently	recently	ADV
dpc-4176	21	2	,	,	PUNCT
dpc-4176	21	3	its	its	PRON
dpc-4176	21	4	utility	utility	NOUN
dpc-4176	21	5	in	in	ADP
dpc-4176	21	6	stewart	stewart	PROPN
dpc-4176	21	7	-	-	PUNCT
dpc-4176	21	8	treves	treve	NOUN
dpc-4176	21	9	angiosarcoma	angiosarcoma	PROPN
dpc-4176	21	10	(	(	PUNCT
dpc-4176	21	11	sta	sta	NOUN
dpc-4176	21	12	)	)	PUNCT
dpc-4176	21	13	has	have	AUX
dpc-4176	21	14	been	be	AUX
dpc-4176	21	15	exemplified	exemplify	VERB
dpc-4176	21	16	.	.	PUNCT
dpc-4176	22	1	conclusion	conclusion	NOUN
dpc-4176	22	2	:	:	PUNCT
dpc-4176	22	3	guselkumab	guselkumab	NOUN
dpc-4176	22	4	usage	usage	NOUN
dpc-4176	22	5	is	be	AUX
dpc-4176	22	6	not	not	PART
dpc-4176	22	7	limited	limit	VERB
dpc-4176	22	8	to	to	ADP
dpc-4176	22	9	psoriasis	psoriasis	NOUN
dpc-4176	22	10	.	.	PUNCT
dpc-4176	23	1	its	its	PRON
dpc-4176	23	2	benefit	benefit	NOUN
dpc-4176	23	3	extends	extend	VERB
dpc-4176	23	4	to	to	ADP
dpc-4176	23	5	many	many	ADJ
dpc-4176	23	6	more	more	ADJ
dpc-4176	23	7	dermatologic	dermatologic	ADJ
dpc-4176	23	8	conditions	condition	NOUN
dpc-4176	23	9	.	.	PUNCT
dpc-4176	24	1	its	its	PRON
dpc-4176	24	2	utility	utility	NOUN
dpc-4176	24	3	in	in	ADP
dpc-4176	24	4	sta	sta	NOUN
dpc-4176	24	5	could	could	AUX
dpc-4176	24	6	open	open	VERB
dpc-4176	24	7	an	an	DET
dpc-4176	24	8	avenue	avenue	NOUN
dpc-4176	24	9	for	for	ADP
dpc-4176	24	10	its	its	PRON
dpc-4176	24	11	application	application	NOUN
dpc-4176	24	12	in	in	ADP
dpc-4176	24	13	the	the	DET
dpc-4176	24	14	field	field	NOUN
dpc-4176	24	15	of	of	ADP
dpc-4176	24	16	oncology	oncology	NOUN
dpc-4176	24	17	.	.	PUNCT
dpc-4176	25	1	furthermore	furthermore	ADV
dpc-4176	25	2	,	,	PUNCT
dpc-4176	25	3	it	it	PRON
dpc-4176	25	4	has	have	VERB
dpc-4176	25	5	an	an	DET
dpc-4176	25	6	acceptable	acceptable	ADJ
dpc-4176	25	7	safety	safety	NOUN
dpc-4176	25	8	profile	profile	NOUN
dpc-4176	25	9	.	.	PUNCT
dpc-4176	26	1	abstract	abstract	ADJ
dpc-4176	26	2	2	2	NUM
dpc-4176	26	3	review	review	NOUN
dpc-4176	26	4	|	|	ADV
dpc-4176	26	5	dermatol	dermatol	ADJ
dpc-4176	26	6	pract	pract	NOUN
dpc-4176	26	7	concept	concept	NOUN
dpc-4176	26	8	.	.	PUNCT
dpc-4176	27	1	2024;14(3):e2024181	2024;14(3):e2024181	NUM
dpc-4176	27	2	objectives	objective	VERB
dpc-4176	27	3	the	the	DET
dpc-4176	27	4	aim	aim	NOUN
dpc-4176	27	5	of	of	ADP
dpc-4176	27	6	this	this	DET
dpc-4176	27	7	narrative	narrative	NOUN
dpc-4176	27	8	review	review	NOUN
dpc-4176	27	9	is	be	AUX
dpc-4176	27	10	to	to	PART
dpc-4176	27	11	describe	describe	VERB
dpc-4176	27	12	the	the	DET
dpc-4176	27	13	utility	utility	NOUN
dpc-4176	27	14	of	of	ADP
dpc-4176	27	15	guselkumab	guselkumab	NOUN
dpc-4176	27	16	in	in	ADP
dpc-4176	27	17	psoriasis	psoriasis	NOUN
dpc-4176	27	18	as	as	ADV
dpc-4176	27	19	well	well	ADV
dpc-4176	27	20	as	as	ADP
dpc-4176	27	21	its	its	PRON
dpc-4176	27	22	implication	implication	NOUN
dpc-4176	27	23	in	in	ADP
dpc-4176	27	24	off	off	ADP
dpc-4176	27	25	-	-	PUNCT
dpc-4176	27	26	label	label	NOUN
dpc-4176	27	27	dermatologic	dermatologic	ADJ
dpc-4176	27	28	disorders	disorder	NOUN
dpc-4176	27	29	.	.	PUNCT
dpc-4176	28	1	methods	method	NOUN
dpc-4176	28	2	we	we	PRON
dpc-4176	28	3	carried	carry	VERB
dpc-4176	28	4	out	out	ADP
dpc-4176	28	5	a	a	DET
dpc-4176	28	6	search	search	NOUN
dpc-4176	28	7	of	of	ADP
dpc-4176	28	8	english	english	ADJ
dpc-4176	28	9	language	language	NOUN
dpc-4176	28	10	literature	literature	NOUN
dpc-4176	28	11	,	,	PUNCT
dpc-4176	28	12	regarding	regard	VERB
dpc-4176	28	13	psoriasis	psoriasis	NOUN
dpc-4176	28	14	,	,	PUNCT
dpc-4176	28	15	pityriasis	pityriasis	NOUN
dpc-4176	28	16	rubra	rubra	NOUN
dpc-4176	28	17	pilaris	pilaris	NOUN
dpc-4176	28	18	,	,	PUNCT
dpc-4176	28	19	pyoderma	pyoderma	NOUN
dpc-4176	28	20	gangrenosum	gangrenosum	NOUN
dpc-4176	28	21	,	,	PUNCT
dpc-4176	28	22	hidradenitis	hidradenitis	PROPN
dpc-4176	28	23	suppurativa	suppurativa	PROPN
dpc-4176	28	24	,	,	PUNCT
dpc-4176	28	25	lichen	lichen	NOUN
dpc-4176	28	26	planus	planus	NOUN
dpc-4176	28	27	and	and	CCONJ
dpc-4176	28	28	other	other	ADJ
dpc-4176	28	29	dermatological	dermatological	ADJ
dpc-4176	28	30	disorders	disorder	NOUN
dpc-4176	28	31	,	,	PUNCT
dpc-4176	28	32	with	with	ADP
dpc-4176	28	33	focus	focus	NOUN
dpc-4176	28	34	on	on	ADP
dpc-4176	28	35	guselkumab	guselkumab	NOUN
dpc-4176	28	36	utility	utility	NOUN
dpc-4176	28	37	for	for	ADP
dpc-4176	28	38	these	these	DET
dpc-4176	28	39	conditions	condition	NOUN
dpc-4176	28	40	.	.	PUNCT
dpc-4176	29	1	original	original	ADJ
dpc-4176	29	2	articles	article	NOUN
dpc-4176	29	3	,	,	PUNCT
dpc-4176	29	4	case	case	NOUN
dpc-4176	29	5	series	series	NOUN
dpc-4176	29	6	,	,	PUNCT
dpc-4176	29	7	case	case	NOUN
dpc-4176	29	8	reports	report	NOUN
dpc-4176	29	9	and	and	CCONJ
dpc-4176	29	10	review	review	VERB
dpc-4176	29	11	articles	article	NOUN
dpc-4176	29	12	were	be	AUX
dpc-4176	29	13	studied	study	VERB
dpc-4176	29	14	using	use	VERB
dpc-4176	29	15	the	the	DET
dpc-4176	29	16	following	follow	VERB
dpc-4176	29	17	databases	database	NOUN
dpc-4176	29	18	pubmed	pubmed	PROPN
dpc-4176	29	19	,	,	PUNCT
dpc-4176	29	20	google	google	PROPN
dpc-4176	29	21	scholar	scholar	NOUN
dpc-4176	29	22	,	,	PUNCT
dpc-4176	29	23	scopus	scopus	NOUN
dpc-4176	29	24	and	and	CCONJ
dpc-4176	29	25	researchgate	researchgate	NOUN
dpc-4176	29	26	.	.	PUNCT
dpc-4176	30	1	all	all	DET
dpc-4176	30	2	articles	article	NOUN
dpc-4176	30	3	published	publish	VERB
dpc-4176	30	4	in	in	ADP
dpc-4176	30	5	last	last	ADJ
dpc-4176	30	6	fifteen	fifteen	NUM
dpc-4176	30	7	years	year	NOUN
dpc-4176	30	8	were	be	AUX
dpc-4176	30	9	reviewed	review	VERB
dpc-4176	30	10	.	.	PUNCT
dpc-4176	31	1	results	result	NOUN
dpc-4176	31	2	clinical	clinical	ADJ
dpc-4176	31	3	uses	use	VERB
dpc-4176	31	4	plaque	plaque	NOUN
dpc-4176	31	5	psoriasis	psoriasis	NOUN
dpc-4176	31	6	il-23	il-23	NOUN
dpc-4176	31	7	is	be	AUX
dpc-4176	31	8	a	a	DET
dpc-4176	31	9	proinflammatory	proinflammatory	ADJ
dpc-4176	31	10	cytokine	cytokine	NOUN
dpc-4176	31	11	,	,	PUNCT
dpc-4176	31	12	closely	closely	ADV
dpc-4176	31	13	implicated	implicate	VERB
dpc-4176	31	14	in	in	ADP
dpc-4176	31	15	the	the	DET
dpc-4176	31	16	pathogenesis	pathogenesis	NOUN
dpc-4176	31	17	of	of	ADP
dpc-4176	31	18	psoriasis	psoriasis	NOUN
dpc-4176	31	19	,	,	PUNCT
dpc-4176	31	20	details	detail	NOUN
dpc-4176	31	21	of	of	ADP
dpc-4176	31	22	which	which	PRON
dpc-4176	31	23	are	be	AUX
dpc-4176	31	24	elucidated	elucidate	VERB
dpc-4176	31	25	in	in	ADP
dpc-4176	31	26	figure	figure	NOUN
dpc-4176	31	27	2	2	NUM
dpc-4176	32	1	[	[	X
dpc-4176	32	2	2	2	NUM
dpc-4176	32	3	-	-	SYM
dpc-4176	32	4	8	8	NUM
dpc-4176	32	5	]	]	PUNCT
dpc-4176	32	6	.	.	PUNCT
dpc-4176	33	1	guselkumab	guselkumab	NOUN
dpc-4176	33	2	acts	act	NOUN
dpc-4176	33	3	against	against	ADP
dpc-4176	33	4	the	the	DET
dpc-4176	33	5	il-23p19	il-23p19	PROPN
dpc-4176	33	6	figure	figure	NOUN
dpc-4176	33	7	1	1	NUM
dpc-4176	33	8	.	.	PUNCT
dpc-4176	33	9	level	level	NOUN
dpc-4176	33	10	of	of	ADP
dpc-4176	33	11	evidence	evidence	NOUN
dpc-4176	33	12	for	for	ADP
dpc-4176	33	13	the	the	DET
dpc-4176	33	14	utility	utility	NOUN
dpc-4176	33	15	of	of	ADP
dpc-4176	33	16	guselkumab	guselkumab	NOUN
dpc-4176	33	17	in	in	ADP
dpc-4176	33	18	off	off	ADP
dpc-4176	33	19	-	-	PUNCT
dpc-4176	33	20	label	label	NOUN
dpc-4176	33	21	dermatologic	dermatologic	ADJ
dpc-4176	33	22	indications	indication	NOUN
dpc-4176	33	23	.	.	PUNCT
dpc-4176	34	1	a	a	DET
dpc-4176	34	2	:	:	PUNCT
dpc-4176	34	3	double	double	ADJ
dpc-4176	34	4	blind	blind	ADJ
dpc-4176	34	5	study	study	NOUN
dpc-4176	34	6	:	:	PUNCT
dpc-4176	34	7	at	at	ADP
dpc-4176	34	8	least	least	ADV
dpc-4176	34	9	one	one	NUM
dpc-4176	34	10	prospective	prospective	ADJ
dpc-4176	34	11	randomized	randomize	VERB
dpc-4176	34	12	double	double	ADJ
dpc-4176	34	13	blind	blind	NOUN
dpc-4176	34	14	controlled	control	VERB
dpc-4176	34	15	trial	trial	NOUN
dpc-4176	34	16	without	without	ADP
dpc-4176	34	17	major	major	ADJ
dpc-4176	34	18	design	design	NOUN
dpc-4176	34	19	flaws	flaw	NOUN
dpc-4176	34	20	.	.	PUNCT
dpc-4176	35	1	b	b	X
dpc-4176	35	2	:	:	PUNCT
dpc-4176	35	3	clinical	clinical	ADJ
dpc-4176	35	4	trial	trial	NOUN
dpc-4176	35	5	with	with	ADP
dpc-4176	35	6	20	20	NUM
dpc-4176	35	7	or	or	CCONJ
dpc-4176	35	8	more	more	ADJ
dpc-4176	35	9	subjects	subject	NOUN
dpc-4176	35	10	:	:	PUNCT
dpc-4176	35	11	prospective	prospective	ADJ
dpc-4176	35	12	clinical	clinical	ADJ
dpc-4176	35	13	trials	trial	NOUN
dpc-4176	35	14	with	with	ADP
dpc-4176	35	15	20	20	NUM
dpc-4176	35	16	or	or	CCONJ
dpc-4176	35	17	more	more	ADJ
dpc-4176	35	18	subjects	subject	NOUN
dpc-4176	35	19	,	,	PUNCT
dpc-4176	35	20	trials	trial	NOUN
dpc-4176	35	21	lacking	lack	VERB
dpc-4176	35	22	adequate	adequate	ADJ
dpc-4176	35	23	controls	control	NOUN
dpc-4176	35	24	or	or	CCONJ
dpc-4176	35	25	another	another	DET
dpc-4176	35	26	key	key	ADJ
dpc-4176	35	27	facet	facet	ADJ
dpc-4176	35	28	design	design	NOUN
dpc-4176	35	29	,	,	PUNCT
dpc-4176	35	30	which	which	PRON
dpc-4176	35	31	would	would	AUX
dpc-4176	35	32	normally	normally	ADV
dpc-4176	35	33	be	be	AUX
dpc-4176	35	34	considered	consider	VERB
dpc-4176	35	35	desirable	desirable	ADJ
dpc-4176	35	36	.	.	PUNCT
dpc-4176	36	1	c	c	X
dpc-4176	36	2	:	:	PUNCT
dpc-4176	36	3	clinical	clinical	ADJ
dpc-4176	36	4	trial	trial	NOUN
dpc-4176	36	5	with	with	ADP
dpc-4176	36	6	less	less	ADJ
dpc-4176	36	7	than	than	ADP
dpc-4176	36	8	20	20	NUM
dpc-4176	36	9	subjects	subject	NOUN
dpc-4176	36	10	:	:	PUNCT
dpc-4176	36	11	small	small	ADJ
dpc-4176	36	12	trials	trial	NOUN
dpc-4176	36	13	with	with	ADP
dpc-4176	36	14	less	less	ADJ
dpc-4176	36	15	than	than	ADP
dpc-4176	36	16	20	20	NUM
dpc-4176	36	17	subjects	subject	NOUN
dpc-4176	36	18	with	with	ADP
dpc-4176	36	19	significant	significant	ADJ
dpc-4176	36	20	design	design	NOUN
dpc-4176	36	21	limitations	limitation	NOUN
dpc-4176	36	22	,	,	PUNCT
dpc-4176	36	23	very	very	ADV
dpc-4176	36	24	large	large	ADJ
dpc-4176	36	25	number	number	NOUN
dpc-4176	36	26	of	of	ADP
dpc-4176	36	27	case	case	NOUN
dpc-4176	36	28	reports	report	NOUN
dpc-4176	36	29	(	(	PUNCT
dpc-4176	36	30	at	at	ADP
dpc-4176	36	31	least	least	ADV
dpc-4176	36	32	20	20	NUM
dpc-4176	36	33	such	such	ADJ
dpc-4176	36	34	in	in	ADP
dpc-4176	36	35	literature	literature	NOUN
dpc-4176	36	36	)	)	PUNCT
dpc-4176	36	37	.	.	PUNCT
dpc-4176	37	1	d.	d.	PROPN
dpc-4176	37	2	series	series	PROPN
dpc-4176	37	3	of	of	ADP
dpc-4176	37	4	5	5	NUM
dpc-4176	37	5	or	or	CCONJ
dpc-4176	37	6	less	less	ADJ
dpc-4176	37	7	subjects	subject	NOUN
dpc-4176	37	8	:	:	PUNCT
dpc-4176	37	9	series	series	NOUN
dpc-4176	37	10	of	of	ADP
dpc-4176	37	11	patients	patient	NOUN
dpc-4176	37	12	reported	report	VERB
dpc-4176	37	13	to	to	PART
dpc-4176	37	14	respond	respond	VERB
dpc-4176	37	15	with	with	ADP
dpc-4176	37	16	at	at	ADV
dpc-4176	37	17	least	least	ADV
dpc-4176	37	18	five	five	NUM
dpc-4176	37	19	reports	report	NOUN
dpc-4176	37	20	of	of	ADP
dpc-4176	37	21	the	the	DET
dpc-4176	37	22	same	same	ADJ
dpc-4176	37	23	in	in	ADP
dpc-4176	37	24	literature	literature	NOUN
dpc-4176	37	25	.	.	PUNCT
dpc-4176	38	1	e	e	X
dpc-4176	38	2	:	:	PUNCT
dpc-4176	38	3	anecdotal	anecdotal	ADJ
dpc-4176	38	4	case	case	NOUN
dpc-4176	38	5	reports	report	VERB
dpc-4176	38	6	.	.	PUNCT
dpc-4176	39	1	figure	figure	NOUN
dpc-4176	39	2	2	2	NUM
dpc-4176	39	3	.	.	PUNCT
dpc-4176	39	4	role	role	NOUN
dpc-4176	39	5	of	of	ADP
dpc-4176	39	6	il-23	il-23	NOUN
dpc-4176	39	7	in	in	ADP
dpc-4176	39	8	psoriasis	psoriasis	NOUN
dpc-4176	39	9	pathogenesis	pathogenesis	NOUN
dpc-4176	39	10	.	.	PUNCT
dpc-4176	40	1	review	review	VERB
dpc-4176	40	2	|	|	ADV
dpc-4176	40	3	dermatol	dermatol	ADJ
dpc-4176	40	4	pract	pract	NOUN
dpc-4176	40	5	concept	concept	NOUN
dpc-4176	40	6	.	.	PUNCT
dpc-4176	41	1	2024;14(3):e2024181	2024;14(3):e2024181	NUM
dpc-4176	41	2	3	3	NUM
dpc-4176	41	3	subunit	subunit	NOUN
dpc-4176	41	4	of	of	ADP
dpc-4176	41	5	il-23	il-23	NOUN
dpc-4176	41	6	receptor	receptor	NOUN
dpc-4176	41	7	;	;	PUNCT
dpc-4176	41	8	and	and	CCONJ
dpc-4176	41	9	thus	thus	ADV
dpc-4176	41	10	prevents	prevent	VERB
dpc-4176	41	11	il-23	il-23	NOUN
dpc-4176	41	12	binding	binding	ADJ
dpc-4176	41	13	and	and	CCONJ
dpc-4176	41	14	subsequent	subsequent	ADJ
dpc-4176	41	15	progression	progression	NOUN
dpc-4176	41	16	of	of	ADP
dpc-4176	41	17	inflammation	inflammation	NOUN
dpc-4176	41	18	[	[	X
dpc-4176	41	19	9	9	NUM
dpc-4176	41	20	]	]	PUNCT
dpc-4176	41	21	.	.	PUNCT
dpc-4176	42	1	guselkumab	guselkumab	NOUN
dpc-4176	42	2	is	be	AUX
dpc-4176	42	3	administered	administer	VERB
dpc-4176	42	4	subcutaneously	subcutaneously	ADV
dpc-4176	42	5	(	(	PUNCT
dpc-4176	42	6	sc	sc	PROPN
dpc-4176	42	7	)	)	PUNCT
dpc-4176	42	8	and	and	CCONJ
dpc-4176	42	9	has	have	VERB
dpc-4176	42	10	a	a	DET
dpc-4176	42	11	lower	low	ADJ
dpc-4176	42	12	frequency	frequency	NOUN
dpc-4176	42	13	of	of	ADP
dpc-4176	42	14	administration	administration	NOUN
dpc-4176	42	15	(	(	PUNCT
dpc-4176	42	16	100	100	NUM
dpc-4176	42	17	mg	mg	NOUN
dpc-4176	42	18	at	at	ADP
dpc-4176	42	19	weeks	week	NOUN
dpc-4176	42	20	0	0	NUM
dpc-4176	42	21	,	,	PUNCT
dpc-4176	42	22	4	4	NUM
dpc-4176	42	23	,	,	PUNCT
dpc-4176	42	24	and	and	CCONJ
dpc-4176	42	25	then	then	ADV
dpc-4176	42	26	once	once	ADV
dpc-4176	42	27	every	every	DET
dpc-4176	42	28	8	8	NUM
dpc-4176	42	29	weeks	week	NOUN
dpc-4176	42	30	)	)	PUNCT
dpc-4176	42	31	,	,	PUNCT
dpc-4176	42	32	when	when	SCONJ
dpc-4176	42	33	compared	compare	VERB
dpc-4176	42	34	to	to	ADP
dpc-4176	42	35	other	other	ADJ
dpc-4176	42	36	biologics	biologic	NOUN
dpc-4176	42	37	,	,	PUNCT
dpc-4176	42	38	with	with	ADP
dpc-4176	42	39	therapeutic	therapeutic	ADJ
dpc-4176	42	40	responses	response	NOUN
dpc-4176	42	41	persisting	persist	VERB
dpc-4176	42	42	over	over	ADP
dpc-4176	42	43	time	time	NOUN
dpc-4176	42	44	even	even	ADV
dpc-4176	42	45	after	after	ADP
dpc-4176	42	46	drug	drug	NOUN
dpc-4176	42	47	discontinuation	discontinuation	NOUN
dpc-4176	42	48	;	;	PUNCT
dpc-4176	42	49	thus	thus	ADV
dpc-4176	42	50	demonstrating	demonstrate	VERB
dpc-4176	42	51	longterm	longterm	ADJ
dpc-4176	42	52	efficacy	efficacy	NOUN
dpc-4176	42	53	[	[	X
dpc-4176	42	54	10	10	NUM
dpc-4176	42	55	]	]	PUNCT
dpc-4176	42	56	,	,	PUNCT
dpc-4176	42	57	that	that	PRON
dpc-4176	42	58	has	have	AUX
dpc-4176	42	59	been	be	AUX
dpc-4176	42	60	attributed	attribute	VERB
dpc-4176	42	61	to	to	ADP
dpc-4176	42	62	inhibition	inhibition	NOUN
dpc-4176	42	63	of	of	ADP
dpc-4176	42	64	il-23p19	il-23p19	PROPN
dpc-4176	42	65	subunit	subunit	NOUN
dpc-4176	42	66	,	,	PUNCT
dpc-4176	42	67	which	which	PRON
dpc-4176	42	68	has	have	VERB
dpc-4176	42	69	broader	broad	ADJ
dpc-4176	42	70	impact	impact	NOUN
dpc-4176	42	71	on	on	ADP
dpc-4176	42	72	inflammatory	inflammatory	ADJ
dpc-4176	42	73	cytokines	cytokine	NOUN
dpc-4176	42	74	involved	involve	VERB
dpc-4176	42	75	in	in	ADP
dpc-4176	42	76	psoriasis	psoriasis	NOUN
dpc-4176	42	77	.	.	PUNCT
dpc-4176	43	1	besides	besides	SCONJ
dpc-4176	43	2	,	,	PUNCT
dpc-4176	43	3	tissue	tissue	NOUN
dpc-4176	43	4	-	-	PUNCT
dpc-4176	43	5	resident	resident	NOUN
dpc-4176	43	6	memory	memory	NOUN
dpc-4176	43	7	t	t	PROPN
dpc-4176	43	8	-	-	PUNCT
dpc-4176	43	9	cells	cell	NOUN
dpc-4176	43	10	that	that	PRON
dpc-4176	43	11	are	be	AUX
dpc-4176	43	12	responsible	responsible	ADJ
dpc-4176	43	13	for	for	ADP
dpc-4176	43	14	persistence	persistence	NOUN
dpc-4176	43	15	and	and	CCONJ
dpc-4176	43	16	recurrence	recurrence	NOUN
dpc-4176	43	17	of	of	ADP
dpc-4176	43	18	psoriasis	psoriasis	NOUN
dpc-4176	43	19	are	be	AUX
dpc-4176	43	20	sustained	sustain	VERB
dpc-4176	43	21	in	in	ADP
dpc-4176	43	22	their	their	PRON
dpc-4176	43	23	pathogenic	pathogenic	ADJ
dpc-4176	43	24	state	state	NOUN
dpc-4176	43	25	by	by	ADP
dpc-4176	43	26	localized	localized	ADJ
dpc-4176	43	27	il-23	il-23	NOUN
dpc-4176	43	28	produced	produce	VERB
dpc-4176	43	29	by	by	ADP
dpc-4176	43	30	various	various	ADJ
dpc-4176	43	31	subtypes	subtype	NOUN
dpc-4176	43	32	of	of	ADP
dpc-4176	43	33	antigen	antigen	ADJ
dpc-4176	43	34	presenting	present	VERB
dpc-4176	43	35	cells	cell	NOUN
dpc-4176	43	36	,	,	PUNCT
dpc-4176	43	37	and	and	CCONJ
dpc-4176	43	38	blocking	block	VERB
dpc-4176	43	39	this	this	DET
dpc-4176	43	40	pathway	pathway	NOUN
dpc-4176	43	41	therefore	therefore	ADV
dpc-4176	43	42	enables	enable	VERB
dpc-4176	43	43	durable	durable	ADJ
dpc-4176	43	44	responses	response	NOUN
dpc-4176	43	45	and	and	CCONJ
dpc-4176	43	46	low	low	ADJ
dpc-4176	43	47	incidence	incidence	NOUN
dpc-4176	43	48	of	of	ADP
dpc-4176	43	49	disease	disease	NOUN
dpc-4176	43	50	recurrence	recurrence	NOUN
dpc-4176	44	1	[	[	X
dpc-4176	44	2	11,12	11,12	NOUN
dpc-4176	44	3	]	]	PUNCT
dpc-4176	44	4	.	.	PUNCT
dpc-4176	45	1	additionally	additionally	ADV
dpc-4176	45	2	,	,	PUNCT
dpc-4176	45	3	guselkumab	guselkumab	NOUN
dpc-4176	45	4	has	have	VERB
dpc-4176	45	5	lower	low	ADJ
dpc-4176	45	6	risk	risk	NOUN
dpc-4176	45	7	of	of	ADP
dpc-4176	45	8	reactivation	reactivation	NOUN
dpc-4176	45	9	of	of	ADP
dpc-4176	45	10	tuberculosis	tuberculosis	NOUN
dpc-4176	45	11	and	and	CCONJ
dpc-4176	45	12	viral	viral	ADJ
dpc-4176	45	13	hepatitis	hepatitis	NOUN
dpc-4176	45	14	,	,	PUNCT
dpc-4176	45	15	and	and	CCONJ
dpc-4176	45	16	is	be	AUX
dpc-4176	45	17	not	not	PART
dpc-4176	45	18	associated	associate	VERB
dpc-4176	45	19	with	with	ADP
dpc-4176	45	20	de	de	X
dpc-4176	45	21	novo	novo	NOUN
dpc-4176	45	22	onset	onset	NOUN
dpc-4176	45	23	or	or	CCONJ
dpc-4176	45	24	worsening	worsen	VERB
dpc-4176	45	25	of	of	ADP
dpc-4176	45	26	inflammatory	inflammatory	ADJ
dpc-4176	45	27	bowel	bowel	NOUN
dpc-4176	45	28	disease	disease	NOUN
dpc-4176	45	29	(	(	PUNCT
dpc-4176	45	30	ibd	ibd	NOUN
dpc-4176	45	31	)	)	PUNCT
dpc-4176	45	32	in	in	ADP
dpc-4176	45	33	treated	treat	VERB
dpc-4176	45	34	patients	patient	NOUN
dpc-4176	45	35	;	;	PUNCT
dpc-4176	45	36	making	make	VERB
dpc-4176	45	37	it	it	PRON
dpc-4176	45	38	safe	safe	ADJ
dpc-4176	45	39	and	and	CCONJ
dpc-4176	45	40	effective	effective	ADJ
dpc-4176	45	41	in	in	ADP
dpc-4176	45	42	these	these	DET
dpc-4176	45	43	patients	patient	NOUN
dpc-4176	45	44	[	[	X
dpc-4176	45	45	13	13	NUM
dpc-4176	45	46	]	]	PUNCT
dpc-4176	45	47	.	.	PUNCT
dpc-4176	46	1	furthermore	furthermore	ADV
dpc-4176	46	2	,	,	PUNCT
dpc-4176	46	3	guselkumab	guselkumab	NOUN
dpc-4176	46	4	demonstrates	demonstrate	VERB
dpc-4176	46	5	superiority	superiority	NOUN
dpc-4176	46	6	to	to	ADP
dpc-4176	46	7	adalimumab	adalimumab	NOUN
dpc-4176	46	8	,	,	PUNCT
dpc-4176	46	9	ustekinumab	ustekinumab	NOUN
dpc-4176	46	10	and	and	CCONJ
dpc-4176	46	11	secukinumab	secukinumab	NOUN
dpc-4176	46	12	,	,	PUNCT
dpc-4176	46	13	with	with	ADP
dpc-4176	46	14	more	more	ADV
dpc-4176	46	15	consistent	consistent	ADJ
dpc-4176	46	16	responses	response	NOUN
dpc-4176	46	17	in	in	ADP
dpc-4176	46	18	chronic	chronic	ADJ
dpc-4176	46	19	plaque	plaque	NOUN
dpc-4176	46	20	psoriasis	psoriasis	NOUN
dpc-4176	46	21	[	[	X
dpc-4176	46	22	14	14	NUM
dpc-4176	46	23	-	-	SYM
dpc-4176	46	24	16	16	NUM
dpc-4176	46	25	]	]	PUNCT
dpc-4176	46	26	.	.	PUNCT
dpc-4176	47	1	moreover	moreover	ADV
dpc-4176	47	2	,	,	PUNCT
dpc-4176	47	3	significant	significant	ADJ
dpc-4176	47	4	benefit	benefit	NOUN
dpc-4176	47	5	with	with	ADP
dpc-4176	47	6	guselkumab	guselkumab	NOUN
dpc-4176	47	7	is	be	AUX
dpc-4176	47	8	observed	observe	VERB
dpc-4176	47	9	in	in	ADP
dpc-4176	47	10	those	those	DET
dpc-4176	47	11	patients	patient	NOUN
dpc-4176	47	12	where	where	SCONJ
dpc-4176	47	13	ustekinumab	ustekinumab	NOUN
dpc-4176	47	14	is	be	AUX
dpc-4176	47	15	ineffective	ineffective	ADJ
dpc-4176	47	16	,	,	PUNCT
dpc-4176	47	17	making	make	VERB
dpc-4176	47	18	guselkumab	guselkumab	NOUN
dpc-4176	47	19	an	an	DET
dpc-4176	47	20	ideal	ideal	ADJ
dpc-4176	47	21	switch	switch	NOUN
dpc-4176	47	22	over	over	ADP
dpc-4176	47	23	drug	drug	NOUN
dpc-4176	47	24	in	in	ADP
dpc-4176	47	25	such	such	ADJ
dpc-4176	47	26	scenarios	scenario	NOUN
dpc-4176	47	27	[	[	X
dpc-4176	47	28	15	15	NUM
dpc-4176	47	29	]	]	PUNCT
dpc-4176	47	30	.	.	PUNCT
dpc-4176	48	1	in	in	ADP
dpc-4176	48	2	comparison	comparison	NOUN
dpc-4176	48	3	with	with	ADP
dpc-4176	48	4	tildrakizumab	tildrakizumab	NOUN
dpc-4176	48	5	however	however	ADV
dpc-4176	48	6	,	,	PUNCT
dpc-4176	48	7	no	no	DET
dpc-4176	48	8	advantage	advantage	NOUN
dpc-4176	48	9	has	have	AUX
dpc-4176	48	10	been	be	AUX
dpc-4176	48	11	observed	observe	VERB
dpc-4176	48	12	with	with	ADP
dpc-4176	48	13	guselkumab	guselkumab	NOUN
dpc-4176	48	14	.	.	PUNCT
dpc-4176	49	1	both	both	DET
dpc-4176	49	2	drugs	drug	NOUN
dpc-4176	49	3	were	be	AUX
dpc-4176	49	4	equally	equally	ADV
dpc-4176	49	5	potent	potent	ADJ
dpc-4176	49	6	and	and	CCONJ
dpc-4176	49	7	safe	safe	ADJ
dpc-4176	49	8	in	in	ADP
dpc-4176	49	9	treating	treat	VERB
dpc-4176	49	10	psoriasis	psoriasis	NOUN
dpc-4176	49	11	patients	patient	NOUN
dpc-4176	49	12	[	[	X
dpc-4176	49	13	17	17	NUM
dpc-4176	49	14	]	]	PUNCT
dpc-4176	49	15	.	.	PUNCT
dpc-4176	50	1	details	detail	NOUN
dpc-4176	50	2	of	of	ADP
dpc-4176	50	3	randomized	randomized	ADJ
dpc-4176	50	4	controlled	control	VERB
dpc-4176	50	5	trials(rcts	trials(rct	NOUN
dpc-4176	50	6	)	)	PUNCT
dpc-4176	50	7	utilizing	utilize	VERB
dpc-4176	50	8	guselkumab	guselkumab	NOUN
dpc-4176	50	9	in	in	ADP
dpc-4176	50	10	chronic	chronic	ADJ
dpc-4176	50	11	plaque	plaque	NOUN
dpc-4176	50	12	psoriasis	psoriasis	NOUN
dpc-4176	50	13	has	have	AUX
dpc-4176	50	14	been	be	AUX
dpc-4176	50	15	described	describe	VERB
dpc-4176	50	16	in	in	ADP
dpc-4176	50	17	table	table	NOUN
dpc-4176	50	18	1	1	NUM
dpc-4176	50	19	[	[	SYM
dpc-4176	50	20	14	14	NUM
dpc-4176	50	21	-	-	SYM
dpc-4176	50	22	16,18,19	16,18,19	NUM
dpc-4176	50	23	]	]	PUNCT
dpc-4176	50	24	.	.	PUNCT
dpc-4176	51	1	guttate	guttate	ADJ
dpc-4176	51	2	psoriasis	psoriasis	NOUN
dpc-4176	51	3	guttate	guttate	NOUN
dpc-4176	51	4	psoriasis	psoriasis	NOUN
dpc-4176	51	5	(	(	PUNCT
dpc-4176	51	6	gp	gp	NOUN
dpc-4176	51	7	)	)	PUNCT
dpc-4176	51	8	is	be	AUX
dpc-4176	51	9	an	an	DET
dpc-4176	51	10	uncommon	uncommon	ADJ
dpc-4176	51	11	variant	variant	NOUN
dpc-4176	51	12	of	of	ADP
dpc-4176	51	13	psoriasis	psoriasis	NOUN
dpc-4176	51	14	,	,	PUNCT
dpc-4176	51	15	classically	classically	ADV
dpc-4176	51	16	associated	associate	VERB
dpc-4176	51	17	with	with	ADP
dpc-4176	51	18	underlying	underlie	VERB
dpc-4176	51	19	streptococcal	streptococcal	ADJ
dpc-4176	51	20	infection	infection	NOUN
dpc-4176	51	21	.	.	PUNCT
dpc-4176	52	1	however	however	ADV
dpc-4176	52	2	,	,	PUNCT
dpc-4176	52	3	gp	gp	NOUN
dpc-4176	52	4	has	have	AUX
dpc-4176	52	5	also	also	ADV
dpc-4176	52	6	been	be	AUX
dpc-4176	52	7	observed	observe	VERB
dpc-4176	52	8	with	with	ADP
dpc-4176	52	9	no	no	DET
dpc-4176	52	10	recent	recent	ADJ
dpc-4176	52	11	infection	infection	NOUN
dpc-4176	52	12	.	.	PUNCT
dpc-4176	53	1	complete	complete	ADJ
dpc-4176	53	2	resolution	resolution	NOUN
dpc-4176	53	3	of	of	ADP
dpc-4176	53	4	gp	gp	NOUN
dpc-4176	53	5	was	be	AUX
dpc-4176	53	6	first	first	ADV
dpc-4176	53	7	described	describe	VERB
dpc-4176	53	8	by	by	ADP
dpc-4176	53	9	hall	hall	PROPN
dpc-4176	53	10	et	et	PROPN
dpc-4176	53	11	al	al	PROPN
dpc-4176	53	12	,	,	PUNCT
dpc-4176	53	13	after	after	ADP
dpc-4176	53	14	one	one	NUM
dpc-4176	53	15	dose	dose	NOUN
dpc-4176	53	16	of	of	ADP
dpc-4176	53	17	guselkumab	guselkumab	NOUN
dpc-4176	53	18	[	[	X
dpc-4176	53	19	20	20	NUM
dpc-4176	53	20	]	]	PUNCT
dpc-4176	53	21	.	.	PUNCT
dpc-4176	54	1	another	another	DET
dpc-4176	54	2	report	report	NOUN
dpc-4176	54	3	illustrated	illustrate	VERB
dpc-4176	54	4	complete	complete	ADJ
dpc-4176	54	5	remission	remission	NOUN
dpc-4176	54	6	of	of	ADP
dpc-4176	54	7	sunburn	sunburn	NOUN
dpc-4176	54	8	-	-	PUNCT
dpc-4176	54	9	induced	induce	VERB
dpc-4176	54	10	guttate	guttate	NOUN
dpc-4176	54	11	psoriasis	psoriasis	NOUN
dpc-4176	54	12	following	follow	VERB
dpc-4176	54	13	6	6	NUM
dpc-4176	54	14	doses	dose	NOUN
dpc-4176	54	15	of	of	ADP
dpc-4176	54	16	guselkumab	guselkumab	NOUN
dpc-4176	54	17	,	,	PUNCT
dpc-4176	54	18	with	with	ADP
dpc-4176	54	19	cure	cure	NOUN
dpc-4176	54	20	maintained	maintain	VERB
dpc-4176	54	21	on	on	ADP
dpc-4176	54	22	drug	drug	NOUN
dpc-4176	54	23	cessation	cessation	NOUN
dpc-4176	54	24	.	.	PUNCT
dpc-4176	55	1	the	the	DET
dpc-4176	55	2	onset	onset	NOUN
dpc-4176	55	3	of	of	ADP
dpc-4176	55	4	gp	gp	NOUN
dpc-4176	55	5	in	in	ADP
dpc-4176	55	6	this	this	DET
dpc-4176	55	7	case	case	NOUN
dpc-4176	55	8	was	be	AUX
dpc-4176	55	9	connected	connect	VERB
dpc-4176	55	10	to	to	ADP
dpc-4176	55	11	the	the	DET
dpc-4176	55	12	activation	activation	NOUN
dpc-4176	55	13	of	of	ADP
dpc-4176	55	14	il-23	il-23	NOUN
dpc-4176	55	15	/	/	SYM
dpc-4176	55	16	il-17	il-17	NUM
dpc-4176	55	17	by	by	ADP
dpc-4176	55	18	various	various	ADJ
dpc-4176	55	19	cytokines	cytokine	NOUN
dpc-4176	55	20	and	and	CCONJ
dpc-4176	55	21	keratinocytes	keratinocyte	NOUN
dpc-4176	55	22	,	,	PUNCT
dpc-4176	55	23	following	follow	VERB
dpc-4176	55	24	sunburn	sunburn	NOUN
dpc-4176	55	25	in	in	ADP
dpc-4176	55	26	a	a	DET
dpc-4176	55	27	genetically	genetically	ADV
dpc-4176	55	28	predisposed	predispose	VERB
dpc-4176	55	29	individual	individual	NOUN
dpc-4176	55	30	[	[	X
dpc-4176	55	31	21,22	21,22	NOUN
dpc-4176	55	32	]	]	X
dpc-4176	55	33	.	.	PUNCT
dpc-4176	56	1	nail	nail	NOUN
dpc-4176	56	2	psoriasis	psoriasis	NOUN
dpc-4176	56	3	nail	nail	NOUN
dpc-4176	56	4	psoriasis	psoriasis	NOUN
dpc-4176	56	5	(	(	PUNCT
dpc-4176	56	6	np	np	INTJ
dpc-4176	56	7	)	)	PUNCT
dpc-4176	56	8	presents	present	NOUN
dpc-4176	56	9	with	with	ADP
dpc-4176	56	10	heterogenous	heterogenous	ADJ
dpc-4176	56	11	clinical	clinical	ADJ
dpc-4176	56	12	patterns	pattern	NOUN
dpc-4176	56	13	.	.	PUNCT
dpc-4176	57	1	as	as	SCONJ
dpc-4176	57	2	the	the	DET
dpc-4176	57	3	nail	nail	NOUN
dpc-4176	57	4	unit	unit	NOUN
dpc-4176	57	5	is	be	AUX
dpc-4176	57	6	closely	closely	ADV
dpc-4176	57	7	linked	link	VERB
dpc-4176	57	8	to	to	ADP
dpc-4176	57	9	the	the	DET
dpc-4176	57	10	extensor	extensor	NOUN
dpc-4176	57	11	tendon	tendon	NOUN
dpc-4176	57	12	fibers	fiber	NOUN
dpc-4176	57	13	and	and	CCONJ
dpc-4176	57	14	periosteum	periosteum	NOUN
dpc-4176	57	15	of	of	ADP
dpc-4176	57	16	the	the	DET
dpc-4176	57	17	distal	distal	ADJ
dpc-4176	57	18	phalanx	phalanx	NOUN
dpc-4176	57	19	,	,	PUNCT
dpc-4176	57	20	psoriasis	psoriasis	NOUN
dpc-4176	57	21	of	of	ADP
dpc-4176	57	22	nails	nail	NOUN
dpc-4176	57	23	is	be	AUX
dpc-4176	57	24	often	often	ADV
dpc-4176	57	25	associated	associate	VERB
dpc-4176	57	26	with	with	ADP
dpc-4176	57	27	psoriatic	psoriatic	ADJ
dpc-4176	57	28	arthropathy	arthropathy	ADJ
dpc-4176	57	29	(	(	PUNCT
dpc-4176	57	30	psa	psa	NOUN
dpc-4176	57	31	)	)	PUNCT
dpc-4176	58	1	[	[	X
dpc-4176	58	2	23	23	NUM
dpc-4176	58	3	]	]	PUNCT
dpc-4176	58	4	.	.	PUNCT
dpc-4176	59	1	owing	owe	VERB
dpc-4176	59	2	to	to	ADP
dpc-4176	59	3	the	the	DET
dpc-4176	59	4	distinctive	distinctive	ADJ
dpc-4176	59	5	anatomy	anatomy	NOUN
dpc-4176	59	6	of	of	ADP
dpc-4176	59	7	the	the	DET
dpc-4176	59	8	nail	nail	NOUN
dpc-4176	59	9	unit	unit	NOUN
dpc-4176	59	10	,	,	PUNCT
dpc-4176	59	11	it	it	PRON
dpc-4176	59	12	becomes	become	VERB
dpc-4176	59	13	mandatory	mandatory	ADJ
dpc-4176	59	14	for	for	SCONJ
dpc-4176	59	15	practitioners	practitioner	NOUN
dpc-4176	59	16	to	to	PART
dpc-4176	59	17	have	have	VERB
dpc-4176	59	18	a	a	DET
dpc-4176	59	19	detailed	detailed	ADJ
dpc-4176	59	20	understanding	understanding	NOUN
dpc-4176	59	21	regarding	regard	VERB
dpc-4176	59	22	the	the	DET
dpc-4176	59	23	therapeutic	therapeutic	ADJ
dpc-4176	59	24	aspects	aspect	NOUN
dpc-4176	59	25	in	in	ADP
dpc-4176	59	26	relation	relation	NOUN
dpc-4176	59	27	to	to	ADP
dpc-4176	59	28	np	np	INTJ
dpc-4176	59	29	,	,	PUNCT
dpc-4176	59	30	in	in	ADP
dpc-4176	59	31	order	order	NOUN
dpc-4176	59	32	to	to	PART
dpc-4176	59	33	obtain	obtain	VERB
dpc-4176	59	34	better	well	ADJ
dpc-4176	59	35	clinical	clinical	ADJ
dpc-4176	59	36	outcomes	outcome	NOUN
dpc-4176	59	37	and	and	CCONJ
dpc-4176	59	38	an	an	DET
dpc-4176	59	39	improved	improved	ADJ
dpc-4176	59	40	quality	quality	NOUN
dpc-4176	59	41	of	of	ADP
dpc-4176	59	42	life	life	NOUN
dpc-4176	59	43	(	(	PUNCT
dpc-4176	59	44	qol	qol	NOUN
dpc-4176	59	45	)	)	PUNCT
dpc-4176	60	1	[	[	X
dpc-4176	60	2	24,25	24,25	NUM
dpc-4176	60	3	]	]	PUNCT
dpc-4176	60	4	.	.	PUNCT
dpc-4176	61	1	though	though	SCONJ
dpc-4176	61	2	often	often	ADV
dpc-4176	61	3	associated	associate	VERB
dpc-4176	61	4	with	with	ADP
dpc-4176	61	5	plaque	plaque	NOUN
dpc-4176	61	6	psoriasis	psoriasis	NOUN
dpc-4176	61	7	,	,	PUNCT
dpc-4176	61	8	in	in	ADP
dpc-4176	61	9	5%-10	5%-10	NUM
dpc-4176	61	10	%	%	NOUN
dpc-4176	61	11	of	of	ADP
dpc-4176	61	12	patients	patient	NOUN
dpc-4176	61	13	np	np	INTJ
dpc-4176	61	14	can	can	AUX
dpc-4176	61	15	present	present	VERB
dpc-4176	61	16	as	as	ADP
dpc-4176	61	17	an	an	DET
dpc-4176	61	18	isolated	isolated	ADJ
dpc-4176	61	19	finding	finding	NOUN
dpc-4176	61	20	[	[	X
dpc-4176	61	21	26	26	NUM
dpc-4176	61	22	]	]	PUNCT
dpc-4176	61	23	.	.	PUNCT
dpc-4176	62	1	guselkumab	guselkumab	NOUN
dpc-4176	62	2	is	be	AUX
dpc-4176	62	3	effective	effective	ADJ
dpc-4176	62	4	in	in	ADP
dpc-4176	62	5	np	np	ADP
dpc-4176	62	6	,	,	PUNCT
dpc-4176	62	7	with	with	ADP
dpc-4176	62	8	a	a	DET
dpc-4176	62	9	longer	long	ADJ
dpc-4176	62	10	remission	remission	NOUN
dpc-4176	62	11	period	period	NOUN
dpc-4176	62	12	following	follow	VERB
dpc-4176	62	13	withdrawal	withdrawal	PROPN
dpc-4176	62	14	,	,	PUNCT
dpc-4176	62	15	when	when	SCONJ
dpc-4176	62	16	compared	compare	VERB
dpc-4176	62	17	to	to	ADP
dpc-4176	62	18	cutaneous	cutaneous	ADJ
dpc-4176	62	19	psoriasis	psoriasis	NOUN
dpc-4176	62	20	.	.	PUNCT
dpc-4176	63	1	besides	besides	SCONJ
dpc-4176	63	2	,	,	PUNCT
dpc-4176	63	3	it	it	PRON
dpc-4176	63	4	is	be	AUX
dpc-4176	63	5	seen	see	VERB
dpc-4176	63	6	that	that	SCONJ
dpc-4176	63	7	less	less	ADV
dpc-4176	63	8	severe	severe	ADJ
dpc-4176	63	9	nail	nail	NOUN
dpc-4176	63	10	disease	disease	NOUN
dpc-4176	63	11	(	(	PUNCT
dpc-4176	63	12	lower	low	ADJ
dpc-4176	63	13	baseline	baseline	NOUN
dpc-4176	63	14	nail	nail	NOUN
dpc-4176	63	15	psoriasis	psoriasis	NOUN
dpc-4176	63	16	severity	severity	NOUN
dpc-4176	63	17	index	index	NOUN
dpc-4176	63	18	[	[	X
dpc-4176	63	19	napsi	napsi	NOUN
dpc-4176	63	20	]	]	PUNCT
dpc-4176	63	21	)	)	PUNCT
dpc-4176	63	22	and	and	CCONJ
dpc-4176	63	23	lower	low	ADJ
dpc-4176	63	24	pasi	pasi	NOUN
dpc-4176	63	25	scores	score	NOUN
dpc-4176	63	26	at	at	ADP
dpc-4176	63	27	week	week	NOUN
dpc-4176	63	28	16	16	NUM
dpc-4176	63	29	following	follow	VERB
dpc-4176	63	30	treatment	treatment	NOUN
dpc-4176	63	31	,	,	PUNCT
dpc-4176	63	32	are	be	AUX
dpc-4176	63	33	associated	associate	VERB
dpc-4176	63	34	with	with	ADP
dpc-4176	63	35	greater	great	ADJ
dpc-4176	63	36	probability	probability	NOUN
dpc-4176	63	37	of	of	ADP
dpc-4176	63	38	near	near	ADJ
dpc-4176	63	39	or	or	CCONJ
dpc-4176	63	40	complete	complete	ADJ
dpc-4176	63	41	np	np	INTJ
dpc-4176	63	42	clearance	clearance	NOUN
dpc-4176	63	43	(	(	PUNCT
dpc-4176	63	44	napsi	napsi	NOUN
dpc-4176	63	45	0/1	0/1	NUM
dpc-4176	63	46	)	)	PUNCT
dpc-4176	63	47	at	at	ADP
dpc-4176	63	48	weeks	week	NOUN
dpc-4176	63	49	24	24	NUM
dpc-4176	63	50	and	and	CCONJ
dpc-4176	63	51	48	48	NUM
dpc-4176	63	52	,	,	PUNCT
dpc-4176	63	53	thereby	thereby	ADV
dpc-4176	63	54	attributing	attribute	VERB
dpc-4176	63	55	a	a	DET
dpc-4176	63	56	direct	direct	ADJ
dpc-4176	63	57	association	association	NOUN
dpc-4176	63	58	between	between	ADP
dpc-4176	63	59	skin	skin	NOUN
dpc-4176	63	60	and	and	CCONJ
dpc-4176	63	61	nail	nail	NOUN
dpc-4176	63	62	responsiveness	responsiveness	NOUN
dpc-4176	63	63	to	to	PART
dpc-4176	63	64	guselkumab	guselkumab	NOUN
dpc-4176	63	65	[	[	X
dpc-4176	63	66	27	27	NUM
dpc-4176	63	67	]	]	PUNCT
dpc-4176	63	68	.	.	PUNCT
dpc-4176	64	1	additionally	additionally	ADV
dpc-4176	64	2	,	,	PUNCT
dpc-4176	64	3	cigarette	cigarette	NOUN
dpc-4176	64	4	smoking	smoking	NOUN
dpc-4176	64	5	is	be	AUX
dpc-4176	64	6	associated	associate	VERB
dpc-4176	64	7	with	with	ADP
dpc-4176	64	8	a	a	DET
dpc-4176	64	9	negative	negative	ADJ
dpc-4176	64	10	impact	impact	NOUN
dpc-4176	64	11	on	on	ADP
dpc-4176	64	12	treatment	treatment	NOUN
dpc-4176	64	13	response	response	NOUN
dpc-4176	64	14	with	with	ADP
dpc-4176	64	15	guselkumab	guselkumab	NOUN
dpc-4176	64	16	in	in	ADP
dpc-4176	64	17	np	np	ADP
dpc-4176	64	18	,	,	PUNCT
dpc-4176	64	19	possibly	possibly	ADV
dpc-4176	64	20	due	due	ADP
dpc-4176	64	21	to	to	ADP
dpc-4176	64	22	local	local	ADJ
dpc-4176	64	23	angiopathic	angiopathic	ADJ
dpc-4176	64	24	factors	factor	NOUN
dpc-4176	64	25	,	,	PUNCT
dpc-4176	64	26	koebnerization	koebnerization	ADJ
dpc-4176	64	27	and	and	CCONJ
dpc-4176	64	28	systemic	systemic	ADJ
dpc-4176	64	29	effects	effect	NOUN
dpc-4176	64	30	of	of	ADP
dpc-4176	64	31	cigarette	cigarette	NOUN
dpc-4176	64	32	smoke	smoke	NOUN
dpc-4176	64	33	[	[	X
dpc-4176	64	34	28	28	NUM
dpc-4176	64	35	]	]	PUNCT
dpc-4176	64	36	.	.	PUNCT
dpc-4176	65	1	interestingly	interestingly	ADV
dpc-4176	65	2	,	,	PUNCT
dpc-4176	65	3	no	no	DET
dpc-4176	65	4	statistically	statistically	ADV
dpc-4176	65	5	significant	significant	ADJ
dpc-4176	65	6	association	association	NOUN
dpc-4176	65	7	has	have	AUX
dpc-4176	65	8	been	be	AUX
dpc-4176	65	9	observed	observe	VERB
dpc-4176	65	10	with	with	ADP
dpc-4176	65	11	guselkumab	guselkumab	NOUN
dpc-4176	65	12	in	in	ADP
dpc-4176	65	13	relation	relation	NOUN
dpc-4176	65	14	to	to	ADP
dpc-4176	65	15	body	body	NOUN
dpc-4176	65	16	mass	mass	NOUN
dpc-4176	65	17	index	index	NOUN
dpc-4176	65	18	(	(	PUNCT
dpc-4176	65	19	bmi	bmi	PROPN
dpc-4176	65	20	)	)	PUNCT
dpc-4176	65	21	and	and	CCONJ
dpc-4176	65	22	the	the	DET
dpc-4176	65	23	probability	probability	NOUN
dpc-4176	65	24	of	of	ADP
dpc-4176	65	25	obtaining	obtain	VERB
dpc-4176	65	26	napsi	napsi	NOUN
dpc-4176	65	27	0/1	0/1	NUM
dpc-4176	65	28	.	.	PUNCT
dpc-4176	66	1	this	this	DET
dpc-4176	66	2	caries	carie	NOUN
dpc-4176	66	3	significance	significance	NOUN
dpc-4176	66	4	because	because	SCONJ
dpc-4176	66	5	obesity	obesity	NOUN
dpc-4176	66	6	is	be	AUX
dpc-4176	66	7	a	a	DET
dpc-4176	66	8	common	common	ADJ
dpc-4176	66	9	comorbidity	comorbidity	NOUN
dpc-4176	66	10	in	in	ADP
dpc-4176	66	11	psoriasis	psoriasis	NOUN
dpc-4176	66	12	patients	patient	NOUN
dpc-4176	66	13	,	,	PUNCT
dpc-4176	66	14	and	and	CCONJ
dpc-4176	66	15	in	in	ADP
dpc-4176	66	16	cutaneous	cutaneous	ADJ
dpc-4176	66	17	psoriasis	psoriasis	NOUN
dpc-4176	66	18	,	,	PUNCT
dpc-4176	66	19	guselkumab	guselkumab	NOUN
dpc-4176	66	20	has	have	AUX
dpc-4176	66	21	demonstrated	demonstrate	VERB
dpc-4176	66	22	pasi	pasi	NOUN
dpc-4176	66	23	90	90	NUM
dpc-4176	66	24	to	to	PART
dpc-4176	66	25	be	be	AUX
dpc-4176	66	26	more	more	ADV
dpc-4176	66	27	likely	likely	ADJ
dpc-4176	66	28	in	in	ADP
dpc-4176	66	29	patients	patient	NOUN
dpc-4176	66	30	with	with	ADP
dpc-4176	66	31	bmi	bmi	PROPN
dpc-4176	66	32	<	<	X
dpc-4176	66	33	25	25	NUM
dpc-4176	66	34	kg	kg	NOUN
dpc-4176	66	35	/	/	SYM
dpc-4176	66	36	m2	m2	PROPN
dpc-4176	66	37	than	than	ADP
dpc-4176	66	38	in	in	ADP
dpc-4176	66	39	those	those	PRON
dpc-4176	66	40	having	have	VERB
dpc-4176	66	41	a	a	DET
dpc-4176	66	42	bmi	bmi	NOUN
dpc-4176	66	43	>	>	X
dpc-4176	66	44	30	30	NUM
dpc-4176	66	45	kg	kg	NOUN
dpc-4176	66	46	/	/	SYM
dpc-4176	66	47	m2	m2	PROPN
dpc-4176	67	1	[	[	X
dpc-4176	67	2	29	29	NUM
dpc-4176	67	3	-	-	SYM
dpc-4176	67	4	31	31	NUM
dpc-4176	67	5	]	]	PUNCT
dpc-4176	67	6	.	.	PUNCT
dpc-4176	68	1	further	far	ADV
dpc-4176	68	2	,	,	PUNCT
dpc-4176	68	3	napsi	napsi	NOUN
dpc-4176	68	4	0/1	0/1	NUM
dpc-4176	68	5	responses	response	NOUN
dpc-4176	68	6	at	at	ADP
dpc-4176	68	7	weeks	week	NOUN
dpc-4176	68	8	24	24	NUM
dpc-4176	68	9	and	and	CCONJ
dpc-4176	68	10	48	48	NUM
dpc-4176	68	11	with	with	ADP
dpc-4176	68	12	guselkumab	guselkumab	NOUN
dpc-4176	68	13	are	be	AUX
dpc-4176	68	14	not	not	PART
dpc-4176	68	15	impacted	impact	VERB
dpc-4176	68	16	in	in	ADP
dpc-4176	68	17	patients	patient	NOUN
dpc-4176	68	18	who	who	PRON
dpc-4176	68	19	have	have	AUX
dpc-4176	68	20	previously	previously	ADV
dpc-4176	68	21	received	receive	VERB
dpc-4176	68	22	tnfα	tnfα	NOUN
dpc-4176	68	23	antagonist	antagonist	NOUN
dpc-4176	68	24	biologic	biologic	NOUN
dpc-4176	68	25	agents	agent	NOUN
dpc-4176	68	26	,	,	PUNCT
dpc-4176	68	27	making	make	VERB
dpc-4176	68	28	it	it	PRON
dpc-4176	68	29	an	an	DET
dpc-4176	68	30	ideal	ideal	ADJ
dpc-4176	68	31	drug	drug	NOUN
dpc-4176	68	32	for	for	ADP
dpc-4176	68	33	np	np	PRON
dpc-4176	68	34	even	even	ADV
dpc-4176	68	35	in	in	ADP
dpc-4176	68	36	bio	bio	ADJ
dpc-4176	68	37	-	-	ADJ
dpc-4176	68	38	experienced	experienced	ADJ
dpc-4176	68	39	individuals	individual	NOUN
dpc-4176	68	40	[	[	X
dpc-4176	68	41	19	19	NUM
dpc-4176	68	42	-	-	SYM
dpc-4176	68	43	32	32	NUM
dpc-4176	68	44	]	]	PUNCT
dpc-4176	68	45	.	.	PUNCT
dpc-4176	69	1	besides	besides	SCONJ
dpc-4176	69	2	,	,	PUNCT
dpc-4176	69	3	the	the	DET
dpc-4176	69	4	efficacy	efficacy	NOUN
dpc-4176	69	5	of	of	ADP
dpc-4176	69	6	guselkumab	guselkumab	NOUN
dpc-4176	69	7	in	in	ADP
dpc-4176	69	8	np	np	ADV
dpc-4176	69	9	is	be	AUX
dpc-4176	69	10	similar	similar	ADJ
dpc-4176	69	11	to	to	ADP
dpc-4176	69	12	adalimumab	adalimumab	NOUN
dpc-4176	69	13	,	,	PUNCT
dpc-4176	69	14	but	but	CCONJ
dpc-4176	69	15	ixekizumab	ixekizumab	NOUN
dpc-4176	69	16	has	have	AUX
dpc-4176	69	17	demonstrated	demonstrate	VERB
dpc-4176	69	18	greater	great	ADJ
dpc-4176	69	19	profitability	profitability	NOUN
dpc-4176	69	20	in	in	ADP
dpc-4176	69	21	np	np	NOUN
dpc-4176	69	22	[	[	X
dpc-4176	69	23	32,33	32,33	NUM
dpc-4176	69	24	]	]	PUNCT
dpc-4176	69	25	.	.	PUNCT
dpc-4176	70	1	reports	report	NOUN
dpc-4176	70	2	delineating	delineate	VERB
dpc-4176	70	3	the	the	DET
dpc-4176	70	4	efficacy	efficacy	NOUN
dpc-4176	70	5	of	of	ADP
dpc-4176	70	6	guselkumab	guselkumab	NOUN
dpc-4176	70	7	in	in	ADP
dpc-4176	70	8	np	np	INTJ
dpc-4176	70	9	are	be	AUX
dpc-4176	70	10	presented	present	VERB
dpc-4176	70	11	in	in	ADP
dpc-4176	70	12	table	table	NOUN
dpc-4176	70	13	2	2	NUM
dpc-4176	71	1	[	[	X
dpc-4176	71	2	19,32,34,35	19,32,34,35	NUM
dpc-4176	71	3	]	]	X
dpc-4176	71	4	.	.	PUNCT
dpc-4176	72	1	currently	currently	ADV
dpc-4176	72	2	,	,	PUNCT
dpc-4176	72	3	with	with	ADP
dpc-4176	72	4	this	this	DET
dpc-4176	72	5	preliminary	preliminary	ADJ
dpc-4176	72	6	data	datum	NOUN
dpc-4176	72	7	of	of	ADP
dpc-4176	72	8	newer	new	ADJ
dpc-4176	72	9	biologic	biologic	NOUN
dpc-4176	72	10	drugs	drug	NOUN
dpc-4176	72	11	for	for	ADP
dpc-4176	72	12	np	np	INTJ
dpc-4176	72	13	,	,	PUNCT
dpc-4176	72	14	establishing	establish	VERB
dpc-4176	72	15	the	the	DET
dpc-4176	72	16	drug	drug	NOUN
dpc-4176	72	17	of	of	ADP
dpc-4176	72	18	choice	choice	NOUN
dpc-4176	72	19	would	would	AUX
dpc-4176	72	20	not	not	PART
dpc-4176	72	21	be	be	AUX
dpc-4176	72	22	very	very	ADV
dpc-4176	72	23	practical	practical	ADJ
dpc-4176	72	24	.	.	PUNCT
dpc-4176	73	1	more	more	ADJ
dpc-4176	73	2	data	datum	NOUN
dpc-4176	73	3	and	and	CCONJ
dpc-4176	73	4	dedicated	dedicated	ADJ
dpc-4176	73	5	head	head	NOUN
dpc-4176	73	6	on	on	ADP
dpc-4176	73	7	comparative	comparative	ADJ
dpc-4176	73	8	trials	trial	NOUN
dpc-4176	73	9	of	of	ADP
dpc-4176	73	10	these	these	DET
dpc-4176	73	11	drugs	drug	NOUN
dpc-4176	73	12	in	in	ADP
dpc-4176	73	13	np	np	PART
dpc-4176	73	14	become	become	VERB
dpc-4176	73	15	imperative	imperative	ADJ
dpc-4176	73	16	to	to	PART
dpc-4176	73	17	establish	establish	VERB
dpc-4176	73	18	an	an	DET
dpc-4176	73	19	evidence	evidence	NOUN
dpc-4176	73	20	-	-	PUNCT
dpc-4176	73	21	based	base	VERB
dpc-4176	73	22	treatment	treatment	NOUN
dpc-4176	73	23	algorithm	algorithm	NOUN
dpc-4176	73	24	for	for	ADP
dpc-4176	73	25	the	the	DET
dpc-4176	73	26	same	same	ADJ
dpc-4176	73	27	.	.	PUNCT
dpc-4176	74	1	palmoplantar	palmoplantar	NOUN
dpc-4176	74	2	psoriasis	psoriasis	NOUN
dpc-4176	74	3	(	(	PUNCT
dpc-4176	74	4	non	non	ADJ
dpc-4176	74	5	-	-	ADJ
dpc-4176	74	6	pustular	pustular	ADJ
dpc-4176	74	7	)	)	PUNCT
dpc-4176	74	8	palmoplantar	palmoplantar	NOUN
dpc-4176	74	9	psoriasis	psoriasis	NOUN
dpc-4176	74	10	(	(	PUNCT
dpc-4176	74	11	ppp	ppp	NOUN
dpc-4176	74	12	)	)	PUNCT
dpc-4176	74	13	is	be	AUX
dpc-4176	74	14	a	a	DET
dpc-4176	74	15	variant	variant	NOUN
dpc-4176	74	16	of	of	ADP
dpc-4176	74	17	psoriasis	psoriasis	NOUN
dpc-4176	74	18	characterized	characterize	VERB
dpc-4176	74	19	by	by	ADP
dpc-4176	74	20	hyperkeratotic	hyperkeratotic	ADJ
dpc-4176	74	21	and	and	CCONJ
dpc-4176	74	22	fissured	fissured	ADJ
dpc-4176	74	23	plaques	plaque	NOUN
dpc-4176	74	24	involving	involve	VERB
dpc-4176	74	25	the	the	DET
dpc-4176	74	26	palms	palm	NOUN
dpc-4176	74	27	and	and	CCONJ
dpc-4176	74	28	soles	sol	NOUN
dpc-4176	74	29	and	and	CCONJ
dpc-4176	74	30	often	often	ADV
dpc-4176	74	31	recalcitrant	recalcitrant	ADJ
dpc-4176	74	32	to	to	ADP
dpc-4176	74	33	treatment	treatment	NOUN
dpc-4176	74	34	[	[	X
dpc-4176	74	35	36	36	NUM
dpc-4176	74	36	]	]	PUNCT
dpc-4176	74	37	.	.	PUNCT
dpc-4176	75	1	at	at	ADP
dpc-4176	75	2	present	present	ADJ
dpc-4176	75	3	,	,	PUNCT
dpc-4176	75	4	no	no	DET
dpc-4176	75	5	gold	gold	NOUN
dpc-4176	75	6	-	-	PUNCT
dpc-4176	75	7	standard	standard	NOUN
dpc-4176	75	8	therapy	therapy	NOUN
dpc-4176	75	9	is	be	AUX
dpc-4176	75	10	recognized	recognize	VERB
dpc-4176	75	11	for	for	ADP
dpc-4176	75	12	ppp	ppp	NOUN
dpc-4176	75	13	,	,	PUNCT
dpc-4176	75	14	despite	despite	SCONJ
dpc-4176	75	15	the	the	DET
dpc-4176	75	16	availability	availability	NOUN
dpc-4176	75	17	of	of	ADP
dpc-4176	75	18	broad	broad	ADJ
dpc-4176	75	19	and	and	CCONJ
dpc-4176	75	20	effective	effective	ADJ
dpc-4176	75	21	biologic	biologic	NOUN
dpc-4176	75	22	treatment	treatment	NOUN
dpc-4176	75	23	options	option	NOUN
dpc-4176	75	24	for	for	ADP
dpc-4176	75	25	moderate	moderate	ADJ
dpc-4176	75	26	-	-	PUNCT
dpc-4176	75	27	to	to	ADP
dpc-4176	75	28	-	-	PUNCT
dpc-4176	75	29	severe	severe	ADJ
dpc-4176	75	30	plaque	plaque	NOUN
dpc-4176	75	31	psoriasis	psoriasis	NOUN
dpc-4176	75	32	.	.	PUNCT
dpc-4176	76	1	moreover	moreover	ADV
dpc-4176	76	2	,	,	PUNCT
dpc-4176	76	3	clinical	clinical	ADJ
dpc-4176	76	4	trials	trial	NOUN
dpc-4176	76	5	for	for	ADP
dpc-4176	76	6	ppp	ppp	NOUN
dpc-4176	76	7	have	have	AUX
dpc-4176	76	8	been	be	AUX
dpc-4176	76	9	challenging	challenge	VERB
dpc-4176	76	10	because	because	SCONJ
dpc-4176	76	11	many	many	ADJ
dpc-4176	76	12	patients	patient	NOUN
dpc-4176	76	13	do	do	AUX
dpc-4176	76	14	not	not	PART
dpc-4176	76	15	meet	meet	VERB
dpc-4176	76	16	typical	typical	ADJ
dpc-4176	76	17	inclusion	inclusion	NOUN
dpc-4176	76	18	criteria	criterion	NOUN
dpc-4176	76	19	needed	need	VERB
dpc-4176	76	20	for	for	ADP
dpc-4176	76	21	these	these	DET
dpc-4176	76	22	trials	trial	NOUN
dpc-4176	76	23	,	,	PUNCT
dpc-4176	76	24	owing	owe	VERB
dpc-4176	76	25	to	to	ADP
dpc-4176	76	26	low	low	ADJ
dpc-4176	76	27	body	body	NOUN
dpc-4176	76	28	surface	surface	NOUN
dpc-4176	76	29	area	area	NOUN
dpc-4176	76	30	(	(	PUNCT
dpc-4176	76	31	bsa	bsa	PROPN
dpc-4176	76	32	)	)	PUNCT
dpc-4176	76	33	involvement	involvement	NOUN
dpc-4176	76	34	,	,	PUNCT
dpc-4176	76	35	often	often	ADV
dpc-4176	76	36	<	<	X
dpc-4176	76	37	10	10	NUM
dpc-4176	76	38	%	%	NOUN
dpc-4176	77	1	[	[	X
dpc-4176	77	2	37	37	NUM
dpc-4176	77	3	]	]	SYM
dpc-4176	77	4	.	.	PUNCT
dpc-4176	78	1	4	4	NUM
dpc-4176	78	2	review	review	NOUN
dpc-4176	78	3	|	|	ADV
dpc-4176	78	4	dermatol	dermatol	ADJ
dpc-4176	78	5	pract	pract	NOUN
dpc-4176	78	6	concept	concept	NOUN
dpc-4176	78	7	.	.	PUNCT
dpc-4176	79	1	2024;14(3):e2024181	2024;14(3):e2024181	NUM
dpc-4176	79	2	table	table	NOUN
dpc-4176	79	3	1	1	NUM
dpc-4176	79	4	.	.	PUNCT
dpc-4176	79	5	salient	salient	NOUN
dpc-4176	79	6	features	feature	NOUN
dpc-4176	79	7	of	of	ADP
dpc-4176	79	8	various	various	ADJ
dpc-4176	79	9	studies	study	NOUN
dpc-4176	79	10	demonstrating	demonstrate	VERB
dpc-4176	79	11	the	the	DET
dpc-4176	79	12	efficacy	efficacy	NOUN
dpc-4176	79	13	of	of	ADP
dpc-4176	79	14	guselkumab	guselkumab	NOUN
dpc-4176	79	15	in	in	ADP
dpc-4176	79	16	chronic	chronic	ADJ
dpc-4176	79	17	plaque	plaque	NOUN
dpc-4176	79	18	psoriasis	psoriasis	NOUN
dpc-4176	79	19	serial	serial	NOUN
dpc-4176	79	20	no	no	NOUN
dpc-4176	79	21	.	.	PUNCT
dpc-4176	80	1	authors	author	NOUN
dpc-4176	80	2	/	/	SYM
dpc-4176	80	3	year	year	NOUN
dpc-4176	80	4	details	detail	NOUN
dpc-4176	80	5	remarks	remark	VERB
dpc-4176	80	6	1	1	NUM
dpc-4176	80	7	blauvelt	blauvelt	NOUN
dpc-4176	80	8	et	et	NOUN
dpc-4176	80	9	al	al	PROPN
dpc-4176	81	1	[	[	X
dpc-4176	81	2	14	14	NUM
dpc-4176	81	3	]	]	SYM
dpc-4176	81	4	2017	2017	NUM
dpc-4176	81	5	voyage	voyage	NOUN
dpc-4176	81	6	1	1	NUM
dpc-4176	81	7	trial	trial	NOUN
dpc-4176	81	8	:	:	PUNCT
dpc-4176	81	9	•	•	NUM
dpc-4176	81	10	phase	phase	NOUN
dpc-4176	81	11	iii	iii	NOUN
dpc-4176	81	12	,	,	PUNCT
dpc-4176	81	13	randomized	randomize	VERB
dpc-4176	81	14	double	double	ADJ
dpc-4176	81	15	blind	blind	ADJ
dpc-4176	81	16	trial	trial	NOUN
dpc-4176	81	17	evaluating	evaluating	NOUN
dpc-4176	81	18	effectiveness	effectiveness	NOUN
dpc-4176	81	19	of	of	ADP
dpc-4176	81	20	guselkumab	guselkumab	NOUN
dpc-4176	81	21	in	in	ADP
dpc-4176	81	22	comparison	comparison	NOUN
dpc-4176	81	23	to	to	ADP
dpc-4176	81	24	placebo	placebo	NOUN
dpc-4176	81	25	and	and	CCONJ
dpc-4176	81	26	adalimumab	adalimumab	NOUN
dpc-4176	81	27	.	.	PUNCT
dpc-4176	82	1	•	•	NUM
dpc-4176	82	2	patients	patient	NOUN
dpc-4176	82	3	randomized	randomize	VERB
dpc-4176	82	4	in	in	ADP
dpc-4176	82	5	1:2:2	1:2:2	NUM
dpc-4176	82	6	ratio	ratio	NOUN
dpc-4176	82	7	for	for	ADP
dpc-4176	82	8	one	one	NUM
dpc-4176	82	9	of	of	ADP
dpc-4176	82	10	the	the	DET
dpc-4176	82	11	3	3	NUM
dpc-4176	82	12	treatments	treatment	NOUN
dpc-4176	82	13	:	:	PUNCT
dpc-4176	82	14	•	•	NUM
dpc-4176	82	15	placebo	placebo	NOUN
dpc-4176	82	16	(	(	PUNCT
dpc-4176	82	17	weeks	week	NOUN
dpc-4176	82	18	0	0	NUM
dpc-4176	82	19	,	,	PUNCT
dpc-4176	82	20	4	4	NUM
dpc-4176	82	21	and	and	CCONJ
dpc-4176	82	22	12	12	NUM
dpc-4176	82	23	)	)	PUNCT
dpc-4176	82	24	,	,	PUNCT
dpc-4176	82	25	followed	follow	VERB
dpc-4176	82	26	by	by	ADP
dpc-4176	82	27	guselkumab	guselkumab	NOUN
dpc-4176	82	28	(	(	PUNCT
dpc-4176	82	29	100	100	NUM
dpc-4176	82	30	mg	mg	NUM
dpc-4176	82	31	;	;	PUNCT
dpc-4176	82	32	weeks	week	NOUN
dpc-4176	82	33	16	16	NUM
dpc-4176	82	34	,	,	PUNCT
dpc-4176	82	35	20	20	NUM
dpc-4176	82	36	and	and	CCONJ
dpc-4176	82	37	then	then	ADV
dpc-4176	82	38	every	every	DET
dpc-4176	82	39	8	8	NUM
dpc-4176	82	40	weeks	week	NOUN
dpc-4176	82	41	through	through	ADP
dpc-4176	82	42	week	week	NOUN
dpc-4176	82	43	44	44	NUM
dpc-4176	82	44	)	)	PUNCT
dpc-4176	82	45	(	(	PUNCT
dpc-4176	82	46	n=174	n=174	NUM
dpc-4176	82	47	)	)	PUNCT
dpc-4176	82	48	.	.	PUNCT
dpc-4176	83	1	•	•	NUM
dpc-4176	83	2	guselkumab	guselkumab	NOUN
dpc-4176	83	3	(	(	PUNCT
dpc-4176	83	4	100	100	NUM
dpc-4176	83	5	mg	mg	NOUN
dpc-4176	83	6	,	,	PUNCT
dpc-4176	83	7	weeks	week	NOUN
dpc-4176	83	8	0	0	NUM
dpc-4176	83	9	,	,	PUNCT
dpc-4176	83	10	4	4	NUM
dpc-4176	83	11	and	and	CCONJ
dpc-4176	83	12	then	then	ADV
dpc-4176	83	13	every	every	DET
dpc-4176	83	14	8	8	NUM
dpc-4176	83	15	weeks	week	NOUN
dpc-4176	83	16	through	through	ADP
dpc-4176	83	17	week	week	NOUN
dpc-4176	83	18	44	44	NUM
dpc-4176	83	19	)	)	PUNCT
dpc-4176	83	20	(	(	PUNCT
dpc-4176	83	21	n=329	n=329	PROPN
dpc-4176	83	22	)	)	PUNCT
dpc-4176	83	23	.	.	PUNCT
dpc-4176	84	1	•	•	NUM
dpc-4176	84	2	adalimumab	adalimumab	NOUN
dpc-4176	84	3	(	(	PUNCT
dpc-4176	84	4	80	80	NUM
dpc-4176	84	5	mg	mg	NOUN
dpc-4176	84	6	at	at	ADP
dpc-4176	84	7	week	week	NOUN
dpc-4176	84	8	0	0	NUM
dpc-4176	84	9	,	,	PUNCT
dpc-4176	84	10	40	40	NUM
dpc-4176	84	11	mg	mg	NOUN
dpc-4176	84	12	at	at	ADP
dpc-4176	84	13	week1	week1	PROPN
dpc-4176	84	14	,	,	PUNCT
dpc-4176	84	15	and	and	CCONJ
dpc-4176	84	16	40	40	NUM
dpc-4176	84	17	mg	mg	NOUN
dpc-4176	84	18	every	every	DET
dpc-4176	84	19	2	2	NUM
dpc-4176	84	20	weeks	week	NOUN
dpc-4176	84	21	through	through	ADP
dpc-4176	84	22	week	week	NOUN
dpc-4176	84	23	47	47	NUM
dpc-4176	84	24	)	)	PUNCT
dpc-4176	84	25	(	(	PUNCT
dpc-4176	84	26	n=334	n=334	NUM
dpc-4176	84	27	)	)	PUNCT
dpc-4176	84	28	.	.	PUNCT
dpc-4176	85	1	•	•	NUM
dpc-4176	85	2	psoriasis	psoriasis	NOUN
dpc-4176	85	3	area	area	NOUN
dpc-4176	85	4	severity	severity	NOUN
dpc-4176	85	5	index	index	NOUN
dpc-4176	85	6	(	(	PUNCT
dpc-4176	85	7	pasi	pasi	NOUN
dpc-4176	85	8	)	)	PUNCT
dpc-4176	85	9	75	75	NUM
dpc-4176	85	10	at	at	ADP
dpc-4176	85	11	week	week	NOUN
dpc-4176	85	12	16	16	NUM
dpc-4176	85	13	:	:	SYM
dpc-4176	85	14	•	•	NUM
dpc-4176	85	15	guselkumab	guselkumab	NOUN
dpc-4176	85	16	(	(	PUNCT
dpc-4176	85	17	91.2	91.2	NUM
dpc-4176	85	18	%	%	NOUN
dpc-4176	85	19	)	)	PUNCT
dpc-4176	85	20	•	•	NUM
dpc-4176	85	21	adalimumab	adalimumab	NOUN
dpc-4176	85	22	(	(	PUNCT
dpc-4176	85	23	73.1	73.1	NUM
dpc-4176	85	24	%	%	NOUN
dpc-4176	85	25	)	)	PUNCT
dpc-4176	85	26	•	•	NUM
dpc-4176	85	27	placebo	placebo	NOUN
dpc-4176	85	28	(	(	PUNCT
dpc-4176	85	29	5.7	5.7	NUM
dpc-4176	85	30	%	%	NOUN
dpc-4176	85	31	)	)	PUNCT
dpc-4176	85	32	•	•	NOUN
dpc-4176	85	33	pasi	pasi	NOUN
dpc-4176	85	34	90	90	NUM
dpc-4176	85	35	at	at	ADP
dpc-4176	85	36	week	week	NOUN
dpc-4176	85	37	16	16	NUM
dpc-4176	85	38	:	:	SYM
dpc-4176	85	39	•	•	NUM
dpc-4176	85	40	guselkumab	guselkumab	NOUN
dpc-4176	85	41	(	(	PUNCT
dpc-4176	85	42	73.3	73.3	NUM
dpc-4176	85	43	%	%	NOUN
dpc-4176	85	44	)	)	PUNCT
dpc-4176	85	45	•	•	NUM
dpc-4176	85	46	adalimumab	adalimumab	NOUN
dpc-4176	85	47	(	(	PUNCT
dpc-4176	85	48	49.7	49.7	NUM
dpc-4176	85	49	%	%	NOUN
dpc-4176	85	50	)	)	PUNCT
dpc-4176	85	51	•	•	NUM
dpc-4176	85	52	placebo	placebo	NOUN
dpc-4176	85	53	(	(	PUNCT
dpc-4176	85	54	2.9	2.9	NUM
dpc-4176	85	55	%	%	NOUN
dpc-4176	85	56	)	)	PUNCT
dpc-4176	85	57	•	•	NOUN
dpc-4176	85	58	pasi	pasi	NOUN
dpc-4176	85	59	100	100	NUM
dpc-4176	85	60	at	at	ADP
dpc-4176	85	61	week	week	NOUN
dpc-4176	85	62	16	16	NUM
dpc-4176	85	63	:	:	SYM
dpc-4176	85	64	•	•	NUM
dpc-4176	85	65	guselkumab	guselkumab	NOUN
dpc-4176	85	66	(	(	PUNCT
dpc-4176	85	67	37.4	37.4	NUM
dpc-4176	85	68	%	%	NOUN
dpc-4176	85	69	)	)	PUNCT
dpc-4176	85	70	•	•	NUM
dpc-4176	85	71	adalimumab	adalimumab	NOUN
dpc-4176	85	72	(	(	PUNCT
dpc-4176	85	73	17.1	17.1	NUM
dpc-4176	85	74	%	%	NOUN
dpc-4176	85	75	)	)	PUNCT
dpc-4176	85	76	•	•	NUM
dpc-4176	85	77	placebo	placebo	NOUN
dpc-4176	85	78	(	(	PUNCT
dpc-4176	85	79	0.6	0.6	NUM
dpc-4176	85	80	%	%	NOUN
dpc-4176	85	81	)	)	PUNCT
dpc-4176	85	82	•	•	NOUN
dpc-4176	85	83	pasi	pasi	NOUN
dpc-4176	85	84	75	75	NUM
dpc-4176	85	85	at	at	ADP
dpc-4176	85	86	week	week	NOUN
dpc-4176	85	87	48	48	NUM
dpc-4176	85	88	:	:	SYM
dpc-4176	85	89	•	•	NUM
dpc-4176	85	90	guselkumab	guselkumab	NOUN
dpc-4176	85	91	(	(	PUNCT
dpc-4176	85	92	87.8	87.8	NUM
dpc-4176	85	93	%	%	NOUN
dpc-4176	85	94	)	)	PUNCT
dpc-4176	85	95	•	•	NUM
dpc-4176	85	96	adalimumab	adalimumab	NOUN
dpc-4176	85	97	(	(	PUNCT
dpc-4176	85	98	62.6	62.6	NUM
dpc-4176	85	99	%	%	NOUN
dpc-4176	85	100	)	)	PUNCT
dpc-4176	85	101	•	•	NOUN
dpc-4176	85	102	pasi	pasi	NOUN
dpc-4176	85	103	90	90	NUM
dpc-4176	85	104	at	at	ADP
dpc-4176	85	105	week	week	NOUN
dpc-4176	85	106	48	48	NUM
dpc-4176	85	107	:	:	SYM
dpc-4176	85	108	•	•	NUM
dpc-4176	85	109	guselkumab	guselkumab	NOUN
dpc-4176	85	110	(	(	PUNCT
dpc-4176	85	111	76.3	76.3	NUM
dpc-4176	85	112	%	%	NOUN
dpc-4176	85	113	)	)	PUNCT
dpc-4176	85	114	•	•	NUM
dpc-4176	85	115	adalimumab	adalimumab	NOUN
dpc-4176	85	116	(	(	PUNCT
dpc-4176	85	117	47.9	47.9	NUM
dpc-4176	85	118	%	%	NOUN
dpc-4176	85	119	)	)	PUNCT
dpc-4176	85	120	•	•	NOUN
dpc-4176	85	121	pasi	pasi	NOUN
dpc-4176	85	122	100	100	NUM
dpc-4176	85	123	at	at	ADP
dpc-4176	85	124	week	week	NOUN
dpc-4176	85	125	48	48	NUM
dpc-4176	85	126	:	:	SYM
dpc-4176	85	127	•	•	NUM
dpc-4176	85	128	guselkumab	guselkumab	NOUN
dpc-4176	85	129	(	(	PUNCT
dpc-4176	85	130	47.4	47.4	NUM
dpc-4176	85	131	%	%	NOUN
dpc-4176	85	132	)	)	PUNCT
dpc-4176	85	133	•	•	NUM
dpc-4176	85	134	adalimumab	adalimumab	NOUN
dpc-4176	85	135	(	(	PUNCT
dpc-4176	85	136	23.4	23.4	NUM
dpc-4176	85	137	%	%	NOUN
dpc-4176	85	138	)	)	PUNCT
dpc-4176	85	139	•	•	NOUN
dpc-4176	85	140	investigator	investigator	NOUN
dpc-4176	85	141	global	global	ADJ
dpc-4176	85	142	assessment	assessment	NOUN
dpc-4176	85	143	(	(	PUNCT
dpc-4176	85	144	iga	iga	PROPN
dpc-4176	85	145	)	)	PUNCT
dpc-4176	85	146	0/1	0/1	PROPN
dpc-4176	85	147	at	at	ADP
dpc-4176	85	148	16	16	NUM
dpc-4176	85	149	 	 	SPACE
dpc-4176	85	150	weeks	week	NOUN
dpc-4176	85	151	:	:	PUNCT
dpc-4176	85	152	•	•	NUM
dpc-4176	85	153	guselkumab	guselkumab	NOUN
dpc-4176	85	154	(	(	PUNCT
dpc-4176	85	155	85.1	85.1	NUM
dpc-4176	85	156	%	%	NOUN
dpc-4176	85	157	)	)	PUNCT
dpc-4176	85	158	•	•	NUM
dpc-4176	85	159	adalimumab	adalimumab	NOUN
dpc-4176	85	160	(	(	PUNCT
dpc-4176	85	161	65.9	65.9	NUM
dpc-4176	85	162	%	%	NOUN
dpc-4176	85	163	)	)	PUNCT
dpc-4176	85	164	•	•	NUM
dpc-4176	85	165	placebo	placebo	NOUN
dpc-4176	85	166	(	(	PUNCT
dpc-4176	85	167	6.9	6.9	NUM
dpc-4176	85	168	%	%	NOUN
dpc-4176	85	169	)	)	PUNCT
dpc-4176	85	170	•	•	NUM
dpc-4176	85	171	iga	iga	PROPN
dpc-4176	85	172	0/1	0/1	NUM
dpc-4176	85	173	at	at	ADP
dpc-4176	85	174	48	48	NUM
dpc-4176	85	175	weeks	week	NOUN
dpc-4176	85	176	:	:	PUNCT
dpc-4176	85	177	•	•	NUM
dpc-4176	85	178	guselkumab	guselkumab	NOUN
dpc-4176	85	179	(	(	PUNCT
dpc-4176	85	180	80.5	80.5	NUM
dpc-4176	85	181	%	%	NOUN
dpc-4176	85	182	)	)	PUNCT
dpc-4176	85	183	•	•	NUM
dpc-4176	85	184	adalimumab	adalimumab	NOUN
dpc-4176	85	185	(	(	PUNCT
dpc-4176	85	186	55.4	55.4	NUM
dpc-4176	85	187	%	%	NOUN
dpc-4176	85	188	)	)	PUNCT
dpc-4176	85	189	•	•	NOUN
dpc-4176	85	190	dermatology	dermatology	NOUN
dpc-4176	85	191	life	life	NOUN
dpc-4176	85	192	quality	quality	NOUN
dpc-4176	85	193	index	index	NOUN
dpc-4176	85	194	(	(	PUNCT
dpc-4176	85	195	dlqi	dlqi	PROPN
dpc-4176	85	196	)	)	PUNCT
dpc-4176	85	197	at	at	ADP
dpc-4176	85	198	16	16	NUM
dpc-4176	85	199	 	 	SPACE
dpc-4176	85	200	weeks	week	NOUN
dpc-4176	85	201	:	:	PUNCT
dpc-4176	85	202	•	•	NUM
dpc-4176	85	203	guselkumab	guselkumab	NOUN
dpc-4176	85	204	(	(	PUNCT
dpc-4176	85	205	56.3	56.3	NUM
dpc-4176	85	206	%	%	NOUN
dpc-4176	85	207	)	)	PUNCT
dpc-4176	85	208	•	•	NUM
dpc-4176	85	209	adalimumab	adalimumab	NOUN
dpc-4176	85	210	(	(	PUNCT
dpc-4176	85	211	38.6	38.6	NUM
dpc-4176	85	212	%	%	NOUN
dpc-4176	85	213	)	)	PUNCT
dpc-4176	85	214	•	•	NUM
dpc-4176	85	215	placebo	placebo	NOUN
dpc-4176	85	216	(	(	PUNCT
dpc-4176	85	217	4.2	4.2	NUM
dpc-4176	85	218	%	%	NOUN
dpc-4176	85	219	)	)	PUNCT
dpc-4176	85	220	•	•	NOUN
dpc-4176	85	221	dlqi	dlqi	VERB
dpc-4176	85	222	at	at	ADP
dpc-4176	85	223	48	48	NUM
dpc-4176	85	224	weeks	week	NOUN
dpc-4176	85	225	:	:	PUNCT
dpc-4176	85	226	•	•	NUM
dpc-4176	85	227	guselkumab	guselkumab	NOUN
dpc-4176	85	228	(	(	PUNCT
dpc-4176	85	229	62.5	62.5	NUM
dpc-4176	85	230	%	%	NOUN
dpc-4176	85	231	)	)	PUNCT
dpc-4176	85	232	•	•	NUM
dpc-4176	85	233	adalimumab	adalimumab	NOUN
dpc-4176	85	234	(	(	PUNCT
dpc-4176	85	235	38.9	38.9	NUM
dpc-4176	85	236	%	%	NOUN
dpc-4176	85	237	)	)	PUNCT
dpc-4176	85	238	2	2	NUM
dpc-4176	85	239	langley	langley	NOUN
dpc-4176	85	240	et	et	PROPN
dpc-4176	85	241	al	al	PROPN
dpc-4176	86	1	[	[	X
dpc-4176	86	2	15	15	NUM
dpc-4176	86	3	]	]	SYM
dpc-4176	86	4	2018	2018	NUM
dpc-4176	86	5	navigate	navigate	VERB
dpc-4176	86	6	trial	trial	NOUN
dpc-4176	86	7	•	•	NUM
dpc-4176	86	8	patients	patient	NOUN
dpc-4176	86	9	received	receive	VERB
dpc-4176	86	10	open	open	ADJ
dpc-4176	86	11	label	label	NOUN
dpc-4176	86	12	ustekinumab	ustekinumab	NOUN
dpc-4176	86	13	(	(	PUNCT
dpc-4176	86	14	45	45	NUM
dpc-4176	86	15	mg	mg	NOUN
dpc-4176	86	16	for	for	ADP
dpc-4176	86	17	patients	patient	NOUN
dpc-4176	86	18	≤100	≤100	VERB
dpc-4176	86	19	kg	kg	INTJ
dpc-4176	86	20	,	,	PUNCT
dpc-4176	86	21	90	90	NUM
dpc-4176	86	22	mg	mg	NOUN
dpc-4176	86	23	for	for	ADP
dpc-4176	86	24	patients	patient	NOUN
dpc-4176	86	25	>	>	PUNCT
dpc-4176	86	26	100	100	NUM
dpc-4176	86	27	kg	kg	NOUN
dpc-4176	86	28	)	)	PUNCT
dpc-4176	86	29	at	at	ADP
dpc-4176	86	30	weeks	week	NOUN
dpc-4176	86	31	0	0	NUM
dpc-4176	86	32	and	and	CCONJ
dpc-4176	86	33	4	4	NUM
dpc-4176	86	34	.	.	NOUN
dpc-4176	86	35	•	•	NUM
dpc-4176	86	36	at	at	ADP
dpc-4176	86	37	week	week	NOUN
dpc-4176	86	38	16	16	NUM
dpc-4176	86	39	,	,	PUNCT
dpc-4176	86	40	268	268	NUM
dpc-4176	86	41	patients	patient	NOUN
dpc-4176	86	42	with	with	ADP
dpc-4176	86	43	inadequate	inadequate	ADJ
dpc-4176	86	44	response	response	NOUN
dpc-4176	86	45	,	,	PUNCT
dpc-4176	86	46	considered	consider	VERB
dpc-4176	86	47	as	as	ADP
dpc-4176	86	48	an	an	DET
dpc-4176	86	49	iga	iga	PROPN
dpc-4176	86	50	score	score	NOUN
dpc-4176	86	51	of	of	ADP
dpc-4176	86	52	2	2	NUM
dpc-4176	86	53	or	or	CCONJ
dpc-4176	86	54	more	more	ADJ
dpc-4176	86	55	,	,	PUNCT
dpc-4176	86	56	were	be	AUX
dpc-4176	86	57	randomized	randomize	VERB
dpc-4176	86	58	(	(	PUNCT
dpc-4176	86	59	double	double	ADJ
dpc-4176	86	60	-	-	PUNCT
dpc-4176	86	61	blind	blind	ADJ
dpc-4176	86	62	)	)	PUNCT
dpc-4176	86	63	to	to	PART
dpc-4176	86	64	receive	receive	VERB
dpc-4176	86	65	:	:	PUNCT
dpc-4176	86	66	a	a	DET
dpc-4176	86	67	)	)	PUNCT
dpc-4176	86	68	guselkumab	guselkumab	NOUN
dpc-4176	86	69	(	(	PUNCT
dpc-4176	86	70	100	100	NUM
dpc-4176	86	71	mg	mg	NUM
dpc-4176	86	72	;	;	PUNCT
dpc-4176	86	73	weeks	week	NOUN
dpc-4176	86	74	16	16	NUM
dpc-4176	86	75	,	,	PUNCT
dpc-4176	86	76	20	20	NUM
dpc-4176	86	77	and	and	CCONJ
dpc-4176	86	78	every	every	DET
dpc-4176	86	79	8	8	NUM
dpc-4176	86	80	weeks	week	NOUN
dpc-4176	86	81	thereafter	thereafter	ADV
dpc-4176	86	82	through	through	ADP
dpc-4176	86	83	week	week	NOUN
dpc-4176	86	84	44	44	NUM
dpc-4176	86	85	)	)	PUNCT
dpc-4176	86	86	(	(	PUNCT
dpc-4176	86	87	n=135	n=135	ADV
dpc-4176	86	88	)	)	PUNCT
dpc-4176	86	89	.	.	PUNCT
dpc-4176	87	1	b	b	X
dpc-4176	87	2	)	)	PUNCT
dpc-4176	87	3	continued	continue	VERB
dpc-4176	87	4	with	with	ADP
dpc-4176	87	5	ustekinumab	ustekinumab	NOUN
dpc-4176	87	6	(	(	PUNCT
dpc-4176	87	7	week	week	NOUN
dpc-4176	87	8	16	16	NUM
dpc-4176	87	9	and	and	CCONJ
dpc-4176	87	10	every	every	DET
dpc-4176	87	11	12	12	NUM
dpc-4176	87	12	weeks	week	NOUN
dpc-4176	87	13	after	after	ADP
dpc-4176	87	14	that	that	PRON
dpc-4176	87	15	through	through	ADP
dpc-4176	87	16	week	week	NOUN
dpc-4176	87	17	40	40	NUM
dpc-4176	87	18	)	)	PUNCT
dpc-4176	87	19	(	(	PUNCT
dpc-4176	87	20	n=133	n=133	ADJ
dpc-4176	87	21	)	)	PUNCT
dpc-4176	87	22	.	.	PUNCT
dpc-4176	88	1	•	•	NUM
dpc-4176	88	2	pasi	pasi	NOUN
dpc-4176	88	3	90	90	NUM
dpc-4176	88	4	at	at	ADP
dpc-4176	88	5	week	week	NOUN
dpc-4176	88	6	52	52	NUM
dpc-4176	88	7	:	:	SYM
dpc-4176	88	8	•	•	NUM
dpc-4176	88	9	guselkumab	guselkumab	NOUN
dpc-4176	88	10	(	(	PUNCT
dpc-4176	88	11	51.1	51.1	NUM
dpc-4176	88	12	%	%	NOUN
dpc-4176	88	13	)	)	PUNCT
dpc-4176	88	14	•	•	NUM
dpc-4176	88	15	ustekinumab	ustekinumab	NOUN
dpc-4176	88	16	(	(	PUNCT
dpc-4176	88	17	24.1	24.1	NUM
dpc-4176	88	18	%	%	NOUN
dpc-4176	88	19	)	)	PUNCT
dpc-4176	88	20	•	•	NOUN
dpc-4176	88	21	pasi	pasi	NOUN
dpc-4176	88	22	100	100	NUM
dpc-4176	88	23	at	at	ADP
dpc-4176	88	24	week	week	NOUN
dpc-4176	88	25	52	52	NUM
dpc-4176	88	26	:	:	SYM
dpc-4176	88	27	•	•	NUM
dpc-4176	88	28	guselkumab	guselkumab	NOUN
dpc-4176	88	29	(	(	PUNCT
dpc-4176	88	30	20	20	NUM
dpc-4176	88	31	%	%	NOUN
dpc-4176	88	32	)	)	PUNCT
dpc-4176	88	33	•	•	NUM
dpc-4176	88	34	ustekinumab	ustekinumab	NOUN
dpc-4176	88	35	(	(	PUNCT
dpc-4176	88	36	7.5	7.5	NUM
dpc-4176	88	37	%	%	NOUN
dpc-4176	88	38	)	)	PUNCT
dpc-4176	88	39	•	•	NUM
dpc-4176	88	40	iga	iga	PROPN
dpc-4176	88	41	0/1	0/1	PROPN
dpc-4176	88	42	at	at	ADP
dpc-4176	88	43	week	week	NOUN
dpc-4176	88	44	52	52	NUM
dpc-4176	88	45	:	:	SYM
dpc-4176	88	46	•	•	NUM
dpc-4176	88	47	guselkumab	guselkumab	NOUN
dpc-4176	88	48	(	(	PUNCT
dpc-4176	88	49	36.3	36.3	NUM
dpc-4176	88	50	%	%	NOUN
dpc-4176	88	51	)	)	PUNCT
dpc-4176	88	52	•	•	NUM
dpc-4176	88	53	ustekinumab	ustekinumab	NOUN
dpc-4176	88	54	(	(	PUNCT
dpc-4176	88	55	17.3	17.3	NUM
dpc-4176	88	56	%	%	NOUN
dpc-4176	88	57	)	)	PUNCT
dpc-4176	88	58	•	•	NOUN
dpc-4176	88	59	dlqi	dlqi	VERB
dpc-4176	88	60	at	at	ADP
dpc-4176	88	61	week	week	NOUN
dpc-4176	88	62	52	52	NUM
dpc-4176	88	63	:	:	SYM
dpc-4176	88	64	•	•	NUM
dpc-4176	88	65	guselkumab	guselkumab	NOUN
dpc-4176	88	66	(	(	PUNCT
dpc-4176	88	67	35.8	35.8	NUM
dpc-4176	88	68	%	%	NOUN
dpc-4176	88	69	)	)	PUNCT
dpc-4176	88	70	•	•	NUM
dpc-4176	88	71	ustekinumab	ustekinumab	NOUN
dpc-4176	88	72	(	(	PUNCT
dpc-4176	88	73	19	19	NUM
dpc-4176	88	74	%	%	NOUN
dpc-4176	88	75	)	)	PUNCT
dpc-4176	88	76	review	review	NOUN
dpc-4176	88	77	|	|	ADV
dpc-4176	88	78	dermatol	dermatol	ADJ
dpc-4176	88	79	pract	pract	NOUN
dpc-4176	88	80	concept	concept	NOUN
dpc-4176	88	81	.	.	PUNCT
dpc-4176	89	1	2024;14(3):e2024181	2024;14(3):e2024181	NUM
dpc-4176	89	2	5	5	NUM
dpc-4176	89	3	serial	serial	NOUN
dpc-4176	89	4	no	no	NOUN
dpc-4176	89	5	.	.	PUNCT
dpc-4176	90	1	authors	author	NOUN
dpc-4176	90	2	/	/	SYM
dpc-4176	90	3	year	year	NOUN
dpc-4176	90	4	details	detail	NOUN
dpc-4176	90	5	remarks	remark	VERB
dpc-4176	90	6	3	3	NUM
dpc-4176	90	7	reich	reich	NOUN
dpc-4176	90	8	et	et	NOUN
dpc-4176	90	9	al	al	PROPN
dpc-4176	91	1	[	[	X
dpc-4176	91	2	16	16	NUM
dpc-4176	91	3	]	]	SYM
dpc-4176	91	4	2019	2019	NUM
dpc-4176	91	5	eclipse	eclipse	NOUN
dpc-4176	91	6	trial	trial	NOUN
dpc-4176	91	7	•	•	NOUN
dpc-4176	91	8	phase	phase	NOUN
dpc-4176	91	9	3	3	NUM
dpc-4176	91	10	,	,	PUNCT
dpc-4176	91	11	randomized	randomize	VERB
dpc-4176	91	12	controlled	control	VERB
dpc-4176	91	13	trial	trial	NOUN
dpc-4176	91	14	.	.	PUNCT
dpc-4176	92	1	•	•	NUM
dpc-4176	92	2	comparison	comparison	NOUN
dpc-4176	92	3	of	of	ADP
dpc-4176	92	4	guselkumab	guselkumab	NOUN
dpc-4176	92	5	(	(	PUNCT
dpc-4176	92	6	n=534	n=534	PROPN
dpc-4176	92	7	)	)	PUNCT
dpc-4176	92	8	versus	versus	ADP
dpc-4176	92	9	secukinumab	secukinumab	NOUN
dpc-4176	92	10	(	(	PUNCT
dpc-4176	92	11	n=514	n=514	NOUN
dpc-4176	92	12	)	)	PUNCT
dpc-4176	92	13	for	for	ADP
dpc-4176	92	14	moderate	moderate	ADJ
dpc-4176	92	15	-	-	PUNCT
dpc-4176	92	16	to	to	ADP
dpc-4176	92	17	-	-	PUNCT
dpc-4176	92	18	severe	severe	ADJ
dpc-4176	92	19	chronic	chronic	ADJ
dpc-4176	92	20	plaque	plaque	NOUN
dpc-4176	92	21	psoriasis	psoriasis	NOUN
dpc-4176	92	22	.	.	PUNCT
dpc-4176	93	1	•	•	NUM
dpc-4176	93	2	guselkumab	guselkumab	NOUN
dpc-4176	93	3	(	(	PUNCT
dpc-4176	93	4	100	100	NUM
dpc-4176	93	5	mg	mg	NOUN
dpc-4176	93	6	)	)	PUNCT
dpc-4176	93	7	given	give	VERB
dpc-4176	93	8	by	by	ADP
dpc-4176	93	9	sc	sc	PROPN
dpc-4176	93	10	route	route	NOUN
dpc-4176	93	11	at	at	ADP
dpc-4176	93	12	weeks	week	NOUN
dpc-4176	93	13	0	0	NUM
dpc-4176	93	14	,	,	PUNCT
dpc-4176	93	15	4	4	NUM
dpc-4176	93	16	,	,	PUNCT
dpc-4176	93	17	12	12	NUM
dpc-4176	93	18	and	and	CCONJ
dpc-4176	93	19	every	every	DET
dpc-4176	93	20	8	8	NUM
dpc-4176	93	21	 	 	SPACE
dpc-4176	93	22	weeks	week	NOUN
dpc-4176	93	23	thereafter	thereafter	ADV
dpc-4176	93	24	till	till	SCONJ
dpc-4176	93	25	week	week	NOUN
dpc-4176	93	26	44	44	NUM
dpc-4176	93	27	.	.	PUNCT
dpc-4176	94	1	•	•	NUM
dpc-4176	94	2	secukinumab	secukinumab	NOUN
dpc-4176	94	3	(	(	PUNCT
dpc-4176	94	4	300	300	NUM
dpc-4176	94	5	mg	mg	NOUN
dpc-4176	94	6	)	)	PUNCT
dpc-4176	94	7	given	give	VERB
dpc-4176	94	8	by	by	ADP
dpc-4176	94	9	sc	sc	PROPN
dpc-4176	94	10	route	route	NOUN
dpc-4176	94	11	at	at	ADP
dpc-4176	94	12	weeks	week	NOUN
dpc-4176	94	13	0	0	NUM
dpc-4176	94	14	,	,	PUNCT
dpc-4176	94	15	1	1	NUM
dpc-4176	94	16	,	,	PUNCT
dpc-4176	94	17	2	2	NUM
dpc-4176	94	18	,	,	PUNCT
dpc-4176	94	19	3	3	NUM
dpc-4176	94	20	and	and	CCONJ
dpc-4176	94	21	4	4	NUM
dpc-4176	94	22	and	and	CCONJ
dpc-4176	94	23	every	every	DET
dpc-4176	94	24	4	4	NUM
dpc-4176	94	25	weeks	week	NOUN
dpc-4176	94	26	thereafter	thereafter	ADV
dpc-4176	94	27	till	till	SCONJ
dpc-4176	94	28	week	week	NOUN
dpc-4176	94	29	44	44	NUM
dpc-4176	94	30	.	.	PUNCT
dpc-4176	94	31	•	•	NUM
dpc-4176	94	32	pasi	pasi	NOUN
dpc-4176	94	33	75	75	NUM
dpc-4176	94	34	at	at	ADP
dpc-4176	94	35	week	week	NOUN
dpc-4176	94	36	12	12	NUM
dpc-4176	94	37	:	:	SYM
dpc-4176	94	38	•	•	NUM
dpc-4176	94	39	guselkumab	guselkumab	NOUN
dpc-4176	94	40	(	(	PUNCT
dpc-4176	94	41	89	89	NUM
dpc-4176	94	42	%	%	NOUN
dpc-4176	94	43	)	)	PUNCT
dpc-4176	94	44	•	•	NUM
dpc-4176	94	45	secukinumab	secukinumab	NOUN
dpc-4176	94	46	(	(	PUNCT
dpc-4176	94	47	92	92	NUM
dpc-4176	94	48	%	%	NOUN
dpc-4176	94	49	)	)	PUNCT
dpc-4176	94	50	•	•	NOUN
dpc-4176	94	51	pasi	pasi	NOUN
dpc-4176	94	52	90	90	NUM
dpc-4176	94	53	at	at	ADP
dpc-4176	94	54	week	week	NOUN
dpc-4176	94	55	12	12	NUM
dpc-4176	94	56	:	:	SYM
dpc-4176	94	57	•	•	NUM
dpc-4176	94	58	guselkumab	guselkumab	NOUN
dpc-4176	94	59	(	(	PUNCT
dpc-4176	94	60	69	69	NUM
dpc-4176	94	61	%	%	NOUN
dpc-4176	94	62	)	)	PUNCT
dpc-4176	94	63	•	•	NUM
dpc-4176	94	64	secukinumab	secukinumab	NOUN
dpc-4176	94	65	(	(	PUNCT
dpc-4176	94	66	76	76	NUM
dpc-4176	94	67	%	%	NOUN
dpc-4176	94	68	)	)	PUNCT
dpc-4176	94	69	•	•	NOUN
dpc-4176	94	70	at	at	ADP
dpc-4176	94	71	week	week	NOUN
dpc-4176	94	72	48	48	NUM
dpc-4176	94	73	:	:	SYM
dpc-4176	94	74	•	•	NUM
dpc-4176	94	75	pasi	pasi	NOUN
dpc-4176	94	76	100	100	NUM
dpc-4176	94	77	•	•	NOUN
dpc-4176	94	78	guselkumab	guselkumab	NOUN
dpc-4176	94	79	(	(	PUNCT
dpc-4176	94	80	58	58	NUM
dpc-4176	94	81	%	%	NOUN
dpc-4176	94	82	)	)	PUNCT
dpc-4176	94	83	•	•	NUM
dpc-4176	94	84	secukinumab	secukinumab	NOUN
dpc-4176	94	85	(	(	PUNCT
dpc-4176	94	86	48	48	NUM
dpc-4176	94	87	%	%	NOUN
dpc-4176	94	88	)	)	PUNCT
dpc-4176	94	89	•	•	ADP
dpc-4176	94	90	iga	iga	PROPN
dpc-4176	94	91	score	score	NOUN
dpc-4176	94	92	of	of	ADP
dpc-4176	94	93	0	0	NUM
dpc-4176	94	94	•	•	NOUN
dpc-4176	94	95	guselkumab	guselkumab	NOUN
dpc-4176	94	96	(	(	PUNCT
dpc-4176	94	97	62	62	NUM
dpc-4176	94	98	%	%	NOUN
dpc-4176	94	99	)	)	PUNCT
dpc-4176	94	100	•	•	NUM
dpc-4176	94	101	secukinumab	secukinumab	NOUN
dpc-4176	94	102	(	(	PUNCT
dpc-4176	94	103	50	50	NUM
dpc-4176	94	104	%	%	NOUN
dpc-4176	94	105	)	)	PUNCT
dpc-4176	94	106	•	•	NUM
dpc-4176	94	107	guselkumab	guselkumab	NOUN
dpc-4176	94	108	has	have	VERB
dpc-4176	94	109	better	well	ADJ
dpc-4176	94	110	long	long	ADJ
dpc-4176	94	111	-	-	PUNCT
dpc-4176	94	112	term	term	NOUN
dpc-4176	94	113	responses	response	NOUN
dpc-4176	94	114	when	when	SCONJ
dpc-4176	94	115	compared	compare	VERB
dpc-4176	94	116	to	to	ADP
dpc-4176	94	117	secukinumab	secukinumab	VERB
dpc-4176	94	118	.	.	PUNCT
dpc-4176	95	1	4	4	NUM
dpc-4176	95	2	griffiths	griffiths	PROPN
dpc-4176	95	3	et	et	PROPN
dpc-4176	95	4	al	al	PROPN
dpc-4176	96	1	[	[	X
dpc-4176	96	2	18	18	NUM
dpc-4176	96	3	]	]	SYM
dpc-4176	96	4	2020	2020	NUM
dpc-4176	96	5	•	•	NOUN
dpc-4176	96	6	extension	extension	NOUN
dpc-4176	96	7	of	of	ADP
dpc-4176	96	8	the	the	DET
dpc-4176	96	9	voyage	voyage	NOUN
dpc-4176	96	10	1	1	NUM
dpc-4176	96	11	trial	trial	NOUN
dpc-4176	96	12	assessing	assess	VERB
dpc-4176	96	13	the	the	DET
dpc-4176	96	14	long	long	ADJ
dpc-4176	96	15	-	-	PUNCT
dpc-4176	96	16	term	term	NOUN
dpc-4176	96	17	clinical	clinical	ADJ
dpc-4176	96	18	efficacy	efficacy	NOUN
dpc-4176	96	19	of	of	ADP
dpc-4176	96	20	guselkumab	guselkumab	NOUN
dpc-4176	96	21	through	through	ADP
dpc-4176	96	22	4	4	NUM
dpc-4176	96	23	 	 	SPACE
dpc-4176	96	24	years	year	NOUN
dpc-4176	96	25	in	in	ADP
dpc-4176	96	26	patients	patient	NOUN
dpc-4176	96	27	with	with	ADP
dpc-4176	96	28	moderate	moderate	ADJ
dpc-4176	96	29	-	-	PUNCT
dpc-4176	96	30	tosevere	tosevere	NOUN
dpc-4176	96	31	psoriasis	psoriasis	NOUN
dpc-4176	96	32	.	.	PUNCT
dpc-4176	97	1	•	•	NOUN
dpc-4176	97	2	this	this	DET
dpc-4176	97	3	publication	publication	NOUN
dpc-4176	97	4	represents	represent	VERB
dpc-4176	97	5	data	datum	NOUN
dpc-4176	97	6	over	over	ADP
dpc-4176	97	7	the	the	DET
dpc-4176	97	8	longest	long	ADJ
dpc-4176	97	9	treatment	treatment	NOUN
dpc-4176	97	10	period	period	NOUN
dpc-4176	97	11	reported	report	VERB
dpc-4176	97	12	for	for	ADP
dpc-4176	97	13	an	an	DET
dpc-4176	97	14	il-23	il-23	NOUN
dpc-4176	97	15	inhibitor	inhibitor	NOUN
dpc-4176	97	16	in	in	ADP
dpc-4176	97	17	psoriasis	psoriasis	NOUN
dpc-4176	97	18	till	till	SCONJ
dpc-4176	97	19	date	date	NOUN
dpc-4176	97	20	.	.	PUNCT
dpc-4176	98	1	•	•	NUM
dpc-4176	98	2	high	high	ADJ
dpc-4176	98	3	efficacy	efficacy	NOUN
dpc-4176	98	4	response	response	NOUN
dpc-4176	98	5	rates	rate	NOUN
dpc-4176	98	6	were	be	AUX
dpc-4176	98	7	maintained	maintain	VERB
dpc-4176	98	8	through	through	ADP
dpc-4176	98	9	week	week	NOUN
dpc-4176	98	10	204	204	NUM
dpc-4176	98	11	of	of	ADP
dpc-4176	98	12	treatment	treatment	NOUN
dpc-4176	98	13	with	with	ADP
dpc-4176	98	14	guselkumab	guselkumab	NOUN
dpc-4176	98	15	.	.	PUNCT
dpc-4176	99	1	•	•	NUM
dpc-4176	99	2	>	>	SYM
dpc-4176	99	3	80	80	NUM
dpc-4176	99	4	%	%	NOUN
dpc-4176	99	5	patients	patient	NOUN
dpc-4176	99	6	maintained	maintain	VERB
dpc-4176	99	7	cleared	clear	VERB
dpc-4176	99	8	or	or	CCONJ
dpc-4176	99	9	minimal	minimal	ADJ
dpc-4176	99	10	psoriasis	psoriasis	NOUN
dpc-4176	99	11	(	(	PUNCT
dpc-4176	99	12	pasi	pasi	NOUN
dpc-4176	99	13	90	90	NUM
dpc-4176	99	14	and	and	CCONJ
dpc-4176	99	15	iga	iga	PROPN
dpc-4176	99	16	0	0	PROPN
dpc-4176	99	17	/	/	SYM
dpc-4176	99	18	i	i	PROPN
dpc-4176	99	19	)	)	PUNCT
dpc-4176	99	20	.	.	PUNCT
dpc-4176	100	1	•	•	NUM
dpc-4176	100	2	>	>	SYM
dpc-4176	100	3	50	50	NUM
dpc-4176	100	4	%	%	NOUN
dpc-4176	100	5	patients	patient	NOUN
dpc-4176	100	6	maintained	maintain	VERB
dpc-4176	100	7	cleared	clear	VERB
dpc-4176	100	8	disease	disease	NOUN
dpc-4176	100	9	(	(	PUNCT
dpc-4176	100	10	pasi	pasi	NOUN
dpc-4176	100	11	100	100	NUM
dpc-4176	100	12	and	and	CCONJ
dpc-4176	100	13	iga	iga	PROPN
dpc-4176	100	14	0	0	NUM
dpc-4176	100	15	)	)	PUNCT
dpc-4176	100	16	.	.	PUNCT
dpc-4176	101	1	•	•	NUM
dpc-4176	101	2	safety	safety	NOUN
dpc-4176	101	3	profile	profile	NOUN
dpc-4176	101	4	of	of	ADP
dpc-4176	101	5	guselkumab	guselkumab	NOUN
dpc-4176	101	6	remained	remain	VERB
dpc-4176	101	7	favourable	favourable	ADJ
dpc-4176	101	8	with	with	ADP
dpc-4176	101	9	no	no	DET
dpc-4176	101	10	new	new	ADJ
dpc-4176	101	11	signals	signal	NOUN
dpc-4176	101	12	of	of	ADP
dpc-4176	101	13	concern	concern	NOUN
dpc-4176	101	14	revealed	reveal	VERB
dpc-4176	101	15	with	with	ADP
dpc-4176	101	16	longer	long	ADJ
dpc-4176	101	17	treatment	treatment	NOUN
dpc-4176	101	18	for	for	ADP
dpc-4176	101	19	4	4	NUM
dpc-4176	101	20	years	year	NOUN
dpc-4176	101	21	.	.	PUNCT
dpc-4176	102	1	5	5	NUM
dpc-4176	102	2	ohtsuki	ohtsuki	ADJ
dpc-4176	102	3	et	et	PROPN
dpc-4176	102	4	al	al	PROPN
dpc-4176	103	1	[	[	X
dpc-4176	103	2	19	19	NUM
dpc-4176	103	3	]	]	SYM
dpc-4176	103	4	2018	2018	NUM
dpc-4176	103	5	•	•	NOUN
dpc-4176	103	6	a	a	DET
dpc-4176	103	7	phase	phase	NOUN
dpc-4176	103	8	3	3	NUM
dpc-4176	103	9	,	,	PUNCT
dpc-4176	103	10	randomized	randomize	VERB
dpc-4176	103	11	,	,	PUNCT
dpc-4176	103	12	double	double	ADJ
dpc-4176	103	13	-	-	PUNCT
dpc-4176	103	14	blind	blind	ADJ
dpc-4176	103	15	,	,	PUNCT
dpc-4176	103	16	placebo	placebo	NOUN
dpc-4176	103	17	-	-	PUNCT
dpc-4176	103	18	controlled	control	VERB
dpc-4176	103	19	study	study	NOUN
dpc-4176	103	20	evaluating	evaluate	VERB
dpc-4176	103	21	the	the	DET
dpc-4176	103	22	safety	safety	NOUN
dpc-4176	103	23	and	and	CCONJ
dpc-4176	103	24	efficacy	efficacy	NOUN
dpc-4176	103	25	of	of	ADP
dpc-4176	103	26	guselkumab	guselkumab	NOUN
dpc-4176	103	27	in	in	ADP
dpc-4176	103	28	moderate	moderate	ADJ
dpc-4176	103	29	-	-	PUNCT
dpc-4176	103	30	to	to	ADP
dpc-4176	103	31	-	-	PUNCT
dpc-4176	103	32	severe	severe	ADJ
dpc-4176	103	33	plaque	plaque	NOUN
dpc-4176	103	34	-	-	PUNCT
dpc-4176	103	35	type	type	NOUN
dpc-4176	103	36	psoriasis	psoriasis	NOUN
dpc-4176	103	37	in	in	ADP
dpc-4176	103	38	japanese	japanese	ADJ
dpc-4176	103	39	patients	patient	NOUN
dpc-4176	103	40	.	.	PUNCT
dpc-4176	104	1	•	•	NUM
dpc-4176	104	2	patients	patient	NOUN
dpc-4176	104	3	were	be	AUX
dpc-4176	104	4	randomized	randomize	VERB
dpc-4176	104	5	in	in	ADP
dpc-4176	104	6	1:1:1	1:1:1	PROPN
dpc-4176	104	7	ratio	ratio	NOUN
dpc-4176	104	8	for	for	ADP
dpc-4176	104	9	one	one	NUM
dpc-4176	104	10	of	of	ADP
dpc-4176	104	11	the	the	DET
dpc-4176	104	12	three	three	NUM
dpc-4176	104	13	treatments	treatment	NOUN
dpc-4176	104	14	.	.	PUNCT
dpc-4176	105	1	•	•	NUM
dpc-4176	105	2	guselkumab	guselkumab	NOUN
dpc-4176	105	3	(	(	PUNCT
dpc-4176	105	4	50	50	NUM
dpc-4176	105	5	mg	mg	NOUN
dpc-4176	105	6	,	,	PUNCT
dpc-4176	105	7	weeks	week	NOUN
dpc-4176	105	8	0	0	NUM
dpc-4176	105	9	,	,	PUNCT
dpc-4176	105	10	4	4	NUM
dpc-4176	105	11	and	and	CCONJ
dpc-4176	105	12	then	then	ADV
dpc-4176	105	13	every	every	DET
dpc-4176	105	14	8	8	NUM
dpc-4176	105	15	weeks	week	NOUN
dpc-4176	105	16	)	)	PUNCT
dpc-4176	105	17	(	(	PUNCT
dpc-4176	105	18	n=65	n=65	NOUN
dpc-4176	105	19	)	)	PUNCT
dpc-4176	105	20	.	.	PUNCT
dpc-4176	106	1	•	•	NUM
dpc-4176	106	2	guselkumab	guselkumab	NOUN
dpc-4176	106	3	(	(	PUNCT
dpc-4176	106	4	100	100	NUM
dpc-4176	106	5	mg	mg	ADJ
dpc-4176	106	6	,	,	PUNCT
dpc-4176	106	7	similar	similar	ADJ
dpc-4176	106	8	schedule	schedule	NOUN
dpc-4176	106	9	)	)	PUNCT
dpc-4176	106	10	(	(	PUNCT
dpc-4176	106	11	n=64	n=64	PROPN
dpc-4176	106	12	)	)	PUNCT
dpc-4176	106	13	.	.	PUNCT
dpc-4176	107	1	•	•	NUM
dpc-4176	107	2	placebo	placebo	NOUN
dpc-4176	107	3	(	(	PUNCT
dpc-4176	107	4	weeks	week	NOUN
dpc-4176	107	5	0	0	NUM
dpc-4176	107	6	,	,	PUNCT
dpc-4176	107	7	4	4	NUM
dpc-4176	107	8	,	,	PUNCT
dpc-4176	107	9	and	and	CCONJ
dpc-4176	107	10	8	8	NUM
dpc-4176	107	11	weekly	weekly	ADJ
dpc-4176	107	12	)	)	PUNCT
dpc-4176	107	13	,	,	PUNCT
dpc-4176	107	14	followed	follow	VERB
dpc-4176	107	15	by	by	ADP
dpc-4176	107	16	guselkumab	guselkumab	NOUN
dpc-4176	107	17	50	50	NUM
dpc-4176	107	18	mg/100	mg/100	NOUN
dpc-4176	107	19	mg	mg	ADV
dpc-4176	107	20	at	at	ADP
dpc-4176	107	21	weeks	week	NOUN
dpc-4176	107	22	16	16	NUM
dpc-4176	107	23	and	and	CCONJ
dpc-4176	107	24	20	20	NUM
dpc-4176	107	25	,	,	PUNCT
dpc-4176	107	26	and	and	CCONJ
dpc-4176	107	27	every	every	DET
dpc-4176	107	28	8	8	NUM
dpc-4176	107	29	weeks	week	NOUN
dpc-4176	107	30	thereafter	thereafter	ADV
dpc-4176	107	31	(	(	PUNCT
dpc-4176	107	32	n=63	n=63	ADJ
dpc-4176	107	33	)	)	PUNCT
dpc-4176	107	34	.	.	PUNCT
dpc-4176	108	1	•	•	NUM
dpc-4176	108	2	pasi	pasi	NOUN
dpc-4176	108	3	90	90	NUM
dpc-4176	108	4	at	at	ADP
dpc-4176	108	5	week	week	NOUN
dpc-4176	108	6	16	16	NUM
dpc-4176	108	7	:	:	SYM
dpc-4176	108	8	•	•	ADP
dpc-4176	108	9	guselkumab(50	guselkumab(50	NOUN
dpc-4176	108	10	mg	mg	NOUN
dpc-4176	108	11	)	)	PUNCT
dpc-4176	108	12	(	(	PUNCT
dpc-4176	108	13	70.8	70.8	NUM
dpc-4176	108	14	%	%	NOUN
dpc-4176	108	15	)	)	PUNCT
dpc-4176	108	16	•	•	NOUN
dpc-4176	108	17	guselkumab(100	guselkumab(100	PROPN
dpc-4176	108	18	mg	mg	PROPN
dpc-4176	108	19	)	)	PUNCT
dpc-4176	108	20	(	(	PUNCT
dpc-4176	108	21	69.8	69.8	NUM
dpc-4176	108	22	%	%	NOUN
dpc-4176	108	23	)	)	PUNCT
dpc-4176	108	24	•	•	NUM
dpc-4176	108	25	placebo	placebo	NOUN
dpc-4176	108	26	0	0	NUM
dpc-4176	108	27	%	%	NOUN
dpc-4176	108	28	•	•	NOUN
dpc-4176	108	29	iga	iga	PROPN
dpc-4176	108	30	0	0	NUM
dpc-4176	108	31	/	/	SYM
dpc-4176	108	32	i	i	PRON
dpc-4176	108	33	at	at	ADP
dpc-4176	108	34	week	week	NOUN
dpc-4176	108	35	16	16	NUM
dpc-4176	108	36	:	:	SYM
dpc-4176	108	37	•	•	NUM
dpc-4176	108	38	guselkumab	guselkumab	NOUN
dpc-4176	108	39	(	(	PUNCT
dpc-4176	108	40	50	50	NUM
dpc-4176	108	41	mg	mg	NUM
dpc-4176	108	42	)	)	PUNCT
dpc-4176	108	43	(	(	PUNCT
dpc-4176	108	44	92.3	92.3	NUM
dpc-4176	108	45	%	%	NOUN
dpc-4176	108	46	)	)	PUNCT
dpc-4176	108	47	•	•	NOUN
dpc-4176	108	48	guselkumab	guselkumab	NOUN
dpc-4176	108	49	(	(	PUNCT
dpc-4176	108	50	100	100	NUM
dpc-4176	108	51	mg	mg	NUM
dpc-4176	108	52	)	)	PUNCT
dpc-4176	108	53	(	(	PUNCT
dpc-4176	108	54	88.9	88.9	NUM
dpc-4176	108	55	%	%	NOUN
dpc-4176	108	56	)	)	PUNCT
dpc-4176	108	57	•	•	NUM
dpc-4176	108	58	placebo	placebo	NOUN
dpc-4176	108	59	(	(	PUNCT
dpc-4176	108	60	7.8	7.8	NUM
dpc-4176	108	61	%	%	NOUN
dpc-4176	108	62	)	)	PUNCT
dpc-4176	108	63	•	•	NOUN
dpc-4176	108	64	pasi	pasi	NOUN
dpc-4176	108	65	90	90	NUM
dpc-4176	108	66	(	(	PUNCT
dpc-4176	108	67	through	through	ADP
dpc-4176	108	68	week	week	NOUN
dpc-4176	108	69	52	52	NUM
dpc-4176	108	70	):	):	PUNCT
dpc-4176	108	71	•	•	NUM
dpc-4176	108	72	guselkumab	guselkumab	NOUN
dpc-4176	108	73	(	(	PUNCT
dpc-4176	108	74	50	50	NUM
dpc-4176	108	75	mg	mg	NUM
dpc-4176	108	76	)	)	PUNCT
dpc-4176	108	77	(	(	PUNCT
dpc-4176	108	78	75.4	75.4	NUM
dpc-4176	108	79	%	%	NOUN
dpc-4176	108	80	)	)	PUNCT
dpc-4176	108	81	•	•	NUM
dpc-4176	108	82	guselkumab	guselkumab	NOUN
dpc-4176	108	83	(	(	PUNCT
dpc-4176	108	84	100	100	NUM
dpc-4176	108	85	mg	mg	NUM
dpc-4176	108	86	)	)	PUNCT
dpc-4176	108	87	(	(	PUNCT
dpc-4176	108	88	77.8	77.8	NUM
dpc-4176	108	89	%	%	NOUN
dpc-4176	108	90	)	)	PUNCT
dpc-4176	108	91	•	•	NUM
dpc-4176	108	92	placebo	placebo	NOUN
dpc-4176	108	93	guselkumab	guselkumab	NOUN
dpc-4176	108	94	(	(	PUNCT
dpc-4176	108	95	50	50	NUM
dpc-4176	108	96	mg	mg	NUM
dpc-4176	108	97	)	)	PUNCT
dpc-4176	108	98	(	(	PUNCT
dpc-4176	108	99	92.3	92.3	NUM
dpc-4176	108	100	%	%	NOUN
dpc-4176	108	101	)	)	PUNCT
dpc-4176	108	102	•	•	NUM
dpc-4176	108	103	placebo	placebo	NOUN
dpc-4176	108	104	guselkumab	guselkumab	NOUN
dpc-4176	108	105	(	(	PUNCT
dpc-4176	108	106	100	100	NUM
dpc-4176	108	107	mg	mg	NUM
dpc-4176	108	108	)	)	PUNCT
dpc-4176	108	109	(	(	PUNCT
dpc-4176	108	110	73.1	73.1	NUM
dpc-4176	108	111	%	%	NOUN
dpc-4176	108	112	)	)	PUNCT
dpc-4176	108	113	•	•	ADV
dpc-4176	108	114	however	however	ADV
dpc-4176	108	115	,	,	PUNCT
dpc-4176	108	116	with	with	ADP
dpc-4176	108	117	progression	progression	NOUN
dpc-4176	108	118	of	of	ADP
dpc-4176	108	119	time	time	NOUN
dpc-4176	108	120	,	,	PUNCT
dpc-4176	108	121	complete	complete	ADJ
dpc-4176	108	122	clearance	clearance	NOUN
dpc-4176	108	123	of	of	ADP
dpc-4176	108	124	psoriasis	psoriasis	NOUN
dpc-4176	108	125	was	be	AUX
dpc-4176	108	126	observed	observe	VERB
dpc-4176	108	127	in	in	ADP
dpc-4176	108	128	the	the	DET
dpc-4176	108	129	guselkumab	guselkumab	NOUN
dpc-4176	108	130	(	(	PUNCT
dpc-4176	108	131	100	100	NUM
dpc-4176	108	132	mg	mg	NUM
dpc-4176	108	133	)	)	PUNCT
dpc-4176	108	134	group	group	NOUN
dpc-4176	108	135	.	.	PUNCT
dpc-4176	109	1	•	•	NUM
dpc-4176	110	1	for	for	ADP
dpc-4176	110	2	most	most	ADJ
dpc-4176	110	3	efficacy	efficacy	NOUN
dpc-4176	110	4	measures	measure	NOUN
dpc-4176	110	5	a	a	DET
dpc-4176	110	6	dose	dose	NOUN
dpc-4176	110	7	response	response	NOUN
dpc-4176	110	8	was	be	AUX
dpc-4176	110	9	not	not	PART
dpc-4176	110	10	generally	generally	ADV
dpc-4176	110	11	observed	observe	VERB
dpc-4176	110	12	.	.	PUNCT
dpc-4176	111	1	in	in	ADP
dpc-4176	111	2	a	a	DET
dpc-4176	111	3	multicenter	multicenter	ADJ
dpc-4176	111	4	placebo	placebo	NOUN
dpc-4176	111	5	-	-	PUNCT
dpc-4176	111	6	controlled	control	VERB
dpc-4176	111	7	trial	trial	NOUN
dpc-4176	111	8	evaluating	evaluate	VERB
dpc-4176	111	9	the	the	DET
dpc-4176	111	10	efficacy	efficacy	NOUN
dpc-4176	111	11	of	of	ADP
dpc-4176	111	12	guselkumab	guselkumab	NOUN
dpc-4176	111	13	for	for	ADP
dpc-4176	111	14	ppp	ppp	NOUN
dpc-4176	111	15	,	,	PUNCT
dpc-4176	111	16	though	though	SCONJ
dpc-4176	111	17	the	the	DET
dpc-4176	111	18	primary	primary	ADJ
dpc-4176	111	19	end	end	NOUN
dpc-4176	111	20	point	point	NOUN
dpc-4176	111	21	of	of	ADP
dpc-4176	111	22	pppasi	pppasi	NOUN
dpc-4176	111	23	75	75	NUM
dpc-4176	111	24	response	response	NOUN
dpc-4176	111	25	at	at	ADP
dpc-4176	111	26	16	16	NUM
dpc-4176	111	27	weeks	week	NOUN
dpc-4176	111	28	(	(	PUNCT
dpc-4176	111	29	guselkumab	guselkumab	NOUN
dpc-4176	111	30	:	:	PUNCT
dpc-4176	111	31	35.9	35.9	NUM
dpc-4176	111	32	%	%	NOUN
dpc-4176	111	33	,	,	PUNCT
dpc-4176	111	34	placebo	placebo	NOUN
dpc-4176	111	35	:	:	PUNCT
dpc-4176	111	36	28.2	28.2	NUM
dpc-4176	111	37	%	%	NOUN
dpc-4176	111	38	,	,	PUNCT
dpc-4176	111	39	p	p	X
dpc-4176	111	40	=	=	NOUN
dpc-4176	111	41	0.533	0.533	NUM
dpc-4176	111	42	)	)	PUNCT
dpc-4176	111	43	was	be	AUX
dpc-4176	111	44	not	not	PART
dpc-4176	111	45	met	meet	VERB
dpc-4176	111	46	,	,	PUNCT
dpc-4176	111	47	more	more	ADV
dpc-4176	111	48	pronounced	pronounced	ADJ
dpc-4176	111	49	numerical	numerical	ADJ
dpc-4176	111	50	improvements	improvement	NOUN
dpc-4176	111	51	favoring	favor	VERB
dpc-4176	111	52	guselkumab	guselkumab	NOUN
dpc-4176	111	53	were	be	AUX
dpc-4176	111	54	seen	see	VERB
dpc-4176	111	55	for	for	ADP
dpc-4176	111	56	more	more	ADV
dpc-4176	111	57	stringent	stringent	ADJ
dpc-4176	111	58	efficacy	efficacy	NOUN
dpc-4176	111	59	endpoints	endpoint	NOUN
dpc-4176	111	60	such	such	ADJ
dpc-4176	111	61	as	as	ADP
dpc-4176	111	62	ppiga	ppiga	NOUN
dpc-4176	111	63	0/1	0/1	NUM
dpc-4176	111	64	response	response	NOUN
dpc-4176	111	65	at	at	ADP
dpc-4176	111	66	week	week	NOUN
dpc-4176	111	67	16	16	NUM
dpc-4176	111	68	(	(	PUNCT
dpc-4176	111	69	guselkumab	guselkumab	NOUN
dpc-4176	111	70	34.6	34.6	NUM
dpc-4176	111	71	%	%	NOUN
dpc-4176	111	72	,	,	PUNCT
dpc-4176	111	73	placebo	placebo	NOUN
dpc-4176	111	74	15.4	15.4	NUM
dpc-4176	111	75	%	%	NOUN
dpc-4176	111	76	)	)	PUNCT
dpc-4176	111	77	and	and	CCONJ
dpc-4176	111	78	pppasi90	pppasi90	VERB
dpc-4176	111	79	response	response	VERB
dpc-4176	111	80	at	at	ADP
dpc-4176	111	81	week	week	NOUN
dpc-4176	111	82	16	16	NUM
dpc-4176	111	83	(	(	PUNCT
dpc-4176	111	84	guselkumab	guselkumab	NOUN
dpc-4176	111	85	24.4	24.4	NUM
dpc-4176	111	86	%	%	NOUN
dpc-4176	111	87	,	,	PUNCT
dpc-4176	111	88	placebo	placebo	NOUN
dpc-4176	111	89	15.4	15.4	NUM
dpc-4176	111	90	%	%	NOUN
dpc-4176	111	91	)	)	PUNCT
dpc-4176	111	92	.	.	PUNCT
dpc-4176	112	1	regarding	regard	VERB
dpc-4176	112	2	the	the	DET
dpc-4176	112	3	quality	quality	NOUN
dpc-4176	112	4	of	of	ADP
dpc-4176	112	5	life	life	NOUN
dpc-4176	112	6	,	,	PUNCT
dpc-4176	112	7	greater	great	ADJ
dpc-4176	112	8	proportion	proportion	NOUN
dpc-4176	112	9	of	of	ADP
dpc-4176	112	10	subjects	subject	NOUN
dpc-4176	112	11	in	in	ADP
dpc-4176	112	12	the	the	DET
dpc-4176	112	13	guselkumab	guselkumab	NOUN
dpc-4176	112	14	group	group	NOUN
dpc-4176	112	15	reported	report	VERB
dpc-4176	112	16	a	a	DET
dpc-4176	112	17	dermatology	dermatology	NOUN
dpc-4176	112	18	life	life	NOUN
dpc-4176	112	19	quality	quality	NOUN
dpc-4176	112	20	index	index	NOUN
dpc-4176	112	21	(	(	PUNCT
dpc-4176	112	22	dlqi	dlqi	PROPN
dpc-4176	112	23	)	)	PUNCT
dpc-4176	112	24	0/1	0/1	NUM
dpc-4176	112	25	score	score	NOUN
dpc-4176	112	26	at	at	ADP
dpc-4176	112	27	week	week	NOUN
dpc-4176	112	28	16	16	NUM
dpc-4176	112	29	compared	compare	VERB
dpc-4176	112	30	with	with	ADP
dpc-4176	112	31	the	the	DET
dpc-4176	112	32	placebo	placebo	NOUN
dpc-4176	112	33	group	group	NOUN
dpc-4176	112	34	(	(	PUNCT
dpc-4176	112	35	19.2	19.2	NUM
dpc-4176	112	36	%	%	NOUN
dpc-4176	112	37	versus	versus	ADP
dpc-4176	112	38	7.7	7.7	NUM
dpc-4176	112	39	%	%	NOUN
dpc-4176	112	40	)	)	PUNCT
dpc-4176	112	41	respectively	respectively	ADV
dpc-4176	112	42	.	.	PUNCT
dpc-4176	113	1	besides	besides	SCONJ
dpc-4176	113	2	,	,	PUNCT
dpc-4176	113	3	significant	significant	ADJ
dpc-4176	113	4	reduction	reduction	NOUN
dpc-4176	113	5	of	of	ADP
dpc-4176	113	6	serum	serum	PROPN
dpc-4176	113	7	il-17a	il-17a	PROPN
dpc-4176	113	8	,	,	PUNCT
dpc-4176	113	9	il-17f	il-17f	ADJ
dpc-4176	113	10	and	and	CCONJ
dpc-4176	113	11	il-22	il-22	NOUN
dpc-4176	113	12	was	be	AUX
dpc-4176	113	13	observed	observe	VERB
dpc-4176	113	14	at	at	ADP
dpc-4176	113	15	week	week	NOUN
dpc-4176	113	16	16	16	NUM
dpc-4176	113	17	from	from	ADP
dpc-4176	113	18	baseline	baseline	NOUN
dpc-4176	113	19	in	in	ADP
dpc-4176	113	20	the	the	DET
dpc-4176	113	21	guselkumab	guselkumab	NOUN
dpc-4176	113	22	group	group	NOUN
dpc-4176	113	23	,	,	PUNCT
dpc-4176	113	24	but	but	CCONJ
dpc-4176	113	25	not	not	PART
dpc-4176	113	26	in	in	ADP
dpc-4176	113	27	those	those	DET
dpc-4176	113	28	patients	patient	NOUN
dpc-4176	113	29	receiving	receive	VERB
dpc-4176	113	30	placebo	placebo	NOUN
dpc-4176	113	31	[	[	X
dpc-4176	113	32	38	38	NUM
dpc-4176	113	33	]	]	PUNCT
dpc-4176	113	34	.	.	PUNCT
dpc-4176	114	1	currently	currently	ADV
dpc-4176	114	2	,	,	PUNCT
dpc-4176	114	3	apart	apart	ADV
dpc-4176	114	4	from	from	ADP
dpc-4176	114	5	the	the	DET
dpc-4176	114	6	above	above	ADJ
dpc-4176	114	7	trial	trial	NOUN
dpc-4176	114	8	,	,	PUNCT
dpc-4176	114	9	no	no	DET
dpc-4176	114	10	other	other	ADJ
dpc-4176	114	11	publication	publication	NOUN
dpc-4176	114	12	exists	exist	VERB
dpc-4176	114	13	on	on	ADP
dpc-4176	114	14	assessing	assess	VERB
dpc-4176	114	15	guselkumab	guselkumab	NOUN
dpc-4176	114	16	for	for	ADP
dpc-4176	114	17	non	non	ADJ
dpc-4176	114	18	-	-	ADJ
dpc-4176	114	19	pustular	pustular	ADJ
dpc-4176	114	20	ppp	ppp	NOUN
dpc-4176	114	21	.	.	PUNCT
dpc-4176	115	1	more	more	ADJ
dpc-4176	115	2	studies	study	NOUN
dpc-4176	115	3	are	be	AUX
dpc-4176	115	4	therefore	therefore	ADV
dpc-4176	115	5	warranted	warrant	VERB
dpc-4176	115	6	to	to	PART
dpc-4176	115	7	better	well	ADV
dpc-4176	115	8	understand	understand	VERB
dpc-4176	115	9	the	the	DET
dpc-4176	115	10	impact	impact	NOUN
dpc-4176	115	11	of	of	ADP
dpc-4176	115	12	guselkumab	guselkumab	NOUN
dpc-4176	115	13	treatment	treatment	NOUN
dpc-4176	115	14	for	for	ADP
dpc-4176	115	15	this	this	DET
dpc-4176	115	16	variant	variant	NOUN
dpc-4176	115	17	of	of	ADP
dpc-4176	115	18	psoriasis	psoriasis	NOUN
dpc-4176	115	19	.	.	PUNCT
dpc-4176	116	1	6	6	NUM
dpc-4176	116	2	review	review	NOUN
dpc-4176	116	3	|	|	ADV
dpc-4176	116	4	dermatol	dermatol	ADJ
dpc-4176	116	5	pract	pract	NOUN
dpc-4176	116	6	concept	concept	NOUN
dpc-4176	116	7	.	.	PUNCT
dpc-4176	117	1	2024;14(3):e2024181	2024;14(3):e2024181	NUM
dpc-4176	117	2	table	table	NOUN
dpc-4176	117	3	2	2	NUM
dpc-4176	117	4	.	.	PUNCT
dpc-4176	118	1	studies	study	NOUN
dpc-4176	118	2	elaborating	elaborate	VERB
dpc-4176	118	3	the	the	DET
dpc-4176	118	4	role	role	NOUN
dpc-4176	118	5	of	of	ADP
dpc-4176	118	6	guselkumab	guselkumab	NOUN
dpc-4176	118	7	in	in	ADP
dpc-4176	118	8	nail	nail	NOUN
dpc-4176	118	9	psoriasis	psoriasis	NOUN
dpc-4176	118	10	serial	serial	NOUN
dpc-4176	118	11	no	no	INTJ
dpc-4176	118	12	.	.	PUNCT
dpc-4176	119	1	author(s)/	author(s)/	VERB
dpc-4176	119	2	year	year	NOUN
dpc-4176	119	3	study	study	NOUN
dpc-4176	119	4	type	type	NOUN
dpc-4176	119	5	details	detail	NOUN
dpc-4176	119	6	remarks	remark	VERB
dpc-4176	119	7	adverse	adverse	ADJ
dpc-4176	119	8	events	event	NOUN
dpc-4176	119	9	1	1	NUM
dpc-4176	119	10	ohtsuki	ohtsuki	ADJ
dpc-4176	119	11	et	et	PROPN
dpc-4176	119	12	al	al	PROPN
dpc-4176	120	1	[	[	X
dpc-4176	120	2	19	19	NUM
dpc-4176	120	3	]	]	SYM
dpc-4176	120	4	2018	2018	NUM
dpc-4176	120	5	•	•	NOUN
dpc-4176	120	6	phase	phase	NOUN
dpc-4176	120	7	iii	iii	NOUN
dpc-4176	120	8	,	,	PUNCT
dpc-4176	120	9	randomized	randomize	VERB
dpc-4176	120	10	double	double	ADJ
dpc-4176	120	11	-	-	PUNCT
dpc-4176	120	12	blind	blind	ADJ
dpc-4176	120	13	placebocontrolled	placebocontrolle	VERB
dpc-4176	120	14	study	study	NOUN
dpc-4176	120	15	.	.	PUNCT
dpc-4176	121	1	•	•	NUM
dpc-4176	121	2	patients	patient	NOUN
dpc-4176	121	3	randomized	randomize	VERB
dpc-4176	121	4	1:1:1	1:1:1	NUM
dpc-4176	121	5	to	to	PART
dpc-4176	121	6	receive	receive	VERB
dpc-4176	121	7	guselkumab	guselkumab	NOUN
dpc-4176	121	8	50	50	NUM
dpc-4176	121	9	mg	mg	NOUN
dpc-4176	122	1	(	(	PUNCT
dpc-4176	122	2	44	44	NUM
dpc-4176	122	3	patients	patient	NOUN
dpc-4176	122	4	)	)	PUNCT
dpc-4176	122	5	,	,	PUNCT
dpc-4176	122	6	guselkumab	guselkumab	NOUN
dpc-4176	122	7	10	10	NUM
dpc-4176	122	8	0	0	NUM
dpc-4176	122	9	mg	mg	PROPN
dpc-4176	122	10	(	(	PUNCT
dpc-4176	122	11	40	40	NUM
dpc-4176	122	12	 	 	SPACE
dpc-4176	122	13	patients	patient	NOUN
dpc-4176	122	14	)	)	PUNCT
dpc-4176	122	15	and	and	CCONJ
dpc-4176	122	16	placebo	placebo	NOUN
dpc-4176	122	17	(	(	PUNCT
dpc-4176	122	18	42	42	NUM
dpc-4176	122	19	patients	patient	NOUN
dpc-4176	122	20	)	)	PUNCT
dpc-4176	122	21	.	.	PUNCT
dpc-4176	123	1	•	•	NUM
dpc-4176	123	2	statistically	statistically	ADV
dpc-4176	123	3	significant	significant	ADJ
dpc-4176	123	4	improvement	improvement	NOUN
dpc-4176	123	5	in	in	ADP
dpc-4176	123	6	napsi	napsi	NOUN
dpc-4176	123	7	was	be	AUX
dpc-4176	123	8	seen	see	VERB
dpc-4176	123	9	in	in	ADP
dpc-4176	123	10	both	both	DET
dpc-4176	123	11	guselkumab	guselkumab	NOUN
dpc-4176	123	12	groups	group	NOUN
dpc-4176	123	13	compared	compare	VERB
dpc-4176	123	14	to	to	ADP
dpc-4176	123	15	placebo	placebo	NOUN
dpc-4176	123	16	.	.	PUNCT
dpc-4176	124	1	•	•	NUM
dpc-4176	124	2	in	in	ADP
dpc-4176	124	3	the	the	DET
dpc-4176	124	4	guselkumab	guselkumab	NOUN
dpc-4176	124	5	50	50	NUM
dpc-4176	124	6	mg	mg	PROPN
dpc-4176	124	7	group	group	NOUN
dpc-4176	124	8	(	(	PUNCT
dpc-4176	124	9	p	p	NOUN
dpc-4176	124	10	value	value	NOUN
dpc-4176	124	11	=	=	SYM
dpc-4176	124	12	0.002	0.002	NUM
dpc-4176	124	13	versus	versus	ADP
dpc-4176	124	14	placebo	placebo	NOUN
dpc-4176	124	15	)	)	PUNCT
dpc-4176	124	16	.	.	PUNCT
dpc-4176	125	1	•	•	NOUN
dpc-4176	125	2	in	in	ADP
dpc-4176	125	3	the	the	DET
dpc-4176	125	4	guselkumab	guselkumab	NOUN
dpc-4176	125	5	100	100	NUM
dpc-4176	125	6	mg	mg	PROPN
dpc-4176	125	7	group	group	NOUN
dpc-4176	125	8	(	(	PUNCT
dpc-4176	125	9	p	p	NOUN
dpc-4176	125	10	value	value	NOUN
dpc-4176	125	11	<	<	X
dpc-4176	125	12	0.001	0.001	NUM
dpc-4176	125	13	versus	versus	ADP
dpc-4176	125	14	placebo	placebo	NOUN
dpc-4176	125	15	)	)	PUNCT
dpc-4176	125	16	.	.	PUNCT
dpc-4176	126	1	none	none	NOUN
dpc-4176	126	2	2	2	NUM
dpc-4176	126	3	gerdes	gerde	NOUN
dpc-4176	126	4	et	et	NOUN
dpc-4176	126	5	al	al	PROPN
dpc-4176	127	1	[	[	X
dpc-4176	127	2	34	34	NUM
dpc-4176	127	3	]	]	PUNCT
dpc-4176	127	4	2023	2023	NUM
dpc-4176	127	5	•	•	NOUN
dpc-4176	127	6	noninterventional	noninterventional	ADJ
dpc-4176	127	7	prospective	prospective	ADJ
dpc-4176	127	8	multicentre	multicentre	NOUN
dpc-4176	127	9	study	study	NOUN
dpc-4176	127	10	.	.	PUNCT
dpc-4176	128	1	•	•	NUM
dpc-4176	128	2	136	136	NUM
dpc-4176	128	3	patients	patient	NOUN
dpc-4176	128	4	had	have	VERB
dpc-4176	128	5	≥	≥	NOUN
dpc-4176	128	6	1	1	NUM
dpc-4176	128	7	affected	affect	VERB
dpc-4176	128	8	nail	nail	NOUN
dpc-4176	128	9	at	at	ADP
dpc-4176	128	10	baseline	baseline	NOUN
dpc-4176	128	11	.	.	PUNCT
dpc-4176	129	1	•	•	NUM
dpc-4176	129	2	mean	mean	NOUN
dpc-4176	129	3	target	target	NOUN
dpc-4176	129	4	napsi	napsi	NOUN
dpc-4176	129	5	score	score	NOUN
dpc-4176	129	6	reduced	reduce	VERB
dpc-4176	129	7	from	from	ADP
dpc-4176	129	8	4.2	4.2	NUM
dpc-4176	129	9	at	at	ADP
dpc-4176	129	10	baseline	baseline	NOUN
dpc-4176	129	11	to	to	ADP
dpc-4176	129	12	1	1	NUM
dpc-4176	129	13	(	(	PUNCT
dpc-4176	129	14	at	at	ADP
dpc-4176	129	15	week	week	NOUN
dpc-4176	129	16	104	104	NUM
dpc-4176	129	17	)	)	PUNCT
dpc-4176	129	18	.	.	PUNCT
dpc-4176	130	1	none	none	NOUN
dpc-4176	130	2	3	3	NUM
dpc-4176	130	3	foley	foley	NOUN
dpc-4176	130	4	et	et	PROPN
dpc-4176	130	5	al	al	PROPN
dpc-4176	131	1	[	[	X
dpc-4176	131	2	32	32	NUM
dpc-4176	131	3	]	]	SYM
dpc-4176	131	4	2018	2018	NUM
dpc-4176	131	5	•	•	NOUN
dpc-4176	131	6	a	a	DET
dpc-4176	131	7	secondary	secondary	ADJ
dpc-4176	131	8	analysis	analysis	NOUN
dpc-4176	131	9	of	of	ADP
dpc-4176	131	10	2	2	NUM
dpc-4176	131	11	randomized	randomize	VERB
dpc-4176	131	12	clinical	clinical	ADJ
dpc-4176	131	13	trials	trial	NOUN
dpc-4176	131	14	.	.	PUNCT
dpc-4176	132	1	•	•	NUM
dpc-4176	132	2	of	of	ADP
dpc-4176	132	3	the	the	DET
dpc-4176	132	4	1829	1829	NUM
dpc-4176	132	5	randomized	randomized	ADJ
dpc-4176	132	6	patients	patient	NOUN
dpc-4176	132	7	,	,	PUNCT
dpc-4176	132	8	1049	1049	NUM
dpc-4176	132	9	(	(	PUNCT
dpc-4176	132	10	57.4	57.4	NUM
dpc-4176	132	11	%	%	NOUN
dpc-4176	132	12	)	)	PUNCT
dpc-4176	132	13	presented	present	VERB
dpc-4176	132	14	with	with	ADP
dpc-4176	132	15	fingernail	fingernail	NOUN
dpc-4176	132	16	psoriasis	psoriasis	NOUN
dpc-4176	132	17	.	.	PUNCT
dpc-4176	133	1	•	•	NOUN
dpc-4176	133	2	at	at	ADP
dpc-4176	133	3	week	week	NOUN
dpc-4176	133	4	16	16	NUM
dpc-4176	133	5	,	,	PUNCT
dpc-4176	133	6	number	number	NOUN
dpc-4176	133	7	of	of	ADP
dpc-4176	133	8	patients	patient	NOUN
dpc-4176	133	9	achieving	achieve	VERB
dpc-4176	133	10	the	the	DET
dpc-4176	133	11	target	target	NOUN
dpc-4176	133	12	napsi	napsi	NOUN
dpc-4176	133	13	score	score	NOUN
dpc-4176	133	14	of	of	ADP
dpc-4176	133	15	0	0	NUM
dpc-4176	133	16	was	be	AUX
dpc-4176	133	17	statistically	statistically	ADV
dpc-4176	133	18	significantly	significantly	ADV
dpc-4176	133	19	higher	high	ADJ
dpc-4176	133	20	for	for	ADP
dpc-4176	133	21	the	the	DET
dpc-4176	133	22	guselkumab	guselkumab	NOUN
dpc-4176	133	23	group	group	NOUN
dpc-4176	133	24	(	(	PUNCT
dpc-4176	133	25	16	16	NUM
dpc-4176	133	26	%	%	NOUN
dpc-4176	133	27	)	)	PUNCT
dpc-4176	133	28	compared	compare	VERB
dpc-4176	133	29	with	with	ADP
dpc-4176	133	30	the	the	DET
dpc-4176	133	31	placebo	placebo	NOUN
dpc-4176	133	32	group	group	NOUN
dpc-4176	133	33	(	(	PUNCT
dpc-4176	133	34	5.4	5.4	NUM
dpc-4176	133	35	%	%	NOUN
dpc-4176	133	36	)	)	PUNCT
dpc-4176	134	1	(	(	PUNCT
dpc-4176	134	2	p	p	X
dpc-4176	134	3	 	 	SPACE
dpc-4176	134	4	<	<	X
dpc-4176	134	5	0.001	0.001	NUM
dpc-4176	134	6	)	)	PUNCT
dpc-4176	134	7	.	.	PUNCT
dpc-4176	135	1	•	•	NOUN
dpc-4176	135	2	at	at	ADP
dpc-4176	135	3	week	week	NOUN
dpc-4176	135	4	24	24	NUM
dpc-4176	135	5	,	,	PUNCT
dpc-4176	135	6	napsi	napsi	NOUN
dpc-4176	135	7	0	0	NUM
dpc-4176	135	8	score	score	NOUN
dpc-4176	135	9	was	be	AUX
dpc-4176	135	10	comparable	comparable	ADJ
dpc-4176	135	11	between	between	ADP
dpc-4176	135	12	the	the	DET
dpc-4176	135	13	guselkumab	guselkumab	NOUN
dpc-4176	135	14	group	group	NOUN
dpc-4176	135	15	(	(	PUNCT
dpc-4176	135	16	30.6	30.6	NUM
dpc-4176	135	17	%	%	NOUN
dpc-4176	135	18	)	)	PUNCT
dpc-4176	135	19	and	and	CCONJ
dpc-4176	135	20	the	the	DET
dpc-4176	135	21	adalimumab	adalimumab	NOUN
dpc-4176	135	22	group	group	NOUN
dpc-4176	135	23	(	(	PUNCT
dpc-4176	135	24	32.6	32.6	NUM
dpc-4176	135	25	%	%	NOUN
dpc-4176	135	26	)	)	PUNCT
dpc-4176	135	27	(	(	PUNCT
dpc-4176	135	28	p	p	X
dpc-4176	135	29	=	=	NOUN
dpc-4176	135	30	0.50	0.50	NUM
dpc-4176	135	31	)	)	PUNCT
dpc-4176	135	32	.	.	PUNCT
dpc-4176	136	1	none	none	NOUN
dpc-4176	136	2	4	4	NUM
dpc-4176	136	3	jo	jo	VERB
dpc-4176	136	4	et	et	PROPN
dpc-4176	136	5	al	al	PROPN
dpc-4176	137	1	[	[	X
dpc-4176	137	2	35	35	NUM
dpc-4176	137	3	]	]	SYM
dpc-4176	137	4	2023	2023	NUM
dpc-4176	137	5	•	•	NOUN
dpc-4176	137	6	data	datum	NOUN
dpc-4176	137	7	from	from	ADP
dpc-4176	137	8	voyage	voyage	NOUN
dpc-4176	137	9	1	1	NUM
dpc-4176	137	10	and	and	CCONJ
dpc-4176	137	11	voyage	voyage	NOUN
dpc-4176	137	12	2	2	NUM
dpc-4176	137	13	including	include	VERB
dpc-4176	137	14	patients	patient	NOUN
dpc-4176	137	15	belonging	belong	VERB
dpc-4176	137	16	to	to	ADP
dpc-4176	137	17	the	the	DET
dpc-4176	137	18	asian	asian	ADJ
dpc-4176	137	19	subpopulation	subpopulation	NOUN
dpc-4176	137	20	to	to	PART
dpc-4176	137	21	assess	assess	VERB
dpc-4176	137	22	the	the	DET
dpc-4176	137	23	efficacy	efficacy	NOUN
dpc-4176	137	24	of	of	ADP
dpc-4176	137	25	guselkumab	guselkumab	NOUN
dpc-4176	137	26	and	and	CCONJ
dpc-4176	137	27	adalimumab	adalimumab	NOUN
dpc-4176	137	28	vs	vs	ADP
dpc-4176	137	29	placebo	placebo	NOUN
dpc-4176	137	30	for	for	ADP
dpc-4176	137	31	fingernail	fingernail	NOUN
dpc-4176	137	32	psoriasis	psoriasis	NOUN
dpc-4176	137	33	.	.	PUNCT
dpc-4176	138	1	•	•	NOUN
dpc-4176	138	2	97	97	NUM
dpc-4176	138	3	patients	patient	NOUN
dpc-4176	138	4	had	have	VERB
dpc-4176	138	5	fingernail	fingernail	NOUN
dpc-4176	138	6	psoriasis	psoriasis	NOUN
dpc-4176	138	7	.	.	PUNCT
dpc-4176	139	1	0	0	NUM
dpc-4176	139	2	placebo	placebo	NOUN
dpc-4176	139	3	:	:	PUNCT
dpc-4176	139	4	22	22	NUM
dpc-4176	139	5	0	0	NUM
dpc-4176	139	6	guselkumab	guselkumab	NOUN
dpc-4176	139	7	:	:	PUNCT
dpc-4176	139	8	44	44	NUM
dpc-4176	139	9	0	0	NUM
dpc-4176	139	10	adalimumab	adalimumab	NOUN
dpc-4176	139	11	:	:	PUNCT
dpc-4176	139	12	31	31	NUM
dpc-4176	139	13	•	•	NOUN
dpc-4176	139	14	guselkumab	guselkumab	NOUN
dpc-4176	139	15	showed	show	VERB
dpc-4176	139	16	greater	great	ADJ
dpc-4176	139	17	improvement	improvement	NOUN
dpc-4176	139	18	in	in	ADP
dpc-4176	139	19	than	than	ADP
dpc-4176	139	20	placebo	placebo	NOUN
dpc-4176	139	21	in	in	ADP
dpc-4176	139	22	target	target	NOUN
dpc-4176	139	23	napsi	napsi	NOUN
dpc-4176	139	24	at	at	ADP
dpc-4176	139	25	week	week	NOUN
dpc-4176	139	26	16	16	NUM
dpc-4176	139	27	(	(	PUNCT
dpc-4176	139	28	mean	mean	VERB
dpc-4176	139	29	improvement	improvement	NOUN
dpc-4176	139	30	35.4	35.4	NUM
dpc-4176	139	31	%	%	NOUN
dpc-4176	139	32	versus	versus	ADP
dpc-4176	139	33	10.8	10.8	NUM
dpc-4176	139	34	%	%	NOUN
dpc-4176	139	35	)	)	PUNCT
dpc-4176	139	36	(	(	PUNCT
dpc-4176	139	37	p	p	X
dpc-4176	139	38	=	=	PROPN
dpc-4176	139	39	0.021	0.021	NUM
dpc-4176	139	40	)	)	PUNCT
dpc-4176	139	41	.	.	PUNCT
dpc-4176	140	1	•	•	NOUN
dpc-4176	140	2	at	at	ADP
dpc-4176	140	3	week	week	NOUN
dpc-4176	140	4	24	24	NUM
dpc-4176	140	5	target	target	NOUN
dpc-4176	140	6	napsi	napsi	NOUN
dpc-4176	140	7	was	be	AUX
dpc-4176	140	8	maintained	maintain	VERB
dpc-4176	140	9	with	with	ADP
dpc-4176	140	10	guselkumab	guselkumab	NOUN
dpc-4176	140	11	and	and	CCONJ
dpc-4176	140	12	was	be	AUX
dpc-4176	140	13	comparable	comparable	ADJ
dpc-4176	140	14	to	to	ADP
dpc-4176	140	15	adalimumab	adalimumab	NOUN
dpc-4176	140	16	(	(	PUNCT
dpc-4176	140	17	mean	mean	VERB
dpc-4176	140	18	improvement	improvement	NOUN
dpc-4176	140	19	39.9	39.9	NUM
dpc-4176	140	20	%	%	NOUN
dpc-4176	140	21	versus	versus	ADP
dpc-4176	140	22	35.9	35.9	NUM
dpc-4176	140	23	%	%	NOUN
dpc-4176	140	24	(	(	PUNCT
dpc-4176	140	25	p	p	NOUN
dpc-4176	140	26	=	=	NOUN
dpc-4176	140	27	0.618	0.618	NUM
dpc-4176	140	28	)	)	PUNCT
dpc-4176	140	29	,	,	PUNCT
dpc-4176	140	30	respectively	respectively	ADV
dpc-4176	140	31	)	)	PUNCT
dpc-4176	140	32	•	•	NOUN
dpc-4176	140	33	at	at	ADP
dpc-4176	140	34	week	week	NOUN
dpc-4176	140	35	24	24	NUM
dpc-4176	140	36	,	,	PUNCT
dpc-4176	140	37	similar	similar	ADJ
dpc-4176	140	38	proportions	proportion	NOUN
dpc-4176	140	39	of	of	ADP
dpc-4176	140	40	patients	patient	NOUN
dpc-4176	140	41	in	in	ADP
dpc-4176	140	42	the	the	DET
dpc-4176	140	43	guselkumab	guselkumab	NOUN
dpc-4176	140	44	and	and	CCONJ
dpc-4176	140	45	adalimumab	adalimumab	NOUN
dpc-4176	140	46	group	group	NOUN
dpc-4176	140	47	achieved	achieve	VERB
dpc-4176	140	48	a	a	DET
dpc-4176	140	49	100	100	NUM
dpc-4176	140	50	%	%	NOUN
dpc-4176	140	51	improvement	improvement	NOUN
dpc-4176	140	52	in	in	ADP
dpc-4176	140	53	target	target	NOUN
dpc-4176	140	54	napsi	napsi	NOUN
dpc-4176	140	55	(	(	PUNCT
dpc-4176	140	56	20	20	NUM
dpc-4176	140	57	%	%	NOUN
dpc-4176	140	58	versus	versus	ADP
dpc-4176	140	59	21	21	NUM
dpc-4176	140	60	%	%	NOUN
dpc-4176	140	61	respectively	respectively	ADV
dpc-4176	140	62	)	)	PUNCT
dpc-4176	141	1	(	(	PUNCT
dpc-4176	141	2	p	p	X
dpc-4176	141	3	=	=	NOUN
dpc-4176	141	4	0.864	0.864	NUM
dpc-4176	141	5	)	)	PUNCT
dpc-4176	141	6	.	.	PUNCT
dpc-4176	142	1	none	none	NOUN
dpc-4176	142	2	napsi	napsi	NOUN
dpc-4176	142	3	=	=	SYM
dpc-4176	142	4	nail	nail	NOUN
dpc-4176	142	5	psoriasis	psoriasis	NOUN
dpc-4176	142	6	severity	severity	NOUN
dpc-4176	142	7	index	index	NOUN
dpc-4176	142	8	.	.	PUNCT
dpc-4176	143	1	palmoplantar	palmoplantar	NOUN
dpc-4176	143	2	pustulosis	pustulosis	NOUN
dpc-4176	143	3	palmoplantar	palmoplantar	NOUN
dpc-4176	143	4	pustulosis	pustulosis	NOUN
dpc-4176	143	5	presents	present	NOUN
dpc-4176	143	6	as	as	ADP
dpc-4176	143	7	multiple	multiple	ADJ
dpc-4176	143	8	,	,	PUNCT
dpc-4176	143	9	sterile	sterile	ADJ
dpc-4176	143	10	pustules/	pustules/	NUM
dpc-4176	143	11	vesiculopustules	vesiculopustule	NOUN
dpc-4176	143	12	,	,	PUNCT
dpc-4176	143	13	crusting	crust	VERB
dpc-4176	143	14	and	and	CCONJ
dpc-4176	143	15	erythema	erythema	ADV
dpc-4176	143	16	involving	involve	VERB
dpc-4176	143	17	the	the	DET
dpc-4176	143	18	palms	palm	NOUN
dpc-4176	143	19	and	and	CCONJ
dpc-4176	143	20	soles	sol	NOUN
dpc-4176	143	21	,	,	PUNCT
dpc-4176	143	22	and	and	CCONJ
dpc-4176	143	23	is	be	AUX
dpc-4176	143	24	considered	consider	VERB
dpc-4176	143	25	a	a	DET
dpc-4176	143	26	localized	localized	ADJ
dpc-4176	143	27	variant	variant	NOUN
dpc-4176	143	28	of	of	ADP
dpc-4176	143	29	pustular	pustular	ADJ
dpc-4176	143	30	psoriasis	psoriasis	NOUN
dpc-4176	144	1	[	[	X
dpc-4176	144	2	39	39	NUM
dpc-4176	144	3	]	]	PUNCT
dpc-4176	144	4	.	.	PUNCT
dpc-4176	145	1	the	the	DET
dpc-4176	145	2	clinical	clinical	ADJ
dpc-4176	145	3	efficacy	efficacy	NOUN
dpc-4176	145	4	of	of	ADP
dpc-4176	145	5	sc	sc	PROPN
dpc-4176	145	6	injections	injection	NOUN
dpc-4176	145	7	of	of	ADP
dpc-4176	145	8	guselkumab	guselkumab	NOUN
dpc-4176	145	9	(	(	PUNCT
dpc-4176	145	10	200	200	NUM
dpc-4176	145	11	mg	mg	NOUN
dpc-4176	145	12	at	at	ADP
dpc-4176	145	13	weeks	week	NOUN
dpc-4176	145	14	0	0	NUM
dpc-4176	145	15	and	and	CCONJ
dpc-4176	145	16	4	4	NUM
dpc-4176	145	17	)	)	PUNCT
dpc-4176	145	18	was	be	AUX
dpc-4176	145	19	assessed	assess	VERB
dpc-4176	145	20	for	for	ADP
dpc-4176	145	21	moderate	moderate	ADJ
dpc-4176	145	22	-	-	PUNCT
dpc-4176	145	23	to	to	ADP
dpc-4176	145	24	severe	severe	ADJ
dpc-4176	145	25	palmoplantar	palmoplantar	NOUN
dpc-4176	145	26	pustulosis	pustulosis	NOUN
dpc-4176	145	27	that	that	PRON
dpc-4176	145	28	had	have	AUX
dpc-4176	145	29	been	be	AUX
dpc-4176	145	30	unresponsive	unresponsive	ADJ
dpc-4176	145	31	to	to	ADP
dpc-4176	145	32	topical	topical	ADJ
dpc-4176	145	33	steroids	steroid	NOUN
dpc-4176	145	34	,	,	PUNCT
dpc-4176	145	35	vitamin	vitamin	NOUN
dpc-4176	145	36	d3	d3	PROPN
dpc-4176	145	37	analogues	analogue	NOUN
dpc-4176	145	38	,	,	PUNCT
dpc-4176	145	39	etretinate	etretinate	NOUN
dpc-4176	145	40	and	and	CCONJ
dpc-4176	145	41	phototherapy	phototherapy	NOUN
dpc-4176	145	42	,	,	PUNCT
dpc-4176	145	43	in	in	ADP
dpc-4176	145	44	a	a	DET
dpc-4176	145	45	randomized	randomized	ADJ
dpc-4176	145	46	double	double	ADJ
dpc-4176	145	47	-	-	PUNCT
dpc-4176	145	48	blind	blind	ADJ
dpc-4176	145	49	placebo	placebo	NOUN
dpc-4176	145	50	-	-	PUNCT
dpc-4176	145	51	controlled	control	VERB
dpc-4176	145	52	review	review	NOUN
dpc-4176	145	53	|	|	ADV
dpc-4176	145	54	dermatol	dermatol	ADJ
dpc-4176	145	55	pract	pract	NOUN
dpc-4176	145	56	concept	concept	NOUN
dpc-4176	145	57	.	.	PUNCT
dpc-4176	146	1	2024;14(3):e2024181	2024;14(3):e2024181	NUM
dpc-4176	146	2	7	7	NUM
dpc-4176	146	3	clinical	clinical	ADJ
dpc-4176	146	4	trial	trial	NOUN
dpc-4176	146	5	.	.	PUNCT
dpc-4176	147	1	at	at	ADP
dpc-4176	147	2	week	week	NOUN
dpc-4176	147	3	16	16	NUM
dpc-4176	147	4	,	,	PUNCT
dpc-4176	147	5	there	there	PRON
dpc-4176	147	6	was	be	VERB
dpc-4176	147	7	significant	significant	ADJ
dpc-4176	147	8	reduction	reduction	NOUN
dpc-4176	147	9	in	in	ADP
dpc-4176	147	10	the	the	DET
dpc-4176	147	11	mean	mean	ADJ
dpc-4176	147	12	(	(	PUNCT
dpc-4176	147	13	sd	sd	NOUN
dpc-4176	147	14	)	)	PUNCT
dpc-4176	147	15	palmoplantar	palmoplantar	NOUN
dpc-4176	147	16	pustulosis	pustulosis	NOUN
dpc-4176	147	17	severity	severity	NOUN
dpc-4176	147	18	index	index	NOUN
dpc-4176	147	19	(	(	PUNCT
dpc-4176	147	20	ppsi	ppsi	NOUN
dpc-4176	147	21	)	)	PUNCT
dpc-4176	147	22	total	total	ADJ
dpc-4176	147	23	scores	score	NOUN
dpc-4176	147	24	from	from	ADP
dpc-4176	147	25	baseline	baseline	NOUN
dpc-4176	147	26	in	in	ADP
dpc-4176	147	27	the	the	DET
dpc-4176	147	28	guselkumab	guselkumab	NOUN
dpc-4176	147	29	group	group	NOUN
dpc-4176	147	30	(	(	PUNCT
dpc-4176	147	31	-3.3	-3.3	PROPN
dpc-4176	147	32	[	[	X
dpc-4176	147	33	2.43	2.43	NUM
dpc-4176	147	34	]	]	PUNCT
dpc-4176	147	35	)	)	PUNCT
dpc-4176	147	36	versus	versus	ADP
dpc-4176	147	37	placebo	placebo	NOUN
dpc-4176	147	38	group	group	NOUN
dpc-4176	147	39	(	(	PUNCT
dpc-4176	147	40	-1.8	-1.8	PROPN
dpc-4176	148	1	[	[	X
dpc-4176	148	2	2.09	2.09	NUM
dpc-4176	148	3	]	]	PUNCT
dpc-4176	148	4	)	)	PUNCT
dpc-4176	148	5	.	.	PUNCT
dpc-4176	149	1	this	this	DET
dpc-4176	149	2	reduction	reduction	NOUN
dpc-4176	149	3	was	be	AUX
dpc-4176	149	4	maintained	maintain	VERB
dpc-4176	149	5	at	at	ADP
dpc-4176	149	6	week	week	NOUN
dpc-4176	149	7	24	24	NUM
dpc-4176	149	8	in	in	ADP
dpc-4176	149	9	the	the	DET
dpc-4176	149	10	guselkumab	guselkumab	NOUN
dpc-4176	149	11	group	group	NOUN
dpc-4176	149	12	(	(	PUNCT
dpc-4176	149	13	-3.9	-3.9	NOUN
dpc-4176	149	14	[	[	X
dpc-4176	149	15	2.47	2.47	NUM
dpc-4176	149	16	]	]	PUNCT
dpc-4176	149	17	)	)	PUNCT
dpc-4176	149	18	versus	versus	ADP
dpc-4176	149	19	placebo	placebo	NOUN
dpc-4176	149	20	group	group	NOUN
dpc-4176	149	21	(	(	PUNCT
dpc-4176	149	22	-2.5	-2.5	PROPN
dpc-4176	150	1	[	[	X
dpc-4176	150	2	2.78	2.78	NUM
dpc-4176	150	3	]	]	PUNCT
dpc-4176	150	4	)	)	PUNCT
dpc-4176	150	5	.	.	PUNCT
dpc-4176	151	1	regarding	regard	VERB
dpc-4176	151	2	biomarkers	biomarker	NOUN
dpc-4176	151	3	,	,	PUNCT
dpc-4176	151	4	notable	notable	ADJ
dpc-4176	151	5	reduction	reduction	NOUN
dpc-4176	151	6	from	from	ADP
dpc-4176	151	7	baseline	baseline	NOUN
dpc-4176	151	8	in	in	ADP
dpc-4176	151	9	circulating	circulate	VERB
dpc-4176	151	10	il17a	il17a	PROPN
dpc-4176	151	11	levels	level	NOUN
dpc-4176	151	12	was	be	AUX
dpc-4176	151	13	observed	observe	VERB
dpc-4176	151	14	at	at	ADP
dpc-4176	151	15	week	week	NOUN
dpc-4176	151	16	4	4	NUM
dpc-4176	151	17	and	and	CCONJ
dpc-4176	151	18	16	16	NUM
dpc-4176	151	19	for	for	ADP
dpc-4176	151	20	guselkumab	guselkumab	NOUN
dpc-4176	151	21	treated	treat	VERB
dpc-4176	151	22	patients	patient	NOUN
dpc-4176	151	23	,	,	PUNCT
dpc-4176	151	24	while	while	SCONJ
dpc-4176	151	25	no	no	DET
dpc-4176	151	26	remarkable	remarkable	ADJ
dpc-4176	151	27	change	change	NOUN
dpc-4176	151	28	was	be	AUX
dpc-4176	151	29	noted	note	VERB
dpc-4176	151	30	in	in	ADP
dpc-4176	151	31	the	the	DET
dpc-4176	151	32	placebo	placebo	NOUN
dpc-4176	151	33	group	group	NOUN
dpc-4176	152	1	[	[	X
dpc-4176	152	2	40	40	NUM
dpc-4176	152	3	]	]	PUNCT
dpc-4176	152	4	.	.	PUNCT
dpc-4176	153	1	in	in	ADP
dpc-4176	153	2	a	a	DET
dpc-4176	153	3	phase	phase	NOUN
dpc-4176	153	4	3	3	NUM
dpc-4176	153	5	rct	rct	NOUN
dpc-4176	153	6	,	,	PUNCT
dpc-4176	153	7	patients	patient	NOUN
dpc-4176	153	8	were	be	AUX
dpc-4176	153	9	assigned	assign	VERB
dpc-4176	153	10	to	to	PART
dpc-4176	153	11	receive	receive	VERB
dpc-4176	153	12	guselkumab	guselkumab	NOUN
dpc-4176	153	13	(	(	PUNCT
dpc-4176	153	14	100	100	NUM
dpc-4176	153	15	mg	mg	NUM
dpc-4176	153	16	;	;	PUNCT
dpc-4176	153	17	n	n	PROPN
dpc-4176	153	18	=	=	SYM
dpc-4176	153	19	54	54	NUM
dpc-4176	153	20	)	)	PUNCT
dpc-4176	153	21	,	,	PUNCT
dpc-4176	153	22	guselkumab	guselkumab	NOUN
dpc-4176	153	23	(	(	PUNCT
dpc-4176	153	24	200	200	NUM
dpc-4176	153	25	mg	mg	NOUN
dpc-4176	153	26	;	;	PUNCT
dpc-4176	153	27	n	n	PROPN
dpc-4176	153	28	=	=	SYM
dpc-4176	153	29	52	52	NUM
dpc-4176	153	30	)	)	PUNCT
dpc-4176	153	31	or	or	CCONJ
dpc-4176	153	32	placebo	placebo	NOUN
dpc-4176	153	33	(	(	PUNCT
dpc-4176	153	34	n	n	NOUN
dpc-4176	153	35	=	=	SYM
dpc-4176	153	36	53	53	NUM
dpc-4176	153	37	)	)	PUNCT
dpc-4176	153	38	for	for	ADP
dpc-4176	153	39	palmoplantar	palmoplantar	NOUN
dpc-4176	153	40	pustulosis	pustulosis	NOUN
dpc-4176	153	41	.	.	PUNCT
dpc-4176	154	1	a	a	DET
dpc-4176	154	2	significantly	significantly	ADV
dpc-4176	154	3	higher	high	ADJ
dpc-4176	154	4	proportion	proportion	NOUN
dpc-4176	154	5	of	of	ADP
dpc-4176	154	6	patients	patient	NOUN
dpc-4176	154	7	in	in	ADP
dpc-4176	154	8	the	the	DET
dpc-4176	154	9	guselkumab	guselkumab	NOUN
dpc-4176	154	10	(	(	PUNCT
dpc-4176	154	11	100	100	NUM
dpc-4176	154	12	mg	mg	NUM
dpc-4176	154	13	)	)	PUNCT
dpc-4176	154	14	group	group	NOUN
dpc-4176	154	15	achieved	achieve	VERB
dpc-4176	154	16	a	a	DET
dpc-4176	154	17	pppasi	pppasi	ADJ
dpc-4176	154	18	50	50	NUM
dpc-4176	154	19	response	response	NOUN
dpc-4176	154	20	(	(	PUNCT
dpc-4176	154	21	57.4	57.4	NUM
dpc-4176	154	22	%	%	NOUN
dpc-4176	154	23	)	)	PUNCT
dpc-4176	154	24	at	at	ADP
dpc-4176	154	25	week	week	NOUN
dpc-4176	154	26	16	16	NUM
dpc-4176	154	27	,	,	PUNCT
dpc-4176	154	28	when	when	SCONJ
dpc-4176	154	29	compared	compare	VERB
dpc-4176	154	30	to	to	ADP
dpc-4176	154	31	the	the	DET
dpc-4176	154	32	guselkumab	guselkumab	NOUN
dpc-4176	154	33	(	(	PUNCT
dpc-4176	154	34	200	200	NUM
dpc-4176	154	35	mg	mg	NOUN
dpc-4176	154	36	;	;	PUNCT
dpc-4176	154	37	36.5	36.5	NUM
dpc-4176	154	38	%	%	NOUN
dpc-4176	154	39	)	)	PUNCT
dpc-4176	154	40	and	and	CCONJ
dpc-4176	154	41	placebo	placebo	NOUN
dpc-4176	154	42	(	(	PUNCT
dpc-4176	154	43	34	34	NUM
dpc-4176	154	44	%	%	NOUN
dpc-4176	154	45	)	)	PUNCT
dpc-4176	154	46	groups	group	NOUN
dpc-4176	154	47	.	.	PUNCT
dpc-4176	155	1	however	however	ADV
dpc-4176	155	2	,	,	PUNCT
dpc-4176	155	3	the	the	DET
dpc-4176	155	4	proportions	proportion	NOUN
dpc-4176	155	5	of	of	ADP
dpc-4176	155	6	patients	patient	NOUN
dpc-4176	155	7	achieving	achieve	VERB
dpc-4176	155	8	a	a	DET
dpc-4176	155	9	pppasi	pppasi	NOUN
dpc-4176	155	10	50	50	NUM
dpc-4176	155	11	response	response	NOUN
dpc-4176	155	12	increased	increase	VERB
dpc-4176	155	13	over	over	ADP
dpc-4176	155	14	time	time	NOUN
dpc-4176	155	15	,	,	PUNCT
dpc-4176	155	16	and	and	CCONJ
dpc-4176	155	17	at	at	ADP
dpc-4176	155	18	week	week	NOUN
dpc-4176	155	19	52	52	NUM
dpc-4176	155	20	,	,	PUNCT
dpc-4176	155	21	83.3	83.3	NUM
dpc-4176	155	22	%	%	NOUN
dpc-4176	155	23	patients	patient	NOUN
dpc-4176	155	24	in	in	ADP
dpc-4176	155	25	the	the	DET
dpc-4176	155	26	guselkumab	guselkumab	NOUN
dpc-4176	155	27	(	(	PUNCT
dpc-4176	155	28	100	100	NUM
dpc-4176	155	29	mg	mg	NUM
dpc-4176	155	30	)	)	PUNCT
dpc-4176	155	31	group	group	NOUN
dpc-4176	155	32	and	and	CCONJ
dpc-4176	155	33	84.6	84.6	NUM
dpc-4176	155	34	%	%	NOUN
dpc-4176	155	35	patients	patient	NOUN
dpc-4176	155	36	in	in	ADP
dpc-4176	155	37	the	the	DET
dpc-4176	155	38	guselkumab	guselkumab	NOUN
dpc-4176	155	39	(	(	PUNCT
dpc-4176	155	40	200	200	NUM
dpc-4176	155	41	mg	mg	NOUN
dpc-4176	155	42	)	)	PUNCT
dpc-4176	155	43	group	group	NOUN
dpc-4176	155	44	demonstrated	demonstrate	VERB
dpc-4176	155	45	this	this	DET
dpc-4176	155	46	change	change	NOUN
dpc-4176	155	47	.	.	PUNCT
dpc-4176	156	1	besides	besides	SCONJ
dpc-4176	156	2	,	,	PUNCT
dpc-4176	156	3	there	there	PRON
dpc-4176	156	4	was	be	VERB
dpc-4176	156	5	remarkable	remarkable	ADJ
dpc-4176	156	6	improvement	improvement	NOUN
dpc-4176	156	7	in	in	ADP
dpc-4176	156	8	the	the	DET
dpc-4176	156	9	dlqi	dlqi	NOUN
dpc-4176	156	10	and	and	CCONJ
dpc-4176	156	11	physician	physician	NOUN
dpc-4176	156	12	global	global	ADJ
dpc-4176	156	13	assessment	assessment	NOUN
dpc-4176	156	14	(	(	PUNCT
dpc-4176	156	15	pga	pga	PROPN
dpc-4176	156	16	)	)	PUNCT
dpc-4176	156	17	scores	score	NOUN
dpc-4176	156	18	(	(	PUNCT
dpc-4176	156	19	of	of	ADP
dpc-4176	156	20	cleared	clear	VERB
dpc-4176	156	21	and	and	CCONJ
dpc-4176	156	22	almost	almost	ADV
dpc-4176	156	23	cleared	clear	VERB
dpc-4176	156	24	)	)	PUNCT
dpc-4176	156	25	in	in	ADP
dpc-4176	156	26	both	both	DET
dpc-4176	156	27	guselkumab	guselkumab	NOUN
dpc-4176	156	28	groups	group	NOUN
dpc-4176	156	29	when	when	SCONJ
dpc-4176	156	30	compared	compare	VERB
dpc-4176	156	31	to	to	ADP
dpc-4176	156	32	the	the	DET
dpc-4176	156	33	placebo	placebo	NOUN
dpc-4176	156	34	group	group	NOUN
dpc-4176	156	35	[	[	X
dpc-4176	156	36	41	41	NUM
dpc-4176	156	37	]	]	PUNCT
dpc-4176	156	38	.	.	PUNCT
dpc-4176	157	1	in	in	ADP
dpc-4176	157	2	another	another	DET
dpc-4176	157	3	study	study	NOUN
dpc-4176	157	4	,	,	PUNCT
dpc-4176	157	5	guselkumab	guselkumab	NOUN
dpc-4176	157	6	demonstrated	demonstrate	VERB
dpc-4176	157	7	efficacy	efficacy	NOUN
dpc-4176	157	8	on	on	ADP
dpc-4176	157	9	palmoplantar	palmoplantar	ADJ
dpc-4176	157	10	pustulosis	pustulosis	NOUN
dpc-4176	157	11	through	through	ADP
dpc-4176	157	12	week	week	NOUN
dpc-4176	157	13	60	60	NUM
dpc-4176	157	14	with	with	ADP
dpc-4176	157	15	sustenance	sustenance	NOUN
dpc-4176	157	16	of	of	ADP
dpc-4176	157	17	efficacy	efficacy	NOUN
dpc-4176	157	18	until	until	ADP
dpc-4176	157	19	week	week	NOUN
dpc-4176	157	20	84	84	NUM
dpc-4176	157	21	,	,	PUNCT
dpc-4176	157	22	along	along	ADP
dpc-4176	157	23	with	with	ADP
dpc-4176	157	24	considerable	considerable	ADJ
dpc-4176	157	25	improvement	improvement	NOUN
dpc-4176	157	26	in	in	ADP
dpc-4176	157	27	hr	hr	NOUN
dpc-4176	157	28	-	-	NOUN
dpc-4176	157	29	qol	qol	NOUN
dpc-4176	157	30	.	.	PUNCT
dpc-4176	158	1	at	at	ADP
dpc-4176	158	2	week	week	NOUN
dpc-4176	158	3	60	60	NUM
dpc-4176	158	4	,	,	PUNCT
dpc-4176	158	5	pppasi	pppasi	NOUN
dpc-4176	158	6	50	50	NUM
dpc-4176	158	7	was	be	AUX
dpc-4176	158	8	79.6	79.6	NUM
dpc-4176	158	9	%	%	NOUN
dpc-4176	158	10	,	,	PUNCT
dpc-4176	158	11	84.6	84.6	NUM
dpc-4176	158	12	%	%	NOUN
dpc-4176	158	13	,	,	PUNCT
dpc-4176	158	14	80.0	80.0	NUM
dpc-4176	158	15	%	%	NOUN
dpc-4176	158	16	and	and	CCONJ
dpc-4176	158	17	80.8	80.8	NUM
dpc-4176	158	18	%	%	NOUN
dpc-4176	158	19	in	in	ADP
dpc-4176	158	20	the	the	DET
dpc-4176	158	21	guselkumab	guselkumab	NOUN
dpc-4176	158	22	(	(	PUNCT
dpc-4176	158	23	100	100	NUM
dpc-4176	158	24	mg	mg	NUM
dpc-4176	158	25	)	)	PUNCT
dpc-4176	158	26	,	,	PUNCT
dpc-4176	158	27	guselkumab	guselkumab	NOUN
dpc-4176	158	28	(	(	PUNCT
dpc-4176	158	29	200	200	NUM
dpc-4176	158	30	mg	mg	NOUN
dpc-4176	158	31	)	)	PUNCT
dpc-4176	158	32	,	,	PUNCT
dpc-4176	158	33	placebo	placebo	NOUN
dpc-4176	158	34	to	to	ADP
dpc-4176	158	35	guselkumab	guselkumab	NOUN
dpc-4176	158	36	(	(	PUNCT
dpc-4176	158	37	100	100	NUM
dpc-4176	158	38	mg	mg	NUM
dpc-4176	158	39	)	)	PUNCT
dpc-4176	158	40	and	and	CCONJ
dpc-4176	158	41	placebo	placebo	NOUN
dpc-4176	158	42	to	to	ADP
dpc-4176	158	43	guselkumab	guselkumab	NOUN
dpc-4176	158	44	(	(	PUNCT
dpc-4176	158	45	200	200	NUM
dpc-4176	158	46	mg	mg	NOUN
dpc-4176	158	47	)	)	PUNCT
dpc-4176	158	48	groups	group	NOUN
dpc-4176	158	49	respectively	respectively	ADV
dpc-4176	158	50	,	,	PUNCT
dpc-4176	158	51	which	which	PRON
dpc-4176	158	52	had	have	AUX
dpc-4176	158	53	increased	increase	VERB
dpc-4176	158	54	to	to	ADP
dpc-4176	158	55	88.9	88.9	NUM
dpc-4176	158	56	%	%	NOUN
dpc-4176	158	57	,	,	PUNCT
dpc-4176	158	58	95.3	95.3	NUM
dpc-4176	158	59	%	%	NOUN
dpc-4176	158	60	,	,	PUNCT
dpc-4176	158	61	85.7	85.7	NUM
dpc-4176	158	62	%	%	NOUN
dpc-4176	158	63	and	and	CCONJ
dpc-4176	158	64	87.5	87.5	NUM
dpc-4176	158	65	%	%	NOUN
dpc-4176	158	66	respectively	respectively	ADV
dpc-4176	158	67	at	at	ADP
dpc-4176	158	68	week	week	NOUN
dpc-4176	158	69	84	84	NUM
dpc-4176	159	1	[	[	X
dpc-4176	159	2	42	42	NUM
dpc-4176	159	3	]	]	PUNCT
dpc-4176	159	4	.	.	PUNCT
dpc-4176	160	1	the	the	DET
dpc-4176	160	2	propitious	propitious	ADJ
dpc-4176	160	3	effects	effect	NOUN
dpc-4176	160	4	of	of	ADP
dpc-4176	160	5	guselkumab	guselkumab	NOUN
dpc-4176	160	6	in	in	ADP
dpc-4176	160	7	palmoplantar	palmoplantar	ADJ
dpc-4176	160	8	pustulosis	pustulosis	NOUN
dpc-4176	160	9	is	be	AUX
dpc-4176	160	10	connected	connect	VERB
dpc-4176	160	11	to	to	ADP
dpc-4176	160	12	significant	significant	ADJ
dpc-4176	160	13	reduction	reduction	NOUN
dpc-4176	160	14	of	of	ADP
dpc-4176	160	15	levels	level	NOUN
dpc-4176	160	16	of	of	ADP
dpc-4176	160	17	cytokines	cytokine	NOUN
dpc-4176	160	18	like	like	ADP
dpc-4176	160	19	il-17a	il-17a	PROPN
dpc-4176	160	20	,	,	PUNCT
dpc-4176	160	21	il-17f	il-17f	ADJ
dpc-4176	160	22	and	and	CCONJ
dpc-4176	160	23	il-22	il-22	NOUN
dpc-4176	160	24	,	,	PUNCT
dpc-4176	160	25	that	that	PRON
dpc-4176	160	26	are	be	AUX
dpc-4176	160	27	considerably	considerably	ADV
dpc-4176	160	28	elevated	elevate	VERB
dpc-4176	160	29	,	,	PUNCT
dpc-4176	160	30	and	and	CCONJ
dpc-4176	160	31	correlate	correlate	VERB
dpc-4176	160	32	with	with	ADP
dpc-4176	160	33	pppasi	pppasi	NOUN
dpc-4176	160	34	disease	disease	NOUN
dpc-4176	160	35	scores	score	NOUN
dpc-4176	160	36	.	.	PUNCT
dpc-4176	161	1	guselkumab	guselkumab	NOUN
dpc-4176	161	2	therapy	therapy	NOUN
dpc-4176	161	3	results	result	VERB
dpc-4176	161	4	in	in	ADP
dpc-4176	161	5	1.8	1.8	NUM
dpc-4176	161	6	-	-	PUNCT
dpc-4176	161	7	to-3	to-3	NOUN
dpc-4176	161	8	-	-	ADJ
dpc-4176	161	9	fold	fold	ADJ
dpc-4176	161	10	reduction	reduction	NOUN
dpc-4176	161	11	of	of	ADP
dpc-4176	161	12	these	these	DET
dpc-4176	161	13	cytokines	cytokine	NOUN
dpc-4176	161	14	by	by	ADP
dpc-4176	161	15	week	week	NOUN
dpc-4176	161	16	72	72	NUM
dpc-4176	161	17	,	,	PUNCT
dpc-4176	161	18	with	with	ADP
dpc-4176	161	19	greater	great	ADJ
dpc-4176	161	20	levels	level	NOUN
dpc-4176	161	21	of	of	ADP
dpc-4176	161	22	reduction	reduction	NOUN
dpc-4176	161	23	in	in	ADP
dpc-4176	161	24	il-22	il-22	NOUN
dpc-4176	161	25	that	that	PRON
dpc-4176	161	26	is	be	AUX
dpc-4176	161	27	crucial	crucial	ADJ
dpc-4176	161	28	in	in	ADP
dpc-4176	161	29	bringing	bring	VERB
dpc-4176	161	30	about	about	ADP
dpc-4176	161	31	an	an	DET
dpc-4176	161	32	overall	overall	ADJ
dpc-4176	161	33	better	well	ADJ
dpc-4176	161	34	pppasi	pppasi	NOUN
dpc-4176	161	35	improvement	improvement	NOUN
dpc-4176	161	36	[	[	X
dpc-4176	161	37	43	43	NUM
dpc-4176	161	38	]	]	PUNCT
dpc-4176	161	39	.	.	PUNCT
dpc-4176	162	1	psoriatic	psoriatic	ADJ
dpc-4176	162	2	arthropathy	arthropathy	ADJ
dpc-4176	162	3	psoriatic	psoriatic	ADJ
dpc-4176	162	4	arthropathy	arthropathy	ADJ
dpc-4176	162	5	(	(	PUNCT
dpc-4176	162	6	psa	psa	NOUN
dpc-4176	162	7	)	)	PUNCT
dpc-4176	162	8	is	be	AUX
dpc-4176	162	9	a	a	DET
dpc-4176	162	10	heterogenous	heterogenous	ADJ
dpc-4176	162	11	inflammatory	inflammatory	ADJ
dpc-4176	162	12	disorder	disorder	NOUN
dpc-4176	162	13	associated	associate	VERB
dpc-4176	162	14	with	with	ADP
dpc-4176	162	15	peripheral	peripheral	ADJ
dpc-4176	162	16	joint	joint	ADJ
dpc-4176	162	17	inflammation	inflammation	NOUN
dpc-4176	162	18	,	,	PUNCT
dpc-4176	162	19	enthesitis	enthesitis	PROPN
dpc-4176	162	20	,	,	PUNCT
dpc-4176	162	21	dactylitis	dactylitis	NOUN
dpc-4176	162	22	,	,	PUNCT
dpc-4176	162	23	axial	axial	ADJ
dpc-4176	162	24	disease	disease	NOUN
dpc-4176	162	25	along	along	ADP
dpc-4176	162	26	with	with	ADP
dpc-4176	162	27	cutaneous/	cutaneous/	NUM
dpc-4176	162	28	nail	nail	NOUN
dpc-4176	162	29	involvement	involvement	NOUN
dpc-4176	162	30	and	and	CCONJ
dpc-4176	162	31	significant	significant	ADJ
dpc-4176	162	32	physical	physical	ADJ
dpc-4176	162	33	and	and	CCONJ
dpc-4176	162	34	psychologic	psychologic	ADJ
dpc-4176	162	35	repercussions	repercussion	NOUN
dpc-4176	162	36	.	.	PUNCT
dpc-4176	163	1	il-23	il-23	NOUN
dpc-4176	163	2	/	/	SYM
dpc-4176	163	3	th17	th17	NOUN
dpc-4176	163	4	axis	axis	NOUN
dpc-4176	163	5	has	have	AUX
dpc-4176	163	6	shown	show	VERB
dpc-4176	163	7	to	to	PART
dpc-4176	163	8	be	be	AUX
dpc-4176	163	9	critical	critical	ADJ
dpc-4176	163	10	in	in	ADP
dpc-4176	163	11	the	the	DET
dpc-4176	163	12	pathogenesis	pathogenesis	NOUN
dpc-4176	163	13	of	of	ADP
dpc-4176	163	14	psa	psa	NOUN
dpc-4176	163	15	(	(	PUNCT
dpc-4176	163	16	including	include	VERB
dpc-4176	163	17	enthesitis	enthesitis	NOUN
dpc-4176	163	18	and	and	CCONJ
dpc-4176	163	19	dactylitis	dactylitis	NOUN
dpc-4176	163	20	)	)	PUNCT
dpc-4176	164	1	[	[	X
dpc-4176	164	2	44	44	NUM
dpc-4176	164	3	]	]	PUNCT
dpc-4176	164	4	.	.	PUNCT
dpc-4176	165	1	resident	resident	ADJ
dpc-4176	165	2	myeloid	myeloid	ADJ
dpc-4176	165	3	cells	cell	NOUN
dpc-4176	165	4	within	within	ADP
dpc-4176	165	5	the	the	DET
dpc-4176	165	6	enthesis	enthesis	NOUN
dpc-4176	165	7	of	of	ADP
dpc-4176	165	8	normal	normal	ADJ
dpc-4176	165	9	human	human	ADJ
dpc-4176	165	10	subjects	subject	NOUN
dpc-4176	165	11	are	be	AUX
dpc-4176	165	12	capable	capable	ADJ
dpc-4176	165	13	of	of	ADP
dpc-4176	165	14	producing	produce	VERB
dpc-4176	165	15	il-23	il-23	NOUN
dpc-4176	165	16	,	,	PUNCT
dpc-4176	165	17	which	which	PRON
dpc-4176	165	18	in	in	ADP
dpc-4176	165	19	turn	turn	NOUN
dpc-4176	165	20	permits	permit	VERB
dpc-4176	165	21	downstream	downstream	ADJ
dpc-4176	165	22	il-17a	il-17a	PROPN
dpc-4176	165	23	expression	expression	NOUN
dpc-4176	165	24	and	and	CCONJ
dpc-4176	165	25	induces	induce	VERB
dpc-4176	165	26	il-22	il-22	PRON
dpc-4176	165	27	and	and	CCONJ
dpc-4176	165	28	tnf	tnf	PROPN
dpc-4176	165	29	release	release	NOUN
dpc-4176	165	30	,	,	PUNCT
dpc-4176	165	31	thereby	thereby	ADV
dpc-4176	165	32	eliciting	elicit	VERB
dpc-4176	165	33	articular	articular	ADJ
dpc-4176	165	34	symptoms	symptom	NOUN
dpc-4176	165	35	and	and	CCONJ
dpc-4176	165	36	subsequent	subsequent	ADJ
dpc-4176	165	37	joint	joint	ADJ
dpc-4176	165	38	damage	damage	NOUN
dpc-4176	165	39	.	.	PUNCT
dpc-4176	166	1	further	far	ADV
dpc-4176	166	2	,	,	PUNCT
dpc-4176	166	3	il-17a	il-17a	PROPN
dpc-4176	166	4	has	have	AUX
dpc-4176	166	5	shown	show	VERB
dpc-4176	166	6	to	to	PART
dpc-4176	166	7	have	have	VERB
dpc-4176	166	8	an	an	DET
dpc-4176	166	9	equal	equal	ADJ
dpc-4176	166	10	role	role	NOUN
dpc-4176	166	11	in	in	ADP
dpc-4176	166	12	bone	bone	NOUN
dpc-4176	166	13	remodeling	remodeling	NOUN
dpc-4176	166	14	by	by	ADP
dpc-4176	166	15	stimulating	stimulate	VERB
dpc-4176	166	16	osteoclastogenesis	osteoclastogenesis	NOUN
dpc-4176	166	17	and	and	CCONJ
dpc-4176	166	18	facilitating	facilitate	VERB
dpc-4176	166	19	expression	expression	NOUN
dpc-4176	166	20	of	of	ADP
dpc-4176	166	21	the	the	DET
dpc-4176	166	22	receptor	receptor	NOUN
dpc-4176	166	23	activator	activator	NOUN
dpc-4176	166	24	of	of	ADP
dpc-4176	166	25	nuclear	nuclear	ADJ
dpc-4176	166	26	factor	factor	NOUN
dpc-4176	166	27	κβ	κβ	PROPN
dpc-4176	166	28	ligand	ligand	NOUN
dpc-4176	166	29	(	(	PUNCT
dpc-4176	166	30	an	an	DET
dpc-4176	166	31	osteoclast	osteoclast	ADJ
dpc-4176	166	32	differentiation	differentiation	NOUN
dpc-4176	166	33	factor	factor	NOUN
dpc-4176	166	34	)	)	PUNCT
dpc-4176	166	35	in	in	ADP
dpc-4176	166	36	osteoclast	osteoclast	ADJ
dpc-4176	166	37	supporting	support	VERB
dpc-4176	166	38	cells	cell	NOUN
dpc-4176	166	39	,	,	PUNCT
dpc-4176	166	40	furthering	further	VERB
dpc-4176	166	41	joint	joint	ADJ
dpc-4176	166	42	destruction	destruction	NOUN
dpc-4176	167	1	[	[	X
dpc-4176	167	2	45,46	45,46	NOUN
dpc-4176	167	3	]	]	X
dpc-4176	167	4	.	.	PUNCT
dpc-4176	168	1	as	as	SCONJ
dpc-4176	168	2	il-23	il-23	NOUN
dpc-4176	168	3	is	be	AUX
dpc-4176	168	4	involved	involve	VERB
dpc-4176	168	5	in	in	ADP
dpc-4176	168	6	the	the	DET
dpc-4176	168	7	regulation	regulation	NOUN
dpc-4176	168	8	of	of	ADP
dpc-4176	168	9	numerous	numerous	ADJ
dpc-4176	168	10	cytokines	cytokine	NOUN
dpc-4176	168	11	in	in	ADP
dpc-4176	168	12	the	the	DET
dpc-4176	168	13	pathogenesis	pathogenesis	NOUN
dpc-4176	168	14	of	of	ADP
dpc-4176	168	15	psa	psa	NOUN
dpc-4176	168	16	,	,	PUNCT
dpc-4176	168	17	targeting	target	VERB
dpc-4176	168	18	il-23	il-23	NOUN
dpc-4176	168	19	individually	individually	ADV
dpc-4176	168	20	,	,	PUNCT
dpc-4176	168	21	results	result	NOUN
dpc-4176	168	22	in	in	ADP
dpc-4176	168	23	the	the	DET
dpc-4176	168	24	inhibition	inhibition	NOUN
dpc-4176	168	25	of	of	ADP
dpc-4176	168	26	all	all	DET
dpc-4176	168	27	other	other	ADJ
dpc-4176	168	28	cytokines	cytokine	NOUN
dpc-4176	168	29	.	.	PUNCT
dpc-4176	169	1	guselkumab	guselkumab	NOUN
dpc-4176	169	2	,	,	PUNCT
dpc-4176	169	3	by	by	ADP
dpc-4176	169	4	blocking	block	VERB
dpc-4176	169	5	the	the	DET
dpc-4176	169	6	il-23	il-23	NOUN
dpc-4176	169	7	receptor	receptor	NOUN
dpc-4176	169	8	,	,	PUNCT
dpc-4176	169	9	prevents	prevent	VERB
dpc-4176	169	10	generation	generation	NOUN
dpc-4176	169	11	of	of	ADP
dpc-4176	169	12	inflammatory	inflammatory	ADJ
dpc-4176	169	13	cascades	cascade	NOUN
dpc-4176	169	14	in	in	ADP
dpc-4176	169	15	psa	psa	NOUN
dpc-4176	169	16	.	.	PUNCT
dpc-4176	170	1	besides	besides	ADV
dpc-4176	170	2	,	,	PUNCT
dpc-4176	170	3	as	as	SCONJ
dpc-4176	170	4	it	it	PRON
dpc-4176	170	5	selectively	selectively	ADV
dpc-4176	170	6	binds	bind	VERB
dpc-4176	170	7	to	to	ADP
dpc-4176	170	8	the	the	DET
dpc-4176	170	9	p19	p19	NOUN
dpc-4176	170	10	subunit	subunit	NOUN
dpc-4176	170	11	,	,	PUNCT
dpc-4176	170	12	it	it	PRON
dpc-4176	170	13	spares	spare	VERB
dpc-4176	170	14	il-12	il-12	NOUN
dpc-4176	170	15	,	,	PUNCT
dpc-4176	170	16	a	a	DET
dpc-4176	170	17	cytokine	cytokine	NOUN
dpc-4176	170	18	associated	associate	VERB
dpc-4176	170	19	with	with	ADP
dpc-4176	170	20	protection	protection	NOUN
dpc-4176	170	21	from	from	ADP
dpc-4176	170	22	autoimmune	autoimmune	ADJ
dpc-4176	170	23	inflammation	inflammation	NOUN
dpc-4176	170	24	and	and	CCONJ
dpc-4176	170	25	t	t	NOUN
dpc-4176	170	26	cell	cell	NOUN
dpc-4176	170	27	exhaustion	exhaustion	NOUN
dpc-4176	170	28	,	,	PUNCT
dpc-4176	170	29	giving	give	VERB
dpc-4176	170	30	it	it	PRON
dpc-4176	170	31	an	an	DET
dpc-4176	170	32	added	add	VERB
dpc-4176	170	33	advantage	advantage	NOUN
dpc-4176	170	34	[	[	X
dpc-4176	170	35	47	47	NUM
dpc-4176	170	36	-	-	SYM
dpc-4176	170	37	49	49	NUM
dpc-4176	170	38	]	]	PUNCT
dpc-4176	170	39	.	.	PUNCT
dpc-4176	171	1	table	table	NOUN
dpc-4176	171	2	3	3	NUM
dpc-4176	171	3	outlines	outline	VERB
dpc-4176	171	4	the	the	DET
dpc-4176	171	5	salient	salient	NOUN
dpc-4176	171	6	features	feature	NOUN
dpc-4176	171	7	of	of	ADP
dpc-4176	171	8	various	various	ADJ
dpc-4176	171	9	studies	study	NOUN
dpc-4176	171	10	employing	employ	VERB
dpc-4176	171	11	guselkumab	guselkumab	NOUN
dpc-4176	171	12	in	in	ADP
dpc-4176	171	13	the	the	DET
dpc-4176	171	14	treatment	treatment	NOUN
dpc-4176	171	15	of	of	ADP
dpc-4176	171	16	psa	psa	NOUN
dpc-4176	171	17	[	[	PUNCT
dpc-4176	171	18	50	50	NUM
dpc-4176	171	19	-	-	SYM
dpc-4176	171	20	53	53	NUM
dpc-4176	171	21	]	]	PUNCT
dpc-4176	171	22	.	.	PUNCT
dpc-4176	172	1	hidradenitis	hidradenitis	PROPN
dpc-4176	172	2	suppurativa	suppurativa	PROPN
dpc-4176	172	3	hs	hs	PROPN
dpc-4176	172	4	is	be	AUX
dpc-4176	172	5	a	a	DET
dpc-4176	172	6	chronic	chronic	ADJ
dpc-4176	172	7	inflammatory	inflammatory	ADJ
dpc-4176	172	8	condition	condition	NOUN
dpc-4176	172	9	of	of	ADP
dpc-4176	172	10	hair	hair	NOUN
dpc-4176	172	11	follicles	follicle	NOUN
dpc-4176	172	12	and	and	CCONJ
dpc-4176	172	13	can	can	AUX
dpc-4176	172	14	severely	severely	ADV
dpc-4176	172	15	affect	affect	VERB
dpc-4176	172	16	patients	patient	NOUN
dpc-4176	172	17	physically	physically	ADV
dpc-4176	172	18	and	and	CCONJ
dpc-4176	172	19	psychologically	psychologically	ADV
dpc-4176	172	20	.	.	PUNCT
dpc-4176	173	1	the	the	DET
dpc-4176	173	2	pathogenesis	pathogenesis	NOUN
dpc-4176	173	3	of	of	ADP
dpc-4176	173	4	hs	hs	PROPN
dpc-4176	173	5	occurs	occur	VERB
dpc-4176	173	6	secondary	secondary	ADJ
dpc-4176	173	7	to	to	ADP
dpc-4176	173	8	immune	immune	ADJ
dpc-4176	173	9	dysregulation	dysregulation	NOUN
dpc-4176	173	10	,	,	PUNCT
dpc-4176	173	11	with	with	ADP
dpc-4176	173	12	increased	increase	VERB
dpc-4176	173	13	levels	level	NOUN
dpc-4176	173	14	of	of	ADP
dpc-4176	173	15	proinflammatory	proinflammatory	ADJ
dpc-4176	173	16	cytokines	cytokine	NOUN
dpc-4176	173	17	in	in	ADP
dpc-4176	173	18	lesional	lesional	ADJ
dpc-4176	173	19	skin	skin	NOUN
dpc-4176	173	20	[	[	X
dpc-4176	173	21	54	54	NUM
dpc-4176	173	22	]	]	PUNCT
dpc-4176	173	23	.	.	PUNCT
dpc-4176	174	1	il-23	il-23	NOUN
dpc-4176	174	2	is	be	AUX
dpc-4176	174	3	involved	involve	VERB
dpc-4176	174	4	in	in	ADP
dpc-4176	174	5	the	the	DET
dpc-4176	174	6	differentiation	differentiation	NOUN
dpc-4176	174	7	of	of	ADP
dpc-4176	174	8	th17	th17	PROPN
dpc-4176	174	9	cells	cell	NOUN
dpc-4176	174	10	and	and	CCONJ
dpc-4176	174	11	thus	thus	ADV
dpc-4176	174	12	plays	play	VERB
dpc-4176	174	13	a	a	DET
dpc-4176	174	14	major	major	ADJ
dpc-4176	174	15	role	role	NOUN
dpc-4176	174	16	in	in	ADP
dpc-4176	174	17	hs	hs	PROPN
dpc-4176	174	18	,	,	PUNCT
dpc-4176	174	19	as	as	SCONJ
dpc-4176	174	20	both	both	DET
dpc-4176	174	21	il23	il23	PROPN
dpc-4176	174	22	and	and	CCONJ
dpc-4176	174	23	th17	th17	PROPN
dpc-4176	174	24	are	be	AUX
dpc-4176	174	25	elevated	elevate	VERB
dpc-4176	174	26	in	in	ADP
dpc-4176	174	27	lesional	lesional	ADJ
dpc-4176	174	28	skin	skin	NOUN
dpc-4176	174	29	of	of	ADP
dpc-4176	174	30	hs	hs	PROPN
dpc-4176	174	31	,	,	PUNCT
dpc-4176	174	32	and	and	CCONJ
dpc-4176	174	33	serum	serum	NOUN
dpc-4176	174	34	levels	level	NOUN
dpc-4176	174	35	of	of	ADP
dpc-4176	174	36	il-17a	il-17a	PROPN
dpc-4176	174	37	produced	produce	VERB
dpc-4176	174	38	by	by	ADP
dpc-4176	174	39	th17	th17	NOUN
dpc-4176	174	40	correlate	correlate	VERB
dpc-4176	174	41	with	with	ADP
dpc-4176	174	42	severity	severity	NOUN
dpc-4176	174	43	of	of	ADP
dpc-4176	174	44	inflammation	inflammation	NOUN
dpc-4176	174	45	in	in	ADP
dpc-4176	174	46	hs	hs	PROPN
dpc-4176	175	1	[	[	X
dpc-4176	175	2	55,56	55,56	NOUN
dpc-4176	175	3	]	]	PUNCT
dpc-4176	175	4	.	.	PUNCT
dpc-4176	176	1	this	this	DET
dpc-4176	176	2	upregulation	upregulation	NOUN
dpc-4176	176	3	supports	support	VERB
dpc-4176	176	4	the	the	DET
dpc-4176	176	5	rationale	rationale	NOUN
dpc-4176	176	6	for	for	ADP
dpc-4176	176	7	guselkumab	guselkumab	NOUN
dpc-4176	176	8	in	in	ADP
dpc-4176	176	9	the	the	DET
dpc-4176	176	10	treatment	treatment	NOUN
dpc-4176	176	11	of	of	ADP
dpc-4176	176	12	hs	hs	PROPN
dpc-4176	176	13	.	.	PUNCT
dpc-4176	176	14	however	however	ADV
dpc-4176	176	15	,	,	PUNCT
dpc-4176	176	16	in	in	ADP
dpc-4176	176	17	many	many	ADJ
dpc-4176	176	18	hs	hs	PROPN
dpc-4176	176	19	patients	patient	NOUN
dpc-4176	176	20	,	,	PUNCT
dpc-4176	176	21	guselkumab	guselkumab	NOUN
dpc-4176	176	22	has	have	AUX
dpc-4176	176	23	not	not	PART
dpc-4176	176	24	been	be	AUX
dpc-4176	176	25	effective	effective	ADJ
dpc-4176	176	26	,	,	PUNCT
dpc-4176	176	27	suggesting	suggest	VERB
dpc-4176	176	28	other	other	ADJ
dpc-4176	176	29	cells(that	cells(that	PROPN
dpc-4176	176	30	are	be	AUX
dpc-4176	176	31	il-23	il-23	NOUN
dpc-4176	176	32	independent	independent	ADJ
dpc-4176	176	33	)	)	PUNCT
dpc-4176	176	34	,	,	PUNCT
dpc-4176	176	35	to	to	PART
dpc-4176	176	36	be	be	AUX
dpc-4176	176	37	involved	involve	VERB
dpc-4176	176	38	in	in	ADP
dpc-4176	176	39	the	the	DET
dpc-4176	176	40	pathophysiology	pathophysiology	NOUN
dpc-4176	176	41	of	of	ADP
dpc-4176	176	42	hs	hs	PROPN
dpc-4176	177	1	[	[	X
dpc-4176	177	2	57	57	NUM
dpc-4176	177	3	]	]	PUNCT
dpc-4176	177	4	.	.	PUNCT
dpc-4176	178	1	alternatively	alternatively	ADV
dpc-4176	178	2	,	,	PUNCT
dpc-4176	178	3	despite	despite	SCONJ
dpc-4176	178	4	the	the	DET
dpc-4176	178	5	cellular	cellular	ADJ
dpc-4176	178	6	effects	effect	NOUN
dpc-4176	178	7	of	of	ADP
dpc-4176	178	8	guselkumab	guselkumab	NOUN
dpc-4176	178	9	on	on	ADP
dpc-4176	178	10	psoriatic	psoriatic	ADJ
dpc-4176	178	11	lesional	lesional	ADJ
dpc-4176	178	12	tissue	tissue	NOUN
dpc-4176	178	13	,	,	PUNCT
dpc-4176	178	14	its	its	PRON
dpc-4176	178	15	uptake	uptake	NOUN
dpc-4176	178	16	in	in	ADP
dpc-4176	178	17	lesions	lesion	NOUN
dpc-4176	178	18	/	/	SYM
dpc-4176	178	19	fistulas	fistula	NOUN
dpc-4176	178	20	of	of	ADP
dpc-4176	178	21	hs	hs	PROPN
dpc-4176	178	22	is	be	AUX
dpc-4176	178	23	generally	generally	ADV
dpc-4176	178	24	less	less	ADV
dpc-4176	178	25	efficient	efficient	ADJ
dpc-4176	178	26	that	that	PRON
dpc-4176	178	27	may	may	AUX
dpc-4176	178	28	account	account	VERB
dpc-4176	178	29	for	for	ADP
dpc-4176	178	30	its	its	PRON
dpc-4176	178	31	reduced	reduce	VERB
dpc-4176	178	32	efficacy	efficacy	NOUN
dpc-4176	178	33	in	in	ADP
dpc-4176	178	34	hs	hs	PROPN
dpc-4176	179	1	[	[	X
dpc-4176	179	2	11	11	NUM
dpc-4176	179	3	]	]	PUNCT
dpc-4176	179	4	.	.	PUNCT
dpc-4176	180	1	although	although	SCONJ
dpc-4176	180	2	positive	positive	ADJ
dpc-4176	180	3	outcomes	outcome	NOUN
dpc-4176	180	4	of	of	ADP
dpc-4176	180	5	guselkumab	guselkumab	NOUN
dpc-4176	180	6	have	have	AUX
dpc-4176	180	7	been	be	AUX
dpc-4176	180	8	demonstrated	demonstrate	VERB
dpc-4176	180	9	in	in	ADP
dpc-4176	180	10	case	case	NOUN
dpc-4176	180	11	reports	report	NOUN
dpc-4176	180	12	/	/	SYM
dpc-4176	180	13	series	series	NOUN
dpc-4176	180	14	,	,	PUNCT
dpc-4176	180	15	phase	phase	NOUN
dpc-4176	180	16	2	2	NUM
dpc-4176	180	17	studies	study	NOUN
dpc-4176	180	18	have	have	AUX
dpc-4176	180	19	not	not	PART
dpc-4176	180	20	confirmed	confirm	VERB
dpc-4176	180	21	this	this	DET
dpc-4176	180	22	positive	positive	ADJ
dpc-4176	180	23	trend	trend	NOUN
dpc-4176	180	24	,	,	PUNCT
dpc-4176	180	25	suggesting	suggest	VERB
dpc-4176	180	26	guselkumab	guselkumab	NOUN
dpc-4176	180	27	to	to	PART
dpc-4176	180	28	be	be	AUX
dpc-4176	180	29	effective	effective	ADJ
dpc-4176	180	30	in	in	ADP
dpc-4176	180	31	only	only	ADV
dpc-4176	180	32	a	a	DET
dpc-4176	180	33	subgroup	subgroup	NOUN
dpc-4176	180	34	of	of	ADP
dpc-4176	180	35	hs	hs	PROPN
dpc-4176	180	36	patients	patient	NOUN
dpc-4176	180	37	.	.	PUNCT
dpc-4176	181	1	further	further	ADJ
dpc-4176	181	2	details	detail	NOUN
dpc-4176	181	3	are	be	AUX
dpc-4176	181	4	elaborated	elaborate	VERB
dpc-4176	181	5	in	in	ADP
dpc-4176	181	6	table	table	NOUN
dpc-4176	181	7	4	4	NUM
dpc-4176	182	1	[	[	SYM
dpc-4176	182	2	58	58	NUM
dpc-4176	182	3	-	-	SYM
dpc-4176	182	4	63	63	NUM
dpc-4176	182	5	]	]	PUNCT
dpc-4176	182	6	.	.	PUNCT
dpc-4176	183	1	interestingly	interestingly	ADV
dpc-4176	183	2	,	,	PUNCT
dpc-4176	183	3	guselkumab	guselkumab	NOUN
dpc-4176	183	4	has	have	AUX
dpc-4176	183	5	shown	show	VERB
dpc-4176	183	6	to	to	PART
dpc-4176	183	7	be	be	AUX
dpc-4176	183	8	advantageous	advantageous	ADJ
dpc-4176	183	9	in	in	ADP
dpc-4176	183	10	the	the	DET
dpc-4176	183	11	management	management	NOUN
dpc-4176	183	12	of	of	ADP
dpc-4176	183	13	paradoxical	paradoxical	ADJ
dpc-4176	183	14	hs	hs	PROPN
dpc-4176	183	15	,	,	PUNCT
dpc-4176	183	16	as	as	ADV
dpc-4176	183	17	well	well	ADV
dpc-4176	183	18	as	as	ADP
dpc-4176	183	19	hs	hs	PROPN
dpc-4176	183	20	in	in	ADP
dpc-4176	183	21	patients	patient	NOUN
dpc-4176	183	22	with	with	ADP
dpc-4176	183	23	paradoxical	paradoxical	ADJ
dpc-4176	183	24	psoriasiform	psoriasiform	NOUN
dpc-4176	183	25	reactions	reaction	NOUN
dpc-4176	183	26	,	,	PUNCT
dpc-4176	183	27	following	follow	VERB
dpc-4176	183	28	treatment	treatment	NOUN
dpc-4176	183	29	with	with	ADP
dpc-4176	183	30	adalimumab	adalimumab	NOUN
dpc-4176	183	31	[	[	X
dpc-4176	183	32	64	64	NUM
dpc-4176	183	33	-	-	SYM
dpc-4176	183	34	66	66	NUM
dpc-4176	183	35	]	]	PUNCT
dpc-4176	183	36	.	.	PUNCT
dpc-4176	184	1	also	also	ADV
dpc-4176	184	2	,	,	PUNCT
dpc-4176	184	3	guselkumab	guselkumab	NOUN
dpc-4176	184	4	has	have	AUX
dpc-4176	184	5	been	be	AUX
dpc-4176	184	6	effective	effective	ADJ
dpc-4176	184	7	in	in	ADP
dpc-4176	184	8	treating	treat	VERB
dpc-4176	184	9	hs	hs	PROPN
dpc-4176	184	10	patients	patient	NOUN
dpc-4176	184	11	with	with	ADP
dpc-4176	184	12	other	other	ADJ
dpc-4176	184	13	comorbidities	comorbiditie	NOUN
dpc-4176	184	14	like	like	ADP
dpc-4176	184	15	crohn	crohn	PROPN
dpc-4176	184	16	disease	disease	PROPN
dpc-4176	185	1	[	[	X
dpc-4176	185	2	67	67	NUM
dpc-4176	185	3	-	-	SYM
dpc-4176	185	4	69	69	NUM
dpc-4176	185	5	]	]	PUNCT
dpc-4176	185	6	.	.	PUNCT
dpc-4176	186	1	pyoderma	pyoderma	NOUN
dpc-4176	186	2	gangrenosum	gangrenosum	NOUN
dpc-4176	186	3	pg	pg	PROPN
dpc-4176	186	4	is	be	AUX
dpc-4176	186	5	a	a	DET
dpc-4176	186	6	rare	rare	ADJ
dpc-4176	186	7	ulcerative	ulcerative	ADJ
dpc-4176	186	8	neutrophilic	neutrophilic	ADJ
dpc-4176	186	9	dermatosis	dermatosis	NOUN
dpc-4176	186	10	,	,	PUNCT
dpc-4176	186	11	often	often	ADV
dpc-4176	186	12	resistant	resistant	ADJ
dpc-4176	186	13	to	to	ADP
dpc-4176	186	14	various	various	ADJ
dpc-4176	186	15	forms	form	NOUN
dpc-4176	186	16	of	of	ADP
dpc-4176	186	17	treatment	treatment	NOUN
dpc-4176	186	18	.	.	PUNCT
dpc-4176	187	1	il-23	il-23	NOUN
dpc-4176	187	2	,	,	PUNCT
dpc-4176	187	3	a	a	DET
dpc-4176	187	4	cytokine	cytokine	NOUN
dpc-4176	187	5	implicated	implicate	VERB
dpc-4176	187	6	in	in	ADP
dpc-4176	187	7	neutrophilic	neutrophilic	ADJ
dpc-4176	187	8	diseases	disease	NOUN
dpc-4176	187	9	,	,	PUNCT
dpc-4176	187	10	has	have	AUX
dpc-4176	187	11	shown	show	VERB
dpc-4176	187	12	promise	promise	NOUN
dpc-4176	187	13	as	as	ADP
dpc-4176	187	14	a	a	DET
dpc-4176	187	15	potential	potential	ADJ
dpc-4176	187	16	target	target	NOUN
dpc-4176	187	17	in	in	ADP
dpc-4176	187	18	the	the	DET
dpc-4176	187	19	management	management	NOUN
dpc-4176	187	20	of	of	ADP
dpc-4176	187	21	pg	pg	PROPN
dpc-4176	187	22	[	[	X
dpc-4176	187	23	70	70	NUM
dpc-4176	187	24	]	]	PUNCT
dpc-4176	187	25	.	.	PUNCT
dpc-4176	188	1	additionally	additionally	ADV
dpc-4176	188	2	,	,	PUNCT
dpc-4176	188	3	il-23	il-23	NOUN
dpc-4176	188	4	plays	play	VERB
dpc-4176	188	5	an	an	DET
dpc-4176	188	6	essential	essential	ADJ
dpc-4176	188	7	role	role	NOUN
dpc-4176	188	8	in	in	ADP
dpc-4176	188	9	advancing	advance	VERB
dpc-4176	188	10	and	and	CCONJ
dpc-4176	188	11	bolstering	bolster	VERB
dpc-4176	188	12	8	8	NUM
dpc-4176	188	13	review	review	NOUN
dpc-4176	188	14	|	|	ADV
dpc-4176	188	15	dermatol	dermatol	ADJ
dpc-4176	188	16	pract	pract	NOUN
dpc-4176	188	17	concept	concept	NOUN
dpc-4176	188	18	.	.	PUNCT
dpc-4176	189	1	2024;14(3):e2024181	2024;14(3):e2024181	NUM
dpc-4176	189	2	table	table	NOUN
dpc-4176	189	3	3	3	NUM
dpc-4176	189	4	.	.	PUNCT
dpc-4176	189	5	salient	salient	NOUN
dpc-4176	189	6	features	feature	NOUN
dpc-4176	189	7	of	of	ADP
dpc-4176	189	8	various	various	ADJ
dpc-4176	189	9	studies	study	NOUN
dpc-4176	189	10	employing	employ	VERB
dpc-4176	189	11	guselkumab	guselkumab	NOUN
dpc-4176	189	12	in	in	ADP
dpc-4176	189	13	psoriatic	psoriatic	ADJ
dpc-4176	189	14	arthropathy	arthropathy	ADJ
dpc-4176	189	15	serial	serial	ADJ
dpc-4176	189	16	no	no	NOUN
dpc-4176	189	17	.	.	PUNCT
dpc-4176	190	1	authors	author	NOUN
dpc-4176	190	2	/	/	SYM
dpc-4176	190	3	year	year	NOUN
dpc-4176	190	4	details	detail	NOUN
dpc-4176	190	5	remarks	remark	VERB
dpc-4176	190	6	1	1	NUM
dpc-4176	190	7	deodhar	deodhar	NOUN
dpc-4176	190	8	et	et	NOUN
dpc-4176	190	9	al	al	PROPN
dpc-4176	191	1	[	[	X
dpc-4176	191	2	50	50	NUM
dpc-4176	191	3	]	]	SYM
dpc-4176	191	4	2018	2018	NUM
dpc-4176	191	5	•	•	NOUN
dpc-4176	191	6	a	a	DET
dpc-4176	191	7	randomized	randomized	ADJ
dpc-4176	191	8	,	,	PUNCT
dpc-4176	191	9	double	double	ADJ
dpc-4176	191	10	-	-	PUNCT
dpc-4176	191	11	blind	blind	ADJ
dpc-4176	191	12	placebo	placebo	NOUN
dpc-4176	191	13	-	-	PUNCT
dpc-4176	191	14	controlled	control	VERB
dpc-4176	191	15	,	,	PUNCT
dpc-4176	191	16	phase	phase	NOUN
dpc-4176	191	17	2	2	NUM
dpc-4176	191	18	study	study	NOUN
dpc-4176	191	19	•	•	NUM
dpc-4176	191	20	guselkumab	guselkumab	NOUN
dpc-4176	191	21	group	group	NOUN
dpc-4176	191	22	(	(	PUNCT
dpc-4176	191	23	n=100	n=100	NUM
dpc-4176	191	24	)	)	PUNCT
dpc-4176	191	25	given	give	VERB
dpc-4176	191	26	100	100	NUM
dpc-4176	191	27	mg	mg	NOUN
dpc-4176	191	28	at	at	ADP
dpc-4176	191	29	week	week	NOUN
dpc-4176	191	30	0	0	NUM
dpc-4176	191	31	,	,	PUNCT
dpc-4176	191	32	4	4	NUM
dpc-4176	191	33	and	and	CCONJ
dpc-4176	191	34	then	then	ADV
dpc-4176	191	35	every	every	DET
dpc-4176	191	36	8	8	NUM
dpc-4176	191	37	weeks	week	NOUN
dpc-4176	191	38	.	.	PUNCT
dpc-4176	192	1	•	•	NUM
dpc-4176	192	2	placebo	placebo	NOUN
dpc-4176	192	3	group	group	NOUN
dpc-4176	192	4	(	(	PUNCT
dpc-4176	192	5	n=49	n=49	NUM
dpc-4176	192	6	)	)	PUNCT
dpc-4176	192	7	given	give	VERB
dpc-4176	192	8	a	a	DET
dpc-4176	192	9	placebo	placebo	NOUN
dpc-4176	192	10	similarly	similarly	ADV
dpc-4176	192	11	till	till	SCONJ
dpc-4176	192	12	week	week	NOUN
dpc-4176	192	13	24	24	NUM
dpc-4176	192	14	,	,	PUNCT
dpc-4176	192	15	following	follow	VERB
dpc-4176	192	16	which	which	PRON
dpc-4176	192	17	they	they	PRON
dpc-4176	192	18	received	receive	VERB
dpc-4176	192	19	guselkumab	guselkumab	NOUN
dpc-4176	192	20	(	(	PUNCT
dpc-4176	192	21	100	100	NUM
dpc-4176	192	22	mg	mg	NOUN
dpc-4176	192	23	)	)	PUNCT
dpc-4176	192	24	at	at	ADP
dpc-4176	192	25	week	week	NOUN
dpc-4176	192	26	24	24	NUM
dpc-4176	192	27	,	,	PUNCT
dpc-4176	192	28	28	28	NUM
dpc-4176	192	29	,	,	PUNCT
dpc-4176	192	30	36	36	NUM
dpc-4176	192	31	and	and	CCONJ
dpc-4176	192	32	44	44	NUM
dpc-4176	192	33	.	.	PUNCT
dpc-4176	193	1	at	at	ADP
dpc-4176	193	2	week	week	NOUN
dpc-4176	193	3	24	24	NUM
dpc-4176	193	4	:	:	SYM
dpc-4176	193	5	•	•	NUM
dpc-4176	193	6	american	american	PROPN
dpc-4176	193	7	college	college	PROPN
dpc-4176	193	8	of	of	ADP
dpc-4176	193	9	rheumatology	rheumatology	NOUN
dpc-4176	193	10	(	(	PUNCT
dpc-4176	193	11	acr	acr	PROPN
dpc-4176	193	12	)	)	PUNCT
dpc-4176	193	13	20	20	NUM
dpc-4176	193	14	 	 	SPACE
dpc-4176	193	15	response	response	NOUN
dpc-4176	193	16	:	:	PUNCT
dpc-4176	193	17	•	•	NUM
dpc-4176	193	18	guselkumab	guselkumab	NOUN
dpc-4176	193	19	group	group	NOUN
dpc-4176	193	20	:	:	PUNCT
dpc-4176	193	21	58	58	NUM
dpc-4176	193	22	%	%	NOUN
dpc-4176	193	23	•	•	NUM
dpc-4176	193	24	placebo	placebo	NOUN
dpc-4176	193	25	:	:	PUNCT
dpc-4176	193	26	9	9	NUM
dpc-4176	193	27	%	%	NOUN
dpc-4176	193	28	•	•	NOUN
dpc-4176	193	29	acr	acr	PROPN
dpc-4176	193	30	50	50	NUM
dpc-4176	193	31	response	response	NOUN
dpc-4176	193	32	:	:	PUNCT
dpc-4176	193	33	•	•	NUM
dpc-4176	193	34	guselkumab	guselkumab	NOUN
dpc-4176	193	35	group	group	NOUN
dpc-4176	193	36	:	:	PUNCT
dpc-4176	193	37	34	34	NUM
dpc-4176	193	38	%	%	NOUN
dpc-4176	193	39	•	•	NUM
dpc-4176	193	40	placebo	placebo	NOUN
dpc-4176	193	41	group	group	NOUN
dpc-4176	193	42	:	:	PUNCT
dpc-4176	193	43	5	5	NUM
dpc-4176	193	44	%	%	NOUN
dpc-4176	193	45	•	•	NUM
dpc-4176	193	46	resolved	resolve	VERB
dpc-4176	193	47	dactylitis	dactylitis	NOUN
dpc-4176	193	48	:	:	PUNCT
dpc-4176	193	49	•	•	NUM
dpc-4176	193	50	guselkumab:55	guselkumab:55	NOUN
dpc-4176	193	51	%	%	NOUN
dpc-4176	193	52	•	•	NOUN
dpc-4176	193	53	placebo	placebo	NOUN
dpc-4176	193	54	:	:	PUNCT
dpc-4176	193	55	17	17	NUM
dpc-4176	193	56	%	%	NOUN
dpc-4176	193	57	•	•	NUM
dpc-4176	193	58	resolved	resolve	VERB
dpc-4176	193	59	enthesitis	enthesitis	NOUN
dpc-4176	193	60	:	:	PUNCT
dpc-4176	193	61	•	•	NUM
dpc-4176	193	62	guselkumab	guselkumab	NOUN
dpc-4176	193	63	:	:	PUNCT
dpc-4176	193	64	57	57	NUM
dpc-4176	193	65	%	%	NOUN
dpc-4176	193	66	•	•	NUM
dpc-4176	193	67	placebo	placebo	NOUN
dpc-4176	193	68	:	:	PUNCT
dpc-4176	193	69	29	29	NUM
dpc-4176	193	70	%	%	NOUN
dpc-4176	193	71	•	•	ADP
dpc-4176	193	72	all	all	DET
dpc-4176	193	73	patients	patient	NOUN
dpc-4176	193	74	tolerated	tolerate	VERB
dpc-4176	193	75	the	the	DET
dpc-4176	193	76	drug	drug	NOUN
dpc-4176	193	77	well	well	NOUN
dpc-4176	193	78	with	with	ADP
dpc-4176	193	79	no	no	DET
dpc-4176	193	80	major	major	ADJ
dpc-4176	193	81	adverse	adverse	ADJ
dpc-4176	193	82	effects	effect	NOUN
dpc-4176	193	83	being	be	AUX
dpc-4176	193	84	reported	report	VERB
dpc-4176	193	85	.	.	PUNCT
dpc-4176	194	1	2	2	NUM
dpc-4176	194	2	mease	mease	NOUN
dpc-4176	194	3	et	et	NOUN
dpc-4176	194	4	al	al	PROPN
dpc-4176	195	1	[	[	X
dpc-4176	195	2	51	51	NUM
dpc-4176	195	3	]	]	SYM
dpc-4176	195	4	2020	2020	NUM
dpc-4176	195	5	•	•	NUM
dpc-4176	195	6	randomized	randomize	VERB
dpc-4176	195	7	,	,	PUNCT
dpc-4176	195	8	placebo	placebo	NOUN
dpc-4176	195	9	controlled	control	VERB
dpc-4176	195	10	,	,	PUNCT
dpc-4176	195	11	phase	phase	NOUN
dpc-4176	195	12	ii	ii	PROPN
dpc-4176	195	13	study	study	NOUN
dpc-4176	195	14	in	in	ADP
dpc-4176	195	15	patients	patient	NOUN
dpc-4176	195	16	with	with	ADP
dpc-4176	195	17	dactylitis	dactylitis	NOUN
dpc-4176	195	18	and	and	CCONJ
dpc-4176	195	19	enthesitis	enthesitis	NOUN
dpc-4176	195	20	in	in	ADP
dpc-4176	195	21	psa	psa	PROPN
dpc-4176	195	22	.	.	PROPN
dpc-4176	196	1	•	•	NUM
dpc-4176	196	2	patients	patient	NOUN
dpc-4176	196	3	with	with	ADP
dpc-4176	196	4	enthesitis	enthesitis	PROPN
dpc-4176	196	5	at	at	ADP
dpc-4176	196	6	baseline	baseline	PROPN
dpc-4176	196	7	guselkumab	guselkumab	NOUN
dpc-4176	196	8	group	group	PROPN
dpc-4176	196	9	(	(	PUNCT
dpc-4176	196	10	n=76	n=76	NOUN
dpc-4176	196	11	)	)	PUNCT
dpc-4176	196	12	placebo	placebo	NOUN
dpc-4176	196	13	(	(	PUNCT
dpc-4176	196	14	n=31	n=31	PROPN
dpc-4176	196	15	)	)	PUNCT
dpc-4176	196	16	.	.	PUNCT
dpc-4176	197	1	•	•	NUM
dpc-4176	197	2	patients	patient	NOUN
dpc-4176	197	3	with	with	ADP
dpc-4176	197	4	dactylitis	dactylitis	NOUN
dpc-4176	197	5	at	at	ADP
dpc-4176	197	6	baseline	baseline	PROPN
dpc-4176	197	7	guselkumab	guselkumab	NOUN
dpc-4176	197	8	group	group	PROPN
dpc-4176	197	9	(	(	PUNCT
dpc-4176	197	10	n=58	n=58	PROPN
dpc-4176	197	11	)	)	PUNCT
dpc-4176	197	12	.	.	PUNCT
dpc-4176	198	1	placebo	placebo	NOUN
dpc-4176	198	2	group	group	NOUN
dpc-4176	198	3	(	(	PUNCT
dpc-4176	198	4	n=23	n=23	PROPN
dpc-4176	198	5	)	)	PUNCT
dpc-4176	198	6	•	•	NUM
dpc-4176	198	7	guselkumab	guselkumab	NOUN
dpc-4176	198	8	100	100	NUM
dpc-4176	198	9	mg	mg	PROPN
dpc-4176	198	10	sc	sc	PROPN
dpc-4176	198	11	(	(	PUNCT
dpc-4176	198	12	label	label	NOUN
dpc-4176	198	13	dosing	dosing	NOUN
dpc-4176	198	14	)	)	PUNCT
dpc-4176	198	15	was	be	AUX
dpc-4176	198	16	administered	administer	VERB
dpc-4176	198	17	.	.	PUNCT
dpc-4176	199	1	at	at	ADP
dpc-4176	199	2	week	week	NOUN
dpc-4176	199	3	24	24	NUM
dpc-4176	199	4	:	:	PUNCT
dpc-4176	199	5	•	•	NUM
dpc-4176	199	6	proportion	proportion	NOUN
dpc-4176	199	7	of	of	ADP
dpc-4176	199	8	patients	patient	NOUN
dpc-4176	199	9	with	with	ADP
dpc-4176	199	10	enthesitis	enthesitis	ADJ
dpc-4176	199	11	resolution	resolution	NOUN
dpc-4176	199	12	:	:	PUNCT
dpc-4176	199	13	•	•	NUM
dpc-4176	199	14	guselkumab	guselkumab	NOUN
dpc-4176	199	15	:	:	PUNCT
dpc-4176	199	16	56.6	56.6	NUM
dpc-4176	199	17	%	%	NOUN
dpc-4176	199	18	•	•	NUM
dpc-4176	199	19	placebo	placebo	NOUN
dpc-4176	199	20	:	:	PUNCT
dpc-4176	199	21	29.0	29.0	NUM
dpc-4176	199	22	%	%	NOUN
dpc-4176	199	23	•	•	NOUN
dpc-4176	199	24	proportion	proportion	NOUN
dpc-4176	199	25	of	of	ADP
dpc-4176	199	26	patients	patient	NOUN
dpc-4176	199	27	with	with	ADP
dpc-4176	199	28	dactylitis	dactylitis	NOUN
dpc-4176	199	29	resolution	resolution	NOUN
dpc-4176	199	30	•	•	NOUN
dpc-4176	199	31	guselkumab	guselkumab	NOUN
dpc-4176	199	32	:	:	PUNCT
dpc-4176	199	33	55.2	55.2	NUM
dpc-4176	199	34	%	%	NOUN
dpc-4176	199	35	•	•	NUM
dpc-4176	199	36	placebo	placebo	NOUN
dpc-4176	199	37	:	:	PUNCT
dpc-4176	199	38	17.4	17.4	NUM
dpc-4176	199	39	%	%	NOUN
dpc-4176	199	40	at	at	ADP
dpc-4176	199	41	week	week	NOUN
dpc-4176	199	42	56	56	NUM
dpc-4176	199	43	:	:	SYM
dpc-4176	199	44	•	•	NUM
dpc-4176	199	45	proportions	proportion	NOUN
dpc-4176	199	46	of	of	ADP
dpc-4176	199	47	patients	patient	NOUN
dpc-4176	199	48	with	with	ADP
dpc-4176	199	49	enthesitis	enthesitis	ADJ
dpc-4176	199	50	resolution	resolution	NOUN
dpc-4176	199	51	:	:	PUNCT
dpc-4176	199	52	•	•	NUM
dpc-4176	199	53	guselkumab	guselkumab	NOUN
dpc-4176	199	54	:	:	PUNCT
dpc-4176	199	55	70.8	70.8	NUM
dpc-4176	199	56	%	%	NOUN
dpc-4176	199	57	•	•	NOUN
dpc-4176	199	58	placebo	placebo	NOUN
dpc-4176	199	59	(	(	PUNCT
dpc-4176	199	60	crossover	crossover	NOUN
dpc-4176	199	61	):	):	PUNCT
dpc-4176	199	62	62.5	62.5	NUM
dpc-4176	199	63	%	%	NOUN
dpc-4176	199	64	•	•	NOUN
dpc-4176	199	65	proportion	proportion	NOUN
dpc-4176	199	66	of	of	ADP
dpc-4176	199	67	patients	patient	NOUN
dpc-4176	199	68	with	with	ADP
dpc-4176	199	69	dactylitis	dactylitis	NOUN
dpc-4176	199	70	resolution	resolution	NOUN
dpc-4176	199	71	:	:	PUNCT
dpc-4176	199	72	•	•	NUM
dpc-4176	199	73	guselkumab	guselkumab	NOUN
dpc-4176	199	74	:	:	PUNCT
dpc-4176	199	75	93.7	93.7	NUM
dpc-4176	199	76	%	%	NOUN
dpc-4176	199	77	•	•	NOUN
dpc-4176	199	78	placebo	placebo	NOUN
dpc-4176	199	79	(	(	PUNCT
dpc-4176	199	80	crossover	crossover	NOUN
dpc-4176	199	81	):	):	PUNCT
dpc-4176	199	82	75	75	NUM
dpc-4176	199	83	%	%	NOUN
dpc-4176	199	84	3	3	NUM
dpc-4176	199	85	mease	mease	NOUN
dpc-4176	199	86	et	et	NOUN
dpc-4176	199	87	al	al	PROPN
dpc-4176	200	1	[	[	X
dpc-4176	200	2	52	52	NUM
dpc-4176	200	3	]	]	SYM
dpc-4176	200	4	2020	2020	NUM
dpc-4176	200	5	•	•	NOUN
dpc-4176	200	6	a	a	DET
dpc-4176	200	7	double	double	ADJ
dpc-4176	200	8	-	-	PUNCT
dpc-4176	200	9	blind	blind	ADJ
dpc-4176	200	10	,	,	PUNCT
dpc-4176	200	11	randomized	randomize	VERB
dpc-4176	200	12	placebo	placebo	NOUN
dpc-4176	200	13	-	-	PUNCT
dpc-4176	200	14	controlled	control	VERB
dpc-4176	200	15	phase	phase	NOUN
dpc-4176	200	16	3	3	NUM
dpc-4176	200	17	trial	trial	NOUN
dpc-4176	200	18	evaluating	evaluating	NOUN
dpc-4176	200	19	guselkumab	guselkumab	NOUN
dpc-4176	200	20	in	in	ADP
dpc-4176	200	21	biologic	biologic	ADJ
dpc-4176	200	22	naïve	naïve	ADJ
dpc-4176	200	23	patients	patient	NOUN
dpc-4176	200	24	with	with	ADP
dpc-4176	200	25	active	active	ADJ
dpc-4176	200	26	psa	psa	NOUN
dpc-4176	200	27	.	.	PROPN
dpc-4176	200	28	•	•	NUM
dpc-4176	200	29	random	random	ADJ
dpc-4176	200	30	allocation	allocation	NOUN
dpc-4176	200	31	of	of	ADP
dpc-4176	200	32	patients	patient	NOUN
dpc-4176	200	33	into	into	ADP
dpc-4176	200	34	3	3	NUM
dpc-4176	200	35	group	group	NOUN
dpc-4176	200	36	guselkumab	guselkumab	NOUN
dpc-4176	200	37	(	(	PUNCT
dpc-4176	200	38	100	100	NUM
dpc-4176	200	39	mg	mg	NOUN
dpc-4176	200	40	q4	q4	PROPN
dpc-4176	200	41	weekly	weekly	NOUN
dpc-4176	200	42	)	)	PUNCT
dpc-4176	200	43	(	(	PUNCT
dpc-4176	200	44	n=246	n=246	PROPN
dpc-4176	200	45	)	)	PUNCT
dpc-4176	200	46	guselkumab	guselkumab	NOUN
dpc-4176	200	47	(	(	PUNCT
dpc-4176	200	48	100	100	NUM
dpc-4176	200	49	mg	mg	PROPN
dpc-4176	200	50	q8	q8	PROPN
dpc-4176	200	51	weekly	weekly	NOUN
dpc-4176	200	52	)	)	PUNCT
dpc-4176	200	53	(	(	PUNCT
dpc-4176	200	54	n=248	n=248	NUM
dpc-4176	200	55	)	)	PUNCT
dpc-4176	200	56	placebo	placebo	NOUN
dpc-4176	200	57	(	(	PUNCT
dpc-4176	200	58	n=247	n=247	NOUN
dpc-4176	200	59	)	)	PUNCT
dpc-4176	200	60	.	.	PUNCT
dpc-4176	201	1	•	•	NUM
dpc-4176	201	2	100	100	NUM
dpc-4176	201	3	-	-	PUNCT
dpc-4176	201	4	week	week	NOUN
dpc-4176	201	5	treatment	treatment	NOUN
dpc-4176	201	6	phase	phase	NOUN
dpc-4176	201	7	.	.	PUNCT
dpc-4176	202	1	•	•	NUM
dpc-4176	202	2	placebo	placebo	NOUN
dpc-4176	202	3	group	group	NOUN
dpc-4176	202	4	crossover	crossover	NOUN
dpc-4176	202	5	to	to	PART
dpc-4176	202	6	guselkumab	guselkumab	NOUN
dpc-4176	202	7	from	from	ADP
dpc-4176	202	8	week	week	NOUN
dpc-4176	202	9	24	24	NUM
dpc-4176	202	10	to	to	PART
dpc-4176	202	11	100	100	NUM
dpc-4176	202	12	.	.	PUNCT
dpc-4176	203	1	at	at	ADP
dpc-4176	203	2	week	week	NOUN
dpc-4176	203	3	24	24	NUM
dpc-4176	203	4	:	:	SYM
dpc-4176	203	5	•	•	NUM
dpc-4176	203	6	acr	acr	PROPN
dpc-4176	203	7	20	20	NUM
dpc-4176	203	8	response	response	NOUN
dpc-4176	203	9	:	:	PUNCT
dpc-4176	203	10	•	•	NUM
dpc-4176	203	11	guselkumab	guselkumab	NOUN
dpc-4176	203	12	q4w	q4w	PROPN
dpc-4176	203	13	(	(	PUNCT
dpc-4176	203	14	64	64	NUM
dpc-4176	203	15	%	%	NOUN
dpc-4176	203	16	)	)	PUNCT
dpc-4176	203	17	•	•	NOUN
dpc-4176	203	18	guselkumab	guselkumab	NOUN
dpc-4176	203	19	q8w	q8w	PROPN
dpc-4176	203	20	(	(	PUNCT
dpc-4176	203	21	64	64	NUM
dpc-4176	203	22	%	%	NOUN
dpc-4176	203	23	)	)	PUNCT
dpc-4176	203	24	•	•	NUM
dpc-4176	203	25	placebo	placebo	NOUN
dpc-4176	203	26	(	(	PUNCT
dpc-4176	203	27	33	33	NUM
dpc-4176	203	28	%	%	NOUN
dpc-4176	203	29	)	)	PUNCT
dpc-4176	203	30	•	•	NOUN
dpc-4176	203	31	acr	acr	PROPN
dpc-4176	203	32	50	50	NUM
dpc-4176	203	33	response	response	NOUN
dpc-4176	203	34	:	:	PUNCT
dpc-4176	203	35	•	•	NUM
dpc-4176	203	36	guselkumab	guselkumab	NOUN
dpc-4176	203	37	q4w	q4w	PROPN
dpc-4176	203	38	(	(	PUNCT
dpc-4176	203	39	33	33	NUM
dpc-4176	203	40	%	%	NOUN
dpc-4176	203	41	)	)	PUNCT
dpc-4176	203	42	•	•	NOUN
dpc-4176	203	43	guselkumab	guselkumab	NOUN
dpc-4176	203	44	q8w	q8w	ADV
dpc-4176	203	45	(	(	PUNCT
dpc-4176	203	46	31	31	NUM
dpc-4176	203	47	%	%	NOUN
dpc-4176	203	48	)	)	PUNCT
dpc-4176	203	49	•	•	NUM
dpc-4176	203	50	placebo	placebo	NOUN
dpc-4176	203	51	(	(	PUNCT
dpc-4176	203	52	14	14	NUM
dpc-4176	203	53	%	%	NOUN
dpc-4176	203	54	)	)	PUNCT
dpc-4176	203	55	•	•	NOUN
dpc-4176	203	56	acr	acr	PROPN
dpc-4176	203	57	70	70	NUM
dpc-4176	203	58	response	response	NOUN
dpc-4176	203	59	:	:	PUNCT
dpc-4176	203	60	•	•	NUM
dpc-4176	203	61	guselkumab	guselkumab	NOUN
dpc-4176	203	62	q4w	q4w	PROPN
dpc-4176	203	63	(	(	PUNCT
dpc-4176	203	64	13	13	NUM
dpc-4176	203	65	%	%	NOUN
dpc-4176	203	66	)	)	PUNCT
dpc-4176	203	67	•	•	NOUN
dpc-4176	203	68	guselkumab	guselkumab	NOUN
dpc-4176	203	69	q8w	q8w	ADV
dpc-4176	203	70	(	(	PUNCT
dpc-4176	203	71	19	19	NUM
dpc-4176	203	72	%	%	NOUN
dpc-4176	203	73	)	)	PUNCT
dpc-4176	203	74	•	•	NUM
dpc-4176	203	75	placebo	placebo	NOUN
dpc-4176	203	76	(	(	PUNCT
dpc-4176	203	77	4	4	NUM
dpc-4176	203	78	%	%	NOUN
dpc-4176	203	79	)	)	PUNCT
dpc-4176	203	80	•	•	ADP
dpc-4176	203	81	resolution	resolution	NOUN
dpc-4176	203	82	of	of	ADP
dpc-4176	203	83	dactylitis	dactylitis	NOUN
dpc-4176	203	84	:	:	PUNCT
dpc-4176	203	85	•	•	NUM
dpc-4176	203	86	guselkumab	guselkumab	NOUN
dpc-4176	203	87	q4w	q4w	PROPN
dpc-4176	203	88	(	(	PUNCT
dpc-4176	203	89	64	64	NUM
dpc-4176	203	90	%	%	NOUN
dpc-4176	203	91	)	)	PUNCT
dpc-4176	203	92	•	•	NOUN
dpc-4176	203	93	guselkumab	guselkumab	NOUN
dpc-4176	203	94	q8w	q8w	PROPN
dpc-4176	203	95	(	(	PUNCT
dpc-4176	203	96	59	59	NUM
dpc-4176	203	97	%	%	NOUN
dpc-4176	203	98	)	)	PUNCT
dpc-4176	203	99	•	•	NUM
dpc-4176	203	100	placebo	placebo	NOUN
dpc-4176	203	101	(	(	PUNCT
dpc-4176	203	102	42	42	NUM
dpc-4176	203	103	%	%	NOUN
dpc-4176	203	104	)	)	PUNCT
dpc-4176	203	105	•	•	ADP
dpc-4176	203	106	resolution	resolution	NOUN
dpc-4176	203	107	of	of	ADP
dpc-4176	203	108	enthesitis	enthesitis	NOUN
dpc-4176	203	109	:	:	PUNCT
dpc-4176	203	110	•	•	NUM
dpc-4176	203	111	guselkumab	guselkumab	NOUN
dpc-4176	203	112	q4w	q4w	PROPN
dpc-4176	203	113	(	(	PUNCT
dpc-4176	203	114	45	45	NUM
dpc-4176	203	115	%	%	NOUN
dpc-4176	203	116	)	)	PUNCT
dpc-4176	203	117	•	•	NOUN
dpc-4176	203	118	guselkumab	guselkumab	NOUN
dpc-4176	203	119	q8w	q8w	ADV
dpc-4176	203	120	(	(	PUNCT
dpc-4176	203	121	50	50	NUM
dpc-4176	203	122	%	%	NOUN
dpc-4176	203	123	)	)	PUNCT
dpc-4176	203	124	•	•	NUM
dpc-4176	203	125	placebo	placebo	NOUN
dpc-4176	203	126	(	(	PUNCT
dpc-4176	203	127	29	29	NUM
dpc-4176	203	128	%	%	NOUN
dpc-4176	203	129	)	)	PUNCT
dpc-4176	203	130	•	•	NUM
dpc-4176	203	131	guselkumab	guselkumab	NOUN
dpc-4176	203	132	was	be	AUX
dpc-4176	203	133	well	well	ADV
dpc-4176	203	134	tolerated	tolerate	VERB
dpc-4176	203	135	with	with	ADP
dpc-4176	203	136	no	no	DET
dpc-4176	203	137	clinically	clinically	ADV
dpc-4176	203	138	meaningful	meaningful	ADJ
dpc-4176	203	139	differences	difference	NOUN
dpc-4176	203	140	between	between	ADP
dpc-4176	203	141	dosing	dose	VERB
dpc-4176	203	142	every	every	DET
dpc-4176	203	143	4	4	NUM
dpc-4176	203	144	or	or	CCONJ
dpc-4176	203	145	8	8	NUM
dpc-4176	203	146	weeks	week	NOUN
dpc-4176	203	147	up	up	ADP
dpc-4176	203	148	to	to	PART
dpc-4176	203	149	24	24	NUM
dpc-4176	203	150	weeks	week	NOUN
dpc-4176	203	151	.	.	PUNCT
dpc-4176	204	1	review	review	VERB
dpc-4176	204	2	|	|	ADV
dpc-4176	204	3	dermatol	dermatol	ADJ
dpc-4176	204	4	pract	pract	NOUN
dpc-4176	204	5	concept	concept	NOUN
dpc-4176	204	6	.	.	PUNCT
dpc-4176	205	1	2024;14(3):e2024181	2024;14(3):e2024181	NUM
dpc-4176	205	2	9	9	NUM
dpc-4176	205	3	serial	serial	NOUN
dpc-4176	205	4	no	no	NOUN
dpc-4176	205	5	.	.	PUNCT
dpc-4176	206	1	authors	author	NOUN
dpc-4176	206	2	/	/	SYM
dpc-4176	206	3	year	year	NOUN
dpc-4176	206	4	details	detail	NOUN
dpc-4176	206	5	remarks	remark	VERB
dpc-4176	206	6	4	4	NUM
dpc-4176	206	7	deodhar	deodhar	ADJ
dpc-4176	206	8	et	et	NOUN
dpc-4176	206	9	al	al	PROPN
dpc-4176	207	1	[	[	X
dpc-4176	207	2	53	53	NUM
dpc-4176	207	3	]	]	SYM
dpc-4176	207	4	2020	2020	NUM
dpc-4176	207	5	•	•	NOUN
dpc-4176	207	6	a	a	DET
dpc-4176	207	7	double	double	ADJ
dpc-4176	207	8	-	-	PUNCT
dpc-4176	207	9	blind	blind	NOUN
dpc-4176	207	10	randomized	randomize	VERB
dpc-4176	207	11	,	,	PUNCT
dpc-4176	207	12	placebo	placebo	NOUN
dpc-4176	207	13	-	-	PUNCT
dpc-4176	207	14	controlled	control	VERB
dpc-4176	207	15	phase	phase	NOUN
dpc-4176	207	16	3	3	NUM
dpc-4176	207	17	trial	trial	NOUN
dpc-4176	207	18	assessing	assess	VERB
dpc-4176	207	19	the	the	DET
dpc-4176	207	20	efficacy	efficacy	NOUN
dpc-4176	207	21	of	of	ADP
dpc-4176	207	22	guselkumab	guselkumab	NOUN
dpc-4176	207	23	in	in	ADP
dpc-4176	207	24	psa	psa	PROPN
dpc-4176	207	25	.	.	PROPN
dpc-4176	207	26	•	•	NUM
dpc-4176	207	27	randomized	randomize	VERB
dpc-4176	207	28	into	into	ADP
dpc-4176	207	29	3	3	NUM
dpc-4176	207	30	groups	group	NOUN
dpc-4176	207	31	•	•	ADV
dpc-4176	207	32	guselkumab	guselkumab	NOUN
dpc-4176	207	33	100	100	NUM
dpc-4176	207	34	mg	mg	NOUN
dpc-4176	207	35	q4w	q4w	PROPN
dpc-4176	207	36	(	(	PUNCT
dpc-4176	207	37	n=128	n=128	PROPN
dpc-4176	207	38	)	)	PUNCT
dpc-4176	207	39	•	•	NUM
dpc-4176	207	40	guselkumab	guselkumab	NOUN
dpc-4176	207	41	100	100	NUM
dpc-4176	207	42	mg	mg	ADP
dpc-4176	207	43	q8w	q8w	ADV
dpc-4176	207	44	(	(	PUNCT
dpc-4176	207	45	n=127	n=127	NOUN
dpc-4176	207	46	)	)	PUNCT
dpc-4176	207	47	•	•	NUM
dpc-4176	207	48	placebo	placebo	NOUN
dpc-4176	207	49	(	(	PUNCT
dpc-4176	207	50	n=126	n=126	NOUN
dpc-4176	207	51	)	)	PUNCT
dpc-4176	207	52	at	at	ADP
dpc-4176	207	53	week	week	NOUN
dpc-4176	207	54	24	24	NUM
dpc-4176	207	55	:	:	SYM
dpc-4176	207	56	•	•	NUM
dpc-4176	207	57	acr	acr	PROPN
dpc-4176	207	58	20	20	NUM
dpc-4176	207	59	response	response	NOUN
dpc-4176	207	60	:	:	PUNCT
dpc-4176	207	61	•	•	NUM
dpc-4176	207	62	guselkumab	guselkumab	NOUN
dpc-4176	207	63	q4w	q4w	PROPN
dpc-4176	207	64	(	(	PUNCT
dpc-4176	207	65	59	59	NUM
dpc-4176	207	66	%	%	NOUN
dpc-4176	207	67	)	)	PUNCT
dpc-4176	207	68	•	•	NOUN
dpc-4176	208	1	guselkumab	guselkumab	NOUN
dpc-4176	209	1	q8w	q8w	PROPN
dpc-4176	210	1	(	(	PUNCT
dpc-4176	210	2	52	52	NUM
dpc-4176	210	3	%	%	NOUN
dpc-4176	210	4	)	)	PUNCT
dpc-4176	210	5	•	•	NUM
dpc-4176	210	6	placebo	placebo	NOUN
dpc-4176	210	7	(	(	PUNCT
dpc-4176	210	8	22	22	NUM
dpc-4176	210	9	%	%	NOUN
dpc-4176	210	10	)	)	PUNCT
dpc-4176	210	11	•	•	NOUN
dpc-4176	210	12	acr	acr	PROPN
dpc-4176	210	13	50	50	NUM
dpc-4176	210	14	response	response	NOUN
dpc-4176	210	15	:	:	PUNCT
dpc-4176	210	16	•	•	NUM
dpc-4176	210	17	guselkumab	guselkumab	NOUN
dpc-4176	210	18	q4w	q4w	PROPN
dpc-4176	210	19	(	(	PUNCT
dpc-4176	210	20	36	36	NUM
dpc-4176	210	21	%	%	NOUN
dpc-4176	210	22	)	)	PUNCT
dpc-4176	210	23	•	•	NOUN
dpc-4176	210	24	guselkumab	guselkumab	NOUN
dpc-4176	210	25	q8w	q8w	PROPN
dpc-4176	210	26	(	(	PUNCT
dpc-4176	210	27	30	30	NUM
dpc-4176	210	28	%	%	NOUN
dpc-4176	210	29	)	)	PUNCT
dpc-4176	210	30	•	•	NUM
dpc-4176	210	31	placebo	placebo	NOUN
dpc-4176	210	32	(	(	PUNCT
dpc-4176	210	33	9	9	NUM
dpc-4176	210	34	%	%	NOUN
dpc-4176	210	35	)	)	PUNCT
dpc-4176	210	36	•	•	NOUN
dpc-4176	210	37	acr	acr	PROPN
dpc-4176	210	38	70	70	NUM
dpc-4176	210	39	response	response	NOUN
dpc-4176	210	40	:	:	PUNCT
dpc-4176	210	41	•	•	NUM
dpc-4176	210	42	guselkumab	guselkumab	NOUN
dpc-4176	210	43	q4w	q4w	PROPN
dpc-4176	210	44	(	(	PUNCT
dpc-4176	210	45	20	20	NUM
dpc-4176	210	46	%	%	NOUN
dpc-4176	210	47	)	)	PUNCT
dpc-4176	210	48	•	•	NOUN
dpc-4176	210	49	guselkumab	guselkumab	NOUN
dpc-4176	210	50	q8w	q8w	ADV
dpc-4176	210	51	(	(	PUNCT
dpc-4176	210	52	12	12	NUM
dpc-4176	210	53	%	%	NOUN
dpc-4176	210	54	)	)	PUNCT
dpc-4176	210	55	•	•	NUM
dpc-4176	210	56	placebo	placebo	NOUN
dpc-4176	210	57	(	(	PUNCT
dpc-4176	210	58	6	6	NUM
dpc-4176	210	59	%	%	NOUN
dpc-4176	210	60	)	)	PUNCT
dpc-4176	210	61	table	table	NOUN
dpc-4176	210	62	4	4	NUM
dpc-4176	210	63	.	.	PUNCT
dpc-4176	211	1	studies	study	NOUN
dpc-4176	211	2	and	and	CCONJ
dpc-4176	211	3	report	report	NOUN
dpc-4176	211	4	evaluating	evaluate	VERB
dpc-4176	211	5	the	the	DET
dpc-4176	211	6	role	role	NOUN
dpc-4176	211	7	of	of	ADP
dpc-4176	211	8	guselkumab	guselkumab	NOUN
dpc-4176	211	9	in	in	ADP
dpc-4176	211	10	hidradenitis	hidradenitis	PROPN
dpc-4176	211	11	suppurativa	suppurativa	PROPN
dpc-4176	211	12	serial	serial	PROPN
dpc-4176	211	13	no	no	NOUN
dpc-4176	211	14	.	.	PUNCT
dpc-4176	212	1	authors	author	NOUN
dpc-4176	212	2	/	/	SYM
dpc-4176	212	3	year	year	NOUN
dpc-4176	212	4	details	detail	NOUN
dpc-4176	212	5	remarks	remark	VERB
dpc-4176	212	6	1	1	NUM
dpc-4176	212	7	dudink	dudink	VERB
dpc-4176	212	8	et	et	NOUN
dpc-4176	212	9	al	al	PROPN
dpc-4176	213	1	[	[	X
dpc-4176	213	2	58	58	NUM
dpc-4176	213	3	]	]	PUNCT
dpc-4176	213	4	2023	2023	NUM
dpc-4176	213	5	•	•	NOUN
dpc-4176	213	6	an	an	DET
dpc-4176	213	7	open	open	ADJ
dpc-4176	213	8	-	-	PUNCT
dpc-4176	213	9	label	label	NOUN
dpc-4176	213	10	multicenter	multicenter	NOUN
dpc-4176	213	11	,	,	PUNCT
dpc-4176	213	12	phase	phase	NOUN
dpc-4176	213	13	iia	iia	NOUN
dpc-4176	213	14	trial	trial	NOUN
dpc-4176	213	15	.	.	PUNCT
dpc-4176	214	1	•	•	NUM
dpc-4176	214	2	20	20	NUM
dpc-4176	214	3	patients	patient	NOUN
dpc-4176	214	4	enrolled	enrol	VERB
dpc-4176	214	5	.	.	PUNCT
dpc-4176	215	1	•	•	NUM
dpc-4176	215	2	2	2	NUM
dpc-4176	215	3	dropped	drop	VERB
dpc-4176	215	4	out	out	ADP
dpc-4176	215	5	.	.	PUNCT
dpc-4176	216	1	•	•	NUM
dpc-4176	216	2	guselkumab	guselkumab	NOUN
dpc-4176	216	3	(	(	PUNCT
dpc-4176	216	4	200	200	NUM
dpc-4176	216	5	mg	mg	PROPN
dpc-4176	216	6	sc	sc	PROPN
dpc-4176	216	7	)	)	PUNCT
dpc-4176	216	8	administered	administer	VERB
dpc-4176	216	9	at	at	ADP
dpc-4176	216	10	week	week	NOUN
dpc-4176	216	11	0	0	NUM
dpc-4176	216	12	,	,	PUNCT
dpc-4176	216	13	4	4	NUM
dpc-4176	216	14	,	,	PUNCT
dpc-4176	216	15	8	8	NUM
dpc-4176	216	16	and	and	CCONJ
dpc-4176	216	17	12	12	NUM
dpc-4176	216	18	.	.	NOUN
dpc-4176	216	19	•	•	NOUN
dpc-4176	216	20	treatment	treatment	NOUN
dpc-4176	216	21	given	give	VERB
dpc-4176	216	22	till	till	SCONJ
dpc-4176	216	23	week	week	NOUN
dpc-4176	216	24	16	16	NUM
dpc-4176	216	25	.	.	PUNCT
dpc-4176	217	1	•	•	NUM
dpc-4176	217	2	follow	follow	VERB
dpc-4176	217	3	up	up	ADV
dpc-4176	217	4	for	for	ADP
dpc-4176	217	5	8	8	NUM
dpc-4176	217	6	weeks	week	NOUN
dpc-4176	217	7	.	.	PUNCT
dpc-4176	218	1	•	•	NUM
dpc-4176	218	2	total	total	ADJ
dpc-4176	218	3	duration	duration	NOUN
dpc-4176	218	4	24	24	NUM
dpc-4176	218	5	weeks	week	NOUN
dpc-4176	218	6	•	•	NOUN
dpc-4176	218	7	65	65	NUM
dpc-4176	218	8	%	%	NOUN
dpc-4176	218	9	patients	patient	NOUN
dpc-4176	218	10	achieved	achieve	VERB
dpc-4176	218	11	hidradenitis	hidradenitis	PROPN
dpc-4176	218	12	suppurativa	suppurativa	PROPN
dpc-4176	218	13	clinical	clinical	ADJ
dpc-4176	218	14	response	response	NOUN
dpc-4176	218	15	(	(	PUNCT
dpc-4176	218	16	hiscr	hiscr	PROPN
dpc-4176	218	17	)	)	PUNCT
dpc-4176	218	18	at	at	ADP
dpc-4176	218	19	24	24	NUM
dpc-4176	218	20	weeks	week	NOUN
dpc-4176	218	21	.	.	PUNCT
dpc-4176	219	1	•	•	NOUN
dpc-4176	219	2	in	in	ADP
dpc-4176	219	3	35	35	NUM
dpc-4176	219	4	%	%	NOUN
dpc-4176	219	5	patients	patient	NOUN
dpc-4176	219	6	,	,	PUNCT
dpc-4176	219	7	75	75	NUM
dpc-4176	219	8	%	%	NOUN
dpc-4176	219	9	improvement	improvement	NOUN
dpc-4176	219	10	of	of	ADP
dpc-4176	219	11	hiscr	hiscr	NOUN
dpc-4176	219	12	was	be	AUX
dpc-4176	219	13	seen	see	VERB
dpc-4176	219	14	.	.	PUNCT
dpc-4176	220	1	•	•	NUM
dpc-4176	220	2	median	median	PROPN
dpc-4176	220	3	international	international	ADJ
dpc-4176	220	4	hidradenitis	hidradenitis	PROPN
dpc-4176	220	5	suppurativa	suppurativa	PROPN
dpc-4176	220	6	score	score	NOUN
dpc-4176	220	7	4	4	NUM
dpc-4176	220	8	(	(	PUNCT
dpc-4176	220	9	ihs4	ihs4	PROPN
dpc-4176	220	10	)	)	PUNCT
dpc-4176	220	11	and	and	CCONJ
dpc-4176	220	12	abscess	abscess	NOUN
dpc-4176	220	13	/	/	SYM
dpc-4176	220	14	nodule	nodule	NOUN
dpc-4176	220	15	count	count	NOUN
dpc-4176	220	16	had	have	AUX
dpc-4176	220	17	significantly	significantly	ADV
dpc-4176	220	18	reduced	reduce	VERB
dpc-4176	220	19	between	between	ADP
dpc-4176	220	20	baseline	baseline	NOUN
dpc-4176	220	21	and	and	CCONJ
dpc-4176	220	22	week	week	NOUN
dpc-4176	220	23	16	16	NUM
dpc-4176	220	24	from	from	ADP
dpc-4176	220	25	8.5	8.5	NUM
dpc-4176	220	26	to	to	PART
dpc-4176	220	27	5	5	NUM
dpc-4176	220	28	.	.	NOUN
dpc-4176	220	29	•	•	NUM
dpc-4176	220	30	common	common	ADJ
dpc-4176	220	31	adverse	adverse	ADJ
dpc-4176	220	32	effects	effect	NOUN
dpc-4176	220	33	encountered	encounter	VERB
dpc-4176	220	34	were	be	AUX
dpc-4176	220	35	headache	headache	NOUN
dpc-4176	220	36	,	,	PUNCT
dpc-4176	220	37	nausea	nausea	NOUN
dpc-4176	220	38	and	and	CCONJ
dpc-4176	220	39	upper	upper	ADJ
dpc-4176	220	40	respiratory	respiratory	ADJ
dpc-4176	220	41	tract	tract	NOUN
dpc-4176	220	42	infection	infection	NOUN
dpc-4176	220	43	.	.	PUNCT
dpc-4176	221	1	•	•	NUM
dpc-4176	221	2	the	the	DET
dpc-4176	221	3	only	only	ADJ
dpc-4176	221	4	serious	serious	ADJ
dpc-4176	221	5	adverse	adverse	ADJ
dpc-4176	221	6	effect	effect	NOUN
dpc-4176	221	7	was	be	AUX
dpc-4176	221	8	a	a	DET
dpc-4176	221	9	case	case	NOUN
dpc-4176	221	10	of	of	ADP
dpc-4176	221	11	myocardial	myocardial	ADJ
dpc-4176	221	12	infarction	infarction	NOUN
dpc-4176	221	13	(	(	PUNCT
dpc-4176	221	14	though	though	SCONJ
dpc-4176	221	15	not	not	PART
dpc-4176	221	16	related	relate	VERB
dpc-4176	221	17	to	to	ADP
dpc-4176	221	18	guselkumab	guselkumab	NOUN
dpc-4176	221	19	therapy	therapy	NOUN
dpc-4176	221	20	)	)	PUNCT
dpc-4176	221	21	.	.	PUNCT
dpc-4176	222	1	2	2	NUM
dpc-4176	222	2	kimball	kimball	PROPN
dpc-4176	222	3	et	et	PROPN
dpc-4176	222	4	al	al	PROPN
dpc-4176	222	5	[	[	X
dpc-4176	222	6	59	59	NUM
dpc-4176	222	7	]	]	PUNCT
dpc-4176	222	8	2023	2023	NUM
dpc-4176	222	9	•	•	NOUN
dpc-4176	222	10	a	a	DET
dpc-4176	222	11	phase	phase	NOUN
dpc-4176	222	12	2	2	NUM
dpc-4176	222	13	,	,	PUNCT
dpc-4176	222	14	multicenter	multicenter	NOUN
dpc-4176	222	15	,	,	PUNCT
dpc-4176	222	16	randomized	randomized	ADJ
dpc-4176	222	17	placebo	placebo	NOUN
dpc-4176	222	18	controlled	control	VERB
dpc-4176	222	19	,	,	PUNCT
dpc-4176	222	20	double	double	ADJ
dpc-4176	222	21	blind	blind	ADJ
dpc-4176	222	22	study	study	NOUN
dpc-4176	222	23	.	.	PUNCT
dpc-4176	223	1	•	•	NOUN
dpc-4176	223	2	184	184	NUM
dpc-4176	223	3	patients	patient	NOUN
dpc-4176	223	4	randomized	randomize	VERB
dpc-4176	223	5	as	as	SCONJ
dpc-4176	223	6	1:1:1	1:1:1	PROPN
dpc-4176	223	7	to	to	PART
dpc-4176	223	8	receive	receive	VERB
dpc-4176	223	9	:	:	PUNCT
dpc-4176	223	10			NUM
dpc-4176	223	11	guselkumab	guselkumab	NOUN
dpc-4176	223	12	(	(	PUNCT
dpc-4176	223	13	200	200	NUM
dpc-4176	223	14	mg	mg	PROPN
dpc-4176	223	15	sc	sc	PROPN
dpc-4176	223	16	)	)	PUNCT
dpc-4176	223	17	q4w	q4w	PROPN
dpc-4176	223	18	for	for	ADP
dpc-4176	223	19	36	36	NUM
dpc-4176	223	20	weeks	week	NOUN
dpc-4176	223	21	(	(	PUNCT
dpc-4176	223	22	guselkumab	guselkumab	NOUN
dpc-4176	223	23	sc	sc	PROPN
dpc-4176	223	24	group	group	NOUN
dpc-4176	223	25	)	)	PUNCT
dpc-4176	223	26	.	.	PUNCT
dpc-4176	224	1			NUM
dpc-4176	224	2	guselkumab	guselkumab	NOUN
dpc-4176	224	3	(	(	PUNCT
dpc-4176	224	4	1200	1200	NUM
dpc-4176	224	5	mg	mg	NUM
dpc-4176	224	6	iv	iv	PROPN
dpc-4176	224	7	)	)	PUNCT
dpc-4176	224	8	q4w	q4w	NOUN
dpc-4176	224	9	for	for	ADP
dpc-4176	224	10	12	12	NUM
dpc-4176	224	11	weeks	week	NOUN
dpc-4176	224	12	and	and	CCONJ
dpc-4176	224	13	then	then	ADV
dpc-4176	224	14	,	,	PUNCT
dpc-4176	224	15	guselkumab	guselkumab	NOUN
dpc-4176	224	16	(	(	PUNCT
dpc-4176	224	17	200	200	NUM
dpc-4176	224	18	mg	mg	PROPN
dpc-4176	224	19	sc	sc	PROPN
dpc-4176	224	20	)	)	PUNCT
dpc-4176	224	21	q4w	q4w	NOUN
dpc-4176	224	22	from	from	ADP
dpc-4176	224	23	12	12	NUM
dpc-4176	224	24	-	-	SYM
dpc-4176	224	25	36	36	NUM
dpc-4176	224	26	weeks	week	NOUN
dpc-4176	224	27	(	(	PUNCT
dpc-4176	224	28	guselkumab	guselkumab	NOUN
dpc-4176	224	29	iv	iv	NUM
dpc-4176	224	30	group	group	NOUN
dpc-4176	224	31	)	)	PUNCT
dpc-4176	224	32	.	.	PUNCT
dpc-4176	225	1			NUM
dpc-4176	225	2	placebo	placebo	NOUN
dpc-4176	225	3	iv	iv	ADP
dpc-4176	225	4	or	or	CCONJ
dpc-4176	225	5	sc	sc	PROPN
dpc-4176	225	6	q4w	q4w	PROPN
dpc-4176	225	7	for	for	ADP
dpc-4176	225	8	12	12	NUM
dpc-4176	225	9	weeks	week	NOUN
dpc-4176	225	10	with	with	ADP
dpc-4176	225	11	rerandomization	rerandomization	NOUN
dpc-4176	225	12	to	to	ADP
dpc-4176	225	13	:	:	PUNCT
dpc-4176	225	14	0	0	NUM
dpc-4176	225	15	guselkumab	guselkumab	NOUN
dpc-4176	225	16	200mgsc	200mgsc	PROPN
dpc-4176	225	17	q4w	q4w	NOUN
dpc-4176	225	18	from	from	ADP
dpc-4176	225	19	week	week	NOUN
dpc-4176	225	20	16	16	NUM
dpc-4176	225	21	to	to	PART
dpc-4176	225	22	36	36	NUM
dpc-4176	225	23	(	(	PUNCT
dpc-4176	225	24	placebo	placebo	NOUN
dpc-4176	225	25	-	-	PUNCT
dpc-4176	225	26	guselkumab	guselkumab	NOUN
dpc-4176	225	27	200	200	NUM
dpc-4176	225	28	mg	mg	PROPN
dpc-4176	225	29	group	group	NOUN
dpc-4176	225	30	)	)	PUNCT
dpc-4176	225	31	or	or	CCONJ
dpc-4176	225	32	0	0	NUM
dpc-4176	225	33	guselkumab	guselkumab	NOUN
dpc-4176	225	34	100	100	NUM
dpc-4176	225	35	mg	mg	PROPN
dpc-4176	225	36	sc	sc	PROPN
dpc-4176	225	37	at	at	ADP
dpc-4176	225	38	weeks	week	NOUN
dpc-4176	225	39	16	16	NUM
dpc-4176	225	40	,	,	PUNCT
dpc-4176	225	41	20	20	NUM
dpc-4176	225	42	,	,	PUNCT
dpc-4176	225	43	28	28	NUM
dpc-4176	225	44	and	and	CCONJ
dpc-4176	225	45	36	36	NUM
dpc-4176	225	46	,	,	PUNCT
dpc-4176	225	47	placebo	placebo	NOUN
dpc-4176	225	48	at	at	ADP
dpc-4176	225	49	weeks	week	NOUN
dpc-4176	225	50	24	24	NUM
dpc-4176	225	51	and	and	CCONJ
dpc-4176	225	52	32(placebo	32(placebo	NUM
dpc-4176	225	53	–	–	PUNCT
dpc-4176	225	54	guselkumab	guselkumab	NOUN
dpc-4176	225	55	100	100	NUM
dpc-4176	225	56	mg	mg	NUM
dpc-4176	225	57	)	)	PUNCT
dpc-4176	225	58	group	group	NOUN
dpc-4176	225	59	.	.	PUNCT
dpc-4176	226	1	•	•	NUM
dpc-4176	226	2	at	at	ADP
dpc-4176	226	3	week	week	NOUN
dpc-4176	226	4	16	16	NUM
dpc-4176	226	5	,	,	PUNCT
dpc-4176	226	6	the	the	DET
dpc-4176	226	7	proportions	proportion	NOUN
dpc-4176	226	8	of	of	ADP
dpc-4176	226	9	patients	patient	NOUN
dpc-4176	226	10	achieving	achieve	VERB
dpc-4176	226	11	hiscr	hiscr	NOUN
dpc-4176	226	12	:	:	PUNCT
dpc-4176	226	13	•	•	NUM
dpc-4176	226	14	guselkumab	guselkumab	NOUN
dpc-4176	226	15	sc	sc	PROPN
dpc-4176	226	16	group	group	NOUN
dpc-4176	226	17	(	(	PUNCT
dpc-4176	226	18	50.8	50.8	NUM
dpc-4176	226	19	%	%	NOUN
dpc-4176	226	20	)	)	PUNCT
dpc-4176	226	21	•	•	NOUN
dpc-4176	226	22	guselkumab	guselkumab	NOUN
dpc-4176	226	23	iv	iv	NUM
dpc-4176	226	24	group	group	NOUN
dpc-4176	226	25	(	(	PUNCT
dpc-4176	226	26	45	45	NUM
dpc-4176	226	27	%	%	NOUN
dpc-4176	226	28	)	)	PUNCT
dpc-4176	226	29	.	.	PUNCT
dpc-4176	227	1	•	•	NUM
dpc-4176	227	2	placebo	placebo	NOUN
dpc-4176	227	3	group	group	NOUN
dpc-4176	227	4	(	(	PUNCT
dpc-4176	227	5	38.7	38.7	NUM
dpc-4176	227	6	%	%	NOUN
dpc-4176	227	7	)	)	PUNCT
dpc-4176	227	8	.	.	PUNCT
dpc-4176	228	1	•	•	NOUN
dpc-4176	228	2	at	at	ADP
dpc-4176	228	3	week	week	NOUN
dpc-4176	228	4	40	40	NUM
dpc-4176	228	5	hiscr	hiscr	NOUN
dpc-4176	228	6	response	response	NOUN
dpc-4176	228	7	rates	rate	NOUN
dpc-4176	228	8	:	:	PUNCT
dpc-4176	228	9			NUM
dpc-4176	228	10	guselkumab	guselkumab	NOUN
dpc-4176	228	11	sc	sc	PROPN
dpc-4176	228	12	group	group	NOUN
dpc-4176	228	13	(	(	PUNCT
dpc-4176	228	14	45.8	45.8	NUM
dpc-4176	228	15	%	%	NOUN
dpc-4176	228	16	)	)	PUNCT
dpc-4176	228	17	.	.	PUNCT
dpc-4176	229	1			NUM
dpc-4176	229	2	guselkumab	guselkumab	NOUN
dpc-4176	229	3	iv	iv	NUM
dpc-4176	229	4	group	group	NOUN
dpc-4176	229	5	(	(	PUNCT
dpc-4176	229	6	48.3	48.3	NUM
dpc-4176	229	7	%	%	NOUN
dpc-4176	229	8	)	)	PUNCT
dpc-4176	229	9	.	.	PUNCT
dpc-4176	230	1			NUM
dpc-4176	230	2	guselkumab	guselkumab	VERB
dpc-4176	230	3	100	100	NUM
dpc-4176	230	4	mg	mg	PROPN
dpc-4176	230	5	group	group	NOUN
dpc-4176	230	6	(	(	PUNCT
dpc-4176	230	7	placebo	placebo	NOUN
dpc-4176	230	8	crossover	crossover	NOUN
dpc-4176	230	9	)	)	PUNCT
dpc-4176	230	10	(	(	PUNCT
dpc-4176	230	11	46.4	46.4	NUM
dpc-4176	230	12	%	%	NOUN
dpc-4176	230	13	)	)	PUNCT
dpc-4176	230	14			NUM
dpc-4176	230	15	guselkumab	guselkumab	VERB
dpc-4176	230	16	200	200	NUM
dpc-4176	230	17	mg	mg	PROPN
dpc-4176	230	18	group	group	NOUN
dpc-4176	230	19	(	(	PUNCT
dpc-4176	230	20	placebo	placebo	NOUN
dpc-4176	230	21	crossover	crossover	NOUN
dpc-4176	230	22	)	)	PUNCT
dpc-4176	230	23	(	(	PUNCT
dpc-4176	230	24	53.6	53.6	NUM
dpc-4176	230	25	%	%	NOUN
dpc-4176	230	26	)	)	PUNCT
dpc-4176	230	27			NUM
dpc-4176	230	28	primary	primary	ADJ
dpc-4176	230	29	end	end	NOUN
dpc-4176	230	30	point	point	NOUN
dpc-4176	230	31	was	be	AUX
dpc-4176	230	32	not	not	PART
dpc-4176	230	33	met	meet	VERB
dpc-4176	230	34	here	here	ADV
dpc-4176	230	35			NUM
dpc-4176	230	36	guselkumab	guselkumab	NOUN
dpc-4176	230	37	was	be	AUX
dpc-4176	230	38	not	not	PART
dpc-4176	230	39	very	very	ADV
dpc-4176	230	40	effective	effective	ADJ
dpc-4176	230	41	here	here	ADV
dpc-4176	230	42	for	for	ADP
dpc-4176	230	43	hs	hs	PROPN
dpc-4176	230	44	.	.	PROPN
dpc-4176	230	45	•	•	NUM
dpc-4176	230	46	anemia	anemia	NOUN
dpc-4176	230	47	and	and	CCONJ
dpc-4176	230	48	nephrolithiasis	nephrolithiasis	NOUN
dpc-4176	230	49	were	be	AUX
dpc-4176	230	50	reported	report	VERB
dpc-4176	230	51	in	in	ADP
dpc-4176	230	52	one	one	NUM
dpc-4176	230	53	patient	patient	NOUN
dpc-4176	230	54	and	and	CCONJ
dpc-4176	230	55	cholelithiasis	cholelithiasis	NOUN
dpc-4176	230	56	in	in	ADP
dpc-4176	230	57	another	another	PRON
dpc-4176	230	58	,	,	PUNCT
dpc-4176	230	59	though	though	SCONJ
dpc-4176	230	60	none	none	NOUN
dpc-4176	230	61	were	be	AUX
dpc-4176	230	62	related	relate	VERB
dpc-4176	230	63	to	to	ADP
dpc-4176	230	64	guselkumab	guselkumab	NOUN
dpc-4176	230	65	therapy	therapy	NOUN
dpc-4176	230	66	.	.	PUNCT
dpc-4176	231	1	table	table	NOUN
dpc-4176	231	2	4	4	NUM
dpc-4176	231	3	continues	continue	VERB
dpc-4176	231	4	10	10	NUM
dpc-4176	231	5	review	review	NOUN
dpc-4176	231	6	|	|	ADV
dpc-4176	231	7	dermatol	dermatol	ADJ
dpc-4176	231	8	pract	pract	NOUN
dpc-4176	231	9	concept	concept	NOUN
dpc-4176	231	10	.	.	PUNCT
dpc-4176	232	1	2024;14(3):e2024181	2024;14(3):e2024181	NUM
dpc-4176	232	2	serial	serial	ADJ
dpc-4176	232	3	no	no	NOUN
dpc-4176	232	4	.	.	PUNCT
dpc-4176	233	1	authors	author	NOUN
dpc-4176	233	2	/	/	SYM
dpc-4176	233	3	year	year	NOUN
dpc-4176	233	4	details	detail	NOUN
dpc-4176	233	5	remarks	remark	VERB
dpc-4176	233	6	3	3	NUM
dpc-4176	233	7	casseres	cassere	NOUN
dpc-4176	233	8	et	et	NOUN
dpc-4176	233	9	al	al	PROPN
dpc-4176	234	1	[	[	X
dpc-4176	234	2	60	60	NUM
dpc-4176	234	3	]	]	SYM
dpc-4176	234	4	2019	2019	NUM
dpc-4176	234	5	•	•	NOUN
dpc-4176	234	6	retrospective	retrospective	ADJ
dpc-4176	234	7	chart	chart	NOUN
dpc-4176	234	8	review	review	NOUN
dpc-4176	234	9	of	of	ADP
dpc-4176	234	10	8	8	NUM
dpc-4176	234	11	patients	patient	NOUN
dpc-4176	234	12	.	.	PUNCT
dpc-4176	235	1	•	•	NUM
dpc-4176	235	2	4	4	NUM
dpc-4176	235	3	patients	patient	NOUN
dpc-4176	235	4	:	:	PUNCT
dpc-4176	235	5	hurley	hurley	PROPN
dpc-4176	235	6	stage	stage	VERB
dpc-4176	235	7	3	3	NUM
dpc-4176	235	8	disease	disease	NOUN
dpc-4176	235	9	•	•	NOUN
dpc-4176	235	10	4	4	NUM
dpc-4176	235	11	patients	patient	NOUN
dpc-4176	235	12	:	:	PUNCT
dpc-4176	235	13	hurley	hurley	PROPN
dpc-4176	235	14	stage	stage	VERB
dpc-4176	235	15	2	2	NUM
dpc-4176	235	16	disease	disease	NOUN
dpc-4176	235	17	•	•	NOUN
dpc-4176	235	18	previously	previously	ADV
dpc-4176	235	19	failure	failure	NOUN
dpc-4176	235	20	of	of	ADP
dpc-4176	235	21	treatment	treatment	NOUN
dpc-4176	235	22	with	with	ADP
dpc-4176	235	23	adalimumab	adalimumab	NOUN
dpc-4176	235	24	,	,	PUNCT
dpc-4176	235	25	secukinumab	secukinumab	NOUN
dpc-4176	235	26	,	,	PUNCT
dpc-4176	235	27	ustekinumab	ustekinumab	NOUN
dpc-4176	235	28	and	and	CCONJ
dpc-4176	235	29	ixekizumab	ixekizumab	NOUN
dpc-4176	235	30	.	.	PUNCT
dpc-4176	236	1	•	•	NUM
dpc-4176	236	2	authors	author	NOUN
dpc-4176	236	3	reported	report	VERB
dpc-4176	236	4	improvement	improvement	NOUN
dpc-4176	236	5	of	of	ADP
dpc-4176	236	6	hs	hs	PROPN
dpc-4176	236	7	in	in	ADP
dpc-4176	236	8	5	5	NUM
dpc-4176	236	9	patients	patient	NOUN
dpc-4176	236	10	(	(	PUNCT
dpc-4176	236	11	63	63	NUM
dpc-4176	236	12	%	%	NOUN
dpc-4176	236	13	)	)	PUNCT
dpc-4176	236	14	following	follow	VERB
dpc-4176	236	15	4	4	NUM
dpc-4176	236	16	 	 	SPACE
dpc-4176	236	17	months	month	NOUN
dpc-4176	236	18	of	of	ADP
dpc-4176	236	19	therapy	therapy	NOUN
dpc-4176	236	20	.	.	PUNCT
dpc-4176	237	1	•	•	NUM
dpc-4176	237	2	precise	precise	ADJ
dpc-4176	237	3	data	datum	NOUN
dpc-4176	237	4	,	,	PUNCT
dpc-4176	237	5	though	though	SCONJ
dpc-4176	237	6	was	be	AUX
dpc-4176	237	7	lacking	lack	VERB
dpc-4176	237	8	.	.	PUNCT
dpc-4176	238	1	4	4	NUM
dpc-4176	238	2	montero	montero	NOUN
dpc-4176	238	3	-	-	PUNCT
dpc-4176	238	4	vilichez	vilichez	NOUN
dpc-4176	238	5	et	et	PROPN
dpc-4176	238	6	al	al	PROPN
dpc-4176	239	1	[	[	X
dpc-4176	239	2	61	61	NUM
dpc-4176	239	3	]	]	SYM
dpc-4176	239	4	2020	2020	NUM
dpc-4176	239	5	•	•	NOUN
dpc-4176	239	6	case	case	NOUN
dpc-4176	239	7	series	series	NOUN
dpc-4176	239	8	of	of	ADP
dpc-4176	239	9	4	4	NUM
dpc-4176	239	10	patients	patient	NOUN
dpc-4176	239	11	with	with	ADP
dpc-4176	239	12	hs	hs	PROPN
dpc-4176	239	13	(	(	PUNCT
dpc-4176	239	14	hurley	hurley	PROPN
dpc-4176	239	15	stage	stage	NOUN
dpc-4176	239	16	2	2	NUM
dpc-4176	239	17	and	and	CCONJ
dpc-4176	239	18	3	3	NUM
dpc-4176	239	19	)	)	PUNCT
dpc-4176	239	20	.	.	PUNCT
dpc-4176	240	1	•	•	NUM
dpc-4176	240	2	patients	patient	NOUN
dpc-4176	240	3	were	be	AUX
dpc-4176	240	4	recalcitrant	recalcitrant	ADJ
dpc-4176	240	5	to	to	PART
dpc-4176	240	6	biologic	biologic	VERB
dpc-4176	240	7	treatment	treatment	NOUN
dpc-4176	240	8	with	with	ADP
dpc-4176	240	9	infliximab	infliximab	NOUN
dpc-4176	240	10	,	,	PUNCT
dpc-4176	240	11	adalimumab	adalimumab	NOUN
dpc-4176	240	12	,	,	PUNCT
dpc-4176	240	13	ustekinumab	ustekinumab	NOUN
dpc-4176	240	14	and	and	CCONJ
dpc-4176	240	15	secukinumab	secukinumab	NOUN
dpc-4176	240	16	.	.	PUNCT
dpc-4176	241	1	•	•	NUM
dpc-4176	241	2	guselkumab	guselkumab	NOUN
dpc-4176	241	3	started	start	VERB
dpc-4176	241	4	sc	sc	PROPN
dpc-4176	241	5	as	as	ADP
dpc-4176	241	6	100	100	NUM
dpc-4176	241	7	mg	mg	NOUN
dpc-4176	241	8	at	at	ADP
dpc-4176	241	9	week	week	NOUN
dpc-4176	241	10	0	0	NUM
dpc-4176	241	11	,	,	PUNCT
dpc-4176	241	12	and	and	CCONJ
dpc-4176	241	13	then	then	ADV
dpc-4176	241	14	every	every	DET
dpc-4176	241	15	4	4	NUM
dpc-4176	241	16	weeks	week	NOUN
dpc-4176	241	17	.	.	PUNCT
dpc-4176	241	18	•	•	NUM
dpc-4176	241	19	moderate	moderate	ADJ
dpc-4176	241	20	reduction	reduction	NOUN
dpc-4176	241	21	in	in	ADP
dpc-4176	241	22	hs4	hs4	ADJ
dpc-4176	241	23	,	,	PUNCT
dpc-4176	241	24	visual	visual	ADJ
dpc-4176	241	25	analogue	analogue	NOUN
dpc-4176	241	26	scores	score	NOUN
dpc-4176	241	27	for	for	ADP
dpc-4176	241	28	pain	pain	NOUN
dpc-4176	241	29	and	and	CCONJ
dpc-4176	241	30	dlqi	dlqi	VERB
dpc-4176	241	31	in	in	ADP
dpc-4176	241	32	3	3	NUM
dpc-4176	241	33	patients	patient	NOUN
dpc-4176	241	34	at	at	ADP
dpc-4176	241	35	12	12	NUM
dpc-4176	241	36	weeks	week	NOUN
dpc-4176	241	37	of	of	ADP
dpc-4176	241	38	treatment	treatment	NOUN
dpc-4176	241	39	.	.	PUNCT
dpc-4176	242	1	•	•	NOUN
dpc-4176	242	2	in	in	ADP
dpc-4176	242	3	no	no	DET
dpc-4176	242	4	patient	patient	NOUN
dpc-4176	242	5	was	be	AUX
dpc-4176	242	6	an	an	DET
dpc-4176	242	7	improvement	improvement	NOUN
dpc-4176	242	8	observed	observe	VERB
dpc-4176	242	9	in	in	ADP
dpc-4176	242	10	the	the	DET
dpc-4176	242	11	hs	hs	PROPN
dpc-4176	242	12	-	-	PROPN
dpc-4176	242	13	pga	pga	NOUN
dpc-4176	242	14	score	score	NOUN
dpc-4176	242	15	.	.	PUNCT
dpc-4176	243	1	•	•	NOUN
dpc-4176	243	2	in	in	ADP
dpc-4176	243	3	one	one	NUM
dpc-4176	243	4	patient	patient	NOUN
dpc-4176	243	5	hs	hs	PROPN
dpc-4176	243	6	severity	severity	PROPN
dpc-4176	243	7	had	have	AUX
dpc-4176	243	8	increased	increase	VERB
dpc-4176	243	9	after	after	ADP
dpc-4176	243	10	treatment	treatment	NOUN
dpc-4176	243	11	.	.	PUNCT
dpc-4176	244	1	•	•	NUM
dpc-4176	244	2	no	no	DET
dpc-4176	244	3	guselkumab	guselkumab	NOUN
dpc-4176	244	4	related	relate	VERB
dpc-4176	244	5	adverse	adverse	ADJ
dpc-4176	244	6	event	event	NOUN
dpc-4176	244	7	was	be	AUX
dpc-4176	244	8	observed	observe	VERB
dpc-4176	244	9	.	.	PUNCT
dpc-4176	245	1	5	5	NUM
dpc-4176	245	2	kearney	kearney	PROPN
dpc-4176	245	3	et	et	PROPN
dpc-4176	245	4	al	al	PROPN
dpc-4176	246	1	[	[	X
dpc-4176	246	2	62	62	NUM
dpc-4176	246	3	]	]	SYM
dpc-4176	246	4	2020	2020	NUM
dpc-4176	246	5	•	•	NUM
dpc-4176	246	6	28	28	NUM
dpc-4176	246	7	-	-	PUNCT
dpc-4176	246	8	year	year	NOUN
dpc-4176	246	9	-	-	PUNCT
dpc-4176	246	10	old	old	ADJ
dpc-4176	246	11	female	female	NOUN
dpc-4176	246	12	with	with	ADP
dpc-4176	246	13	history	history	NOUN
dpc-4176	246	14	of	of	ADP
dpc-4176	246	15	latent	latent	NOUN
dpc-4176	246	16	tuberculosis	tuberculosis	NOUN
dpc-4176	246	17	as	as	ADP
dpc-4176	246	18	a	a	DET
dpc-4176	246	19	teenager	teenager	NOUN
dpc-4176	246	20	,	,	PUNCT
dpc-4176	246	21	treated	treat	VERB
dpc-4176	246	22	with	with	ADP
dpc-4176	246	23	rifampicin	rifampicin	VERB
dpc-4176	246	24	for	for	ADP
dpc-4176	246	25	6	6	NUM
dpc-4176	246	26	months	month	NOUN
dpc-4176	246	27	.	.	PUNCT
dpc-4176	247	1	•	•	NUM
dpc-4176	247	2	presented	present	VERB
dpc-4176	247	3	with	with	ADP
dpc-4176	247	4	hs	hs	PROPN
dpc-4176	247	5	(	(	PUNCT
dpc-4176	247	6	hurley	hurley	PROPN
dpc-4176	247	7	stage	stage	NOUN
dpc-4176	247	8	3	3	NUM
dpc-4176	247	9	)	)	PUNCT
dpc-4176	247	10	.	.	PUNCT
dpc-4176	248	1	•	•	NUM
dpc-4176	248	2	previous	previous	ADJ
dpc-4176	248	3	failed	fail	VERB
dpc-4176	248	4	treatment	treatment	NOUN
dpc-4176	248	5	with	with	ADP
dpc-4176	248	6	metformin	metformin	NOUN
dpc-4176	248	7	and	and	CCONJ
dpc-4176	248	8	spironolactone	spironolactone	NOUN
dpc-4176	248	9	was	be	AUX
dpc-4176	248	10	noted	note	VERB
dpc-4176	248	11	.	.	PUNCT
dpc-4176	249	1	•	•	NUM
dpc-4176	249	2	guselkumab	guselkumab	NOUN
dpc-4176	249	3	100	100	NUM
dpc-4176	249	4	mg	mg	NOUN
dpc-4176	249	5	(	(	PUNCT
dpc-4176	249	6	label	label	NOUN
dpc-4176	249	7	dosing	dosing	NOUN
dpc-4176	249	8	)	)	PUNCT
dpc-4176	249	9	given	give	VERB
dpc-4176	249	10	to	to	ADP
dpc-4176	249	11	the	the	DET
dpc-4176	249	12	patient	patient	NOUN
dpc-4176	249	13	.	.	PUNCT
dpc-4176	250	1	•	•	NUM
dpc-4176	250	2	by	by	ADP
dpc-4176	250	3	12	12	NUM
dpc-4176	250	4	weeks	week	NOUN
dpc-4176	250	5	clear	clear	ADJ
dpc-4176	250	6	clinical	clinical	ADJ
dpc-4176	250	7	and	and	CCONJ
dpc-4176	250	8	pain	pain	NOUN
dpc-4176	250	9	improvement	improvement	NOUN
dpc-4176	250	10	was	be	AUX
dpc-4176	250	11	noted	note	VERB
dpc-4176	250	12	.	.	PUNCT
dpc-4176	251	1	•	•	INTJ
dpc-4176	251	2	at	at	ADP
dpc-4176	251	3	24	24	NUM
dpc-4176	251	4	weeks	week	NOUN
dpc-4176	251	5	,	,	PUNCT
dpc-4176	251	6	remission	remission	NOUN
dpc-4176	251	7	was	be	AUX
dpc-4176	251	8	maintained	maintain	VERB
dpc-4176	251	9	.	.	PUNCT
dpc-4176	252	1	•	•	NUM
dpc-4176	252	2	no	no	DET
dpc-4176	252	3	therapy	therapy	NOUN
dpc-4176	252	4	related	relate	VERB
dpc-4176	252	5	adverse	adverse	ADJ
dpc-4176	252	6	events	event	NOUN
dpc-4176	252	7	were	be	AUX
dpc-4176	252	8	encountered	encounter	VERB
dpc-4176	252	9	.	.	PUNCT
dpc-4176	253	1	6	6	NUM
dpc-4176	253	2	kovacs	kovacs	PROPN
dpc-4176	253	3	et	et	PROPN
dpc-4176	253	4	al	al	PROPN
dpc-4176	254	1	[	[	X
dpc-4176	254	2	63	63	NUM
dpc-4176	254	3	]	]	SYM
dpc-4176	254	4	2019	2019	NUM
dpc-4176	254	5	•	•	NOUN
dpc-4176	254	6	case	case	NOUN
dpc-4176	254	7	series	series	NOUN
dpc-4176	254	8	of	of	ADP
dpc-4176	254	9	3	3	NUM
dpc-4176	254	10	patients	patient	NOUN
dpc-4176	254	11	with	with	ADP
dpc-4176	254	12	hs	hs	PROPN
dpc-4176	254	13	(	(	PUNCT
dpc-4176	254	14	hurley	hurley	PROPN
dpc-4176	254	15	stage	stage	NOUN
dpc-4176	254	16	3	3	NUM
dpc-4176	254	17	)	)	PUNCT
dpc-4176	254	18	.	.	PUNCT
dpc-4176	255	1	•	•	NUM
dpc-4176	255	2	2	2	NUM
dpc-4176	255	3	patients	patient	NOUN
dpc-4176	255	4	had	have	AUX
dpc-4176	255	5	failed	fail	VERB
dpc-4176	255	6	treatment	treatment	NOUN
dpc-4176	255	7	with	with	ADP
dpc-4176	255	8	adalimumab	adalimumab	NOUN
dpc-4176	255	9	.	.	PUNCT
dpc-4176	256	1	•	•	NOUN
dpc-4176	256	2	in	in	ADP
dpc-4176	256	3	one	one	NUM
dpc-4176	256	4	patient	patient	ADJ
dpc-4176	256	5	adalimumab	adalimumab	NOUN
dpc-4176	256	6	was	be	AUX
dpc-4176	256	7	contraindicated	contraindicate	VERB
dpc-4176	256	8	due	due	ADJ
dpc-4176	256	9	to	to	ADP
dpc-4176	256	10	an	an	DET
dpc-4176	256	11	unclear	unclear	ADJ
dpc-4176	256	12	history	history	NOUN
dpc-4176	256	13	of	of	ADP
dpc-4176	256	14	sle	sle	PROPN
dpc-4176	256	15	.	.	PUNCT
dpc-4176	257	1	•	•	NUM
dpc-4176	257	2	at	at	ADP
dpc-4176	257	3	12	12	NUM
dpc-4176	257	4	weeks	week	NOUN
dpc-4176	257	5	:	:	PUNCT
dpc-4176	257	6			NUM
dpc-4176	257	7	significant	significant	ADJ
dpc-4176	257	8	improvement	improvement	NOUN
dpc-4176	257	9	in	in	ADP
dpc-4176	257	10	international	international	PROPN
dpc-4176	257	11	hs	hs	PROPN
dpc-4176	257	12	score	score	NOUN
dpc-4176	257	13	system	system	NOUN
dpc-4176	257	14	ranging	range	VERB
dpc-4176	257	15	from	from	ADP
dpc-4176	257	16	52.0%-60.9	52.0%-60.9	NUM
dpc-4176	257	17	%	%	NOUN
dpc-4176	257	18	was	be	AUX
dpc-4176	257	19	seen	see	VERB
dpc-4176	257	20	.	.	PUNCT
dpc-4176	258	1			NUM
dpc-4176	258	2	vas	vas	X
dpc-4176	258	3	pain	pain	NOUN
dpc-4176	258	4	score	score	NOUN
dpc-4176	258	5	improved	improve	VERB
dpc-4176	258	6	by	by	ADP
dpc-4176	258	7	50%-57.1	50%-57.1	NUM
dpc-4176	258	8	%	%	NOUN
dpc-4176	258	9	.	.	PUNCT
dpc-4176	259	1			NUM
dpc-4176	260	1	dlqi	dlqi	NOUN
dpc-4176	260	2	improved	improve	VERB
dpc-4176	260	3	by	by	ADP
dpc-4176	260	4	25%-66.7	25%-66.7	VERB
dpc-4176	260	5	%	%	NOUN
dpc-4176	260	6	.	.	PUNCT
dpc-4176	261	1	dlqi	dlqi	VERB
dpc-4176	261	2	=	=	PUNCT
dpc-4176	261	3	dermatology	dermatology	NOUN
dpc-4176	261	4	life	life	NOUN
dpc-4176	261	5	quality	quality	NOUN
dpc-4176	261	6	index	index	NOUN
dpc-4176	261	7	;	;	PUNCT
dpc-4176	261	8	hs	hs	PROPN
dpc-4176	261	9	=	=	PROPN
dpc-4176	261	10	hidradenitis	hidradenitis	PROPN
dpc-4176	261	11	suppurativa	suppurativa	PROPN
dpc-4176	261	12	;	;	PUNCT
dpc-4176	261	13	pga	pga	NOUN
dpc-4176	261	14	=	=	SYM
dpc-4176	261	15	physician	physician	NOUN
dpc-4176	261	16	global	global	ADJ
dpc-4176	261	17	assessment	assessment	NOUN
dpc-4176	261	18	;	;	PUNCT
dpc-4176	261	19	sc	sc	PROPN
dpc-4176	261	20	=	=	NOUN
dpc-4176	261	21	subcutaneous	subcutaneous	ADJ
dpc-4176	261	22	;	;	PUNCT
dpc-4176	261	23	sle	sle	NOUN
dpc-4176	261	24	=	=	PUNCT
dpc-4176	262	1	systemic	systemic	ADJ
dpc-4176	262	2	lupus	lupus	PROPN
dpc-4176	262	3	erythematosus	erythematosus	NOUN
dpc-4176	262	4	;	;	PUNCT
dpc-4176	262	5	vas	vas	X
dpc-4176	262	6	=	=	SYM
dpc-4176	262	7	visual	visual	ADJ
dpc-4176	262	8	analogue	analogue	NOUN
dpc-4176	262	9	scale	scale	NOUN
dpc-4176	262	10	.	.	PUNCT
dpc-4176	263	1	table	table	NOUN
dpc-4176	263	2	4	4	NUM
dpc-4176	263	3	.	.	PUNCT
dpc-4176	264	1	studies	study	NOUN
dpc-4176	264	2	and	and	CCONJ
dpc-4176	264	3	report	report	NOUN
dpc-4176	264	4	evaluating	evaluate	VERB
dpc-4176	264	5	the	the	DET
dpc-4176	264	6	role	role	NOUN
dpc-4176	264	7	of	of	ADP
dpc-4176	264	8	guselkumab	guselkumab	NOUN
dpc-4176	264	9	in	in	ADP
dpc-4176	264	10	hidradenitis	hidradenitis	PROPN
dpc-4176	264	11	suppurativa	suppurativa	PROPN
dpc-4176	264	12	.	.	PUNCT
dpc-4176	265	1	(	(	PUNCT
dpc-4176	265	2	continued	continue	VERB
dpc-4176	265	3	)	)	PUNCT
dpc-4176	265	4	th17	th17	NOUN
dpc-4176	265	5	cells	cell	NOUN
dpc-4176	265	6	,	,	PUNCT
dpc-4176	265	7	resulting	result	VERB
dpc-4176	265	8	in	in	ADP
dpc-4176	265	9	il-17	il-17	ADP
dpc-4176	265	10	production	production	NOUN
dpc-4176	265	11	,	,	PUNCT
dpc-4176	265	12	that	that	SCONJ
dpc-4176	265	13	further	far	ADV
dpc-4176	265	14	boosts	boost	VERB
dpc-4176	265	15	neutrophilic	neutrophilic	ADJ
dpc-4176	265	16	recruitment	recruitment	NOUN
dpc-4176	265	17	,	,	PUNCT
dpc-4176	265	18	thus	thus	ADV
dpc-4176	265	19	setting	set	VERB
dpc-4176	265	20	up	up	ADP
dpc-4176	265	21	a	a	DET
dpc-4176	265	22	relentlessly	relentlessly	ADV
dpc-4176	265	23	progressive	progressive	ADJ
dpc-4176	265	24	inflammatory	inflammatory	ADJ
dpc-4176	265	25	cycle	cycle	NOUN
dpc-4176	266	1	[	[	X
dpc-4176	266	2	71	71	NUM
dpc-4176	266	3	]	]	SYM
dpc-4176	266	4	.	.	PUNCT
dpc-4176	267	1	baier	baier	PROPN
dpc-4176	267	2	and	and	CCONJ
dpc-4176	267	3	barak	barak	PROPN
dpc-4176	267	4	were	be	AUX
dpc-4176	267	5	the	the	DET
dpc-4176	267	6	first	first	ADJ
dpc-4176	267	7	to	to	PART
dpc-4176	267	8	demonstrate	demonstrate	VERB
dpc-4176	267	9	the	the	DET
dpc-4176	267	10	profitability	profitability	NOUN
dpc-4176	267	11	of	of	ADP
dpc-4176	267	12	guselkumab	guselkumab	NOUN
dpc-4176	267	13	(	(	PUNCT
dpc-4176	267	14	100	100	NUM
dpc-4176	267	15	mg	mg	PROPN
dpc-4176	267	16	,	,	PUNCT
dpc-4176	267	17	monthly	monthly	ADJ
dpc-4176	267	18	dosing	dosing	NOUN
dpc-4176	267	19	)	)	PUNCT
dpc-4176	267	20	in	in	ADP
dpc-4176	267	21	a	a	DET
dpc-4176	267	22	60	60	NUM
dpc-4176	267	23	-	-	PUNCT
dpc-4176	267	24	year	year	NOUN
dpc-4176	267	25	-	-	PUNCT
dpc-4176	267	26	old	old	ADJ
dpc-4176	267	27	woman	woman	NOUN
dpc-4176	267	28	having	have	VERB
dpc-4176	267	29	ulcerative	ulcerative	ADJ
dpc-4176	267	30	pg	pg	NOUN
dpc-4176	267	31	,	,	PUNCT
dpc-4176	267	32	that	that	PRON
dpc-4176	267	33	was	be	AUX
dpc-4176	267	34	rapidly	rapidly	ADV
dpc-4176	267	35	progressive	progressive	ADJ
dpc-4176	267	36	with	with	ADP
dpc-4176	267	37	evident	evident	ADJ
dpc-4176	267	38	tendons	tendon	NOUN
dpc-4176	267	39	,	,	PUNCT
dpc-4176	267	40	ligaments	ligament	NOUN
dpc-4176	267	41	and	and	CCONJ
dpc-4176	267	42	muscles	muscle	NOUN
dpc-4176	267	43	on	on	ADP
dpc-4176	267	44	inspection	inspection	NOUN
dpc-4176	267	45	[	[	X
dpc-4176	267	46	72	72	NUM
dpc-4176	267	47	]	]	PUNCT
dpc-4176	267	48	.	.	PUNCT
dpc-4176	268	1	prior	prior	ADJ
dpc-4176	268	2	treatment	treatment	NOUN
dpc-4176	268	3	with	with	ADP
dpc-4176	268	4	adalimumab	adalimumab	NOUN
dpc-4176	268	5	and	and	CCONJ
dpc-4176	268	6	infliximab	infliximab	NOUN
dpc-4176	268	7	was	be	AUX
dpc-4176	268	8	ineffective	ineffective	ADJ
dpc-4176	268	9	;	;	PUNCT
dpc-4176	268	10	with	with	ADP
dpc-4176	268	11	relapse	relapse	NOUN
dpc-4176	268	12	occurring	occur	VERB
dpc-4176	268	13	following	follow	VERB
dpc-4176	268	14	an	an	DET
dpc-4176	268	15	initial	initial	ADJ
dpc-4176	268	16	favorable	favorable	ADJ
dpc-4176	268	17	response	response	NOUN
dpc-4176	268	18	to	to	ADP
dpc-4176	268	19	ustekinumab	ustekinumab	NOUN
dpc-4176	268	20	(	(	PUNCT
dpc-4176	268	21	linked	link	VERB
dpc-4176	268	22	to	to	ADP
dpc-4176	268	23	the	the	DET
dpc-4176	268	24	development	development	NOUN
dpc-4176	268	25	of	of	ADP
dpc-4176	268	26	neutralizing	neutralize	VERB
dpc-4176	268	27	antibodies	antibody	NOUN
dpc-4176	268	28	)	)	PUNCT
dpc-4176	268	29	.	.	PUNCT
dpc-4176	269	1	within	within	ADP
dpc-4176	269	2	3	3	NUM
dpc-4176	269	3	months	month	NOUN
dpc-4176	269	4	of	of	ADP
dpc-4176	269	5	guselkumab	guselkumab	NOUN
dpc-4176	269	6	treatment	treatment	NOUN
dpc-4176	269	7	,	,	PUNCT
dpc-4176	269	8	tremendous	tremendous	ADJ
dpc-4176	269	9	improvement	improvement	NOUN
dpc-4176	269	10	of	of	ADP
dpc-4176	269	11	the	the	DET
dpc-4176	269	12	lesion	lesion	NOUN
dpc-4176	269	13	was	be	AUX
dpc-4176	269	14	evident	evident	ADJ
dpc-4176	269	15	with	with	ADP
dpc-4176	269	16	95	95	NUM
dpc-4176	269	17	%	%	NOUN
dpc-4176	269	18	reepithelization	reepithelization	NOUN
dpc-4176	269	19	.	.	PUNCT
dpc-4176	270	1	the	the	DET
dpc-4176	270	2	use	use	NOUN
dpc-4176	270	3	of	of	ADP
dpc-4176	270	4	a	a	DET
dpc-4176	270	5	modified	modify	VERB
dpc-4176	270	6	dose	dose	NOUN
dpc-4176	270	7	regimen	regiman	NOUN
dpc-4176	270	8	for	for	ADP
dpc-4176	270	9	pg	pg	PROPN
dpc-4176	270	10	(	(	PUNCT
dpc-4176	270	11	guselkumab	guselkumab	NOUN
dpc-4176	270	12	sc200	sc200	PROPN
dpc-4176	270	13	mg	mg	PROPN
dpc-4176	271	1	[	[	X
dpc-4176	271	2	week	week	NOUN
dpc-4176	271	3	0	0	NUM
dpc-4176	271	4	]	]	PUNCT
dpc-4176	271	5	,	,	PUNCT
dpc-4176	271	6	100	100	NUM
dpc-4176	271	7	mg	mg	NOUN
dpc-4176	272	1	[	[	X
dpc-4176	272	2	week	week	NOUN
dpc-4176	272	3	4	4	NUM
dpc-4176	272	4	]	]	PUNCT
dpc-4176	272	5	,	,	PUNCT
dpc-4176	272	6	100	100	NUM
dpc-4176	272	7	mg	mg	NOUN
dpc-4176	273	1	[	[	X
dpc-4176	273	2	week	week	NOUN
dpc-4176	273	3	10	10	NUM
dpc-4176	273	4	]	]	PUNCT
dpc-4176	273	5	,	,	PUNCT
dpc-4176	273	6	and	and	CCONJ
dpc-4176	273	7	100	100	NUM
dpc-4176	273	8	mg	mg	NOUN
dpc-4176	274	1	[	[	X
dpc-4176	274	2	week	week	NOUN
dpc-4176	274	3	16	16	NUM
dpc-4176	274	4	]	]	PUNCT
dpc-4176	274	5	)	)	PUNCT
dpc-4176	274	6	was	be	AUX
dpc-4176	274	7	described	describe	VERB
dpc-4176	274	8	to	to	PART
dpc-4176	274	9	achieve	achieve	VERB
dpc-4176	274	10	complete	complete	ADJ
dpc-4176	274	11	healing	healing	NOUN
dpc-4176	274	12	of	of	ADP
dpc-4176	274	13	pg	pg	PRON
dpc-4176	274	14	in	in	ADP
dpc-4176	274	15	a	a	DET
dpc-4176	274	16	49	49	NUM
dpc-4176	274	17	-	-	PUNCT
dpc-4176	274	18	year	year	NOUN
dpc-4176	274	19	-	-	PUNCT
dpc-4176	274	20	old	old	ADJ
dpc-4176	274	21	lady	lady	NOUN
dpc-4176	274	22	who	who	PRON
dpc-4176	274	23	had	have	AUX
dpc-4176	274	24	been	be	AUX
dpc-4176	274	25	recalcitrant	recalcitrant	ADJ
dpc-4176	274	26	to	to	ADP
dpc-4176	274	27	intralesional	intralesional	ADJ
dpc-4176	274	28	steroids	steroid	NOUN
dpc-4176	274	29	,	,	PUNCT
dpc-4176	274	30	dapsone	dapsone	PROPN
dpc-4176	274	31	,	,	PUNCT
dpc-4176	274	32	systemic	systemic	ADJ
dpc-4176	274	33	prednisolone	prednisolone	PROPN
dpc-4176	274	34	,	,	PUNCT
dpc-4176	274	35	epifix	epifix	PROPN
dpc-4176	274	36	biologic	biologic	NOUN
dpc-4176	274	37	dressings	dressing	NOUN
dpc-4176	274	38	,	,	PUNCT
dpc-4176	274	39	cyclosporine	cyclosporine	NOUN
dpc-4176	274	40	and	and	CCONJ
dpc-4176	274	41	adalimumab	adalimumab	NOUN
dpc-4176	275	1	[	[	X
dpc-4176	275	2	73	73	NUM
dpc-4176	275	3	]	]	PUNCT
dpc-4176	275	4	.	.	PUNCT
dpc-4176	276	1	in	in	ADP
dpc-4176	276	2	another	another	DET
dpc-4176	276	3	report	report	NOUN
dpc-4176	276	4	,	,	PUNCT
dpc-4176	276	5	guselkumab	guselkumab	NOUN
dpc-4176	276	6	(	(	PUNCT
dpc-4176	276	7	100	100	NUM
dpc-4176	276	8	mg	mg	PROPN
dpc-4176	276	9	,	,	PUNCT
dpc-4176	276	10	sc	sc	NOUN
dpc-4176	276	11	,	,	PUNCT
dpc-4176	276	12	label	label	NOUN
dpc-4176	276	13	dosing	dosing	NOUN
dpc-4176	276	14	)	)	PUNCT
dpc-4176	276	15	was	be	AUX
dpc-4176	276	16	highly	highly	ADV
dpc-4176	276	17	effective	effective	ADJ
dpc-4176	276	18	in	in	ADP
dpc-4176	276	19	the	the	DET
dpc-4176	276	20	management	management	NOUN
dpc-4176	276	21	of	of	ADP
dpc-4176	276	22	ulcerative	ulcerative	ADJ
dpc-4176	276	23	pg	pg	NOUN
dpc-4176	276	24	in	in	ADP
dpc-4176	276	25	a	a	DET
dpc-4176	276	26	78	78	NUM
dpc-4176	276	27	-	-	PUNCT
dpc-4176	276	28	year	year	NOUN
dpc-4176	276	29	-	-	PUNCT
dpc-4176	276	30	old	old	ADJ
dpc-4176	276	31	woman	woman	NOUN
dpc-4176	276	32	[	[	X
dpc-4176	276	33	74	74	NUM
dpc-4176	276	34	]	]	PUNCT
dpc-4176	276	35	.	.	PUNCT
dpc-4176	277	1	pityriasis	pityriasis	PROPN
dpc-4176	277	2	rubra	rubra	NOUN
dpc-4176	277	3	pilaris	pilaris	PROPN
dpc-4176	277	4	prp	prp	PROPN
dpc-4176	277	5	is	be	AUX
dpc-4176	277	6	a	a	DET
dpc-4176	277	7	rare	rare	ADJ
dpc-4176	277	8	idiopathic	idiopathic	ADJ
dpc-4176	277	9	papulo	papulo	NOUN
dpc-4176	277	10	-	-	PUNCT
dpc-4176	277	11	squamous	squamous	ADJ
dpc-4176	277	12	disorder	disorder	NOUN
dpc-4176	277	13	characterized	characterize	VERB
dpc-4176	277	14	by	by	ADP
dpc-4176	277	15	perifollicular	perifollicular	ADJ
dpc-4176	277	16	keratotic	keratotic	ADJ
dpc-4176	277	17	papules	papule	NOUN
dpc-4176	277	18	that	that	PRON
dpc-4176	277	19	essentially	essentially	ADV
dpc-4176	277	20	coalesce	coalesce	VERB
dpc-4176	277	21	to	to	PART
dpc-4176	277	22	form	form	VERB
dpc-4176	277	23	orange	orange	ADJ
dpc-4176	277	24	-	-	PUNCT
dpc-4176	277	25	red	red	ADJ
dpc-4176	277	26	scaly	scaly	NOUN
dpc-4176	277	27	plaques	plaque	NOUN
dpc-4176	277	28	,	,	PUNCT
dpc-4176	277	29	and	and	CCONJ
dpc-4176	277	30	palmoplantar	palmoplantar	PROPN
dpc-4176	277	31	keratoderma	keratoderma	PROPN
dpc-4176	277	32	.	.	PUNCT
dpc-4176	278	1	[	[	X
dpc-4176	278	2	75	75	NUM
dpc-4176	278	3	]	]	PUNCT
dpc-4176	278	4	il-23	il-23	NOUN
dpc-4176	278	5	/	/	SYM
dpc-4176	278	6	th17	th17	NOUN
dpc-4176	278	7	axis	axis	NOUN
dpc-4176	278	8	is	be	AUX
dpc-4176	278	9	closely	closely	ADV
dpc-4176	278	10	involved	involve	VERB
dpc-4176	278	11	in	in	ADP
dpc-4176	278	12	the	the	DET
dpc-4176	278	13	pathogenesis	pathogenesis	NOUN
dpc-4176	278	14	of	of	ADP
dpc-4176	278	15	prp	prp	PROPN
dpc-4176	278	16	[	[	X
dpc-4176	278	17	76	76	NUM
dpc-4176	278	18	]	]	PUNCT
dpc-4176	278	19	.	.	PUNCT
dpc-4176	279	1	by	by	ADP
dpc-4176	279	2	blocking	block	VERB
dpc-4176	279	3	il-23	il-23	NOUN
dpc-4176	279	4	release	release	NOUN
dpc-4176	279	5	,	,	PUNCT
dpc-4176	279	6	guselkumab	guselkumab	NOUN
dpc-4176	279	7	converts	convert	NOUN
dpc-4176	279	8	th17	th17	PROPN
dpc-4176	279	9	cells	cell	NOUN
dpc-4176	279	10	to	to	ADP
dpc-4176	279	11	regulatory	regulatory	ADJ
dpc-4176	279	12	t	t	PROPN
dpc-4176	279	13	-	-	PUNCT
dpc-4176	279	14	cells	cell	NOUN
dpc-4176	279	15	(	(	PUNCT
dpc-4176	279	16	tregs	treg	NOUN
dpc-4176	279	17	)	)	PUNCT
dpc-4176	279	18	and	and	CCONJ
dpc-4176	279	19	eventually	eventually	ADV
dpc-4176	279	20	modifies	modify	VERB
dpc-4176	279	21	the	the	DET
dpc-4176	279	22	immune	immune	ADJ
dpc-4176	279	23	disbalance	disbalance	NOUN
dpc-4176	280	1	[	[	X
dpc-4176	280	2	77	77	NUM
dpc-4176	280	3	]	]	PUNCT
dpc-4176	280	4	.	.	PUNCT
dpc-4176	281	1	currently	currently	ADV
dpc-4176	281	2	,	,	PUNCT
dpc-4176	281	3	there	there	PRON
dpc-4176	281	4	exist	exist	VERB
dpc-4176	281	5	only	only	ADJ
dpc-4176	281	6	case	case	NOUN
dpc-4176	281	7	reports	report	NOUN
dpc-4176	281	8	delineating	delineate	VERB
dpc-4176	281	9	the	the	DET
dpc-4176	281	10	utility	utility	NOUN
dpc-4176	281	11	of	of	ADP
dpc-4176	281	12	guselkumab	guselkumab	NOUN
dpc-4176	281	13	in	in	ADP
dpc-4176	281	14	prp	prp	NOUN
dpc-4176	281	15	and	and	CCONJ
dpc-4176	281	16	is	be	AUX
dpc-4176	281	17	outlined	outline	VERB
dpc-4176	281	18	in	in	ADP
dpc-4176	281	19	table	table	NOUN
dpc-4176	281	20	5	5	NUM
dpc-4176	282	1	[	[	SYM
dpc-4176	282	2	78	78	NUM
dpc-4176	282	3	-	-	SYM
dpc-4176	282	4	80	80	NUM
dpc-4176	282	5	]	]	PUNCT
dpc-4176	282	6	.	.	PUNCT
dpc-4176	283	1	review	review	VERB
dpc-4176	283	2	|	|	ADV
dpc-4176	283	3	dermatol	dermatol	ADJ
dpc-4176	283	4	pract	pract	NOUN
dpc-4176	283	5	concept	concept	NOUN
dpc-4176	283	6	.	.	PUNCT
dpc-4176	284	1	2024;14(3):e2024181	2024;14(3):e2024181	NUM
dpc-4176	284	2	11	11	NUM
dpc-4176	284	3	table	table	NOUN
dpc-4176	284	4	5	5	NUM
dpc-4176	284	5	.	.	PUNCT
dpc-4176	284	6	reports	report	NOUN
dpc-4176	284	7	delineating	delineate	VERB
dpc-4176	284	8	the	the	DET
dpc-4176	284	9	utility	utility	NOUN
dpc-4176	284	10	of	of	ADP
dpc-4176	284	11	guselkumab	guselkumab	NOUN
dpc-4176	284	12	in	in	ADP
dpc-4176	284	13	pityriasis	pityriasis	NOUN
dpc-4176	284	14	rubra	rubra	NOUN
dpc-4176	284	15	pilaris	pilaris	VERB
dpc-4176	284	16	serial	serial	ADJ
dpc-4176	284	17	no	no	NOUN
dpc-4176	284	18	.	.	PUNCT
dpc-4176	285	1	authors	author	NOUN
dpc-4176	285	2	/	/	SYM
dpc-4176	285	3	year	year	NOUN
dpc-4176	285	4	details	detail	NOUN
dpc-4176	285	5	remarks	remark	VERB
dpc-4176	285	6	1	1	NUM
dpc-4176	285	7	pilz	pilz	NOUN
dpc-4176	285	8	et	et	PROPN
dpc-4176	285	9	al	al	PROPN
dpc-4176	286	1	[	[	X
dpc-4176	286	2	78	78	NUM
dpc-4176	286	3	]	]	SYM
dpc-4176	286	4	2019	2019	NUM
dpc-4176	286	5	series	series	NOUN
dpc-4176	286	6	of	of	ADP
dpc-4176	286	7	2	2	NUM
dpc-4176	286	8	patients	patient	NOUN
dpc-4176	286	9	with	with	ADP
dpc-4176	286	10	erythrodermic	erythrodermic	ADJ
dpc-4176	286	11	prp	prp	NOUN
dpc-4176	286	12	:	:	PUNCT
dpc-4176	286	13	•	•	NOUN
dpc-4176	286	14	patient	patient	NOUN
dpc-4176	286	15	1	1	NUM
dpc-4176	286	16	:	:	SYM
dpc-4176	286	17	65	65	NUM
dpc-4176	286	18	-	-	PUNCT
dpc-4176	286	19	year	year	NOUN
dpc-4176	286	20	-	-	PUNCT
dpc-4176	286	21	old	old	ADJ
dpc-4176	286	22	male	male	NOUN
dpc-4176	286	23	.	.	PUNCT
dpc-4176	287	1	•	•	NUM
dpc-4176	287	2	patient	patient	NOUN
dpc-4176	287	3	2	2	NUM
dpc-4176	287	4	:	:	PUNCT
dpc-4176	287	5	75	75	NUM
dpc-4176	287	6	-	-	PUNCT
dpc-4176	287	7	year	year	NOUN
dpc-4176	287	8	-	-	PUNCT
dpc-4176	287	9	old	old	ADJ
dpc-4176	287	10	male	male	NOUN
dpc-4176	287	11	.	.	PUNCT
dpc-4176	288	1	•	•	NUM
dpc-4176	288	2	both	both	DET
dpc-4176	288	3	patients	patient	NOUN
dpc-4176	288	4	were	be	AUX
dpc-4176	288	5	resistant	resistant	ADJ
dpc-4176	288	6	to	to	ADP
dpc-4176	288	7	topical/	topical/	NUM
dpc-4176	288	8	systemic	systemic	ADJ
dpc-4176	288	9	corticosteroids	corticosteroid	NOUN
dpc-4176	288	10	.	.	PUNCT
dpc-4176	289	1	•	•	NUM
dpc-4176	289	2	acitretin	acitretin	NOUN
dpc-4176	289	3	was	be	AUX
dpc-4176	289	4	ineffective	ineffective	ADJ
dpc-4176	289	5	in	in	ADP
dpc-4176	289	6	patient	patient	ADJ
dpc-4176	289	7	1	1	NUM
dpc-4176	289	8	and	and	CCONJ
dpc-4176	289	9	was	be	AUX
dpc-4176	289	10	contraindicated	contraindicate	VERB
dpc-4176	289	11	in	in	ADP
dpc-4176	289	12	patient	patient	ADJ
dpc-4176	289	13	2	2	NUM
dpc-4176	289	14	.	.	NOUN
dpc-4176	289	15	•	•	NUM
dpc-4176	289	16	guselkumab	guselkumab	NOUN
dpc-4176	289	17	(	(	PUNCT
dpc-4176	289	18	100	100	NUM
dpc-4176	289	19	mg	mg	PROPN
dpc-4176	289	20	sc	sc	PROPN
dpc-4176	289	21	)	)	PUNCT
dpc-4176	289	22	was	be	AUX
dpc-4176	289	23	given	give	VERB
dpc-4176	289	24	at	at	ADP
dpc-4176	289	25	week	week	NOUN
dpc-4176	289	26	0	0	NUM
dpc-4176	289	27	,	,	PUNCT
dpc-4176	289	28	4	4	NUM
dpc-4176	289	29	and	and	CCONJ
dpc-4176	289	30	every	every	DET
dpc-4176	289	31	8	8	NUM
dpc-4176	289	32	weeks	week	NOUN
dpc-4176	289	33	.	.	PUNCT
dpc-4176	290	1	•	•	NOUN
dpc-4176	290	2	in	in	ADP
dpc-4176	290	3	both	both	DET
dpc-4176	290	4	patients	patient	NOUN
dpc-4176	290	5	immunohistochemical	immunohistochemical	ADJ
dpc-4176	290	6	analysis	analysis	NOUN
dpc-4176	290	7	of	of	ADP
dpc-4176	290	8	skin	skin	NOUN
dpc-4176	290	9	biopsy	biopsy	NOUN
dpc-4176	290	10	specimens	specimen	NOUN
dpc-4176	290	11	revealed	reveal	VERB
dpc-4176	290	12	a	a	DET
dpc-4176	290	13	distinct	distinct	ADJ
dpc-4176	290	14	expression	expression	NOUN
dpc-4176	290	15	of	of	ADP
dpc-4176	290	16	il-17	il-17	NUM
dpc-4176	290	17	.	.	PUNCT
dpc-4176	291	1	•	•	NUM
dpc-4176	291	2	a	a	DET
dpc-4176	291	3	rapid	rapid	ADJ
dpc-4176	291	4	and	and	CCONJ
dpc-4176	291	5	drastic	drastic	ADJ
dpc-4176	291	6	improvement	improvement	NOUN
dpc-4176	291	7	at	at	ADP
dpc-4176	291	8	week	week	NOUN
dpc-4176	291	9	16	16	NUM
dpc-4176	291	10	was	be	AUX
dpc-4176	291	11	witnessed	witness	VERB
dpc-4176	291	12	in	in	ADP
dpc-4176	291	13	:	:	PUNCT
dpc-4176	291	14	0	0	NUM
dpc-4176	291	15	pga	pga	NOUN
dpc-4176	291	16	score	score	NOUN
dpc-4176	291	17	(	(	PUNCT
dpc-4176	291	18	80	80	NUM
dpc-4176	291	19	%	%	NOUN
dpc-4176	291	20	reduction	reduction	NOUN
dpc-4176	291	21	in	in	ADP
dpc-4176	291	22	both	both	DET
dpc-4176	291	23	patients	patient	NOUN
dpc-4176	291	24	)	)	PUNCT
dpc-4176	291	25	.	.	PUNCT
dpc-4176	292	1	0	0	NUM
dpc-4176	292	2	body	body	NOUN
dpc-4176	292	3	surface	surface	NOUN
dpc-4176	292	4	area	area	NOUN
dpc-4176	292	5	(	(	PUNCT
dpc-4176	292	6	94.73	94.73	NUM
dpc-4176	292	7	%	%	NOUN
dpc-4176	292	8	and	and	CCONJ
dpc-4176	292	9	84.69	84.69	NUM
dpc-4176	292	10	%	%	NOUN
dpc-4176	292	11	reduction	reduction	NOUN
dpc-4176	292	12	in	in	ADP
dpc-4176	292	13	patient	patient	ADJ
dpc-4176	292	14	1	1	NUM
dpc-4176	292	15	and	and	CCONJ
dpc-4176	292	16	2	2	NUM
dpc-4176	292	17	respectively	respectively	ADV
dpc-4176	292	18	)	)	PUNCT
dpc-4176	292	19	.	.	PUNCT
dpc-4176	292	20	0	0	PUNCT
dpc-4176	293	1	dlqi	dlqi	NOUN
dpc-4176	293	2	(	(	PUNCT
dpc-4176	293	3	93.3	93.3	NUM
dpc-4176	293	4	%	%	NOUN
dpc-4176	293	5	and	and	CCONJ
dpc-4176	293	6	89.47	89.47	NUM
dpc-4176	293	7	%	%	NOUN
dpc-4176	293	8	reduction	reduction	NOUN
dpc-4176	293	9	in	in	ADP
dpc-4176	293	10	patient	patient	ADJ
dpc-4176	293	11	1	1	NUM
dpc-4176	293	12	and	and	CCONJ
dpc-4176	293	13	2	2	NUM
dpc-4176	293	14	respectively	respectively	ADV
dpc-4176	293	15	)	)	PUNCT
dpc-4176	293	16	.	.	PUNCT
dpc-4176	294	1	2	2	NUM
dpc-4176	294	2	nagai	nagai	X
dpc-4176	294	3	et	et	NOUN
dpc-4176	294	4	al	al	PROPN
dpc-4176	295	1	[	[	X
dpc-4176	295	2	79	79	NUM
dpc-4176	295	3	]	]	SYM
dpc-4176	295	4	2020	2020	NUM
dpc-4176	295	5	•	•	NUM
dpc-4176	295	6	47	47	NUM
dpc-4176	295	7	-	-	PUNCT
dpc-4176	295	8	year	year	NOUN
dpc-4176	295	9	-	-	PUNCT
dpc-4176	295	10	old	old	ADJ
dpc-4176	295	11	woman	woman	NOUN
dpc-4176	295	12	diagnosed	diagnose	VERB
dpc-4176	295	13	with	with	ADP
dpc-4176	295	14	prp	prp	NOUN
dpc-4176	295	15	for	for	ADP
dpc-4176	295	16	a	a	DET
dpc-4176	295	17	duration	duration	NOUN
dpc-4176	295	18	of	of	ADP
dpc-4176	295	19	3	3	NUM
dpc-4176	295	20	months	month	NOUN
dpc-4176	295	21	with	with	ADP
dpc-4176	295	22	90	90	NUM
dpc-4176	295	23	%	%	NOUN
dpc-4176	295	24	bsa	bsa	PROPN
dpc-4176	295	25	involvement	involvement	NOUN
dpc-4176	295	26	.	.	PUNCT
dpc-4176	296	1	•	•	NUM
dpc-4176	296	2	oral	oral	ADJ
dpc-4176	296	3	etretinate	etretinate	NOUN
dpc-4176	296	4	,	,	PUNCT
dpc-4176	296	5	and	and	CCONJ
dpc-4176	296	6	apremilast	apremilast	NOUN
dpc-4176	296	7	were	be	AUX
dpc-4176	296	8	ineffective	ineffective	ADJ
dpc-4176	296	9	.	.	PUNCT
dpc-4176	297	1	•	•	NUM
dpc-4176	297	2	other	other	ADJ
dpc-4176	297	3	failed	fail	VERB
dpc-4176	297	4	treatments	treatment	NOUN
dpc-4176	297	5	included	include	VERB
dpc-4176	297	6	bathpuva	bathpuva	PROPN
dpc-4176	297	7	and	and	CCONJ
dpc-4176	297	8	topical	topical	ADJ
dpc-4176	297	9	steroids	steroid	NOUN
dpc-4176	297	10	.	.	PUNCT
dpc-4176	298	1	•	•	NUM
dpc-4176	298	2	guselkumab	guselkumab	NOUN
dpc-4176	298	3	100	100	NUM
dpc-4176	298	4	mg	mg	PROPN
dpc-4176	298	5	sc	sc	PROPN
dpc-4176	298	6	was	be	AUX
dpc-4176	298	7	administered	administer	VERB
dpc-4176	298	8	(	(	PUNCT
dpc-4176	298	9	label	label	NOUN
dpc-4176	298	10	dosing	dosing	NOUN
dpc-4176	298	11	)	)	PUNCT
dpc-4176	298	12	after	after	ADP
dpc-4176	298	13	taking	take	VERB
dpc-4176	298	14	an	an	DET
dpc-4176	298	15	informed	informed	ADJ
dpc-4176	298	16	consent	consent	NOUN
dpc-4176	298	17	from	from	ADP
dpc-4176	298	18	patient	patient	NOUN
dpc-4176	298	19	.	.	PUNCT
dpc-4176	299	1	•	•	NOUN
dpc-4176	299	2	after	after	ADP
dpc-4176	299	3	4	4	NUM
dpc-4176	299	4	weeks	week	NOUN
dpc-4176	299	5	,	,	PUNCT
dpc-4176	299	6	slight	slight	ADJ
dpc-4176	299	7	reduction	reduction	NOUN
dpc-4176	299	8	of	of	ADP
dpc-4176	299	9	erythema	erythema	ADJ
dpc-4176	299	10	was	be	AUX
dpc-4176	299	11	noted	note	VERB
dpc-4176	299	12	.	.	PUNCT
dpc-4176	300	1	•	•	INTJ
dpc-4176	300	2	at	at	ADP
dpc-4176	300	3	week	week	NOUN
dpc-4176	300	4	24	24	NUM
dpc-4176	300	5	,	,	PUNCT
dpc-4176	300	6	bsa	bsa	PROPN
dpc-4176	300	7	had	have	AUX
dpc-4176	300	8	reduced	reduce	VERB
dpc-4176	300	9	to	to	ADP
dpc-4176	300	10	2	2	NUM
dpc-4176	300	11	%	%	NOUN
dpc-4176	300	12	from	from	ADP
dpc-4176	300	13	90	90	NUM
dpc-4176	300	14	%	%	NOUN
dpc-4176	300	15	and	and	CCONJ
dpc-4176	300	16	static	static	ADJ
dpc-4176	300	17	physician	physician	NOUN
dpc-4176	300	18	global	global	ADJ
dpc-4176	300	19	assessment	assessment	NOUN
dpc-4176	300	20	(	(	PUNCT
dpc-4176	300	21	spga	spga	NOUN
dpc-4176	300	22	)	)	PUNCT
dpc-4176	300	23	had	have	AUX
dpc-4176	300	24	reduced	reduce	VERB
dpc-4176	300	25	from	from	ADP
dpc-4176	300	26	5	5	NUM
dpc-4176	300	27	to	to	PART
dpc-4176	300	28	1	1	NUM
dpc-4176	300	29	.	.	NOUN
dpc-4176	301	1	•	•	NUM
dpc-4176	301	2	erythema	erythema	ADJ
dpc-4176	301	3	and	and	CCONJ
dpc-4176	301	4	pruritus	pruritus	NOUN
dpc-4176	301	5	were	be	AUX
dpc-4176	301	6	completely	completely	ADV
dpc-4176	301	7	absent	absent	ADJ
dpc-4176	301	8	36	36	NUM
dpc-4176	301	9	weeks	week	NOUN
dpc-4176	301	10	after	after	ADP
dpc-4176	301	11	the	the	DET
dpc-4176	301	12	last	last	ADJ
dpc-4176	301	13	injection	injection	NOUN
dpc-4176	301	14	.	.	PUNCT
dpc-4176	302	1	3	3	NUM
dpc-4176	302	2	nishimura	nishimura	X
dpc-4176	302	3	et	et	PROPN
dpc-4176	302	4	al	al	PROPN
dpc-4176	303	1	[	[	X
dpc-4176	303	2	80	80	NUM
dpc-4176	303	3	]	]	SYM
dpc-4176	303	4	2022	2022	NUM
dpc-4176	303	5	•	•	NOUN
dpc-4176	303	6	a	a	DET
dpc-4176	303	7	60	60	NUM
dpc-4176	303	8	-	-	PUNCT
dpc-4176	303	9	year	year	NOUN
dpc-4176	303	10	-	-	PUNCT
dpc-4176	303	11	old	old	ADJ
dpc-4176	303	12	man	man	NOUN
dpc-4176	303	13	with	with	ADP
dpc-4176	303	14	prp	prp	NOUN
dpc-4176	303	15	who	who	PRON
dpc-4176	303	16	had	have	AUX
dpc-4176	303	17	failed	fail	VERB
dpc-4176	303	18	to	to	PART
dpc-4176	303	19	respond	respond	VERB
dpc-4176	303	20	to	to	ADP
dpc-4176	303	21	systemic	systemic	ADJ
dpc-4176	303	22	therapy	therapy	NOUN
dpc-4176	303	23	that	that	PRON
dpc-4176	303	24	included	include	VERB
dpc-4176	303	25	methotrexate	methotrexate	NOUN
dpc-4176	303	26	,	,	PUNCT
dpc-4176	303	27	retinoids	retinoid	NOUN
dpc-4176	303	28	and	and	CCONJ
dpc-4176	303	29	brodalumab	brodalumab	NOUN
dpc-4176	303	30	.	.	PUNCT
dpc-4176	304	1	•	•	NUM
dpc-4176	304	2	cyclosporine	cyclosporine	NOUN
dpc-4176	304	3	(	(	PUNCT
dpc-4176	304	4	100	100	NUM
dpc-4176	304	5	mg	mg	NUM
dpc-4176	304	6	/	/	SYM
dpc-4176	304	7	day	day	NOUN
dpc-4176	304	8	)	)	PUNCT
dpc-4176	304	9	helped	help	VERB
dpc-4176	304	10	in	in	ADP
dpc-4176	304	11	markedly	markedly	ADV
dpc-4176	304	12	improving	improve	VERB
dpc-4176	304	13	the	the	DET
dpc-4176	304	14	skin	skin	NOUN
dpc-4176	304	15	rash	rash	NOUN
dpc-4176	304	16	after	after	ADP
dpc-4176	304	17	one	one	NUM
dpc-4176	304	18	week	week	NOUN
dpc-4176	304	19	,	,	PUNCT
dpc-4176	304	20	but	but	CCONJ
dpc-4176	304	21	as	as	SCONJ
dpc-4176	304	22	patient	patient	NOUN
dpc-4176	304	23	was	be	AUX
dpc-4176	304	24	hypertensive	hypertensive	ADJ
dpc-4176	304	25	,	,	PUNCT
dpc-4176	304	26	the	the	DET
dpc-4176	304	27	dose	dose	NOUN
dpc-4176	304	28	of	of	ADP
dpc-4176	304	29	cyclosporine	cyclosporine	PROPN
dpc-4176	304	30	was	be	AUX
dpc-4176	304	31	reduced	reduce	VERB
dpc-4176	304	32	to	to	ADP
dpc-4176	304	33	50	50	NUM
dpc-4176	304	34	mg	mg	NUM
dpc-4176	304	35	/	/	SYM
dpc-4176	304	36	day	day	NOUN
dpc-4176	304	37	,	,	PUNCT
dpc-4176	304	38	that	that	DET
dpc-4176	304	39	heralded	herald	VERB
dpc-4176	304	40	relapse	relapse	NOUN
dpc-4176	304	41	.	.	PUNCT
dpc-4176	305	1	•	•	NUM
dpc-4176	305	2	guselkumab	guselkumab	NOUN
dpc-4176	305	3	(	(	PUNCT
dpc-4176	305	4	100	100	NUM
dpc-4176	305	5	mg	mg	PROPN
dpc-4176	305	6	sc	sc	PROPN
dpc-4176	305	7	,	,	PUNCT
dpc-4176	305	8	label	label	NOUN
dpc-4176	305	9	dosing	dosing	NOUN
dpc-4176	305	10	)	)	PUNCT
dpc-4176	305	11	was	be	AUX
dpc-4176	305	12	then	then	ADV
dpc-4176	305	13	started	start	VERB
dpc-4176	305	14	along	along	ADP
dpc-4176	305	15	with	with	ADP
dpc-4176	305	16	cyclosporine	cyclosporine	NOUN
dpc-4176	305	17	(	(	PUNCT
dpc-4176	305	18	50	50	NUM
dpc-4176	305	19	mg	mg	NOUN
dpc-4176	305	20	/	/	SYM
dpc-4176	305	21	day	day	NOUN
dpc-4176	305	22	)	)	PUNCT
dpc-4176	305	23	•	•	NOUN
dpc-4176	305	24	improvement	improvement	NOUN
dpc-4176	305	25	of	of	ADP
dpc-4176	305	26	prp	prp	NOUN
dpc-4176	305	27	was	be	AUX
dpc-4176	305	28	evident	evident	ADJ
dpc-4176	305	29	by	by	ADP
dpc-4176	305	30	12	12	NUM
dpc-4176	305	31	weeks	week	NOUN
dpc-4176	305	32	of	of	ADP
dpc-4176	305	33	guselkumab	guselkumab	NOUN
dpc-4176	305	34	therapy	therapy	NOUN
dpc-4176	305	35	.	.	PUNCT
dpc-4176	306	1	•	•	NOUN
dpc-4176	306	2	skin	skin	NOUN
dpc-4176	306	3	rash	rash	NOUN
dpc-4176	306	4	remained	remain	VERB
dpc-4176	306	5	in	in	ADP
dpc-4176	306	6	complete	complete	ADJ
dpc-4176	306	7	remission	remission	NOUN
dpc-4176	306	8	at	at	ADP
dpc-4176	306	9	9	9	NUM
dpc-4176	306	10	months	month	NOUN
dpc-4176	306	11	.	.	PUNCT
dpc-4176	307	1	•	•	NOUN
dpc-4176	307	2	one	one	NUM
dpc-4176	307	3	year	year	NOUN
dpc-4176	307	4	after	after	ADP
dpc-4176	307	5	initiation	initiation	NOUN
dpc-4176	307	6	of	of	ADP
dpc-4176	307	7	guselkumab	guselkumab	NOUN
dpc-4176	307	8	,	,	PUNCT
dpc-4176	307	9	cyclosporine	cyclosporine	PROPN
dpc-4176	307	10	was	be	AUX
dpc-4176	307	11	discontinued	discontinue	VERB
dpc-4176	307	12	,	,	PUNCT
dpc-4176	307	13	and	and	CCONJ
dpc-4176	307	14	the	the	DET
dpc-4176	307	15	skin	skin	NOUN
dpc-4176	307	16	rash	rash	NOUN
dpc-4176	307	17	remained	remained	AUX
dpc-4176	307	18	well	well	ADV
dpc-4176	307	19	controlled	control	VERB
dpc-4176	307	20	.	.	PUNCT
dpc-4176	308	1	bsa	bsa	PROPN
dpc-4176	308	2	=	=	PROPN
dpc-4176	308	3	body	body	PROPN
dpc-4176	308	4	surface	surface	NOUN
dpc-4176	308	5	area	area	NOUN
dpc-4176	308	6	;	;	PUNCT
dpc-4176	308	7	dlqi	dlqi	ADJ
dpc-4176	308	8	=	=	SYM
dpc-4176	308	9	dermatology	dermatology	NOUN
dpc-4176	308	10	life	life	NOUN
dpc-4176	308	11	quality	quality	NOUN
dpc-4176	308	12	index	index	NOUN
dpc-4176	308	13	;	;	PUNCT
dpc-4176	308	14	pga	pga	NOUN
dpc-4176	308	15	=	=	SYM
dpc-4176	308	16	physician	physician	NOUN
dpc-4176	308	17	global	global	ADJ
dpc-4176	308	18	assessment	assessment	NOUN
dpc-4176	308	19	;	;	PUNCT
dpc-4176	308	20	prp	prp	NOUN
dpc-4176	308	21	=	=	SYM
dpc-4176	308	22	pityriasis	pityriasis	NOUN
dpc-4176	308	23	rubra	rubra	NOUN
dpc-4176	308	24	pilaris	pilaris	NOUN
dpc-4176	308	25	;	;	PUNCT
dpc-4176	308	26	sc	sc	ADJ
dpc-4176	308	27	=	=	NOUN
dpc-4176	308	28	subcutaneous	subcutaneous	ADJ
dpc-4176	308	29	.	.	PUNCT
dpc-4176	309	1	lichen	lichen	NOUN
dpc-4176	309	2	planus	planus	PROPN
dpc-4176	309	3	lp	lp	NOUN
dpc-4176	309	4	is	be	AUX
dpc-4176	309	5	a	a	DET
dpc-4176	309	6	common	common	ADJ
dpc-4176	309	7	,	,	PUNCT
dpc-4176	309	8	chronic	chronic	ADJ
dpc-4176	309	9	relapsing	relapse	VERB
dpc-4176	309	10	inflammatory	inflammatory	ADJ
dpc-4176	309	11	disorder	disorder	NOUN
dpc-4176	309	12	of	of	ADP
dpc-4176	309	13	the	the	DET
dpc-4176	309	14	skin	skin	NOUN
dpc-4176	309	15	and	and	CCONJ
dpc-4176	309	16	mucous	mucous	ADJ
dpc-4176	309	17	membranes	membrane	NOUN
dpc-4176	309	18	which	which	PRON
dpc-4176	309	19	often	often	ADV
dpc-4176	309	20	poses	pose	VERB
dpc-4176	309	21	a	a	DET
dpc-4176	309	22	major	major	ADJ
dpc-4176	309	23	therapeutic	therapeutic	ADJ
dpc-4176	309	24	challenge	challenge	NOUN
dpc-4176	309	25	due	due	ADP
dpc-4176	309	26	to	to	ADP
dpc-4176	309	27	its	its	PRON
dpc-4176	309	28	refractory	refractory	NOUN
dpc-4176	309	29	course	course	NOUN
dpc-4176	309	30	.	.	PUNCT
dpc-4176	310	1	il-23	il-23	NOUN
dpc-4176	310	2	has	have	AUX
dpc-4176	310	3	been	be	AUX
dpc-4176	310	4	expounded	expound	VERB
dpc-4176	310	5	as	as	ADP
dpc-4176	310	6	one	one	NUM
dpc-4176	310	7	of	of	ADP
dpc-4176	310	8	the	the	DET
dpc-4176	310	9	key	key	ADJ
dpc-4176	310	10	drivers	driver	NOUN
dpc-4176	310	11	of	of	ADP
dpc-4176	310	12	pro	pro	ADJ
dpc-4176	310	13	inflammatory	inflammatory	ADJ
dpc-4176	310	14	pathogenic	pathogenic	ADJ
dpc-4176	310	15	th17	th17	NOUN
dpc-4176	310	16	cells	cell	NOUN
dpc-4176	310	17	,	,	PUNCT
dpc-4176	310	18	that	that	PRON
dpc-4176	310	19	are	be	AUX
dpc-4176	310	20	increasingly	increasingly	ADV
dpc-4176	310	21	identified	identify	VERB
dpc-4176	310	22	in	in	ADP
dpc-4176	310	23	lesions	lesion	NOUN
dpc-4176	310	24	of	of	ADP
dpc-4176	310	25	both	both	CCONJ
dpc-4176	310	26	mucocutaneous	mucocutaneous	ADJ
dpc-4176	310	27	and	and	CCONJ
dpc-4176	310	28	oral	oral	ADJ
dpc-4176	311	1	lp	lp	NOUN
dpc-4176	312	1	[	[	X
dpc-4176	312	2	81	81	NUM
dpc-4176	312	3	]	]	PUNCT
dpc-4176	312	4	.	.	PUNCT
dpc-4176	313	1	by	by	ADP
dpc-4176	313	2	impelling	impel	VERB
dpc-4176	313	3	b	b	PRON
dpc-4176	313	4	lymphocyte	lymphocyte	ADV
dpc-4176	313	5	-	-	PUNCT
dpc-4176	313	6	induced	induce	VERB
dpc-4176	313	7	maturation	maturation	NOUN
dpc-4176	313	8	protein	protein	NOUN
dpc-4176	313	9	1(blimp	1(blimp	PROPN
dpc-4176	313	10	1	1	NUM
dpc-4176	313	11	)	)	PUNCT
dpc-4176	313	12	,	,	PUNCT
dpc-4176	313	13	th17	th17	PROPN
dpc-4176	313	14	cells	cell	NOUN
dpc-4176	313	15	prompt	prompt	VERB
dpc-4176	313	16	the	the	DET
dpc-4176	313	17	pathogenesis	pathogenesis	NOUN
dpc-4176	313	18	in	in	ADP
dpc-4176	313	19	lp	lp	NOUN
dpc-4176	313	20	,	,	PUNCT
dpc-4176	313	21	which	which	PRON
dpc-4176	313	22	if	if	SCONJ
dpc-4176	313	23	not	not	PART
dpc-4176	313	24	controlled	control	VERB
dpc-4176	313	25	takes	take	VERB
dpc-4176	313	26	on	on	ADP
dpc-4176	313	27	a	a	DET
dpc-4176	313	28	progressive	progressive	ADJ
dpc-4176	313	29	course	course	NOUN
dpc-4176	313	30	[	[	X
dpc-4176	313	31	82	82	NUM
dpc-4176	313	32	]	]	PUNCT
dpc-4176	313	33	.	.	PUNCT
dpc-4176	314	1	guselkumab	guselkumab	NOUN
dpc-4176	314	2	role	role	NOUN
dpc-4176	314	3	in	in	ADP
dpc-4176	314	4	lp	lp	NOUN
dpc-4176	314	5	is	be	AUX
dpc-4176	314	6	linked	link	VERB
dpc-4176	314	7	to	to	ADP
dpc-4176	314	8	its	its	PRON
dpc-4176	314	9	inhibitory	inhibitory	ADJ
dpc-4176	314	10	role	role	NOUN
dpc-4176	314	11	against	against	ADP
dpc-4176	314	12	il-23	il-23	NOUN
dpc-4176	314	13	release	release	NOUN
dpc-4176	314	14	with	with	ADP
dpc-4176	314	15	subsequent	subsequent	ADJ
dpc-4176	314	16	antagonism	antagonism	NOUN
dpc-4176	314	17	of	of	ADP
dpc-4176	314	18	the	the	DET
dpc-4176	314	19	entire	entire	ADJ
dpc-4176	314	20	inflammatory	inflammatory	ADJ
dpc-4176	314	21	cascade	cascade	NOUN
dpc-4176	314	22	[	[	X
dpc-4176	314	23	83	83	NUM
dpc-4176	314	24	]	]	PUNCT
dpc-4176	314	25	.	.	PUNCT
dpc-4176	315	1	solimani	solimani	PROPN
dpc-4176	315	2	et	et	PROPN
dpc-4176	315	3	al	al	PROPN
dpc-4176	315	4	reported	report	VERB
dpc-4176	315	5	guselkumab	guselkumab	NOUN
dpc-4176	315	6	(	(	PUNCT
dpc-4176	315	7	100	100	NUM
dpc-4176	315	8	mg	mg	PROPN
dpc-4176	315	9	sc	sc	PROPN
dpc-4176	315	10	,	,	PUNCT
dpc-4176	315	11	label	label	NOUN
dpc-4176	315	12	dosing	dosing	NOUN
dpc-4176	315	13	)	)	PUNCT
dpc-4176	315	14	to	to	PART
dpc-4176	315	15	be	be	AUX
dpc-4176	315	16	highly	highly	ADV
dpc-4176	315	17	effective	effective	ADJ
dpc-4176	315	18	in	in	ADP
dpc-4176	315	19	a	a	DET
dpc-4176	315	20	72	72	NUM
dpc-4176	315	21	-	-	PUNCT
dpc-4176	315	22	year	year	NOUN
dpc-4176	315	23	-	-	PUNCT
dpc-4176	315	24	old	old	ADJ
dpc-4176	315	25	female	female	NOUN
dpc-4176	315	26	with	with	ADP
dpc-4176	315	27	recalcitrant	recalcitrant	ADJ
dpc-4176	315	28	erosive	erosive	NOUN
dpc-4176	315	29	lp	lp	NOUN
dpc-4176	315	30	of	of	ADP
dpc-4176	315	31	the	the	DET
dpc-4176	315	32	tongue	tongue	NOUN
dpc-4176	315	33	for	for	ADP
dpc-4176	315	34	5	5	NUM
dpc-4176	315	35	years	year	NOUN
dpc-4176	315	36	that	that	PRON
dpc-4176	315	37	had	have	AUX
dpc-4176	315	38	been	be	AUX
dpc-4176	315	39	unresponsive	unresponsive	ADJ
dpc-4176	315	40	to	to	ADP
dpc-4176	315	41	systemic	systemic	ADJ
dpc-4176	315	42	/	/	SYM
dpc-4176	315	43	topical	topical	ADJ
dpc-4176	315	44	corticosteroids	corticosteroid	NOUN
dpc-4176	315	45	[	[	X
dpc-4176	315	46	84	84	NUM
dpc-4176	315	47	]	]	PUNCT
dpc-4176	315	48	.	.	PUNCT
dpc-4176	316	1	progressive	progressive	ADJ
dpc-4176	316	2	amelioration	amelioration	NOUN
dpc-4176	316	3	of	of	ADP
dpc-4176	316	4	lesions	lesion	NOUN
dpc-4176	316	5	was	be	AUX
dpc-4176	316	6	observed	observe	VERB
dpc-4176	316	7	following	follow	VERB
dpc-4176	316	8	initiation	initiation	NOUN
dpc-4176	316	9	of	of	ADP
dpc-4176	316	10	guselkumab	guselkumab	NOUN
dpc-4176	316	11	therapy	therapy	NOUN
dpc-4176	316	12	with	with	ADP
dpc-4176	316	13	complete	complete	ADJ
dpc-4176	316	14	resolution	resolution	NOUN
dpc-4176	316	15	by	by	ADP
dpc-4176	316	16	week	week	NOUN
dpc-4176	316	17	30	30	NUM
dpc-4176	316	18	.	.	PUNCT
dpc-4176	317	1	stewart	stewart	PROPN
dpc-4176	317	2	-	-	PUNCT
dpc-4176	317	3	treves	treve	NOUN
dpc-4176	317	4	angiosarcoma	angiosarcoma	PROPN
dpc-4176	317	5	sta	sta	NOUN
dpc-4176	317	6	is	be	AUX
dpc-4176	317	7	a	a	DET
dpc-4176	317	8	rare	rare	ADJ
dpc-4176	317	9	cutaneous	cutaneous	ADJ
dpc-4176	317	10	angiosarcoma	angiosarcoma	NOUN
dpc-4176	317	11	,	,	PUNCT
dpc-4176	317	12	that	that	PRON
dpc-4176	317	13	has	have	VERB
dpc-4176	317	14	a	a	DET
dpc-4176	317	15	high	high	ADJ
dpc-4176	317	16	rate	rate	NOUN
dpc-4176	317	17	of	of	ADP
dpc-4176	317	18	metastasis	metastasis	NOUN
dpc-4176	317	19	[	[	X
dpc-4176	317	20	85	85	NUM
dpc-4176	317	21	]	]	PUNCT
dpc-4176	317	22	.	.	PUNCT
dpc-4176	318	1	immunohistochemical	immunohistochemical	ADJ
dpc-4176	318	2	research	research	NOUN
dpc-4176	318	3	has	have	AUX
dpc-4176	318	4	propounded	propound	VERB
dpc-4176	318	5	il-23	il-23	NOUN
dpc-4176	318	6	to	to	PART
dpc-4176	318	7	have	have	VERB
dpc-4176	318	8	a	a	DET
dpc-4176	318	9	significant	significant	ADJ
dpc-4176	318	10	role	role	NOUN
dpc-4176	318	11	in	in	ADP
dpc-4176	318	12	tumor	tumor	NOUN
dpc-4176	318	13	angiogenesis	angiogenesis	NOUN
dpc-4176	318	14	,	,	PUNCT
dpc-4176	318	15	via	via	ADP
dpc-4176	318	16	stimulating	stimulate	VERB
dpc-4176	318	17	the	the	DET
dpc-4176	318	18	th17	th17	PROPN
dpc-4176	318	19	pathway	pathway	NOUN
dpc-4176	318	20	and	and	CCONJ
dpc-4176	318	21	eventual	eventual	ADJ
dpc-4176	318	22	il-17	il-17	NUM
dpc-4176	318	23	production	production	NOUN
dpc-4176	318	24	[	[	X
dpc-4176	318	25	86	86	NUM
dpc-4176	318	26	]	]	PUNCT
dpc-4176	318	27	.	.	PUNCT
dpc-4176	319	1	additionally	additionally	ADV
dpc-4176	319	2	,	,	PUNCT
dpc-4176	319	3	il-23	il-23	NOUN
dpc-4176	319	4	inhibits	inhibit	VERB
dpc-4176	319	5	apoptosis	apoptosis	NOUN
dpc-4176	319	6	,	,	PUNCT
dpc-4176	319	7	and	and	CCONJ
dpc-4176	319	8	recruits	recruit	VERB
dpc-4176	319	9	neutrophils	neutrophil	NOUN
dpc-4176	319	10	and	and	CCONJ
dpc-4176	319	11	macrophages	macrophage	NOUN
dpc-4176	319	12	to	to	ADP
dpc-4176	319	13	the	the	DET
dpc-4176	319	14	tumor	tumor	NOUN
dpc-4176	319	15	site	site	NOUN
dpc-4176	319	16	,	,	PUNCT
dpc-4176	319	17	promoting	promote	VERB
dpc-4176	319	18	production	production	NOUN
dpc-4176	319	19	of	of	ADP
dpc-4176	319	20	other	other	ADJ
dpc-4176	319	21	cytokines	cytokine	NOUN
dpc-4176	319	22	,	,	PUNCT
dpc-4176	319	23	including	include	VERB
dpc-4176	319	24	vascular	vascular	ADJ
dpc-4176	319	25	endothelial	endothelial	ADJ
dpc-4176	319	26	growth	growth	NOUN
dpc-4176	319	27	factor	factor	NOUN
dpc-4176	319	28	,	,	PUNCT
dpc-4176	319	29	that	that	SCONJ
dpc-4176	319	30	further	far	ADV
dpc-4176	319	31	supports	support	VERB
dpc-4176	319	32	tumor	tumor	NOUN
dpc-4176	319	33	12	12	NUM
dpc-4176	319	34	review	review	NOUN
dpc-4176	319	35	|	|	ADV
dpc-4176	319	36	dermatol	dermatol	ADJ
dpc-4176	319	37	pract	pract	NOUN
dpc-4176	319	38	concept	concept	NOUN
dpc-4176	319	39	.	.	PUNCT
dpc-4176	320	1	2024;14(3):e2024181	2024;14(3):e2024181	NUM
dpc-4176	320	2	molecular	molecular	ADJ
dpc-4176	320	3	weight	weight	NOUN
dpc-4176	320	4	of	of	ADP
dpc-4176	320	5	around	around	ADP
dpc-4176	320	6	144,000	144,000	NUM
dpc-4176	320	7	da	da	NOUN
dpc-4176	320	8	,	,	PUNCT
dpc-4176	320	9	likelihood	likelihood	NOUN
dpc-4176	320	10	of	of	ADP
dpc-4176	320	11	its	its	PRON
dpc-4176	320	12	secretion	secretion	NOUN
dpc-4176	320	13	in	in	ADP
dpc-4176	320	14	breast	breast	NOUN
dpc-4176	320	15	milk	milk	NOUN
dpc-4176	320	16	is	be	AUX
dpc-4176	320	17	very	very	ADV
dpc-4176	320	18	low	low	ADJ
dpc-4176	320	19	[	[	X
dpc-4176	320	20	96	96	NUM
dpc-4176	320	21	]	]	PUNCT
dpc-4176	320	22	.	.	PUNCT
dpc-4176	321	1	besides	besides	SCONJ
dpc-4176	321	2	,	,	PUNCT
dpc-4176	321	3	guselkumab	guselkumab	NOUN
dpc-4176	321	4	gets	get	AUX
dpc-4176	321	5	destroyed	destroy	VERB
dpc-4176	321	6	in	in	ADP
dpc-4176	321	7	the	the	DET
dpc-4176	321	8	infant	infant	NOUN
dpc-4176	321	9	gastrointestinal	gastrointestinal	ADJ
dpc-4176	321	10	tract	tract	NOUN
dpc-4176	321	11	making	make	VERB
dpc-4176	321	12	its	its	PRON
dpc-4176	321	13	absorption	absorption	NOUN
dpc-4176	321	14	unlikely	unlikely	ADJ
dpc-4176	321	15	[	[	X
dpc-4176	321	16	97	97	NUM
dpc-4176	321	17	]	]	PUNCT
dpc-4176	321	18	.	.	PUNCT
dpc-4176	322	1	however	however	ADV
dpc-4176	322	2	,	,	PUNCT
dpc-4176	322	3	guselkumab	guselkumab	NOUN
dpc-4176	322	4	still	still	ADV
dpc-4176	322	5	needs	need	VERB
dpc-4176	322	6	to	to	PART
dpc-4176	322	7	be	be	AUX
dpc-4176	322	8	used	use	VERB
dpc-4176	322	9	with	with	ADP
dpc-4176	322	10	caution	caution	NOUN
dpc-4176	322	11	in	in	ADP
dpc-4176	322	12	this	this	DET
dpc-4176	322	13	scenario	scenario	NOUN
dpc-4176	322	14	,	,	PUNCT
dpc-4176	322	15	especially	especially	ADV
dpc-4176	322	16	while	while	SCONJ
dpc-4176	322	17	nursing	nursing	NOUN
dpc-4176	322	18	neonates	neonate	NOUN
dpc-4176	322	19	.	.	PUNCT
dpc-4176	323	1	waiting	wait	VERB
dpc-4176	323	2	at	at	ADV
dpc-4176	323	3	least	least	ADV
dpc-4176	323	4	2	2	NUM
dpc-4176	323	5	weeks	week	NOUN
dpc-4176	323	6	postpartum	postpartum	NOUN
dpc-4176	323	7	to	to	PART
dpc-4176	323	8	resume	resume	VERB
dpc-4176	323	9	treatment	treatment	NOUN
dpc-4176	323	10	may	may	AUX
dpc-4176	323	11	minimize	minimize	VERB
dpc-4176	323	12	transfer	transfer	NOUN
dpc-4176	323	13	to	to	ADP
dpc-4176	323	14	the	the	DET
dpc-4176	323	15	infant	infant	NOUN
dpc-4176	323	16	[	[	X
dpc-4176	323	17	98	98	NUM
dpc-4176	323	18	]	]	SYM
dpc-4176	323	19	.	.	PUNCT
dpc-4176	324	1	pediatric	pediatric	ADJ
dpc-4176	324	2	to	to	ADP
dpc-4176	324	3	date	date	NOUN
dpc-4176	324	4	,	,	PUNCT
dpc-4176	324	5	there	there	PRON
dpc-4176	324	6	are	be	VERB
dpc-4176	324	7	no	no	DET
dpc-4176	324	8	clinical	clinical	ADJ
dpc-4176	324	9	trials	trial	NOUN
dpc-4176	324	10	delineating	delineate	VERB
dpc-4176	324	11	the	the	DET
dpc-4176	324	12	efficacy/	efficacy/	NUM
dpc-4176	324	13	safety	safety	NOUN
dpc-4176	324	14	of	of	ADP
dpc-4176	324	15	guselkumab	guselkumab	NOUN
dpc-4176	324	16	in	in	ADP
dpc-4176	324	17	the	the	DET
dpc-4176	324	18	pediatric	pediatric	ADJ
dpc-4176	324	19	population	population	NOUN
dpc-4176	324	20	.	.	PUNCT
dpc-4176	325	1	scientific	scientific	ADJ
dpc-4176	325	2	evidence	evidence	NOUN
dpc-4176	325	3	for	for	ADP
dpc-4176	325	4	the	the	DET
dpc-4176	325	5	same	same	ADJ
dpc-4176	325	6	is	be	AUX
dpc-4176	325	7	represented	represent	VERB
dpc-4176	325	8	in	in	ADP
dpc-4176	325	9	few	few	ADJ
dpc-4176	325	10	case	case	NOUN
dpc-4176	325	11	reports	report	VERB
dpc-4176	325	12	wherein	wherein	SCONJ
dpc-4176	325	13	patients	patient	NOUN
dpc-4176	325	14	who	who	PRON
dpc-4176	325	15	were	be	AUX
dpc-4176	325	16	unresponsive	unresponsive	ADJ
dpc-4176	325	17	to	to	ADP
dpc-4176	325	18	conventional	conventional	ADJ
dpc-4176	325	19	anti	anti	ADJ
dpc-4176	325	20	-	-	ADJ
dpc-4176	325	21	psoriasis	psoriasis	ADJ
dpc-4176	325	22	treatment	treatment	NOUN
dpc-4176	325	23	and	and	CCONJ
dpc-4176	325	24	at	at	ADV
dpc-4176	325	25	least	least	ADJ
dpc-4176	325	26	one	one	NUM
dpc-4176	325	27	biologic	biologic	NOUN
dpc-4176	325	28	drug	drug	NOUN
dpc-4176	325	29	achieved	achieve	VERB
dpc-4176	325	30	almost	almost	ADV
dpc-4176	325	31	complete	complete	ADJ
dpc-4176	325	32	clinical	clinical	ADJ
dpc-4176	325	33	remission	remission	NOUN
dpc-4176	325	34	with	with	ADP
dpc-4176	325	35	guselkumab	guselkumab	NOUN
dpc-4176	325	36	without	without	ADP
dpc-4176	325	37	encountering	encounter	VERB
dpc-4176	325	38	any	any	DET
dpc-4176	325	39	side	side	NOUN
dpc-4176	325	40	effects	effect	NOUN
dpc-4176	326	1	[	[	X
dpc-4176	326	2	99	99	NUM
dpc-4176	326	3	-	-	SYM
dpc-4176	326	4	100	100	NUM
dpc-4176	326	5	]	]	PUNCT
dpc-4176	326	6	.	.	PUNCT
dpc-4176	327	1	despite	despite	SCONJ
dpc-4176	327	2	insufficient	insufficient	ADJ
dpc-4176	327	3	data	datum	NOUN
dpc-4176	327	4	,	,	PUNCT
dpc-4176	327	5	guselkumab	guselkumab	NOUN
dpc-4176	327	6	can	can	AUX
dpc-4176	327	7	be	be	AUX
dpc-4176	327	8	a	a	DET
dpc-4176	327	9	valuable	valuable	ADJ
dpc-4176	327	10	addon	addon	NOUN
dpc-4176	327	11	in	in	ADP
dpc-4176	327	12	the	the	DET
dpc-4176	327	13	therapeutic	therapeutic	ADJ
dpc-4176	327	14	armamentarium	armamentarium	NOUN
dpc-4176	327	15	of	of	ADP
dpc-4176	327	16	pediatric	pediatric	ADJ
dpc-4176	327	17	psoriasis	psoriasis	NOUN
dpc-4176	327	18	.	.	PUNCT
dpc-4176	328	1	geriatric	geriatric	ADJ
dpc-4176	328	2	currently	currently	ADV
dpc-4176	328	3	,	,	PUNCT
dpc-4176	328	4	data	datum	NOUN
dpc-4176	328	5	on	on	ADP
dpc-4176	328	6	guselkumab	guselkumab	NOUN
dpc-4176	328	7	therapy	therapy	NOUN
dpc-4176	328	8	for	for	ADP
dpc-4176	328	9	elderly	elderly	ADJ
dpc-4176	328	10	patients	patient	NOUN
dpc-4176	328	11	in	in	ADP
dpc-4176	328	12	real	real	ADJ
dpc-4176	328	13	world	world	NOUN
dpc-4176	328	14	clinical	clinical	ADJ
dpc-4176	328	15	practice	practice	NOUN
dpc-4176	328	16	is	be	AUX
dpc-4176	328	17	scant	scant	ADJ
dpc-4176	328	18	.	.	PUNCT
dpc-4176	329	1	nonetheless	nonetheless	ADV
dpc-4176	329	2	,	,	PUNCT
dpc-4176	329	3	available	available	ADJ
dpc-4176	329	4	phase	phase	NOUN
dpc-4176	329	5	iii	iii	NUM
dpc-4176	329	6	trials	trial	NOUN
dpc-4176	329	7	have	have	AUX
dpc-4176	329	8	demonstrated	demonstrate	VERB
dpc-4176	329	9	it	it	PRON
dpc-4176	329	10	to	to	PART
dpc-4176	329	11	be	be	AUX
dpc-4176	329	12	effective	effective	ADJ
dpc-4176	329	13	and	and	CCONJ
dpc-4176	329	14	safe	safe	ADJ
dpc-4176	329	15	in	in	ADP
dpc-4176	329	16	elderly	elderly	ADJ
dpc-4176	329	17	patients	patient	NOUN
dpc-4176	329	18	with	with	ADP
dpc-4176	329	19	no	no	DET
dpc-4176	329	20	difference	difference	NOUN
dpc-4176	329	21	from	from	ADP
dpc-4176	329	22	younger	young	ADJ
dpc-4176	329	23	patients	patient	NOUN
dpc-4176	330	1	[	[	X
dpc-4176	330	2	101	101	NUM
dpc-4176	330	3	]	]	PUNCT
dpc-4176	330	4	.	.	PUNCT
dpc-4176	331	1	progression	progression	NOUN
dpc-4176	332	1	[	[	X
dpc-4176	332	2	87,88	87,88	NOUN
dpc-4176	332	3	]	]	PUNCT
dpc-4176	332	4	.	.	PUNCT
dpc-4176	333	1	by	by	ADP
dpc-4176	333	2	inhibiting	inhibit	VERB
dpc-4176	333	3	il-23	il-23	NOUN
dpc-4176	333	4	,	,	PUNCT
dpc-4176	333	5	guselkumab	guselkumab	NOUN
dpc-4176	333	6	may	may	AUX
dpc-4176	333	7	have	have	VERB
dpc-4176	333	8	a	a	DET
dpc-4176	333	9	role	role	NOUN
dpc-4176	333	10	here	here	ADV
dpc-4176	333	11	.	.	PUNCT
dpc-4176	334	1	esbeen	esbeen	ADJ
dpc-4176	334	2	and	and	CCONJ
dpc-4176	334	3	colleagues	colleague	NOUN
dpc-4176	334	4	reported	report	VERB
dpc-4176	334	5	pronounced	pronounce	VERB
dpc-4176	334	6	clinical	clinical	ADJ
dpc-4176	334	7	improvement	improvement	NOUN
dpc-4176	334	8	of	of	ADP
dpc-4176	334	9	sta	sta	NOUN
dpc-4176	334	10	of	of	ADP
dpc-4176	334	11	the	the	DET
dpc-4176	334	12	left	left	ADJ
dpc-4176	334	13	forearm	forearm	NOUN
dpc-4176	334	14	in	in	ADP
dpc-4176	334	15	an	an	DET
dpc-4176	334	16	87	87	NUM
dpc-4176	334	17	-	-	PUNCT
dpc-4176	334	18	year	year	NOUN
dpc-4176	334	19	-	-	PUNCT
dpc-4176	334	20	old	old	ADJ
dpc-4176	334	21	woman	woman	NOUN
dpc-4176	334	22	following	follow	VERB
dpc-4176	334	23	guselkumab	guselkumab	NOUN
dpc-4176	334	24	(	(	PUNCT
dpc-4176	334	25	100	100	NUM
dpc-4176	334	26	mg	mg	PROPN
dpc-4176	334	27	sc	sc	PROPN
dpc-4176	334	28	,	,	PUNCT
dpc-4176	334	29	monthly	monthly	ADV
dpc-4176	334	30	for	for	ADP
dpc-4176	334	31	3	3	NUM
dpc-4176	334	32	months	month	NOUN
dpc-4176	334	33	)	)	PUNCT
dpc-4176	334	34	treatment	treatment	NOUN
dpc-4176	334	35	[	[	X
dpc-4176	334	36	89	89	NUM
dpc-4176	334	37	]	]	PUNCT
dpc-4176	334	38	.	.	PUNCT
dpc-4176	335	1	after	after	ADP
dpc-4176	335	2	3	3	NUM
dpc-4176	335	3	months	month	NOUN
dpc-4176	335	4	of	of	ADP
dpc-4176	335	5	therapy	therapy	NOUN
dpc-4176	335	6	substantial	substantial	ADJ
dpc-4176	335	7	reduction	reduction	NOUN
dpc-4176	335	8	in	in	ADP
dpc-4176	335	9	tumor	tumor	NOUN
dpc-4176	335	10	size	size	NOUN
dpc-4176	335	11	,	,	PUNCT
dpc-4176	335	12	and	and	CCONJ
dpc-4176	335	13	forearm	forearm	NOUN
dpc-4176	335	14	lymphoedema	lymphoedema	NOUN
dpc-4176	335	15	were	be	AUX
dpc-4176	335	16	observed	observe	VERB
dpc-4176	335	17	.	.	PUNCT
dpc-4176	336	1	also	also	ADV
dpc-4176	336	2	,	,	PUNCT
dpc-4176	336	3	satellite	satellite	NOUN
dpc-4176	336	4	nodules	nodule	NOUN
dpc-4176	336	5	that	that	PRON
dpc-4176	336	6	were	be	AUX
dpc-4176	336	7	attached	attach	VERB
dpc-4176	336	8	to	to	ADP
dpc-4176	336	9	the	the	DET
dpc-4176	336	10	lesion	lesion	NOUN
dpc-4176	336	11	showed	show	VERB
dpc-4176	336	12	considerable	considerable	ADJ
dpc-4176	336	13	regression	regression	NOUN
dpc-4176	336	14	.	.	PUNCT
dpc-4176	337	1	apart	apart	ADV
dpc-4176	337	2	from	from	ADP
dpc-4176	337	3	fatigue	fatigue	NOUN
dpc-4176	337	4	and	and	CCONJ
dpc-4176	337	5	headache	headache	NOUN
dpc-4176	337	6	,	,	PUNCT
dpc-4176	337	7	lasting	last	VERB
dpc-4176	337	8	for	for	ADP
dpc-4176	337	9	few	few	ADJ
dpc-4176	337	10	days	day	NOUN
dpc-4176	337	11	following	follow	VERB
dpc-4176	337	12	guselkumab	guselkumab	NOUN
dpc-4176	337	13	injection	injection	NOUN
dpc-4176	337	14	,	,	PUNCT
dpc-4176	337	15	no	no	DET
dpc-4176	337	16	other	other	ADJ
dpc-4176	337	17	side	side	NOUN
dpc-4176	337	18	effects	effect	NOUN
dpc-4176	337	19	were	be	AUX
dpc-4176	337	20	encountered	encounter	VERB
dpc-4176	337	21	.	.	PUNCT
dpc-4176	338	1	adverse	adverse	ADJ
dpc-4176	338	2	effects	effect	NOUN
dpc-4176	338	3	common	common	ADJ
dpc-4176	338	4	side	side	NOUN
dpc-4176	338	5	effects	effect	NOUN
dpc-4176	338	6	include	include	VERB
dpc-4176	338	7	urti	urti	ADJ
dpc-4176	338	8	,	,	PUNCT
dpc-4176	338	9	gastroenteritis	gastroenteritis	NOUN
dpc-4176	338	10	,	,	PUNCT
dpc-4176	338	11	dermatophytes	dermatophyte	NOUN
dpc-4176	338	12	,	,	PUNCT
dpc-4176	338	13	herpes	herpe	NOUN
dpc-4176	338	14	simplex	simplex	NOUN
dpc-4176	338	15	,	,	PUNCT
dpc-4176	338	16	injection	injection	NOUN
dpc-4176	338	17	site	site	NOUN
dpc-4176	338	18	reactions	reaction	NOUN
dpc-4176	338	19	,	,	PUNCT
dpc-4176	338	20	arthralgia	arthralgia	NOUN
dpc-4176	338	21	,	,	PUNCT
dpc-4176	338	22	bronchitis	bronchitis	NOUN
dpc-4176	338	23	and	and	CCONJ
dpc-4176	338	24	diarrhea	diarrhea	NOUN
dpc-4176	338	25	.	.	PUNCT
dpc-4176	339	1	these	these	PRON
dpc-4176	339	2	are	be	AUX
dpc-4176	339	3	usually	usually	ADV
dpc-4176	339	4	mild	mild	ADJ
dpc-4176	339	5	,	,	PUNCT
dpc-4176	339	6	not	not	PART
dpc-4176	339	7	requiring	require	VERB
dpc-4176	339	8	treatment	treatment	NOUN
dpc-4176	339	9	interruption	interruption	NOUN
dpc-4176	339	10	[	[	X
dpc-4176	339	11	90	90	NUM
dpc-4176	339	12	]	]	PUNCT
dpc-4176	339	13	.	.	PUNCT
dpc-4176	340	1	rarely	rarely	ADV
dpc-4176	340	2	bullous	bullous	ADJ
dpc-4176	340	3	pemphigoid	pemphigoid	NOUN
dpc-4176	340	4	and	and	CCONJ
dpc-4176	340	5	vitiligo	vitiligo	NOUN
dpc-4176	340	6	have	have	AUX
dpc-4176	340	7	been	be	AUX
dpc-4176	340	8	encountered	encounter	VERB
dpc-4176	340	9	.	.	PUNCT
dpc-4176	341	1	[	[	X
dpc-4176	341	2	91,92	91,92	X
dpc-4176	341	3	]	]	X
dpc-4176	341	4	the	the	DET
dpc-4176	341	5	occurrence	occurrence	NOUN
dpc-4176	341	6	of	of	ADP
dpc-4176	341	7	these	these	DET
dpc-4176	341	8	cutaneous	cutaneous	ADJ
dpc-4176	341	9	adverse	adverse	ADJ
dpc-4176	341	10	effects	effect	NOUN
dpc-4176	341	11	may	may	AUX
dpc-4176	341	12	be	be	AUX
dpc-4176	341	13	due	due	ADJ
dpc-4176	341	14	to	to	ADP
dpc-4176	341	15	alteration	alteration	NOUN
dpc-4176	341	16	of	of	ADP
dpc-4176	341	17	cytokine	cytokine	ADJ
dpc-4176	341	18	pathways	pathway	NOUN
dpc-4176	341	19	resulting	result	VERB
dpc-4176	341	20	in	in	ADP
dpc-4176	341	21	cytokine	cytokine	ADJ
dpc-4176	341	22	imbalances	imbalance	NOUN
dpc-4176	341	23	responsible	responsible	ADJ
dpc-4176	341	24	for	for	ADP
dpc-4176	341	25	immunopathogenic	immunopathogenic	ADJ
dpc-4176	341	26	mechanisms	mechanism	NOUN
dpc-4176	341	27	encountered	encounter	VERB
dpc-4176	341	28	here	here	ADV
dpc-4176	341	29	[	[	X
dpc-4176	341	30	93,94	93,94	NUM
dpc-4176	341	31	]	]	PUNCT
dpc-4176	341	32	.	.	PUNCT
dpc-4176	342	1	monitoring	monitor	VERB
dpc-4176	342	2	guidelines	guideline	NOUN
dpc-4176	342	3	(	(	PUNCT
dpc-4176	342	4	figure	figure	NOUN
dpc-4176	342	5	3	3	NUM
dpc-4176	342	6	)	)	PUNCT
dpc-4176	342	7	availability	availability	NOUN
dpc-4176	342	8	,	,	PUNCT
dpc-4176	342	9	administration	administration	NOUN
dpc-4176	342	10	and	and	CCONJ
dpc-4176	342	11	dosing	dosing	NOUN
dpc-4176	342	12	guselkumab	guselkumab	NOUN
dpc-4176	342	13	injection	injection	NOUN
dpc-4176	342	14	is	be	AUX
dpc-4176	342	15	available	available	ADJ
dpc-4176	342	16	as	as	ADP
dpc-4176	342	17	single	single	ADJ
dpc-4176	342	18	dose	dose	NOUN
dpc-4176	342	19	(	(	PUNCT
dpc-4176	342	20	100	100	NUM
dpc-4176	342	21	mg/	mg/	NOUN
dpc-4176	342	22	ml	ml	NOUN
dpc-4176	342	23	)	)	PUNCT
dpc-4176	342	24	pre	pre	ADJ
dpc-4176	342	25	-	-	ADJ
dpc-4176	342	26	filled	filled	ADJ
dpc-4176	342	27	syringes	syrinx	NOUN
dpc-4176	342	28	and	and	CCONJ
dpc-4176	342	29	as	as	ADP
dpc-4176	342	30	single	single	ADJ
dpc-4176	342	31	dose	dose	NOUN
dpc-4176	342	32	(	(	PUNCT
dpc-4176	342	33	100	100	NUM
dpc-4176	342	34	mg	mg	NUM
dpc-4176	342	35	/	/	SYM
dpc-4176	342	36	ml	ml	NOUN
dpc-4176	342	37	)	)	PUNCT
dpc-4176	342	38	onepress	onepress	NOUN
dpc-4176	342	39	patient	patient	NOUN
dpc-4176	342	40	-	-	PUNCT
dpc-4176	342	41	controlled	control	VERB
dpc-4176	342	42	injectors	injector	NOUN
dpc-4176	342	43	.	.	PUNCT
dpc-4176	343	1	it	it	PRON
dpc-4176	343	2	is	be	AUX
dpc-4176	343	3	dosed	dose	VERB
dpc-4176	343	4	as	as	ADP
dpc-4176	343	5	100	100	NUM
dpc-4176	343	6	mg	mg	PROPN
dpc-4176	343	7	sc	sc	PROPN
dpc-4176	343	8	at	at	ADP
dpc-4176	343	9	weeks	week	NOUN
dpc-4176	343	10	0	0	NUM
dpc-4176	343	11	,	,	PUNCT
dpc-4176	343	12	4	4	NUM
dpc-4176	343	13	,	,	PUNCT
dpc-4176	343	14	and	and	CCONJ
dpc-4176	343	15	then	then	ADV
dpc-4176	343	16	once	once	ADV
dpc-4176	343	17	every	every	DET
dpc-4176	343	18	8	8	NUM
dpc-4176	343	19	weeks	week	NOUN
dpc-4176	343	20	.	.	PUNCT
dpc-4176	344	1	it	it	PRON
dpc-4176	344	2	appears	appear	VERB
dpc-4176	344	3	as	as	ADP
dpc-4176	344	4	a	a	DET
dpc-4176	344	5	clear	clear	ADJ
dpc-4176	344	6	and	and	CCONJ
dpc-4176	344	7	colorless	colorless	ADJ
dpc-4176	344	8	to	to	ADP
dpc-4176	344	9	light	light	ADJ
dpc-4176	344	10	yellow	yellow	ADJ
dpc-4176	344	11	solution	solution	NOUN
dpc-4176	344	12	that	that	PRON
dpc-4176	344	13	may	may	AUX
dpc-4176	344	14	contain	contain	VERB
dpc-4176	344	15	small	small	ADJ
dpc-4176	344	16	translucent	translucent	ADJ
dpc-4176	344	17	particles	particle	NOUN
dpc-4176	344	18	.	.	PUNCT
dpc-4176	345	1	it	it	PRON
dpc-4176	345	2	needs	need	VERB
dpc-4176	345	3	to	to	PART
dpc-4176	345	4	be	be	AUX
dpc-4176	345	5	stored	store	VERB
dpc-4176	345	6	at	at	ADP
dpc-4176	345	7	2	2	NUM
dpc-4176	345	8	°	°	NOUN
dpc-4176	345	9	-8	-8	ADJ
dpc-4176	345	10	°	°	ADP
dpc-4176	345	11	c	c	NOUN
dpc-4176	345	12	,	,	PUNCT
dpc-4176	345	13	protected	protect	VERB
dpc-4176	345	14	from	from	ADP
dpc-4176	345	15	light	light	NOUN
dpc-4176	345	16	until	until	ADP
dpc-4176	345	17	use	use	NOUN
dpc-4176	345	18	and	and	CCONJ
dpc-4176	345	19	should	should	AUX
dpc-4176	345	20	not	not	PART
dpc-4176	345	21	be	be	AUX
dpc-4176	345	22	shaken	shake	VERB
dpc-4176	345	23	.	.	PUNCT
dpc-4176	346	1	it	it	PRON
dpc-4176	346	2	needs	need	VERB
dpc-4176	346	3	to	to	PART
dpc-4176	346	4	be	be	AUX
dpc-4176	346	5	kept	keep	VERB
dpc-4176	346	6	out	out	ADP
dpc-4176	346	7	of	of	ADP
dpc-4176	346	8	refrigerator	refrigerator	NOUN
dpc-4176	346	9	30	30	NUM
dpc-4176	346	10	minutes	minute	NOUN
dpc-4176	346	11	prior	prior	ADV
dpc-4176	346	12	to	to	ADP
dpc-4176	346	13	injection	injection	NOUN
dpc-4176	346	14	.	.	PUNCT
dpc-4176	347	1	injection	injection	NOUN
dpc-4176	347	2	sites	site	NOUN
dpc-4176	347	3	include	include	VERB
dpc-4176	347	4	front	front	NOUN
dpc-4176	347	5	of	of	ADP
dpc-4176	347	6	thighs	thigh	NOUN
dpc-4176	347	7	,	,	PUNCT
dpc-4176	347	8	lower	low	ADJ
dpc-4176	347	9	abdomen	abdomen	NOUN
dpc-4176	347	10	(	(	PUNCT
dpc-4176	347	11	except	except	SCONJ
dpc-4176	347	12	for	for	ADP
dpc-4176	347	13	a	a	DET
dpc-4176	347	14	2	2	NUM
dpc-4176	347	15	-	-	PUNCT
dpc-4176	347	16	inch	inch	NOUN
dpc-4176	347	17	area	area	NOUN
dpc-4176	347	18	around	around	ADP
dpc-4176	347	19	the	the	DET
dpc-4176	347	20	umbilicus	umbilicus	NOUN
dpc-4176	347	21	)	)	PUNCT
dpc-4176	347	22	or	or	CCONJ
dpc-4176	347	23	,	,	PUNCT
dpc-4176	347	24	back	back	ADV
dpc-4176	347	25	of	of	ADP
dpc-4176	347	26	the	the	DET
dpc-4176	347	27	arms	arm	NOUN
dpc-4176	347	28	(	(	PUNCT
dpc-4176	347	29	if	if	SCONJ
dpc-4176	347	30	administered	administer	VERB
dpc-4176	347	31	by	by	ADP
dpc-4176	347	32	another	another	DET
dpc-4176	347	33	person	person	NOUN
dpc-4176	347	34	)	)	PUNCT
dpc-4176	347	35	,	,	PUNCT
dpc-4176	347	36	and	and	CCONJ
dpc-4176	347	37	must	must	AUX
dpc-4176	347	38	not	not	PART
dpc-4176	347	39	be	be	AUX
dpc-4176	347	40	erythematous	erythematous	ADJ
dpc-4176	347	41	,	,	PUNCT
dpc-4176	347	42	indurated	indurate	VERB
dpc-4176	347	43	,	,	PUNCT
dpc-4176	347	44	scaly	scaly	NOUN
dpc-4176	347	45	or	or	CCONJ
dpc-4176	347	46	affected	affect	VERB
dpc-4176	347	47	by	by	ADP
dpc-4176	347	48	psoriasis	psoriasis	NOUN
dpc-4176	347	49	[	[	X
dpc-4176	347	50	90	90	NUM
dpc-4176	347	51	]	]	PUNCT
dpc-4176	347	52	.	.	PUNCT
dpc-4176	348	1	use	use	NOUN
dpc-4176	348	2	in	in	ADP
dpc-4176	348	3	specific	specific	ADJ
dpc-4176	348	4	populations	population	NOUN
dpc-4176	348	5	pregnancy	pregnancy	NOUN
dpc-4176	348	6	based	base	VERB
dpc-4176	348	7	on	on	ADP
dpc-4176	348	8	available	available	ADJ
dpc-4176	348	9	data	datum	NOUN
dpc-4176	348	10	,	,	PUNCT
dpc-4176	348	11	it	it	PRON
dpc-4176	348	12	is	be	AUX
dpc-4176	348	13	not	not	PART
dpc-4176	348	14	known	know	VERB
dpc-4176	348	15	if	if	SCONJ
dpc-4176	348	16	taking	take	VERB
dpc-4176	348	17	guselkumab	guselkumab	NOUN
dpc-4176	348	18	increases	increase	NOUN
dpc-4176	348	19	the	the	DET
dpc-4176	348	20	chance	chance	NOUN
dpc-4176	348	21	of	of	ADP
dpc-4176	348	22	birth	birth	NOUN
dpc-4176	348	23	defects	defect	NOUN
dpc-4176	348	24	.	.	PUNCT
dpc-4176	349	1	because	because	SCONJ
dpc-4176	349	2	guselkumab	guselkumab	NOUN
dpc-4176	349	3	is	be	AUX
dpc-4176	349	4	an	an	DET
dpc-4176	349	5	antibody	antibody	NOUN
dpc-4176	349	6	,	,	PUNCT
dpc-4176	349	7	transfer	transfer	NOUN
dpc-4176	349	8	of	of	ADP
dpc-4176	349	9	medication	medication	NOUN
dpc-4176	349	10	to	to	ADP
dpc-4176	349	11	the	the	DET
dpc-4176	349	12	fetus	fetus	NOUN
dpc-4176	349	13	might	might	AUX
dpc-4176	349	14	be	be	AUX
dpc-4176	349	15	low	low	ADJ
dpc-4176	349	16	in	in	ADP
dpc-4176	349	17	early	early	ADJ
dpc-4176	349	18	pregnancy	pregnancy	NOUN
dpc-4176	349	19	,	,	PUNCT
dpc-4176	349	20	when	when	SCONJ
dpc-4176	349	21	organogenesis	organogenesis	NOUN
dpc-4176	349	22	takes	take	VERB
dpc-4176	349	23	place	place	NOUN
dpc-4176	349	24	.	.	PUNCT
dpc-4176	350	1	further	far	ADV
dpc-4176	350	2	,	,	PUNCT
dpc-4176	350	3	currently	currently	ADV
dpc-4176	350	4	it	it	PRON
dpc-4176	350	5	not	not	PART
dpc-4176	350	6	known	know	VERB
dpc-4176	350	7	if	if	SCONJ
dpc-4176	350	8	guselkumab	guselkumab	NOUN
dpc-4176	350	9	can	can	AUX
dpc-4176	350	10	result	result	VERB
dpc-4176	350	11	in	in	ADP
dpc-4176	350	12	any	any	DET
dpc-4176	350	13	other	other	ADJ
dpc-4176	350	14	pregnancy	pregnancy	NOUN
dpc-4176	350	15	complications	complication	NOUN
dpc-4176	350	16	or	or	CCONJ
dpc-4176	350	17	behavioral	behavioral	ADJ
dpc-4176	350	18	and	and	CCONJ
dpc-4176	350	19	learning	learn	VERB
dpc-4176	350	20	issues	issue	NOUN
dpc-4176	350	21	[	[	X
dpc-4176	350	22	95	95	NUM
dpc-4176	350	23	]	]	PUNCT
dpc-4176	350	24	.	.	PUNCT
dpc-4176	351	1	lactation	lactation	NOUN
dpc-4176	351	2	at	at	ADP
dpc-4176	351	3	present	present	ADJ
dpc-4176	351	4	no	no	DET
dpc-4176	351	5	information	information	NOUN
dpc-4176	351	6	is	be	AUX
dpc-4176	351	7	available	available	ADJ
dpc-4176	351	8	on	on	ADP
dpc-4176	351	9	the	the	DET
dpc-4176	351	10	clinical	clinical	ADJ
dpc-4176	351	11	use	use	NOUN
dpc-4176	351	12	of	of	ADP
dpc-4176	351	13	guselkumab	guselkumab	NOUN
dpc-4176	351	14	during	during	ADP
dpc-4176	351	15	lactation	lactation	NOUN
dpc-4176	351	16	.	.	PUNCT
dpc-4176	352	1	as	as	SCONJ
dpc-4176	352	2	guselkumab	guselkumab	NOUN
dpc-4176	352	3	has	have	VERB
dpc-4176	352	4	a	a	DET
dpc-4176	352	5	large	large	ADJ
dpc-4176	352	6	figure	figure	NOUN
dpc-4176	352	7	3	3	X
dpc-4176	352	8	.	.	PUNCT
dpc-4176	352	9	monitoring	monitor	VERB
dpc-4176	352	10	guidelines	guideline	NOUN
dpc-4176	352	11	for	for	ADP
dpc-4176	352	12	guselkumab	guselkumab	NOUN
dpc-4176	352	13	.	.	PUNCT
dpc-4176	353	1	review	review	NOUN
dpc-4176	353	2	|	|	ADV
dpc-4176	353	3	dermatol	dermatol	ADJ
dpc-4176	353	4	pract	pract	NOUN
dpc-4176	353	5	concept	concept	NOUN
dpc-4176	353	6	.	.	PUNCT
dpc-4176	354	1	2024;14(3):e2024181	2024;14(3):e2024181	NUM
dpc-4176	354	2	13	13	NUM
dpc-4176	354	3	13	13	NUM
dpc-4176	354	4	.	.	PUNCT
dpc-4176	355	1	fotiadou	fotiadou	PROPN
dpc-4176	355	2	c	c	PROPN
dpc-4176	355	3	,	,	PUNCT
dpc-4176	355	4	lazaridou	lazaridou	PROPN
dpc-4176	355	5	e	e	NOUN
dpc-4176	355	6	,	,	PUNCT
dpc-4176	355	7	sotiriou	sotiriou	ADJ
dpc-4176	355	8	e	e	NOUN
dpc-4176	355	9	,	,	PUNCT
dpc-4176	355	10	et	et	PROPN
dpc-4176	355	11	al	al	PROPN
dpc-4176	355	12	.	.	PUNCT
dpc-4176	355	13	targeting	target	VERB
dpc-4176	355	14	il-23	il-23	NOUN
dpc-4176	355	15	in	in	ADP
dpc-4176	355	16	psoriasis	psoriasis	NOUN
dpc-4176	355	17	:	:	PUNCT
dpc-4176	355	18	current	current	ADJ
dpc-4176	355	19	perspectives	perspective	NOUN
dpc-4176	355	20	.	.	PUNCT
dpc-4176	356	1	psoriasis	psoriasis	NOUN
dpc-4176	356	2	(	(	PUNCT
dpc-4176	356	3	auckl	auckl	NOUN
dpc-4176	356	4	)	)	PUNCT
dpc-4176	356	5	.	.	PUNCT
dpc-4176	357	1	2018;8:1	2018;8:1	NUM
dpc-4176	357	2	-	-	SYM
dpc-4176	357	3	5	5	NUM
dpc-4176	357	4	.	.	PUNCT
dpc-4176	357	5	doi	doi	NOUN
dpc-4176	357	6	:	:	PUNCT
dpc-4176	357	7	10.2147	10.2147	NUM
dpc-4176	357	8	/	/	SYM
dpc-4176	357	9	ptt.s98893	ptt.s98893	X
dpc-4176	357	10	.	.	PUNCT
dpc-4176	358	1	pmid	pmid	NOUN
dpc-4176	358	2	:	:	PUNCT
dpc-4176	358	3	29441315	29441315	NUM
dpc-4176	358	4	;	;	PUNCT
dpc-4176	358	5	pmcid	pmcid	ADJ
dpc-4176	358	6	:	:	PUNCT
dpc-4176	358	7	pmc5804022	pmc5804022	NOUN
dpc-4176	358	8	.	.	PUNCT
dpc-4176	359	1	14	14	NUM
dpc-4176	359	2	.	.	PUNCT
dpc-4176	360	1	blauvelt	blauvelt	VERB
dpc-4176	360	2	a	a	PRON
dpc-4176	360	3	,	,	PUNCT
dpc-4176	360	4	papp	papp	PROPN
dpc-4176	360	5	ka	ka	PROPN
dpc-4176	360	6	,	,	PUNCT
dpc-4176	360	7	griffiths	griffiths	PROPN
dpc-4176	360	8	cem	cem	PROPN
dpc-4176	360	9	,	,	PUNCT
dpc-4176	360	10	et	et	PROPN
dpc-4176	360	11	al	al	PROPN
dpc-4176	360	12	.	.	PROPN
dpc-4176	360	13	efficacy	efficacy	NOUN
dpc-4176	360	14	and	and	CCONJ
dpc-4176	360	15	safety	safety	NOUN
dpc-4176	360	16	of	of	ADP
dpc-4176	360	17	guselkumab	guselkumab	NOUN
dpc-4176	360	18	,	,	PUNCT
dpc-4176	360	19	an	an	DET
dpc-4176	360	20	anti	anti	ADJ
dpc-4176	360	21	-	-	ADJ
dpc-4176	360	22	interleukin-23	interleukin-23	ADJ
dpc-4176	360	23	monoclonal	monoclonal	NOUN
dpc-4176	360	24	antibody	antibody	NOUN
dpc-4176	360	25	,	,	PUNCT
dpc-4176	360	26	compared	compare	VERB
dpc-4176	360	27	with	with	ADP
dpc-4176	360	28	adalimumab	adalimumab	NOUN
dpc-4176	360	29	for	for	ADP
dpc-4176	360	30	the	the	DET
dpc-4176	360	31	continuous	continuous	ADJ
dpc-4176	360	32	treatment	treatment	NOUN
dpc-4176	360	33	of	of	ADP
dpc-4176	360	34	patients	patient	NOUN
dpc-4176	360	35	with	with	ADP
dpc-4176	360	36	moderate	moderate	ADJ
dpc-4176	360	37	to	to	ADP
dpc-4176	360	38	severe	severe	ADJ
dpc-4176	360	39	psoriasis	psoriasis	NOUN
dpc-4176	360	40	:	:	PUNCT
dpc-4176	360	41	results	result	VERB
dpc-4176	360	42	from	from	ADP
dpc-4176	360	43	the	the	DET
dpc-4176	360	44	phase	phase	NOUN
dpc-4176	360	45	iii	iii	NOUN
dpc-4176	360	46	,	,	PUNCT
dpc-4176	360	47	double	double	ADJ
dpc-4176	360	48	-	-	PUNCT
dpc-4176	360	49	blinded	blind	VERB
dpc-4176	360	50	,	,	PUNCT
dpc-4176	360	51	placeboand	placeboand	VERB
dpc-4176	360	52	active	active	ADJ
dpc-4176	360	53	comparator	comparator	NOUN
dpc-4176	360	54	–	–	PUNCT
dpc-4176	360	55	controlled	control	VERB
dpc-4176	360	56	voyage	voyage	NOUN
dpc-4176	360	57	1	1	NUM
dpc-4176	360	58	trial	trial	NOUN
dpc-4176	360	59	.	.	PUNCT
dpc-4176	361	1	j	j	PROPN
dpc-4176	361	2	amer	amer	PROPN
dpc-4176	361	3	acad	acad	PROPN
dpc-4176	361	4	dermatol	dermatol	NOUN
dpc-4176	361	5	.	.	PUNCT
dpc-4176	362	1	2017;76:405–17	2017;76:405–17	NUM
dpc-4176	362	2	.	.	PUNCT
dpc-4176	363	1	doi:10.1016	doi:10.1016	PROPN
dpc-4176	363	2	/	/	SYM
dpc-4176	363	3	j.jaad.2016.11.041	j.jaad.2016.11.041	PROPN
dpc-4176	363	4	.	.	PUNCT
dpc-4176	364	1	pmid	pmid	NOUN
dpc-4176	364	2	:	:	PUNCT
dpc-4176	364	3	28057360	28057360	NUM
dpc-4176	364	4	.	.	PUNCT
dpc-4176	365	1	15	15	NUM
dpc-4176	365	2	.	.	PUNCT
dpc-4176	366	1	langley	langley	PROPN
dpc-4176	366	2	rg	rg	PROPN
dpc-4176	366	3	,	,	PUNCT
dpc-4176	366	4	tsai	tsai	PROPN
dpc-4176	366	5	t	t	PROPN
dpc-4176	366	6	-	-	PUNCT
dpc-4176	366	7	f.	f.	PROPN
dpc-4176	366	8	,	,	PUNCT
dpc-4176	366	9	flavin	flavin	NOUN
dpc-4176	366	10	s	s	PROPN
dpc-4176	366	11	,	,	PUNCT
dpc-4176	366	12	et	et	PROPN
dpc-4176	366	13	al	al	PROPN
dpc-4176	366	14	.	.	PROPN
dpc-4176	366	15	efficacy	efficacy	NOUN
dpc-4176	366	16	and	and	CCONJ
dpc-4176	366	17	safety	safety	NOUN
dpc-4176	366	18	of	of	ADP
dpc-4176	366	19	guselkumab	guselkumab	NOUN
dpc-4176	366	20	in	in	ADP
dpc-4176	366	21	patients	patient	NOUN
dpc-4176	366	22	with	with	ADP
dpc-4176	366	23	psoriasis	psoriasis	NOUN
dpc-4176	366	24	who	who	PRON
dpc-4176	366	25	have	have	VERB
dpc-4176	366	26	an	an	DET
dpc-4176	366	27	inadequate	inadequate	ADJ
dpc-4176	366	28	response	response	NOUN
dpc-4176	366	29	to	to	ADP
dpc-4176	366	30	ustekinumab	ustekinumab	NOUN
dpc-4176	366	31	:	:	PUNCT
dpc-4176	366	32	results	result	NOUN
dpc-4176	366	33	of	of	ADP
dpc-4176	366	34	the	the	DET
dpc-4176	366	35	randomized	randomized	ADJ
dpc-4176	366	36	,	,	PUNCT
dpc-4176	366	37	double	double	ADJ
dpc-4176	366	38	-	-	PUNCT
dpc-4176	366	39	blind	blind	ADJ
dpc-4176	366	40	,	,	PUNCT
dpc-4176	366	41	phase	phase	NOUN
dpc-4176	366	42	iii	iii	NUM
dpc-4176	366	43	navigate	navigate	VERB
dpc-4176	366	44	trial	trial	NOUN
dpc-4176	366	45	.	.	PUNCT
dpc-4176	367	1	br	br	PROPN
dpc-4176	367	2	j	j	PROPN
dpc-4176	367	3	dermatol	dermatol	NOUN
dpc-4176	367	4	.	.	PUNCT
dpc-4176	368	1	2018;178:114–23	2018;178:114–23	NOUN
dpc-4176	368	2	.	.	PUNCT
dpc-4176	369	1	doi:10.1111	doi:10.1111	ADJ
dpc-4176	369	2	/	/	SYM
dpc-4176	369	3	bjd.15750	bjd.15750	NOUN
dpc-4176	369	4	.	.	PUNCT
dpc-4176	370	1	pmid	pmid	NOUN
dpc-4176	370	2	:	:	PUNCT
dpc-4176	370	3	28635018	28635018	NUM
dpc-4176	370	4	.	.	PUNCT
dpc-4176	371	1	16	16	NUM
dpc-4176	371	2	.	.	PUNCT
dpc-4176	372	1	reich	reich	PROPN
dpc-4176	372	2	k	k	PROPN
dpc-4176	372	3	,	,	PUNCT
dpc-4176	372	4	armstrong	armstrong	PROPN
dpc-4176	372	5	aw	aw	PROPN
dpc-4176	372	6	,	,	PUNCT
dpc-4176	372	7	langley	langley	PROPN
dpc-4176	372	8	rg	rg	PROPN
dpc-4176	372	9	,	,	PUNCT
dpc-4176	372	10	et	et	PROPN
dpc-4176	372	11	al	al	PROPN
dpc-4176	372	12	.	.	PROPN
dpc-4176	372	13	guselkumab	guselkumab	PROPN
dpc-4176	372	14	versus	versus	ADP
dpc-4176	372	15	secukinumab	secukinumab	NOUN
dpc-4176	372	16	for	for	ADP
dpc-4176	372	17	the	the	DET
dpc-4176	372	18	treatment	treatment	NOUN
dpc-4176	372	19	of	of	ADP
dpc-4176	372	20	moderate	moderate	ADJ
dpc-4176	372	21	-	-	PUNCT
dpc-4176	372	22	to	to	ADP
dpc-4176	372	23	-	-	PUNCT
dpc-4176	372	24	severe	severe	ADJ
dpc-4176	372	25	psoriasis	psoriasis	NOUN
dpc-4176	372	26	(	(	PUNCT
dpc-4176	372	27	eclipse	eclipse	NOUN
dpc-4176	372	28	):	):	PUNCT
dpc-4176	372	29	results	result	NOUN
dpc-4176	372	30	from	from	ADP
dpc-4176	372	31	a	a	DET
dpc-4176	372	32	phase	phase	NOUN
dpc-4176	372	33	3	3	NUM
dpc-4176	372	34	,	,	PUNCT
dpc-4176	372	35	randomised	randomise	VERB
dpc-4176	372	36	controlled	control	VERB
dpc-4176	372	37	trial	trial	NOUN
dpc-4176	372	38	.	.	PUNCT
dpc-4176	373	1	lancet	lancet	NOUN
dpc-4176	373	2	.	.	PUNCT
dpc-4176	374	1	2019;394(10201):831–9	2019;394(10201):831–9	NUM
dpc-4176	374	2	.	.	PUNCT
dpc-4176	374	3	doi:10.1016	doi:10.1016	PROPN
dpc-4176	374	4	/	/	SYM
dpc-4176	374	5	s0140	s0140	PROPN
dpc-4176	374	6	-	-	PUNCT
dpc-4176	374	7	6736	6736	NUM
dpc-4176	374	8	(	(	PUNCT
dpc-4176	374	9	19)31773	19)31773	NUM
dpc-4176	374	10	-	-	PUNCT
dpc-4176	374	11	8	8	NUM
dpc-4176	374	12	.	.	PUNCT
dpc-4176	375	1	pmid	pmid	NOUN
dpc-4176	375	2	:	:	PUNCT
dpc-4176	375	3	31402114	31402114	NUM
dpc-4176	375	4	.	.	PUNCT
dpc-4176	376	1	17	17	NUM
dpc-4176	376	2	.	.	PUNCT
dpc-4176	376	3	du	du	PROPN
dpc-4176	376	4	jardin	jardin	PROPN
dpc-4176	376	5	k	k	PROPN
dpc-4176	376	6	,	,	PUNCT
dpc-4176	376	7	lopez	lopez	PROPN
dpc-4176	376	8	p	p	PROPN
dpc-4176	376	9	,	,	PUNCT
dpc-4176	376	10	lange	lange	NOUN
dpc-4176	376	11	m	m	PROPN
dpc-4176	376	12	,	,	PUNCT
dpc-4176	376	13	et	et	PROPN
dpc-4176	376	14	al	al	PROPN
dpc-4176	376	15	.	.	PUNCT
dpc-4176	377	1	a	a	DET
dpc-4176	377	2	systematic	systematic	ADJ
dpc-4176	377	3	literature	literature	NOUN
dpc-4176	377	4	review	review	NOUN
dpc-4176	377	5	and	and	CCONJ
dpc-4176	377	6	bucher	bucher	VERB
dpc-4176	377	7	indirect	indirect	ADJ
dpc-4176	377	8	comparison	comparison	NOUN
dpc-4176	377	9	:	:	PUNCT
dpc-4176	377	10	tildrakizumab	tildrakizumab	NOUN
dpc-4176	377	11	versus	versus	ADP
dpc-4176	377	12	guselkumab	guselkumab	NOUN
dpc-4176	377	13	.	.	PUNCT
dpc-4176	378	1	j	j	PROPN
dpc-4176	378	2	health	health	PROPN
dpc-4176	378	3	econ	econ	PROPN
dpc-4176	378	4	outcomes	outcome	NOUN
dpc-4176	378	5	res	re	NOUN
dpc-4176	378	6	.	.	PUNCT
dpc-4176	378	7	2020;123–9	2020;123–9	NUM
dpc-4176	378	8	.	.	PUNCT
dpc-4176	379	1	doi:10.36469	doi:10.36469	PROPN
dpc-4176	379	2	/	/	SYM
dpc-4176	379	3	jheor.2020.13671	jheor.2020.13671	PROPN
dpc-4176	379	4	.	.	PUNCT
dpc-4176	380	1	pmid	pmid	NOUN
dpc-4176	380	2	:	:	PUNCT
dpc-4176	380	3	32766377	32766377	NUM
dpc-4176	380	4	;	;	PUNCT
dpc-4176	380	5	pmcid	pmcid	NOUN
dpc-4176	380	6	:	:	PUNCT
dpc-4176	380	7	pmc7398610	pmc7398610	NOUN
dpc-4176	380	8	.	.	PUNCT
dpc-4176	381	1	18	18	NUM
dpc-4176	381	2	.	.	PUNCT
dpc-4176	381	3	griffiths	griffiths	PROPN
dpc-4176	381	4	cem	cem	PROPN
dpc-4176	381	5	,	,	PUNCT
dpc-4176	381	6	papp	papp	PROPN
dpc-4176	381	7	ka	ka	PROPN
dpc-4176	381	8	,	,	PUNCT
dpc-4176	381	9	song	song	NOUN
dpc-4176	381	10	m	m	PROPN
dpc-4176	381	11	,	,	PUNCT
dpc-4176	381	12	et	et	PROPN
dpc-4176	381	13	al	al	PROPN
dpc-4176	381	14	.	.	PROPN
dpc-4176	382	1	continuous	continuous	ADJ
dpc-4176	382	2	treatment	treatment	NOUN
dpc-4176	382	3	with	with	ADP
dpc-4176	382	4	guselkumab	guselkumab	NOUN
dpc-4176	382	5	maintains	maintain	VERB
dpc-4176	382	6	clinical	clinical	ADJ
dpc-4176	382	7	responses	response	NOUN
dpc-4176	382	8	through	through	ADP
dpc-4176	382	9	4	4	NUM
dpc-4176	382	10	years	year	NOUN
dpc-4176	382	11	in	in	ADP
dpc-4176	382	12	patients	patient	NOUN
dpc-4176	382	13	with	with	ADP
dpc-4176	382	14	moderate	moderate	ADJ
dpc-4176	382	15	-	-	PUNCT
dpc-4176	382	16	to	to	ADP
dpc-4176	382	17	-	-	PUNCT
dpc-4176	382	18	severe	severe	ADJ
dpc-4176	382	19	psoriasis	psoriasis	NOUN
dpc-4176	382	20	:	:	PUNCT
dpc-4176	382	21	results	result	NOUN
dpc-4176	382	22	from	from	ADP
dpc-4176	382	23	voyage	voyage	NOUN
dpc-4176	382	24	1	1	NUM
dpc-4176	382	25	.	.	PUNCT
dpc-4176	382	26	j	j	PROPN
dpc-4176	382	27	dermatolog	dermatolog	PROPN
dpc-4176	382	28	treat	treat	NOUN
dpc-4176	382	29	.	.	PUNCT
dpc-4176	383	1	2022;33:848–56	2022;33:848–56	X
dpc-4176	383	2	.	.	PUNCT
dpc-4176	384	1	doi:10.108	doi:10.108	VERB
dpc-4176	384	2	0/09546634.2020.1782817	0/09546634.2020.1782817	NOUN
dpc-4176	384	3	.	.	PUNCT
dpc-4176	385	1	pmid	pmid	NOUN
dpc-4176	385	2	:	:	PUNCT
dpc-4176	385	3	32660282	32660282	NUM
dpc-4176	385	4	.	.	PUNCT
dpc-4176	386	1	19	19	NUM
dpc-4176	386	2	.	.	NOUN
dpc-4176	386	3	ohtsuki	ohtsuki	PROPN
dpc-4176	386	4	m	m	PROPN
dpc-4176	386	5	,	,	PUNCT
dpc-4176	386	6	kubo	kubo	PROPN
dpc-4176	386	7	h	h	PROPN
dpc-4176	386	8	,	,	PUNCT
dpc-4176	386	9	morishima	morishima	PROPN
dpc-4176	386	10	h	h	PROPN
dpc-4176	386	11	,	,	PUNCT
dpc-4176	386	12	et	et	PROPN
dpc-4176	386	13	al	al	PROPN
dpc-4176	386	14	.	.	PROPN
dpc-4176	386	15	guselkumab	guselkumab	PROPN
dpc-4176	386	16	,	,	PUNCT
dpc-4176	386	17	an	an	DET
dpc-4176	386	18	anti	anti	ADJ
dpc-4176	386	19	-	-	ADJ
dpc-4176	386	20	interleukin-23	interleukin-23	ADJ
dpc-4176	386	21	monoclonal	monoclonal	NOUN
dpc-4176	386	22	antibody	antibody	NOUN
dpc-4176	386	23	,	,	PUNCT
dpc-4176	386	24	for	for	ADP
dpc-4176	386	25	the	the	DET
dpc-4176	386	26	treatment	treatment	NOUN
dpc-4176	386	27	of	of	ADP
dpc-4176	386	28	moderate	moderate	ADJ
dpc-4176	386	29	to	to	ADP
dpc-4176	386	30	severe	severe	ADJ
dpc-4176	386	31	plaque	plaque	NOUN
dpc-4176	386	32	-	-	PUNCT
dpc-4176	386	33	type	type	NOUN
dpc-4176	386	34	psoriasis	psoriasis	NOUN
dpc-4176	386	35	in	in	ADP
dpc-4176	386	36	japanese	japanese	ADJ
dpc-4176	386	37	patients	patient	NOUN
dpc-4176	386	38	:	:	PUNCT
dpc-4176	386	39	efficacy	efficacy	NOUN
dpc-4176	386	40	and	and	CCONJ
dpc-4176	386	41	safety	safety	NOUN
dpc-4176	386	42	results	result	NOUN
dpc-4176	386	43	from	from	ADP
dpc-4176	386	44	a	a	DET
dpc-4176	386	45	phase	phase	NOUN
dpc-4176	386	46	3	3	NUM
dpc-4176	386	47	,	,	PUNCT
dpc-4176	386	48	randomized	randomize	VERB
dpc-4176	386	49	,	,	PUNCT
dpc-4176	386	50	double	double	ADJ
dpc-4176	386	51	-	-	PUNCT
dpc-4176	386	52	blind	blind	ADJ
dpc-4176	386	53	,	,	PUNCT
dpc-4176	386	54	placebo	placebo	NOUN
dpc-4176	386	55	-	-	PUNCT
dpc-4176	386	56	controlled	control	VERB
dpc-4176	386	57	study	study	NOUN
dpc-4176	386	58	.	.	PUNCT
dpc-4176	387	1	j	j	PROPN
dpc-4176	387	2	dermatol	dermatol	NOUN
dpc-4176	387	3	.	.	PUNCT
dpc-4176	388	1	2018;45:1053–62	2018;45:1053–62	NUM
dpc-4176	388	2	.	.	PUNCT
dpc-4176	389	1	doi	doi	NOUN
dpc-4176	389	2	:	:	PUNCT
dpc-4176	389	3	10.1111/1346	10.1111/1346	NUM
dpc-4176	389	4	-	-	PUNCT
dpc-4176	389	5	8138.14504	8138.14504	NUM
dpc-4176	389	6	.	.	PUNCT
dpc-4176	390	1	pmid	pmid	NOUN
dpc-4176	390	2	:	:	PUNCT
dpc-4176	390	3	29905383	29905383	NUM
dpc-4176	390	4	;	;	PUNCT
dpc-4176	390	5	pmcid	pmcid	NOUN
dpc-4176	390	6	:	:	PUNCT
dpc-4176	390	7	pmc6175099	pmc6175099	NOUN
dpc-4176	390	8	.	.	PUNCT
dpc-4176	391	1	20	20	NUM
dpc-4176	391	2	.	.	PUNCT
dpc-4176	391	3	hall	hall	PROPN
dpc-4176	391	4	sl	sl	PROPN
dpc-4176	391	5	,	,	PUNCT
dpc-4176	391	6	haidari	haidari	ADJ
dpc-4176	391	7	w	w	PROPN
dpc-4176	391	8	,	,	PUNCT
dpc-4176	391	9	feldman	feldman	PROPN
dpc-4176	391	10	sr	sr	PROPN
dpc-4176	391	11	.	.	PUNCT
dpc-4176	392	1	resolution	resolution	NOUN
dpc-4176	392	2	of	of	ADP
dpc-4176	392	3	guttate	guttate	ADJ
dpc-4176	392	4	psoriasis	psoriasis	NOUN
dpc-4176	392	5	plaques	plaque	NOUN
dpc-4176	392	6	after	after	ADP
dpc-4176	392	7	one	one	NUM
dpc-4176	392	8	-	-	PUNCT
dpc-4176	392	9	time	time	NOUN
dpc-4176	392	10	administration	administration	NOUN
dpc-4176	392	11	of	of	ADP
dpc-4176	392	12	guselkumab	guselkumab	NOUN
dpc-4176	392	13	.	.	PUNCT
dpc-4176	393	1	j	j	PROPN
dpc-4176	393	2	drugs	drug	NOUN
dpc-4176	393	3	dermatol	dermatol	NOUN
dpc-4176	393	4	.	.	PUNCT
dpc-4176	394	1	2019;18(8):822–3	2019;18(8):822–3	NUM
dpc-4176	394	2	.	.	PUNCT
dpc-4176	395	1	pmid	pmid	NOUN
dpc-4176	395	2	:	:	PUNCT
dpc-4176	395	3	31424714	31424714	NUM
dpc-4176	395	4	.	.	PUNCT
dpc-4176	396	1	21	21	NUM
dpc-4176	396	2	.	.	PUNCT
dpc-4176	397	1	bartholomew	bartholomew	PROPN
dpc-4176	397	2	e	e	PROPN
dpc-4176	397	3	,	,	PUNCT
dpc-4176	397	4	chung	chung	VERB
dpc-4176	397	5	by	by	ADP
dpc-4176	397	6	,	,	PUNCT
dpc-4176	397	7	davis	davis	PROPN
dpc-4176	397	8	m	m	PROPN
dpc-4176	397	9	,	,	PUNCT
dpc-4176	397	10	et	et	PROPN
dpc-4176	397	11	al	al	PROPN
dpc-4176	397	12	.	.	PROPN
dpc-4176	398	1	rapid	rapid	ADJ
dpc-4176	398	2	remission	remission	NOUN
dpc-4176	398	3	of	of	ADP
dpc-4176	398	4	sunburn	sunburn	NOUN
dpc-4176	398	5	-	-	PUNCT
dpc-4176	398	6	induced	induce	VERB
dpc-4176	398	7	guttate	guttate	NOUN
dpc-4176	398	8	psoriasis	psoriasis	NOUN
dpc-4176	398	9	with	with	ADP
dpc-4176	398	10	guselkumab	guselkumab	NOUN
dpc-4176	398	11	.	.	PUNCT
dpc-4176	399	1	dermatol	dermatol	NOUN
dpc-4176	399	2	ther	ther	ADV
dpc-4176	399	3	(	(	PUNCT
dpc-4176	399	4	heidelb	heidelb	NOUN
dpc-4176	399	5	)	)	PUNCT
dpc-4176	399	6	.	.	PUNCT
dpc-4176	400	1	2023;13:2473–8	2023;13:2473–8	X
dpc-4176	400	2	.	.	PUNCT
dpc-4176	401	1	doi	doi	NOUN
dpc-4176	401	2	:	:	PUNCT
dpc-4176	401	3	10.1007	10.1007	NUM
dpc-4176	401	4	/	/	SYM
dpc-4176	401	5	s13555	s13555	PROPN
dpc-4176	401	6	-	-	PUNCT
dpc-4176	401	7	023	023	NUM
dpc-4176	401	8	-01013	-01013	NUM
dpc-4176	401	9	-	-	PUNCT
dpc-4176	401	10	y.	y.	PROPN
dpc-4176	401	11	pmid	pmid	PROPN
dpc-4176	401	12	:	:	PUNCT
dpc-4176	401	13	37676470	37676470	NUM
dpc-4176	401	14	;	;	PUNCT
dpc-4176	401	15	pmcid	pmcid	ADJ
dpc-4176	401	16	:	:	PUNCT
dpc-4176	401	17	pmc10539232	pmc10539232	NOUN
dpc-4176	401	18	.	.	PUNCT
dpc-4176	402	1	22	22	NUM
dpc-4176	402	2	.	.	PUNCT
dpc-4176	403	1	schwarz	schwarz	PROPN
dpc-4176	403	2	a	a	PROPN
dpc-4176	403	3	,	,	PUNCT
dpc-4176	403	4	bhardwaj	bhardwaj	PROPN
dpc-4176	403	5	r	r	PROPN
dpc-4176	403	6	,	,	PUNCT
dpc-4176	403	7	aragane	aragane	PROPN
dpc-4176	403	8	y	y	PROPN
dpc-4176	403	9	,	,	PUNCT
dpc-4176	403	10	et	et	PROPN
dpc-4176	403	11	al	al	PROPN
dpc-4176	403	12	.	.	PUNCT
dpc-4176	404	1	ultraviolet	ultraviolet	PROPN
dpc-4176	404	2	-	-	PUNCT
dpc-4176	404	3	b	b	NOUN
dpc-4176	404	4	-	-	PUNCT
dpc-4176	404	5	induced	induced	ADJ
dpc-4176	404	6	apoptosis	apoptosis	NOUN
dpc-4176	404	7	of	of	ADP
dpc-4176	404	8	keratinocytes	keratinocyte	NOUN
dpc-4176	404	9	:	:	PUNCT
dpc-4176	404	10	evidence	evidence	NOUN
dpc-4176	404	11	for	for	ADP
dpc-4176	404	12	partial	partial	ADJ
dpc-4176	404	13	involvement	involvement	NOUN
dpc-4176	404	14	of	of	ADP
dpc-4176	404	15	tumor	tumor	NOUN
dpc-4176	404	16	necrosis	necrosis	NOUN
dpc-4176	404	17	factor	factor	NOUN
dpc-4176	404	18	-	-	PUNCT
dpc-4176	404	19	α	α	NOUN
dpc-4176	404	20	in	in	ADP
dpc-4176	404	21	the	the	DET
dpc-4176	404	22	formation	formation	NOUN
dpc-4176	404	23	of	of	ADP
dpc-4176	404	24	sunburn	sunburn	NOUN
dpc-4176	404	25	cells	cell	NOUN
dpc-4176	404	26	.	.	PUNCT
dpc-4176	405	1	j	j	PROPN
dpc-4176	405	2	investig	investig	NOUN
dpc-4176	405	3	dermatol	dermatol	NOUN
dpc-4176	405	4	.	.	PUNCT
dpc-4176	406	1	1995;104:922–7	1995;104:922–7	NUM
dpc-4176	406	2	.	.	PUNCT
dpc-4176	407	1	doi:10.1111/1523	doi:10.1111/1523	NOUN
dpc-4176	407	2	-	-	PUNCT
dpc-4176	407	3	1747	1747	NUM
dpc-4176	407	4	.	.	PUNCT
dpc-4176	408	1	ep12606202	ep12606202	PROPN
dpc-4176	408	2	.	.	PUNCT
dpc-4176	409	1	pmid	pmid	NOUN
dpc-4176	409	2	:	:	PUNCT
dpc-4176	409	3	7769259	7769259	NUM
dpc-4176	409	4	.	.	PUNCT
dpc-4176	410	1	23	23	NUM
dpc-4176	410	2	.	.	X
dpc-4176	411	1	mcgonagle	mcgonagle	PROPN
dpc-4176	411	2	d	d	PROPN
dpc-4176	411	3	,	,	PUNCT
dpc-4176	411	4	tan	tan	PROPN
dpc-4176	411	5	al	al	PROPN
dpc-4176	411	6	,	,	PUNCT
dpc-4176	411	7	benjamin	benjamin	PROPN
dpc-4176	411	8	m.	m.	PROPN
dpc-4176	411	9	the	the	DET
dpc-4176	411	10	nail	nail	NOUN
dpc-4176	411	11	as	as	ADP
dpc-4176	411	12	a	a	DET
dpc-4176	411	13	musculoskeletal	musculoskeletal	ADJ
dpc-4176	411	14	appendage	appendage	NOUN
dpc-4176	411	15	–	–	PUNCT
dpc-4176	411	16	implications	implication	NOUN
dpc-4176	411	17	for	for	ADP
dpc-4176	411	18	an	an	DET
dpc-4176	411	19	improved	improved	ADJ
dpc-4176	411	20	understanding	understanding	NOUN
dpc-4176	411	21	of	of	ADP
dpc-4176	411	22	the	the	DET
dpc-4176	411	23	link	link	NOUN
dpc-4176	411	24	between	between	ADP
dpc-4176	411	25	psoriasis	psoriasis	NOUN
dpc-4176	411	26	and	and	CCONJ
dpc-4176	411	27	arthritis	arthritis	NOUN
dpc-4176	411	28	.	.	PUNCT
dpc-4176	412	1	dermatology	dermatology	NOUN
dpc-4176	412	2	.	.	PUNCT
dpc-4176	413	1	2009;218:97–102	2009;218:97–102	X
dpc-4176	413	2	.	.	PUNCT
dpc-4176	413	3	doi	doi	NOUN
dpc-4176	413	4	:	:	PUNCT
dpc-4176	413	5	10.1159/000182250	10.1159/000182250	NUM
dpc-4176	413	6	.	.	PUNCT
dpc-4176	414	1	pmid	pmid	NOUN
dpc-4176	414	2	:	:	PUNCT
dpc-4176	414	3	19060455	19060455	NUM
dpc-4176	414	4	.	.	PUNCT
dpc-4176	415	1	24	24	NUM
dpc-4176	415	2	.	.	PUNCT
dpc-4176	415	3	kassir	kassir	PROPN
dpc-4176	415	4	m	m	PROPN
dpc-4176	415	5	,	,	PUNCT
dpc-4176	415	6	kircik	kircik	PROPN
dpc-4176	415	7	l	l	PROPN
dpc-4176	415	8	,	,	PUNCT
dpc-4176	415	9	weinberg	weinberg	PROPN
dpc-4176	415	10	j	j	PROPN
dpc-4176	415	11	,	,	PUNCT
dpc-4176	415	12	et	et	PROPN
dpc-4176	415	13	al	al	PROPN
dpc-4176	415	14	.	.	PUNCT
dpc-4176	415	15	treatment	treatment	NOUN
dpc-4176	415	16	of	of	ADP
dpc-4176	415	17	nail	nail	NOUN
dpc-4176	415	18	psoriasis	psoriasis	NOUN
dpc-4176	415	19	.	.	PUNCT
dpc-4176	416	1	j	j	NOUN
dpc-4176	416	2	drugs	drug	NOUN
dpc-4176	416	3	dermatol	dermatol	NOUN
dpc-4176	416	4	.	.	PUNCT
dpc-4176	417	1	2022;21:146–50	2022;21:146–50	NUM
dpc-4176	417	2	.	.	PUNCT
dpc-4176	418	1	pmid	pmid	NOUN
dpc-4176	418	2	:	:	PUNCT
dpc-4176	418	3	35133106	35133106	NUM
dpc-4176	418	4	.	.	PUNCT
dpc-4176	419	1	25	25	NUM
dpc-4176	419	2	.	.	PUNCT
dpc-4176	420	1	egeberg	egeberg	PROPN
dpc-4176	420	2	a	a	PROPN
dpc-4176	420	3	,	,	PUNCT
dpc-4176	420	4	see	see	VERB
dpc-4176	420	5	k	k	PROPN
dpc-4176	420	6	,	,	PUNCT
dpc-4176	420	7	garrelts	garrelt	VERB
dpc-4176	420	8	a	a	PRON
dpc-4176	420	9	,	,	PUNCT
dpc-4176	420	10	burge	burge	PROPN
dpc-4176	420	11	r.	r.	PROPN
dpc-4176	420	12	epidemiology	epidemiology	NOUN
dpc-4176	420	13	of	of	ADP
dpc-4176	420	14	psoriasis	psoriasis	NOUN
dpc-4176	420	15	in	in	ADP
dpc-4176	420	16	hard	hard	ADJ
dpc-4176	420	17	-	-	PUNCT
dpc-4176	420	18	to	to	ADP
dpc-4176	420	19	-	-	PUNCT
dpc-4176	420	20	treat	treat	VERB
dpc-4176	420	21	body	body	NOUN
dpc-4176	420	22	locations	location	NOUN
dpc-4176	420	23	:	:	PUNCT
dpc-4176	420	24	data	datum	NOUN
dpc-4176	420	25	from	from	ADP
dpc-4176	420	26	the	the	DET
dpc-4176	420	27	danish	danish	ADJ
dpc-4176	420	28	skin	skin	NOUN
dpc-4176	420	29	cohort	cohort	NOUN
dpc-4176	420	30	.	.	PUNCT
dpc-4176	421	1	bmc	bmc	ADJ
dpc-4176	421	2	dermatol	dermatol	NOUN
dpc-4176	421	3	.	.	PUNCT
dpc-4176	422	1	2020;20:3	2020;20:3	NOUN
dpc-4176	422	2	.	.	PUNCT
dpc-4176	423	1	doi	doi	NOUN
dpc-4176	423	2	:	:	PUNCT
dpc-4176	423	3	10.1186	10.1186	NUM
dpc-4176	423	4	/	/	SYM
dpc-4176	423	5	s12895	s12895	NOUN
dpc-4176	423	6	-	-	PUNCT
dpc-4176	423	7	020	020	NUM
dpc-4176	423	8	-00099	-00099	ADJ
dpc-4176	423	9	-	-	PUNCT
dpc-4176	423	10	7	7	NUM
dpc-4176	423	11	.	.	PUNCT
dpc-4176	424	1	pmid	pmid	NOUN
dpc-4176	424	2	:	:	PUNCT
dpc-4176	424	3	32434510	32434510	NUM
dpc-4176	424	4	;	;	PUNCT
dpc-4176	424	5	pmcid	pmcid	ADJ
dpc-4176	424	6	:	:	PUNCT
dpc-4176	424	7	pmc7238562	pmc7238562	ADJ
dpc-4176	424	8	.	.	PUNCT
dpc-4176	425	1	conclusions	conclusion	NOUN
dpc-4176	425	2	guselkumab	guselkumab	NOUN
dpc-4176	425	3	is	be	AUX
dpc-4176	425	4	a	a	DET
dpc-4176	425	5	newer	new	ADJ
dpc-4176	425	6	agent	agent	NOUN
dpc-4176	425	7	for	for	ADP
dpc-4176	425	8	the	the	DET
dpc-4176	425	9	management	management	NOUN
dpc-4176	425	10	of	of	ADP
dpc-4176	425	11	psoriasis	psoriasis	NOUN
dpc-4176	425	12	and	and	CCONJ
dpc-4176	425	13	psa	psa	VERB
dpc-4176	425	14	.	.	PUNCT
dpc-4176	426	1	it	it	PRON
dpc-4176	426	2	is	be	AUX
dpc-4176	426	3	also	also	ADV
dpc-4176	426	4	useful	useful	ADJ
dpc-4176	426	5	in	in	ADP
dpc-4176	426	6	the	the	DET
dpc-4176	426	7	treatment	treatment	NOUN
dpc-4176	426	8	of	of	ADP
dpc-4176	426	9	hs	hs	PROPN
dpc-4176	426	10	,	,	PUNCT
dpc-4176	426	11	pg	pg	INTJ
dpc-4176	426	12	,	,	PUNCT
dpc-4176	426	13	prp	prp	NOUN
dpc-4176	426	14	and	and	CCONJ
dpc-4176	426	15	lp	lp	NOUN
dpc-4176	426	16	.	.	PUNCT
dpc-4176	427	1	recently	recently	ADV
dpc-4176	427	2	,	,	PUNCT
dpc-4176	427	3	its	its	PRON
dpc-4176	427	4	utility	utility	NOUN
dpc-4176	427	5	in	in	ADP
dpc-4176	427	6	sta	sta	NOUN
dpc-4176	427	7	and	and	CCONJ
dpc-4176	427	8	its	its	PRON
dpc-4176	427	9	propensity	propensity	NOUN
dpc-4176	427	10	to	to	PART
dpc-4176	427	11	reduce	reduce	VERB
dpc-4176	427	12	tumor	tumor	NOUN
dpc-4176	427	13	size	size	NOUN
dpc-4176	427	14	can	can	AUX
dpc-4176	427	15	have	have	VERB
dpc-4176	427	16	a	a	DET
dpc-4176	427	17	promising	promising	ADJ
dpc-4176	427	18	role	role	NOUN
dpc-4176	427	19	in	in	ADP
dpc-4176	427	20	the	the	DET
dpc-4176	427	21	field	field	NOUN
dpc-4176	427	22	of	of	ADP
dpc-4176	427	23	oncology	oncology	NOUN
dpc-4176	427	24	.	.	PUNCT
dpc-4176	428	1	references	reference	NOUN
dpc-4176	428	2	1	1	NUM
dpc-4176	428	3	.	.	PUNCT
dpc-4176	429	1	markham	markham	PROPN
dpc-4176	429	2	a.	a.	PROPN
dpc-4176	429	3	guselkumab	guselkumab	PROPN
dpc-4176	429	4	:	:	PUNCT
dpc-4176	429	5	first	first	ADJ
dpc-4176	429	6	global	global	ADJ
dpc-4176	429	7	approval	approval	NOUN
dpc-4176	429	8	.	.	PUNCT
dpc-4176	430	1	drugs	drug	NOUN
dpc-4176	430	2	.	.	PUNCT
dpc-4176	431	1	2017;77(13):1487	2017;77(13):1487	NOUN
dpc-4176	431	2	-	-	SYM
dpc-4176	431	3	1492	1492	NUM
dpc-4176	431	4	.	.	PUNCT
dpc-4176	432	1	doi	doi	NOUN
dpc-4176	432	2	:	:	PUNCT
dpc-4176	432	3	10.1007	10.1007	NUM
dpc-4176	432	4	/	/	SYM
dpc-4176	432	5	s40265	s40265	NOUN
dpc-4176	432	6	-	-	PUNCT
dpc-4176	432	7	017	017	NUM
dpc-4176	432	8	-	-	PUNCT
dpc-4176	432	9	0800	0800	NUM
dpc-4176	432	10	-	-	SYM
dpc-4176	432	11	7	7	NUM
dpc-4176	432	12	.	.	PUNCT
dpc-4176	432	13	pmid	pmid	NOUN
dpc-4176	432	14	:	:	PUNCT
dpc-4176	432	15	28819723	28819723	NUM
dpc-4176	432	16	.	.	PUNCT
dpc-4176	433	1	2	2	X
dpc-4176	433	2	.	.	X
dpc-4176	433	3	wilson	wilson	PROPN
dpc-4176	433	4	nj	nj	PROPN
dpc-4176	433	5	,	,	PUNCT
dpc-4176	433	6	boniface	boniface	PROPN
dpc-4176	433	7	k	k	PROPN
dpc-4176	433	8	,	,	PUNCT
dpc-4176	433	9	chan	chan	PROPN
dpc-4176	433	10	jr	jr	PROPN
dpc-4176	433	11	,	,	PUNCT
dpc-4176	433	12	et	et	PROPN
dpc-4176	433	13	al	al	PROPN
dpc-4176	433	14	.	.	PUNCT
dpc-4176	433	15	development	development	PROPN
dpc-4176	433	16	,	,	PUNCT
dpc-4176	433	17	cytokine	cytokine	VERB
dpc-4176	433	18	profile	profile	NOUN
dpc-4176	433	19	and	and	CCONJ
dpc-4176	433	20	function	function	NOUN
dpc-4176	433	21	of	of	ADP
dpc-4176	433	22	human	human	ADJ
dpc-4176	433	23	interleukin	interleukin	NOUN
dpc-4176	433	24	17	17	NUM
dpc-4176	433	25	-	-	PUNCT
dpc-4176	433	26	producing	produce	VERB
dpc-4176	433	27	helper	helper	NOUN
dpc-4176	433	28	t	t	NOUN
dpc-4176	433	29	cells	cell	NOUN
dpc-4176	433	30	.	.	PUNCT
dpc-4176	434	1	nat	nat	PROPN
dpc-4176	434	2	immunol	immunol	NOUN
dpc-4176	434	3	.	.	PUNCT
dpc-4176	435	1	2007;8(9):950	2007;8(9):950	NUM
dpc-4176	435	2	-	-	SYM
dpc-4176	435	3	957	957	NUM
dpc-4176	435	4	.	.	PUNCT
dpc-4176	436	1	doi	doi	NOUN
dpc-4176	436	2	:	:	PUNCT
dpc-4176	436	3	10.1038	10.1038	NUM
dpc-4176	436	4	/	/	SYM
dpc-4176	436	5	ni1497	ni1497	PROPN
dpc-4176	436	6	.	.	PUNCT
dpc-4176	437	1	pmid	pmid	NOUN
dpc-4176	437	2	:	:	PUNCT
dpc-4176	437	3	17676044	17676044	NUM
dpc-4176	437	4	.	.	PUNCT
dpc-4176	438	1	3	3	X
dpc-4176	438	2	.	.	X
dpc-4176	438	3	mcgeachy	mcgeachy	PROPN
dpc-4176	438	4	mj	mj	PROPN
dpc-4176	438	5	,	,	PUNCT
dpc-4176	438	6	bak	bak	PROPN
dpc-4176	438	7	-	-	PROPN
dpc-4176	438	8	jensen	jensen	PROPN
dpc-4176	438	9	ks	ks	PROPN
dpc-4176	438	10	,	,	PUNCT
dpc-4176	438	11	chen	chen	PROPN
dpc-4176	438	12	y	y	PROPN
dpc-4176	438	13	,	,	PUNCT
dpc-4176	438	14	et	et	PROPN
dpc-4176	438	15	al	al	PROPN
dpc-4176	438	16	.	.	PUNCT
dpc-4176	438	17	tgf	tgf	PROPN
dpc-4176	438	18	-	-	PUNCT
dpc-4176	438	19	β	β	PROPN
dpc-4176	438	20	and	and	CCONJ
dpc-4176	438	21	il-6	il-6	NOUN
dpc-4176	438	22	drive	drive	VERB
dpc-4176	438	23	the	the	DET
dpc-4176	438	24	production	production	NOUN
dpc-4176	438	25	of	of	ADP
dpc-4176	438	26	il-17	il-17	NUM
dpc-4176	438	27	and	and	CCONJ
dpc-4176	438	28	il-10	il-10	ADP
dpc-4176	438	29	by	by	ADP
dpc-4176	438	30	t	t	NOUN
dpc-4176	438	31	cells	cell	NOUN
dpc-4176	438	32	and	and	CCONJ
dpc-4176	438	33	restrain	restrain	VERB
dpc-4176	438	34	th-17	th-17	NUM
dpc-4176	438	35	cell	cell	NOUN
dpc-4176	438	36	–	–	PUNCT
dpc-4176	438	37	mediated	mediate	VERB
dpc-4176	438	38	pathology	pathology	NOUN
dpc-4176	438	39	.	.	PUNCT
dpc-4176	439	1	nat	nat	PROPN
dpc-4176	439	2	immunol	immunol	NOUN
dpc-4176	439	3	.	.	PUNCT
dpc-4176	440	1	2007;8(12):1390–7	2007;8(12):1390–7	NUM
dpc-4176	440	2	.	.	PUNCT
dpc-4176	441	1	doi	doi	NOUN
dpc-4176	441	2	:	:	PUNCT
dpc-4176	441	3	10.1038	10.1038	NUM
dpc-4176	441	4	/	/	SYM
dpc-4176	441	5	ni1539	ni1539	PROPN
dpc-4176	441	6	.	.	PUNCT
dpc-4176	442	1	pmid	pmid	NOUN
dpc-4176	442	2	:	:	PUNCT
dpc-4176	442	3	17994024	17994024	NUM
dpc-4176	442	4	.	.	PUNCT
dpc-4176	443	1	4	4	X
dpc-4176	443	2	.	.	X
dpc-4176	443	3	jeon	jeon	PROPN
dpc-4176	443	4	c	c	PROPN
dpc-4176	443	5	,	,	PUNCT
dpc-4176	443	6	sekhon	sekhon	PROPN
dpc-4176	443	7	s	s	PROPN
dpc-4176	443	8	,	,	PUNCT
dpc-4176	443	9	yan	yan	PROPN
dpc-4176	444	1	d	d	NOUN
dpc-4176	444	2	,	,	PUNCT
dpc-4176	444	3	et	et	PROPN
dpc-4176	444	4	al	al	PROPN
dpc-4176	444	5	.	.	PUNCT
dpc-4176	444	6	monoclonal	monoclonal	NOUN
dpc-4176	444	7	antibodies	antibodie	VERB
dpc-4176	444	8	inhibiting	inhibit	VERB
dpc-4176	444	9	il-12	il-12	NOUN
dpc-4176	444	10	,	,	PUNCT
dpc-4176	444	11	-23	-23	PRON
dpc-4176	444	12	,	,	PUNCT
dpc-4176	444	13	and	and	CCONJ
dpc-4176	444	14	-17	-17	PUNCT
dpc-4176	444	15	for	for	ADP
dpc-4176	444	16	the	the	DET
dpc-4176	444	17	treatment	treatment	NOUN
dpc-4176	444	18	of	of	ADP
dpc-4176	444	19	psoriasis	psoriasis	NOUN
dpc-4176	444	20	.	.	PUNCT
dpc-4176	445	1	hum	hum	PROPN
dpc-4176	445	2	vacc	vacc	PROPN
dpc-4176	445	3	immunother	immunother	PROPN
dpc-4176	445	4	.	.	PUNCT
dpc-4176	446	1	2017;13:2247–59	2017;13:2247–59	NUM
dpc-4176	446	2	.	.	PUNCT
dpc-4176	446	3	doi	doi	NOUN
dpc-4176	446	4	:	:	PUNCT
dpc-4176	446	5	10.1080/21645515.2017.1356498	10.1080/21645515.2017.1356498	NUM
dpc-4176	446	6	.	.	PUNCT
dpc-4176	447	1	pmid	pmid	NOUN
dpc-4176	447	2	:	:	PUNCT
dpc-4176	447	3	28825875	28825875	NUM
dpc-4176	447	4	;	;	PUNCT
dpc-4176	447	5	pmcid	pmcid	NOUN
dpc-4176	447	6	:	:	PUNCT
dpc-4176	447	7	pmc5647990	pmc5647990	NOUN
dpc-4176	447	8	.	.	PUNCT
dpc-4176	448	1	5	5	X
dpc-4176	448	2	.	.	X
dpc-4176	448	3	ciric	ciric	PROPN
dpc-4176	448	4	b	b	PROPN
dpc-4176	448	5	,	,	PUNCT
dpc-4176	448	6	el	el	PROPN
dpc-4176	448	7	-	-	PUNCT
dpc-4176	448	8	behi	behi	PROPN
dpc-4176	448	9	m	m	PROPN
dpc-4176	448	10	,	,	PUNCT
dpc-4176	448	11	cabrera	cabrera	PROPN
dpc-4176	448	12	r	r	NOUN
dpc-4176	448	13	,	,	PUNCT
dpc-4176	448	14	et	et	PROPN
dpc-4176	448	15	al	al	PROPN
dpc-4176	448	16	.	.	PROPN
dpc-4176	448	17	il-23	il-23	NOUN
dpc-4176	448	18	drives	drive	VERB
dpc-4176	448	19	pathogenic	pathogenic	ADJ
dpc-4176	448	20	il-17	il-17	ADV
dpc-4176	448	21	-	-	PUNCT
dpc-4176	448	22	producing	produce	VERB
dpc-4176	448	23	cd8	cd8	PROPN
dpc-4176	448	24	+	+	PROPN
dpc-4176	448	25	t	t	NOUN
dpc-4176	448	26	cells	cell	NOUN
dpc-4176	448	27	.	.	PUNCT
dpc-4176	449	1	j	j	PROPN
dpc-4176	449	2	immunol	immunol	NOUN
dpc-4176	449	3	.	.	PUNCT
dpc-4176	450	1	2009;182:5296–305	2009;182:5296–305	X
dpc-4176	450	2	.	.	PUNCT
dpc-4176	451	1	doi	doi	NOUN
dpc-4176	451	2	:	:	PUNCT
dpc-4176	451	3	10.4049	10.4049	NUM
dpc-4176	451	4	/	/	SYM
dpc-4176	451	5	jimmunol.0900036	jimmunol.0900036	PROPN
dpc-4176	451	6	.	.	PUNCT
dpc-4176	452	1	pmid	pmid	NOUN
dpc-4176	452	2	:	:	PUNCT
dpc-4176	452	3	19380776	19380776	NUM
dpc-4176	452	4	.	.	PUNCT
dpc-4176	453	1	6	6	NUM
dpc-4176	453	2	.	.	X
dpc-4176	453	3	lin	lin	PROPN
dpc-4176	453	4	am	be	AUX
dpc-4176	453	5	,	,	PUNCT
dpc-4176	453	6	rubin	rubin	PROPN
dpc-4176	453	7	cj	cj	PROPN
dpc-4176	453	8	,	,	PUNCT
dpc-4176	453	9	khandpur	khandpur	PROPN
dpc-4176	453	10	r	r	NOUN
dpc-4176	453	11	,	,	PUNCT
dpc-4176	453	12	et	et	PROPN
dpc-4176	453	13	al	al	PROPN
dpc-4176	453	14	.	.	PROPN
dpc-4176	454	1	mast	mast	NOUN
dpc-4176	454	2	cells	cell	NOUN
dpc-4176	454	3	and	and	CCONJ
dpc-4176	454	4	neutrophils	neutrophil	NOUN
dpc-4176	454	5	release	release	VERB
dpc-4176	454	6	il-17	il-17	X
dpc-4176	454	7	through	through	ADP
dpc-4176	454	8	extracellular	extracellular	ADJ
dpc-4176	454	9	trap	trap	NOUN
dpc-4176	454	10	formation	formation	NOUN
dpc-4176	454	11	in	in	ADP
dpc-4176	454	12	psoriasis	psoriasis	NOUN
dpc-4176	454	13	.	.	PUNCT
dpc-4176	455	1	the	the	DET
dpc-4176	455	2	j	j	PROPN
dpc-4176	455	3	immunol	immunol	NOUN
dpc-4176	455	4	.	.	PUNCT
dpc-4176	456	1	2011;187:490–500	2011;187:490–500	NUM
dpc-4176	456	2	.	.	PUNCT
dpc-4176	457	1	doi	doi	NOUN
dpc-4176	457	2	:	:	PUNCT
dpc-4176	457	3	10.4049	10.4049	NUM
dpc-4176	457	4	/jimmunol.1100123	/jimmunol.1100123	PRON
dpc-4176	457	5	.	.	PUNCT
dpc-4176	458	1	pmid	pmid	NOUN
dpc-4176	458	2	:	:	PUNCT
dpc-4176	458	3	21606249	21606249	NUM
dpc-4176	458	4	;	;	PUNCT
dpc-4176	458	5	pmcid	pmcid	ADJ
dpc-4176	458	6	:	:	PUNCT
dpc-4176	458	7	pmc3119764	pmc3119764	NOUN
dpc-4176	458	8	.	.	PUNCT
dpc-4176	459	1	7	7	X
dpc-4176	459	2	.	.	X
dpc-4176	459	3	gooderham	gooderham	PROPN
dpc-4176	459	4	mj	mj	PROPN
dpc-4176	459	5	,	,	PUNCT
dpc-4176	459	6	papp	papp	PROPN
dpc-4176	459	7	ka	ka	PROPN
dpc-4176	459	8	,	,	PUNCT
dpc-4176	459	9	lynde	lynde	PROPN
dpc-4176	459	10	cw	cw	PROPN
dpc-4176	459	11	.	.	PUNCT
dpc-4176	459	12	shifting	shift	VERB
dpc-4176	459	13	the	the	DET
dpc-4176	459	14	focus	focus	NOUN
dpc-4176	459	15	–	–	PUNCT
dpc-4176	459	16	the	the	DET
dpc-4176	459	17	primary	primary	ADJ
dpc-4176	459	18	role	role	NOUN
dpc-4176	459	19	of	of	ADP
dpc-4176	459	20	il	il	PROPN
dpc-4176	459	21	‐23	‐23	X
dpc-4176	459	22	in	in	ADP
dpc-4176	459	23	psoriasis	psoriasis	NOUN
dpc-4176	459	24	and	and	CCONJ
dpc-4176	459	25	other	other	ADJ
dpc-4176	459	26	inflammatory	inflammatory	ADJ
dpc-4176	459	27	disorders	disorder	NOUN
dpc-4176	459	28	.	.	PUNCT
dpc-4176	460	1	j	j	PROPN
dpc-4176	460	2	eur	eur	PROPN
dpc-4176	460	3	acad	acad	PROPN
dpc-4176	460	4	dermatol	dermatol	NOUN
dpc-4176	460	5	venereol	venereol	NOUN
dpc-4176	460	6	.	.	PUNCT
dpc-4176	461	1	2018;32:1111–9	2018;32:1111–9	NOUN
dpc-4176	461	2	.	.	PUNCT
dpc-4176	462	1	doi	doi	NOUN
dpc-4176	462	2	:	:	PUNCT
dpc-4176	462	3	10.1111	10.1111	NUM
dpc-4176	462	4	/	/	SYM
dpc-4176	462	5	jdv.14868	jdv.14868	PROPN
dpc-4176	462	6	.	.	PUNCT
dpc-4176	463	1	pmid	pmid	NOUN
dpc-4176	463	2	:	:	PUNCT
dpc-4176	463	3	29438576	29438576	NUM
dpc-4176	463	4	;	;	PUNCT
dpc-4176	463	5	pmcid	pmcid	NOUN
dpc-4176	463	6	:	:	PUNCT
dpc-4176	463	7	pmc6033004	pmc6033004	NOUN
dpc-4176	463	8	.	.	PUNCT
dpc-4176	464	1	8	8	X
dpc-4176	464	2	.	.	PUNCT
dpc-4176	465	1	hawkes	hawkes	PROPN
dpc-4176	465	2	je	je	PROPN
dpc-4176	465	3	,	,	PUNCT
dpc-4176	465	4	yan	yan	PROPN
dpc-4176	465	5	by	by	ADP
dpc-4176	465	6	,	,	PUNCT
dpc-4176	465	7	chan	chan	PROPN
dpc-4176	465	8	tc	tc	PROPN
dpc-4176	465	9	,	,	PUNCT
dpc-4176	465	10	et	et	PROPN
dpc-4176	465	11	al	al	PROPN
dpc-4176	465	12	.	.	PROPN
dpc-4176	465	13	discovery	discovery	PROPN
dpc-4176	465	14	of	of	ADP
dpc-4176	465	15	the	the	DET
dpc-4176	465	16	il-23	il-23	NOUN
dpc-4176	465	17	/	/	SYM
dpc-4176	465	18	il-17	il-17	NOUN
dpc-4176	465	19	signaling	signal	VERB
dpc-4176	465	20	pathway	pathway	NOUN
dpc-4176	465	21	and	and	CCONJ
dpc-4176	465	22	the	the	DET
dpc-4176	465	23	treatment	treatment	NOUN
dpc-4176	465	24	of	of	ADP
dpc-4176	465	25	psoriasis	psoriasis	NOUN
dpc-4176	465	26	.	.	PUNCT
dpc-4176	466	1	j	j	PROPN
dpc-4176	466	2	immunol	immunol	NOUN
dpc-4176	466	3	.	.	PUNCT
dpc-4176	467	1	2018;201:1605–13	2018;201:1605–13	NUM
dpc-4176	467	2	.	.	PUNCT
dpc-4176	467	3	doi	doi	NOUN
dpc-4176	467	4	:	:	PUNCT
dpc-4176	467	5	10.4049	10.4049	NUM
dpc-4176	467	6	/	/	SYM
dpc-4176	467	7	jimmunol.1800013	jimmunol.1800013	PROPN
dpc-4176	467	8	.	.	PUNCT
dpc-4176	467	9	pmid	pmid	PROPN
dpc-4176	467	10	:	:	PUNCT
dpc-4176	467	11	30181299	30181299	NUM
dpc-4176	467	12	;	;	PUNCT
dpc-4176	467	13	pmcid	pmcid	NOUN
dpc-4176	467	14	:	:	PUNCT
dpc-4176	467	15	pmc6129988	pmc6129988	ADJ
dpc-4176	467	16	.	.	PUNCT
dpc-4176	468	1	9	9	X
dpc-4176	468	2	.	.	X
dpc-4176	468	3	chan	chan	PROPN
dpc-4176	468	4	tc	tc	PROPN
dpc-4176	468	5	,	,	PUNCT
dpc-4176	468	6	hawkes	hawkes	PROPN
dpc-4176	468	7	je	je	PROPN
dpc-4176	468	8	,	,	PUNCT
dpc-4176	468	9	krueger	krueger	PROPN
dpc-4176	468	10	jg	jg	PROPN
dpc-4176	468	11	.	.	PUNCT
dpc-4176	469	1	interleukin	interleukin	NOUN
dpc-4176	469	2	23	23	NUM
dpc-4176	469	3	in	in	ADP
dpc-4176	469	4	the	the	DET
dpc-4176	469	5	skin	skin	NOUN
dpc-4176	469	6	:	:	PUNCT
dpc-4176	469	7	role	role	NOUN
dpc-4176	469	8	in	in	ADP
dpc-4176	469	9	psoriasis	psoriasis	NOUN
dpc-4176	469	10	pathogenesis	pathogenesis	NOUN
dpc-4176	469	11	and	and	CCONJ
dpc-4176	469	12	selective	selective	ADJ
dpc-4176	469	13	interleukin	interleukin	NOUN
dpc-4176	469	14	23	23	NUM
dpc-4176	469	15	blockade	blockade	NOUN
dpc-4176	469	16	as	as	ADP
dpc-4176	469	17	treatment	treatment	NOUN
dpc-4176	469	18	.	.	PUNCT
dpc-4176	470	1	ther	ther	PROPN
dpc-4176	470	2	adv	adv	PROPN
dpc-4176	470	3	chron	chron	PROPN
dpc-4176	471	1	dis	dis	PROPN
dpc-4176	471	2	.	.	PUNCT
dpc-4176	471	3	2018;9:111–9	2018;9:111–9	NUM
dpc-4176	471	4	.	.	PUNCT
dpc-4176	471	5	doi:10.1177/2040622318759282	doi:10.1177/2040622318759282	PROPN
dpc-4176	471	6	.	.	PUNCT
dpc-4176	472	1	pmid	pmid	NOUN
dpc-4176	472	2	:	:	PUNCT
dpc-4176	472	3	29796240	29796240	NUM
dpc-4176	472	4	;	;	PUNCT
dpc-4176	472	5	pmcid	pmcid	ADJ
dpc-4176	472	6	:	:	PUNCT
dpc-4176	472	7	pmc5956648	pmc5956648	NOUN
dpc-4176	472	8	.	.	PUNCT
dpc-4176	473	1	10	10	NUM
dpc-4176	473	2	.	.	PUNCT
dpc-4176	474	1	yang	yang	PROPN
dpc-4176	474	2	k	k	PROPN
dpc-4176	474	3	,	,	PUNCT
dpc-4176	474	4	oak	oak	PROPN
dpc-4176	474	5	asw	asw	PROPN
dpc-4176	474	6	,	,	PUNCT
dpc-4176	474	7	elewski	elewski	PROPN
dpc-4176	474	8	be	be	VERB
dpc-4176	474	9	.	.	PUNCT
dpc-4176	475	1	use	use	NOUN
dpc-4176	475	2	of	of	ADP
dpc-4176	475	3	il-23	il-23	NOUN
dpc-4176	475	4	inhibitors	inhibitor	NOUN
dpc-4176	475	5	for	for	ADP
dpc-4176	475	6	the	the	DET
dpc-4176	475	7	treatment	treatment	NOUN
dpc-4176	475	8	of	of	ADP
dpc-4176	475	9	plaque	plaque	NOUN
dpc-4176	475	10	psoriasis	psoriasis	NOUN
dpc-4176	475	11	and	and	CCONJ
dpc-4176	475	12	psoriatic	psoriatic	ADJ
dpc-4176	475	13	arthritis	arthritis	NOUN
dpc-4176	475	14	:	:	PUNCT
dpc-4176	475	15	a	a	DET
dpc-4176	475	16	comprehensive	comprehensive	ADJ
dpc-4176	475	17	review	review	NOUN
dpc-4176	475	18	.	.	PUNCT
dpc-4176	476	1	am	be	AUX
dpc-4176	476	2	j	j	PROPN
dpc-4176	476	3	clin	clin	PROPN
dpc-4176	476	4	dermatol	dermatol	NOUN
dpc-4176	476	5	.	.	PUNCT
dpc-4176	477	1	2021;22:173–92	2021;22:173–92	X
dpc-4176	477	2	.	.	PUNCT
dpc-4176	477	3	doi	doi	NOUN
dpc-4176	477	4	:	:	PUNCT
dpc-4176	477	5	10.1007	10.1007	NUM
dpc-4176	477	6	/	/	SYM
dpc-4176	477	7	s40257	s40257	NOUN
dpc-4176	477	8	-	-	PUNCT
dpc-4176	477	9	020	020	NUM
dpc-4176	477	10	-	-	PUNCT
dpc-4176	477	11	00578	00578	NUM
dpc-4176	477	12	-	-	SYM
dpc-4176	477	13	0	0	NUM
dpc-4176	477	14	.	.	PUNCT
dpc-4176	478	1	pmid	pmid	NOUN
dpc-4176	478	2	:	:	PUNCT
dpc-4176	478	3	33301128	33301128	NUM
dpc-4176	478	4	;	;	PUNCT
dpc-4176	478	5	pmcid	pmcid	NOUN
dpc-4176	478	6	:	:	PUNCT
dpc-4176	478	7	pmc7727454	pmc7727454	NOUN
dpc-4176	478	8	.	.	PUNCT
dpc-4176	479	1	11	11	NUM
dpc-4176	479	2	.	.	PUNCT
dpc-4176	479	3	sofen	sofen	PROPN
dpc-4176	479	4	h	h	PROPN
dpc-4176	479	5	,	,	PUNCT
dpc-4176	479	6	smith	smith	PROPN
dpc-4176	479	7	s	s	PROPN
dpc-4176	479	8	,	,	PUNCT
dpc-4176	479	9	matheson	matheson	PROPN
dpc-4176	479	10	rt	rt	PROPN
dpc-4176	479	11	,	,	PUNCT
dpc-4176	479	12	et	et	PROPN
dpc-4176	479	13	al	al	PROPN
dpc-4176	479	14	.	.	PROPN
dpc-4176	479	15	guselkumab	guselkumab	PROPN
dpc-4176	479	16	(	(	PUNCT
dpc-4176	479	17	an	an	DET
dpc-4176	479	18	il-23	il-23	NOUN
dpc-4176	479	19	–	–	PUNCT
dpc-4176	479	20	specific	specific	ADJ
dpc-4176	479	21	mab	mab	NOUN
dpc-4176	479	22	)	)	PUNCT
dpc-4176	479	23	demonstrates	demonstrate	VERB
dpc-4176	479	24	clinical	clinical	ADJ
dpc-4176	479	25	and	and	CCONJ
dpc-4176	479	26	molecular	molecular	ADJ
dpc-4176	479	27	response	response	NOUN
dpc-4176	479	28	in	in	ADP
dpc-4176	479	29	patients	patient	NOUN
dpc-4176	479	30	with	with	ADP
dpc-4176	479	31	moderate	moderate	ADJ
dpc-4176	479	32	-	-	PUNCT
dpc-4176	479	33	to	to	ADP
dpc-4176	479	34	-	-	PUNCT
dpc-4176	479	35	severe	severe	ADJ
dpc-4176	479	36	psoriasis	psoriasis	NOUN
dpc-4176	479	37	.	.	PUNCT
dpc-4176	480	1	j	j	PROPN
dpc-4176	480	2	allerg	allerg	PROPN
dpc-4176	480	3	clin	clin	PROPN
dpc-4176	480	4	immunol	immunol	PROPN
dpc-4176	480	5	.	.	PUNCT
dpc-4176	481	1	2014;133:1032–40	2014;133:1032–40	NUM
dpc-4176	481	2	.	.	PUNCT
dpc-4176	482	1	doi:10.1016	doi:10.1016	PROPN
dpc-4176	482	2	/	/	SYM
dpc-4176	482	3	j.jaci.2014.01.025	j.jaci.2014.01.025	PROPN
dpc-4176	482	4	.	.	PUNCT
dpc-4176	483	1	pmid	pmid	NOUN
dpc-4176	483	2	:	:	PUNCT
dpc-4176	483	3	24679469	24679469	NUM
dpc-4176	483	4	.	.	PUNCT
dpc-4176	484	1	12	12	NUM
dpc-4176	484	2	.	.	PUNCT
dpc-4176	484	3	martini	martini	PROPN
dpc-4176	484	4	e	e	NOUN
dpc-4176	484	5	,	,	PUNCT
dpc-4176	484	6	wikén	wikén	VERB
dpc-4176	484	7	m	m	PRON
dpc-4176	484	8	,	,	PUNCT
dpc-4176	484	9	cheuk	cheuk	VERB
dpc-4176	484	10	s	s	PART
dpc-4176	484	11	,	,	PUNCT
dpc-4176	484	12	et	et	PROPN
dpc-4176	484	13	al	al	PROPN
dpc-4176	484	14	.	.	PUNCT
dpc-4176	485	1	dynamic	dynamic	ADJ
dpc-4176	485	2	changes	change	NOUN
dpc-4176	485	3	in	in	ADP
dpc-4176	485	4	resident	resident	NOUN
dpc-4176	485	5	and	and	CCONJ
dpc-4176	485	6	infiltrating	infiltrating	ADJ
dpc-4176	485	7	epidermal	epidermal	ADJ
dpc-4176	485	8	dendritic	dendritic	ADJ
dpc-4176	485	9	cells	cell	NOUN
dpc-4176	485	10	in	in	ADP
dpc-4176	485	11	active	active	ADJ
dpc-4176	485	12	and	and	CCONJ
dpc-4176	485	13	resolved	resolve	VERB
dpc-4176	485	14	psoriasis	psoriasis	NOUN
dpc-4176	485	15	.	.	PUNCT
dpc-4176	486	1	j	j	PROPN
dpc-4176	486	2	investig	investig	NOUN
dpc-4176	486	3	dermatol	dermatol	NOUN
dpc-4176	486	4	.	.	PUNCT
dpc-4176	487	1	2017;137:865–73	2017;137:865–73	X
dpc-4176	487	2	.	.	PUNCT
dpc-4176	487	3	doi:10.1016	doi:10.1016	PROPN
dpc-4176	487	4	/	/	SYM
dpc-4176	487	5	j.jid.2016.11.033	j.jid.2016.11.033	PROPN
dpc-4176	487	6	.	.	PUNCT
dpc-4176	488	1	pmid	pmid	NOUN
dpc-4176	488	2	:	:	PUNCT
dpc-4176	488	3	28011143	28011143	NUM
dpc-4176	488	4	.	.	PUNCT
dpc-4176	489	1	14	14	NUM
dpc-4176	489	2	review	review	NOUN
dpc-4176	489	3	|	|	ADV
dpc-4176	489	4	dermatol	dermatol	ADJ
dpc-4176	489	5	pract	pract	NOUN
dpc-4176	489	6	concept	concept	NOUN
dpc-4176	489	7	.	.	PUNCT
dpc-4176	490	1	2024;14(3):e2024181	2024;14(3):e2024181	NUM
dpc-4176	490	2	39	39	NUM
dpc-4176	490	3	.	.	PUNCT
dpc-4176	491	1	brunasso	brunasso	PROPN
dpc-4176	491	2	amg	amg	PROPN
dpc-4176	491	3	,	,	PUNCT
dpc-4176	491	4	massone	massone	PROPN
dpc-4176	491	5	c.	c.	PROPN
dpc-4176	491	6	psoriasis	psoriasis	NOUN
dpc-4176	491	7	and	and	CCONJ
dpc-4176	491	8	palmoplantar	palmoplantar	NOUN
dpc-4176	491	9	pustulosis	pustulosis	NOUN
dpc-4176	491	10	:	:	PUNCT
dpc-4176	491	11	an	an	DET
dpc-4176	491	12	endless	endless	ADJ
dpc-4176	491	13	debate	debate	NOUN
dpc-4176	491	14	?	?	PUNCT
dpc-4176	492	1	j	j	PROPN
dpc-4176	492	2	eur	eur	PROPN
dpc-4176	492	3	acad	acad	PROPN
dpc-4176	492	4	dermatol	dermatol	NOUN
dpc-4176	492	5	venereol	venereol	NOUN
dpc-4176	492	6	.	.	PUNCT
dpc-4176	493	1	2017	2017	NUM
dpc-4176	493	2	;	;	PUNCT
dpc-4176	493	3	31	31	NUM
dpc-4176	493	4	:	:	PUNCT
dpc-4176	493	5	e335	e335	PROPN
dpc-4176	493	6	-	-	PUNCT
dpc-4176	493	7	337	337	NUM
dpc-4176	493	8	.	.	PUNCT
dpc-4176	494	1	doi:10.1111	doi:10.1111	PROPN
dpc-4176	494	2	/	/	SYM
dpc-4176	494	3	jdv.14131	jdv.14131	PROPN
dpc-4176	494	4	.	.	PUNCT
dpc-4176	495	1	pmid	pmid	NOUN
dpc-4176	495	2	:	:	PUNCT
dpc-4176	495	3	28107592	28107592	NUM
dpc-4176	495	4	.	.	PUNCT
dpc-4176	496	1	40	40	NUM
dpc-4176	496	2	.	.	PUNCT
dpc-4176	497	1	terui	terui	PROPN
dpc-4176	497	2	t	t	PROPN
dpc-4176	497	3	,	,	PUNCT
dpc-4176	497	4	kobayashi	kobayashi	PROPN
dpc-4176	497	5	s	s	PROPN
dpc-4176	497	6	,	,	PUNCT
dpc-4176	497	7	okubo	okubo	PROPN
dpc-4176	497	8	y	y	PROPN
dpc-4176	497	9	,	,	PUNCT
dpc-4176	497	10	et	et	PROPN
dpc-4176	497	11	al	al	PROPN
dpc-4176	497	12	.	.	PROPN
dpc-4176	497	13	efficacy	efficacy	NOUN
dpc-4176	497	14	and	and	CCONJ
dpc-4176	497	15	safety	safety	NOUN
dpc-4176	497	16	of	of	ADP
dpc-4176	497	17	guselkumab	guselkumab	NOUN
dpc-4176	497	18	,	,	PUNCT
dpc-4176	497	19	an	an	DET
dpc-4176	497	20	anti	anti	ADJ
dpc-4176	497	21	–	–	NOUN
dpc-4176	497	22	interleukin	interleukin	ADJ
dpc-4176	497	23	23	23	NUM
dpc-4176	497	24	monoclonal	monoclonal	NOUN
dpc-4176	497	25	antibody	antibody	NOUN
dpc-4176	497	26	,	,	PUNCT
dpc-4176	497	27	for	for	ADP
dpc-4176	497	28	palmoplantar	palmoplantar	NOUN
dpc-4176	497	29	pustulosis	pustulosis	NOUN
dpc-4176	497	30	:	:	PUNCT
dpc-4176	497	31	a	a	DET
dpc-4176	497	32	randomized	randomized	ADJ
dpc-4176	497	33	clinical	clinical	ADJ
dpc-4176	497	34	trial	trial	NOUN
dpc-4176	497	35	.	.	PUNCT
dpc-4176	498	1	jama	jama	PROPN
dpc-4176	498	2	dermatol	dermatol	NOUN
dpc-4176	498	3	.	.	PUNCT
dpc-4176	499	1	2018;154:309	2018;154:309	NUM
dpc-4176	499	2	-	-	SYM
dpc-4176	499	3	316	316	NUM
dpc-4176	499	4	.	.	PUNCT
dpc-4176	500	1	doi:10.1001	doi:10.1001	PROPN
dpc-4176	500	2	/	/	SYM
dpc-4176	500	3	jamadermatol	jamadermatol	PROPN
dpc-4176	500	4	.2017.5937	.2017.5937	PROPN
dpc-4176	500	5	.	.	PUNCT
dpc-4176	501	1	pmid	pmid	NOUN
dpc-4176	501	2	:	:	PUNCT
dpc-4176	501	3	29417135	29417135	NUM
dpc-4176	501	4	;	;	PUNCT
dpc-4176	501	5	pmcid	pmcid	ADJ
dpc-4176	501	6	:	:	PUNCT
dpc-4176	501	7	pmc5885837	pmc5885837	NOUN
dpc-4176	501	8	.	.	PUNCT
dpc-4176	502	1	41	41	NUM
dpc-4176	502	2	.	.	PUNCT
dpc-4176	502	3	terui	terui	PROPN
dpc-4176	502	4	t	t	PROPN
dpc-4176	502	5	,	,	PUNCT
dpc-4176	502	6	kobayashi	kobayashi	PROPN
dpc-4176	502	7	s	s	PROPN
dpc-4176	502	8	,	,	PUNCT
dpc-4176	502	9	okubo	okubo	PROPN
dpc-4176	502	10	y	y	PROPN
dpc-4176	502	11	,	,	PUNCT
dpc-4176	502	12	et	et	PROPN
dpc-4176	502	13	al	al	PROPN
dpc-4176	502	14	.	.	PROPN
dpc-4176	502	15	efficacy	efficacy	NOUN
dpc-4176	502	16	and	and	CCONJ
dpc-4176	502	17	safety	safety	NOUN
dpc-4176	502	18	of	of	ADP
dpc-4176	502	19	guselkumab	guselkumab	NOUN
dpc-4176	502	20	in	in	ADP
dpc-4176	502	21	japanese	japanese	ADJ
dpc-4176	502	22	patients	patient	NOUN
dpc-4176	502	23	with	with	ADP
dpc-4176	502	24	palmoplantar	palmoplantar	NOUN
dpc-4176	502	25	pustulosis	pustulosis	NOUN
dpc-4176	502	26	:	:	PUNCT
dpc-4176	502	27	a	a	DET
dpc-4176	502	28	phase	phase	NOUN
dpc-4176	502	29	3	3	NUM
dpc-4176	502	30	randomized	randomize	VERB
dpc-4176	502	31	clinical	clinical	ADJ
dpc-4176	502	32	trial	trial	NOUN
dpc-4176	502	33	.	.	PUNCT
dpc-4176	503	1	jama	jama	PROPN
dpc-4176	503	2	dermatol	dermatol	NOUN
dpc-4176	503	3	.	.	PUNCT
dpc-4176	504	1	2019;155:1153	2019;155:1153	NUM
dpc-4176	504	2	-	-	SYM
dpc-4176	504	3	1161	1161	NUM
dpc-4176	504	4	.	.	PUNCT
dpc-4176	505	1	doi:10.1001	doi:10.1001	NOUN
dpc-4176	505	2	/	/	SYM
dpc-4176	505	3	jamadermatol.2019.1394	jamadermatol.2019.1394	NOUN
dpc-4176	505	4	.	.	PUNCT
dpc-4176	506	1	pmid	pmid	NOUN
dpc-4176	506	2	:	:	PUNCT
dpc-4176	506	3	31268476	31268476	NUM
dpc-4176	506	4	;	;	PUNCT
dpc-4176	506	5	pmcid	pmcid	NOUN
dpc-4176	506	6	:	:	PUNCT
dpc-4176	506	7	pmc6613288	pmc6613288	ADV
dpc-4176	506	8	.	.	PUNCT
dpc-4176	507	1	42	42	NUM
dpc-4176	507	2	.	.	PUNCT
dpc-4176	508	1	okubo	okubo	PROPN
dpc-4176	508	2	y	y	PROPN
dpc-4176	508	3	,	,	PUNCT
dpc-4176	508	4	morishima	morishima	PROPN
dpc-4176	508	5	h	h	PROPN
dpc-4176	508	6	,	,	PUNCT
dpc-4176	508	7	zheng	zheng	PROPN
dpc-4176	508	8	r	r	PROPN
dpc-4176	508	9	,	,	PUNCT
dpc-4176	508	10	et	et	PROPN
dpc-4176	508	11	al	al	PROPN
dpc-4176	508	12	.	.	PROPN
dpc-4176	508	13	sustained	sustain	VERB
dpc-4176	508	14	efficacy	efficacy	NOUN
dpc-4176	508	15	and	and	CCONJ
dpc-4176	508	16	safety	safety	NOUN
dpc-4176	508	17	of	of	ADP
dpc-4176	508	18	guselkumab	guselkumab	NOUN
dpc-4176	508	19	in	in	ADP
dpc-4176	508	20	patients	patient	NOUN
dpc-4176	508	21	with	with	ADP
dpc-4176	508	22	palmoplantar	palmoplantar	ADJ
dpc-4176	508	23	pustulosis	pustulosis	NOUN
dpc-4176	508	24	through	through	ADP
dpc-4176	508	25	1.5	1.5	NUM
dpc-4176	508	26	years	year	NOUN
dpc-4176	508	27	in	in	ADP
dpc-4176	508	28	a	a	DET
dpc-4176	508	29	randomized	randomized	ADJ
dpc-4176	508	30	phase	phase	NOUN
dpc-4176	508	31	3	3	NUM
dpc-4176	508	32	study	study	NOUN
dpc-4176	508	33	.	.	PUNCT
dpc-4176	509	1	j	j	PROPN
dpc-4176	509	2	dermatol	dermatol	NOUN
dpc-4176	509	3	.	.	PUNCT
dpc-4176	510	1	2021;48:1838–53	2021;48:1838–53	NUM
dpc-4176	510	2	.	.	PUNCT
dpc-4176	511	1	doi	doi	NOUN
dpc-4176	511	2	:	:	PUNCT
dpc-4176	511	3	10.1111/1346	10.1111/1346	NUM
dpc-4176	511	4	-	-	SYM
dpc-4176	511	5	8138.16132	8138.16132	NUM
dpc-4176	511	6	.	.	PUNCT
dpc-4176	512	1	pmid	pmid	NOUN
dpc-4176	512	2	:	:	PUNCT
dpc-4176	512	3	34453358	34453358	NUM
dpc-4176	512	4	;	;	PUNCT
dpc-4176	512	5	pmcid	pmcid	ADJ
dpc-4176	512	6	:	:	PUNCT
dpc-4176	512	7	pmc9290648	pmc9290648	NOUN
dpc-4176	512	8	.	.	PUNCT
dpc-4176	513	1	43	43	NUM
dpc-4176	513	2	.	.	PUNCT
dpc-4176	514	1	morita	morita	PROPN
dpc-4176	514	2	a	a	PROPN
dpc-4176	514	3	,	,	PUNCT
dpc-4176	514	4	chen	chen	PROPN
dpc-4176	514	5	y	y	PROPN
dpc-4176	514	6	,	,	PUNCT
dpc-4176	514	7	leung	leung	PROPN
dpc-4176	514	8	mwl	mwl	PROPN
dpc-4176	514	9	,	,	PUNCT
dpc-4176	514	10	et	et	PROPN
dpc-4176	514	11	al	al	PROPN
dpc-4176	514	12	.	.	PROPN
dpc-4176	514	13	effect	effect	NOUN
dpc-4176	514	14	of	of	ADP
dpc-4176	514	15	guselkumab	guselkumab	NOUN
dpc-4176	514	16	on	on	ADP
dpc-4176	514	17	serum	serum	NOUN
dpc-4176	514	18	biomarkers	biomarker	NOUN
dpc-4176	514	19	in	in	ADP
dpc-4176	514	20	japanese	japanese	ADJ
dpc-4176	514	21	palmoplantar	palmoplantar	NOUN
dpc-4176	514	22	pustulosis	pustulosis	NOUN
dpc-4176	514	23	patients	patient	NOUN
dpc-4176	514	24	in	in	ADP
dpc-4176	514	25	a	a	DET
dpc-4176	514	26	randomized	randomized	ADJ
dpc-4176	514	27	phase	phase	NOUN
dpc-4176	514	28	3	3	NUM
dpc-4176	514	29	study	study	NOUN
dpc-4176	514	30	.	.	PUNCT
dpc-4176	515	1	jeadv	jeadv	PROPN
dpc-4176	515	2	clin	clin	PROPN
dpc-4176	515	3	pract	pract	PROPN
dpc-4176	515	4	.	.	PUNCT
dpc-4176	516	1	2023;2:59–72	2023;2:59–72	X
dpc-4176	516	2	.	.	PUNCT
dpc-4176	516	3	doi	doi	NOUN
dpc-4176	516	4	:	:	PUNCT
dpc-4176	516	5	10.1002	10.1002	NUM
dpc-4176	516	6	/	/	SYM
dpc-4176	516	7	jvc2.73	jvc2.73	PROPN
dpc-4176	516	8	.	.	PUNCT
dpc-4176	517	1	44	44	NUM
dpc-4176	517	2	.	.	PUNCT
dpc-4176	518	1	girolomoni	girolomoni	PROPN
dpc-4176	518	2	g	g	NOUN
dpc-4176	518	3	,	,	PUNCT
dpc-4176	518	4	strohal	strohal	ADJ
dpc-4176	518	5	r	r	NOUN
dpc-4176	518	6	,	,	PUNCT
dpc-4176	518	7	puig	puig	X
dpc-4176	518	8	l	l	NOUN
dpc-4176	518	9	,	,	PUNCT
dpc-4176	518	10	et	et	PROPN
dpc-4176	518	11	al	al	PROPN
dpc-4176	518	12	.	.	PUNCT
dpc-4176	519	1	the	the	DET
dpc-4176	519	2	role	role	NOUN
dpc-4176	519	3	of	of	ADP
dpc-4176	519	4	il	il	PROPN
dpc-4176	519	5	-23	-23	PROPN
dpc-4176	519	6	and	and	CCONJ
dpc-4176	519	7	the	the	DET
dpc-4176	519	8	il	il	PROPN
dpc-4176	519	9	-23/	-23/	PROPN
dpc-4176	519	10	th	th	PROPN
dpc-4176	519	11	17	17	NUM
dpc-4176	519	12	immune	immune	ADJ
dpc-4176	519	13	axis	axis	NOUN
dpc-4176	519	14	in	in	ADP
dpc-4176	519	15	the	the	DET
dpc-4176	519	16	pathogenesis	pathogenesis	NOUN
dpc-4176	519	17	and	and	CCONJ
dpc-4176	519	18	treatment	treatment	NOUN
dpc-4176	519	19	of	of	ADP
dpc-4176	519	20	psoriasis	psoriasis	NOUN
dpc-4176	519	21	.	.	PUNCT
dpc-4176	520	1	j	j	PROPN
dpc-4176	520	2	eur	eur	PROPN
dpc-4176	520	3	acad	acad	PROPN
dpc-4176	520	4	dermatol	dermatol	NOUN
dpc-4176	520	5	venereol	venereol	NOUN
dpc-4176	520	6	.	.	PUNCT
dpc-4176	521	1	2017;31:1616–26	2017;31:1616–26	X
dpc-4176	521	2	.	.	PUNCT
dpc-4176	522	1	doi	doi	NOUN
dpc-4176	522	2	:	:	PUNCT
dpc-4176	522	3	10.1111	10.1111	NUM
dpc-4176	522	4	/	/	SYM
dpc-4176	522	5	jdv.14433	jdv.14433	X
dpc-4176	522	6	.	.	PUNCT
dpc-4176	523	1	pmid	pmid	NOUN
dpc-4176	523	2	:	:	PUNCT
dpc-4176	523	3	28653490	28653490	NUM
dpc-4176	523	4	;	;	PUNCT
dpc-4176	523	5	pmcid	pmcid	ADJ
dpc-4176	523	6	:	:	PUNCT
dpc-4176	523	7	pmc5697699	pmc5697699	ADJ
dpc-4176	523	8	.	.	PUNCT
dpc-4176	524	1	45	45	NUM
dpc-4176	524	2	.	.	PUNCT
dpc-4176	525	1	bridgewood	bridgewood	PROPN
dpc-4176	525	2	c	c	PROPN
dpc-4176	525	3	,	,	PUNCT
dpc-4176	525	4	watad	watad	NOUN
dpc-4176	525	5	a	a	PRON
dpc-4176	525	6	,	,	PUNCT
dpc-4176	525	7	russell	russell	PROPN
dpc-4176	525	8	t	t	PROPN
dpc-4176	525	9	,	,	PUNCT
dpc-4176	525	10	et	et	PROPN
dpc-4176	525	11	al	al	PROPN
dpc-4176	525	12	.	.	PUNCT
dpc-4176	525	13	identification	identification	NOUN
dpc-4176	525	14	of	of	ADP
dpc-4176	525	15	myeloid	myeloid	ADJ
dpc-4176	525	16	cells	cell	NOUN
dpc-4176	525	17	in	in	ADP
dpc-4176	525	18	the	the	DET
dpc-4176	525	19	human	human	ADJ
dpc-4176	525	20	enthesis	enthesis	NOUN
dpc-4176	525	21	as	as	ADP
dpc-4176	525	22	the	the	DET
dpc-4176	525	23	main	main	ADJ
dpc-4176	525	24	source	source	NOUN
dpc-4176	525	25	of	of	ADP
dpc-4176	525	26	local	local	ADJ
dpc-4176	525	27	il-23	il-23	NOUN
dpc-4176	525	28	production	production	NOUN
dpc-4176	525	29	.	.	PUNCT
dpc-4176	526	1	ann	ann	PROPN
dpc-4176	526	2	rheum	rheum	PROPN
dpc-4176	526	3	dis	dis	PROPN
dpc-4176	526	4	.	.	PUNCT
dpc-4176	527	1	2019;78:929–33	2019;78:929–33	X
dpc-4176	527	2	.	.	PUNCT
dpc-4176	528	1	doi	doi	NOUN
dpc-4176	528	2	:	:	PUNCT
dpc-4176	528	3	10.1136	10.1136	NUM
dpc-4176	528	4	/	/	SYM
dpc-4176	528	5	annrheumdis-2018	annrheumdis-2018	NOUN
dpc-4176	528	6	-	-	NUM
dpc-4176	528	7	214944	214944	NUM
dpc-4176	528	8	.	.	PUNCT
dpc-4176	529	1	pmid	pmid	NOUN
dpc-4176	529	2	:	:	PUNCT
dpc-4176	529	3	31018959	31018959	NUM
dpc-4176	529	4	;	;	PUNCT
dpc-4176	529	5	pmcid	pmcid	ADJ
dpc-4176	529	6	:	:	PUNCT
dpc-4176	529	7	pmc6585277	pmc6585277	NOUN
dpc-4176	529	8	.	.	PUNCT
dpc-4176	530	1	46	46	NUM
dpc-4176	530	2	.	.	PUNCT
dpc-4176	531	1	lee	lee	PROPN
dpc-4176	531	2	y.	y.	PROPN
dpc-4176	531	3	the	the	DET
dpc-4176	531	4	role	role	NOUN
dpc-4176	531	5	of	of	ADP
dpc-4176	531	6	interleukin-17	interleukin-17	PROPN
dpc-4176	531	7	in	in	ADP
dpc-4176	531	8	bone	bone	NOUN
dpc-4176	531	9	metabolism	metabolism	NOUN
dpc-4176	531	10	and	and	CCONJ
dpc-4176	531	11	inflammatory	inflammatory	ADJ
dpc-4176	531	12	skeletal	skeletal	ADJ
dpc-4176	531	13	diseases	disease	NOUN
dpc-4176	531	14	.	.	PUNCT
dpc-4176	532	1	bmb	bmb	PROPN
dpc-4176	532	2	rep	rep	PROPN
dpc-4176	532	3	.	.	PROPN
dpc-4176	532	4	2013;46:479–83	2013;46:479–83	NUM
dpc-4176	532	5	.	.	PUNCT
dpc-4176	532	6	doi	doi	NOUN
dpc-4176	532	7	:	:	PUNCT
dpc-4176	532	8	10.5483	10.5483	NUM
dpc-4176	532	9	/	/	SYM
dpc-4176	532	10	bmbrep.2013.46.10.141	bmbrep.2013.46.10.141	NOUN
dpc-4176	532	11	.	.	PUNCT
dpc-4176	533	1	pmid	pmid	NOUN
dpc-4176	533	2	:	:	PUNCT
dpc-4176	533	3	24148767	24148767	NUM
dpc-4176	533	4	;	;	PUNCT
dpc-4176	533	5	pmcid	pmcid	ADJ
dpc-4176	533	6	:	:	PUNCT
dpc-4176	533	7	pmc4133834	pmc4133834	NOUN
dpc-4176	533	8	.	.	PUNCT
dpc-4176	534	1	47	47	NUM
dpc-4176	534	2	.	.	PUNCT
dpc-4176	535	1	murphy	murphy	PROPN
dpc-4176	535	2	ca	ca	PROPN
dpc-4176	535	3	,	,	PUNCT
dpc-4176	535	4	langrish	langrish	VERB
dpc-4176	535	5	cl	cl	PROPN
dpc-4176	535	6	,	,	PUNCT
dpc-4176	535	7	chen	chen	PROPN
dpc-4176	535	8	y	y	PROPN
dpc-4176	535	9	,	,	PUNCT
dpc-4176	535	10	et	et	PROPN
dpc-4176	536	1	al	al	PROPN
dpc-4176	536	2	.	.	PROPN
dpc-4176	536	3	divergent	divergent	ADJ
dpc-4176	536	4	proand	proand	NOUN
dpc-4176	536	5	antiinflammatory	antiinflammatory	NOUN
dpc-4176	536	6	roles	role	NOUN
dpc-4176	536	7	for	for	ADP
dpc-4176	536	8	il-23	il-23	NOUN
dpc-4176	536	9	and	and	CCONJ
dpc-4176	536	10	il-12	il-12	NOUN
dpc-4176	536	11	in	in	ADP
dpc-4176	536	12	joint	joint	ADJ
dpc-4176	536	13	autoimmune	autoimmune	ADJ
dpc-4176	536	14	inflammation	inflammation	NOUN
dpc-4176	536	15	.	.	PUNCT
dpc-4176	537	1	j	j	PROPN
dpc-4176	537	2	exp	exp	NOUN
dpc-4176	537	3	med	med	PROPN
dpc-4176	537	4	.	.	PUNCT
dpc-4176	538	1	2003;198:1951–7	2003;198:1951–7	PROPN
dpc-4176	538	2	.	.	PUNCT
dpc-4176	539	1	doi:10.1084	doi:10.1084	PROPN
dpc-4176	539	2	/jem.20030896	/jem.20030896	NOUN
dpc-4176	539	3	.	.	PUNCT
dpc-4176	540	1	pmid	pmid	NOUN
dpc-4176	540	2	:	:	PUNCT
dpc-4176	540	3	14662908	14662908	NUM
dpc-4176	540	4	;	;	PUNCT
dpc-4176	540	5	pmcid	pmcid	NOUN
dpc-4176	540	6	:	:	PUNCT
dpc-4176	540	7	pmc2194162	pmc2194162	ADJ
dpc-4176	540	8	.	.	PUNCT
dpc-4176	541	1	48	48	NUM
dpc-4176	541	2	.	.	PUNCT
dpc-4176	542	1	schurich	schurich	PROPN
dpc-4176	542	2	a	a	PROPN
dpc-4176	542	3	,	,	PUNCT
dpc-4176	542	4	raine	raine	NOUN
dpc-4176	542	5	c	c	AUX
dpc-4176	542	6	,	,	PUNCT
dpc-4176	542	7	morris	morris	PROPN
dpc-4176	542	8	v	v	PROPN
dpc-4176	542	9	,	,	PUNCT
dpc-4176	542	10	et	et	PROPN
dpc-4176	542	11	al	al	PROPN
dpc-4176	542	12	.	.	PUNCT
dpc-4176	543	1	the	the	DET
dpc-4176	543	2	role	role	NOUN
dpc-4176	543	3	of	of	ADP
dpc-4176	543	4	il-12/23	il-12/23	NOUN
dpc-4176	543	5	in	in	ADP
dpc-4176	543	6	t	t	NOUN
dpc-4176	543	7	cell	cell	NOUN
dpc-4176	543	8	–	–	PUNCT
dpc-4176	543	9	related	relate	VERB
dpc-4176	543	10	chronic	chronic	ADJ
dpc-4176	543	11	inflammation	inflammation	NOUN
dpc-4176	543	12	:	:	PUNCT
dpc-4176	543	13	implications	implication	NOUN
dpc-4176	543	14	of	of	ADP
dpc-4176	543	15	immunodeficiency	immunodeficiency	NOUN
dpc-4176	543	16	and	and	CCONJ
dpc-4176	543	17	therapeutic	therapeutic	ADJ
dpc-4176	543	18	blockade	blockade	NOUN
dpc-4176	543	19	.	.	PUNCT
dpc-4176	544	1	rheumatology	rheumatology	NOUN
dpc-4176	544	2	.	.	PUNCT
dpc-4176	545	1	2018;57:246–54	2018;57:246–54	X
dpc-4176	545	2	.	.	X
dpc-4176	545	3	doi	doi	NOUN
dpc-4176	545	4	:	:	PUNCT
dpc-4176	545	5	10.1093	10.1093	NUM
dpc-4176	545	6	/	/	SYM
dpc-4176	545	7	rheumatology	rheumatology	NOUN
dpc-4176	545	8	/	/	SYM
dpc-4176	545	9	kex186	kex186	PROPN
dpc-4176	545	10	.	.	PUNCT
dpc-4176	546	1	pmid	pmid	NOUN
dpc-4176	546	2	:	:	PUNCT
dpc-4176	546	3	28541488	28541488	NUM
dpc-4176	546	4	.	.	PUNCT
dpc-4176	547	1	49	49	NUM
dpc-4176	547	2	.	.	PUNCT
dpc-4176	548	1	kopp	kopp	PROPN
dpc-4176	548	2	t	t	PROPN
dpc-4176	548	3	,	,	PUNCT
dpc-4176	548	4	lenz	lenz	PROPN
dpc-4176	548	5	p	p	PROPN
dpc-4176	548	6	,	,	PUNCT
dpc-4176	548	7	bello	bello	PROPN
dpc-4176	548	8	-	-	PUNCT
dpc-4176	548	9	fernandez	fernandez	PROPN
dpc-4176	548	10	c	c	PROPN
dpc-4176	548	11	,	,	PUNCT
dpc-4176	548	12	et	et	PROPN
dpc-4176	548	13	al	al	PROPN
dpc-4176	548	14	.	.	PROPN
dpc-4176	548	15	il-23	il-23	NOUN
dpc-4176	549	1	production	production	NOUN
dpc-4176	549	2	by	by	ADP
dpc-4176	549	3	cosecretion	cosecretion	NOUN
dpc-4176	549	4	of	of	ADP
dpc-4176	549	5	endogenous	endogenous	ADJ
dpc-4176	549	6	p19	p19	NOUN
dpc-4176	549	7	and	and	CCONJ
dpc-4176	549	8	transgenic	transgenic	NOUN
dpc-4176	549	9	p40	p40	NOUN
dpc-4176	549	10	in	in	ADP
dpc-4176	549	11	keratin	keratin	NOUN
dpc-4176	549	12	14	14	NUM
dpc-4176	549	13	/	/	SYM
dpc-4176	549	14	p40	p40	NOUN
dpc-4176	549	15	transgenic	transgenic	NOUN
dpc-4176	549	16	mice	mouse	NOUN
dpc-4176	549	17	:	:	PUNCT
dpc-4176	549	18	evidence	evidence	NOUN
dpc-4176	549	19	for	for	ADP
dpc-4176	549	20	enhanced	enhanced	ADJ
dpc-4176	549	21	cutaneous	cutaneous	ADJ
dpc-4176	549	22	immunity	immunity	NOUN
dpc-4176	549	23	.	.	PUNCT
dpc-4176	550	1	j	j	PROPN
dpc-4176	550	2	immunol	immunol	NOUN
dpc-4176	550	3	.	.	PUNCT
dpc-4176	551	1	2003;170:5438–44	2003;170:5438–44	X
dpc-4176	551	2	.	.	PUNCT
dpc-4176	552	1	doi	doi	NOUN
dpc-4176	552	2	:	:	PUNCT
dpc-4176	552	3	10.4049	10.4049	NUM
dpc-4176	552	4	/	/	SYM
dpc-4176	552	5	jimmunol	jimmunol	PROPN
dpc-4176	552	6	.170.11.5438	.170.11.5438	PROPN
dpc-4176	552	7	.	.	PUNCT
dpc-4176	553	1	pmid	pmid	NOUN
dpc-4176	553	2	:	:	PUNCT
dpc-4176	553	3	12759419	12759419	NUM
dpc-4176	553	4	.	.	PUNCT
dpc-4176	554	1	50	50	NUM
dpc-4176	554	2	.	.	PUNCT
dpc-4176	555	1	deodhar	deodhar	PROPN
dpc-4176	555	2	a	a	PRON
dpc-4176	555	3	,	,	PUNCT
dpc-4176	555	4	gottlieb	gottlieb	PROPN
dpc-4176	555	5	ab	ab	PROPN
dpc-4176	555	6	,	,	PUNCT
dpc-4176	555	7	boehncke	boehncke	PROPN
dpc-4176	555	8	wh	wh	PROPN
dpc-4176	555	9	,	,	PUNCT
dpc-4176	555	10	et	et	PROPN
dpc-4176	555	11	al	al	PROPN
dpc-4176	555	12	.	.	PROPN
dpc-4176	555	13	efficacy	efficacy	NOUN
dpc-4176	555	14	and	and	CCONJ
dpc-4176	555	15	safety	safety	NOUN
dpc-4176	555	16	of	of	ADP
dpc-4176	555	17	guselkumab	guselkumab	NOUN
dpc-4176	555	18	in	in	ADP
dpc-4176	555	19	patients	patient	NOUN
dpc-4176	555	20	with	with	ADP
dpc-4176	555	21	active	active	ADJ
dpc-4176	555	22	psoriatic	psoriatic	ADJ
dpc-4176	555	23	arthritis	arthritis	NOUN
dpc-4176	555	24	:	:	PUNCT
dpc-4176	555	25	a	a	DET
dpc-4176	555	26	randomised	randomised	ADJ
dpc-4176	555	27	,	,	PUNCT
dpc-4176	555	28	double	double	ADJ
dpc-4176	555	29	-	-	PUNCT
dpc-4176	555	30	blind	blind	ADJ
dpc-4176	555	31	,	,	PUNCT
dpc-4176	555	32	placebo	placebo	NOUN
dpc-4176	555	33	-	-	PUNCT
dpc-4176	555	34	controlled	control	VERB
dpc-4176	555	35	,	,	PUNCT
dpc-4176	555	36	phase	phase	NOUN
dpc-4176	555	37	2	2	NUM
dpc-4176	555	38	study	study	NOUN
dpc-4176	555	39	.	.	PUNCT
dpc-4176	556	1	lancet	lancet	PROPN
dpc-4176	556	2	.	.	PUNCT
dpc-4176	557	1	2018;391:2213–24	2018;391:2213–24	X
dpc-4176	557	2	.	.	PUNCT
dpc-4176	558	1	doi	doi	NOUN
dpc-4176	558	2	:	:	PUNCT
dpc-4176	558	3	10.1016	10.1016	NUM
dpc-4176	558	4	/	/	SYM
dpc-4176	558	5	s0140	s0140	PROPN
dpc-4176	558	6	-	-	PUNCT
dpc-4176	558	7	6736(18)30952	6736(18)30952	NUM
dpc-4176	558	8	-	-	PUNCT
dpc-4176	558	9	8	8	NUM
dpc-4176	558	10	.	.	PUNCT
dpc-4176	559	1	pmid	pmid	NOUN
dpc-4176	559	2	:	:	PUNCT
dpc-4176	559	3	29893222	29893222	NUM
dpc-4176	559	4	.	.	PUNCT
dpc-4176	560	1	51	51	NUM
dpc-4176	560	2	.	.	PUNCT
dpc-4176	561	1	mease	mease	PROPN
dpc-4176	561	2	pj	pj	PROPN
dpc-4176	561	3	,	,	PUNCT
dpc-4176	561	4	gladman	gladman	NOUN
dpc-4176	561	5	dd	dd	PROPN
dpc-4176	561	6	,	,	PUNCT
dpc-4176	561	7	deodhar	deodhar	ADJ
dpc-4176	561	8	a	a	X
dpc-4176	561	9	,	,	PUNCT
dpc-4176	561	10	et	et	PROPN
dpc-4176	561	11	al	al	PROPN
dpc-4176	561	12	.	.	PROPN
dpc-4176	561	13	impact	impact	NOUN
dpc-4176	561	14	of	of	ADP
dpc-4176	561	15	guselkumab	guselkumab	NOUN
dpc-4176	561	16	,	,	PUNCT
dpc-4176	561	17	an	an	DET
dpc-4176	561	18	interleukin-23	interleukin-23	NOUN
dpc-4176	561	19	p19	p19	NOUN
dpc-4176	561	20	subunit	subunit	NOUN
dpc-4176	561	21	inhibitor	inhibitor	NOUN
dpc-4176	561	22	,	,	PUNCT
dpc-4176	561	23	on	on	ADP
dpc-4176	561	24	enthesitis	enthesitis	NOUN
dpc-4176	561	25	and	and	CCONJ
dpc-4176	561	26	dactylitis	dactylitis	NOUN
dpc-4176	561	27	in	in	ADP
dpc-4176	561	28	patients	patient	NOUN
dpc-4176	561	29	with	with	ADP
dpc-4176	561	30	moderate	moderate	ADJ
dpc-4176	561	31	to	to	ADP
dpc-4176	561	32	severe	severe	ADJ
dpc-4176	561	33	psoriatic	psoriatic	ADJ
dpc-4176	561	34	arthritis	arthritis	NOUN
dpc-4176	561	35	:	:	PUNCT
dpc-4176	561	36	results	result	VERB
dpc-4176	561	37	from	from	ADP
dpc-4176	561	38	a	a	DET
dpc-4176	561	39	randomised	randomise	VERB
dpc-4176	561	40	,	,	PUNCT
dpc-4176	561	41	placebo	placebo	NOUN
dpc-4176	561	42	-	-	PUNCT
dpc-4176	561	43	controlled	control	VERB
dpc-4176	561	44	,	,	PUNCT
dpc-4176	561	45	phase	phase	NOUN
dpc-4176	561	46	ii	ii	PROPN
dpc-4176	561	47	study	study	NOUN
dpc-4176	561	48	.	.	PUNCT
dpc-4176	562	1	rmd	rmd	PROPN
dpc-4176	562	2	open	open	VERB
dpc-4176	562	3	.	.	PUNCT
dpc-4176	563	1	2020;6	2020;6	NUM
dpc-4176	563	2	:	:	PUNCT
dpc-4176	563	3	e001217	e001217	NOUN
dpc-4176	563	4	.	.	PUNCT
dpc-4176	563	5	doi	doi	NOUN
dpc-4176	563	6	:	:	PUNCT
dpc-4176	563	7	10.1136	10.1136	NUM
dpc-4176	563	8	/	/	SYM
dpc-4176	563	9	rmdopen-2020	rmdopen-2020	NOUN
dpc-4176	563	10	-	-	PUNCT
dpc-4176	563	11	001217	001217	NUM
dpc-4176	563	12	.	.	PUNCT
dpc-4176	564	1	pmid	pmid	NOUN
dpc-4176	564	2	:	:	PUNCT
dpc-4176	564	3	32665433	32665433	NUM
dpc-4176	564	4	;	;	PUNCT
dpc-4176	564	5	pmcid	pmcid	ADJ
dpc-4176	564	6	:	:	PUNCT
dpc-4176	564	7	pmc7425189	pmc7425189	NOUN
dpc-4176	564	8	.	.	PUNCT
dpc-4176	565	1	26	26	NUM
dpc-4176	565	2	.	.	PUNCT
dpc-4176	566	1	langley	langley	PROPN
dpc-4176	566	2	rg	rg	PROPN
dpc-4176	566	3	,	,	PUNCT
dpc-4176	566	4	daudén	daudén	PROPN
dpc-4176	566	5	e.	e.	PROPN
dpc-4176	566	6	treatment	treatment	PROPN
dpc-4176	566	7	and	and	CCONJ
dpc-4176	566	8	management	management	NOUN
dpc-4176	566	9	of	of	ADP
dpc-4176	566	10	psoriasis	psoriasis	NOUN
dpc-4176	566	11	with	with	ADP
dpc-4176	566	12	nail	nail	NOUN
dpc-4176	566	13	involvement	involvement	NOUN
dpc-4176	566	14	:	:	PUNCT
dpc-4176	566	15	a	a	DET
dpc-4176	566	16	focus	focus	NOUN
dpc-4176	566	17	on	on	ADP
dpc-4176	566	18	biologic	biologic	NOUN
dpc-4176	566	19	therapy	therapy	NOUN
dpc-4176	566	20	.	.	PUNCT
dpc-4176	567	1	dermatology	dermatology	NOUN
dpc-4176	567	2	.	.	PUNCT
dpc-4176	568	1	2010;221(suppl	2010;221(suppl	NUM
dpc-4176	568	2	.	.	PUNCT
dpc-4176	569	1	1):29–42	1):29–42	NUM
dpc-4176	569	2	.	.	PUNCT
dpc-4176	569	3	doi	doi	NOUN
dpc-4176	569	4	:	:	PUNCT
dpc-4176	569	5	10.1159/000316179	10.1159/000316179	NUM
dpc-4176	569	6	.	.	PUNCT
dpc-4176	570	1	pmid	pmid	NOUN
dpc-4176	570	2	:	:	PUNCT
dpc-4176	570	3	20733313	20733313	NUM
dpc-4176	570	4	.	.	PUNCT
dpc-4176	571	1	27	27	NUM
dpc-4176	571	2	.	.	PUNCT
dpc-4176	571	3	kaeley	kaeley	PROPN
dpc-4176	571	4	gs	gs	PROPN
dpc-4176	571	5	,	,	PUNCT
dpc-4176	571	6	eder	eder	NOUN
dpc-4176	571	7	l	l	NOUN
dpc-4176	571	8	,	,	PUNCT
dpc-4176	571	9	aydin	aydin	VERB
dpc-4176	571	10	sz	sz	PROPN
dpc-4176	571	11	,	,	PUNCT
dpc-4176	571	12	et	et	PROPN
dpc-4176	571	13	al	al	PROPN
dpc-4176	571	14	.	.	PUNCT
dpc-4176	571	15	nail	nail	NOUN
dpc-4176	571	16	psoriasis	psoriasis	NOUN
dpc-4176	571	17	:	:	PUNCT
dpc-4176	571	18	diagnosis	diagnosis	NOUN
dpc-4176	571	19	,	,	PUNCT
dpc-4176	571	20	assessment	assessment	NOUN
dpc-4176	571	21	,	,	PUNCT
dpc-4176	571	22	treatment	treatment	NOUN
dpc-4176	571	23	options	option	NOUN
dpc-4176	571	24	,	,	PUNCT
dpc-4176	571	25	and	and	CCONJ
dpc-4176	571	26	unmet	unmet	NOUN
dpc-4176	571	27	clinical	clinical	ADJ
dpc-4176	571	28	needs	need	NOUN
dpc-4176	571	29	.	.	PUNCT
dpc-4176	572	1	j	j	PROPN
dpc-4176	572	2	rheumatol	rheumatol	NOUN
dpc-4176	572	3	.	.	PUNCT
dpc-4176	573	1	2021;48(8):1208–20	2021;48(8):1208–20	PROPN
dpc-4176	573	2	.	.	PUNCT
dpc-4176	574	1	doi:10.3899	doi:10.3899	PROPN
dpc-4176	574	2	/	/	SYM
dpc-4176	574	3	jrheum.201471	jrheum.201471	PROPN
dpc-4176	574	4	.	.	PUNCT
dpc-4176	575	1	pmid	pmid	PROPN
dpc-4176	575	2	:	:	PUNCT
dpc-4176	575	3	33589557	33589557	NUM
dpc-4176	575	4	.	.	PUNCT
dpc-4176	576	1	28	28	NUM
dpc-4176	576	2	.	.	PUNCT
dpc-4176	577	1	temiz	temiz	PROPN
dpc-4176	577	2	sa	sa	PROPN
dpc-4176	577	3	,	,	PUNCT
dpc-4176	577	4	özer	özer	NOUN
dpc-4176	577	5	i̇	i̇	PROPN
dpc-4176	577	6	,	,	PUNCT
dpc-4176	577	7	ataseven	ataseven	NOUN
dpc-4176	577	8	a	a	X
dpc-4176	577	9	,	,	PUNCT
dpc-4176	577	10	et	et	PROPN
dpc-4176	577	11	al	al	PROPN
dpc-4176	577	12	.	.	PUNCT
dpc-4176	578	1	the	the	DET
dpc-4176	578	2	effect	effect	NOUN
dpc-4176	578	3	of	of	ADP
dpc-4176	578	4	smoking	smoke	VERB
dpc-4176	578	5	on	on	ADP
dpc-4176	578	6	the	the	DET
dpc-4176	578	7	psoriasis	psoriasis	NOUN
dpc-4176	578	8	:	:	PUNCT
dpc-4176	578	9	is	be	AUX
dpc-4176	578	10	it	it	PRON
dpc-4176	578	11	related	related	ADJ
dpc-4176	578	12	to	to	ADP
dpc-4176	578	13	nail	nail	NOUN
dpc-4176	578	14	involvement	involvement	NOUN
dpc-4176	578	15	?	?	PUNCT
dpc-4176	579	1	dermatol	dermatol	NOUN
dpc-4176	579	2	ther	ther	ADV
dpc-4176	579	3	.	.	PUNCT
dpc-4176	580	1	2020;33	2020;33	NUM
dpc-4176	580	2	:	:	PUNCT
dpc-4176	580	3	e13960	e13960	NUM
dpc-4176	580	4	.	.	PUNCT
dpc-4176	581	1	doi:10.1111	doi:10.1111	PROPN
dpc-4176	581	2	/	/	SYM
dpc-4176	581	3	dth.13960	dth.13960	PROPN
dpc-4176	581	4	.	.	PUNCT
dpc-4176	582	1	pmid	pmid	NOUN
dpc-4176	582	2	:	:	PUNCT
dpc-4176	582	3	32621631	32621631	NUM
dpc-4176	582	4	.	.	PUNCT
dpc-4176	583	1	29	29	NUM
dpc-4176	583	2	.	.	PUNCT
dpc-4176	583	3	schwarz	schwarz	PROPN
dpc-4176	583	4	cw	cw	PROPN
dpc-4176	583	5	,	,	PUNCT
dpc-4176	583	6	loft	loft	PROPN
dpc-4176	583	7	n	n	PROPN
dpc-4176	583	8	,	,	PUNCT
dpc-4176	583	9	rasmussen	rasmussen	PROPN
dpc-4176	583	10	mk	mk	PROPN
dpc-4176	583	11	,	,	PUNCT
dpc-4176	583	12	et	et	PROPN
dpc-4176	583	13	al	al	PROPN
dpc-4176	583	14	.	.	PUNCT
dpc-4176	583	15	predictors	predictor	NOUN
dpc-4176	583	16	of	of	ADP
dpc-4176	583	17	response	response	NOUN
dpc-4176	583	18	to	to	ADP
dpc-4176	583	19	biologics	biologic	NOUN
dpc-4176	583	20	in	in	ADP
dpc-4176	583	21	patients	patient	NOUN
dpc-4176	583	22	with	with	ADP
dpc-4176	583	23	moderate	moderate	ADJ
dpc-4176	583	24	-	-	PUNCT
dpc-4176	583	25	to	to	ADP
dpc-4176	583	26	-	-	PUNCT
dpc-4176	583	27	severe	severe	ADJ
dpc-4176	583	28	psoriasis	psoriasis	NOUN
dpc-4176	583	29	:	:	PUNCT
dpc-4176	583	30	a	a	DET
dpc-4176	583	31	danish	danish	ADJ
dpc-4176	583	32	nationwide	nationwide	ADJ
dpc-4176	583	33	cohort	cohort	NOUN
dpc-4176	583	34	study	study	NOUN
dpc-4176	583	35	.	.	PUNCT
dpc-4176	584	1	acta	acta	PROPN
dpc-4176	584	2	derm	derm	PROPN
dpc-4176	584	3	venereol	venereol	NOUN
dpc-4176	584	4	.	.	PUNCT
dpc-4176	585	1	2021;101	2021;101	NUM
dpc-4176	585	2	:	:	PUNCT
dpc-4176	585	3	adv00579	adv00579	NOUN
dpc-4176	585	4	.	.	PUNCT
dpc-4176	586	1	doi	doi	NOUN
dpc-4176	586	2	:	:	PUNCT
dpc-4176	586	3	10.2340	10.2340	NUM
dpc-4176	586	4	/	/	SYM
dpc-4176	586	5	actadv.v101.351	actadv.v101.351	NOUN
dpc-4176	586	6	.	.	PUNCT
dpc-4176	587	1	pmid	pmid	NOUN
dpc-4176	587	2	:	:	PUNCT
dpc-4176	587	3	34642768	34642768	NUM
dpc-4176	587	4	;	;	PUNCT
dpc-4176	587	5	pmcid	pmcid	NOUN
dpc-4176	587	6	:	:	PUNCT
dpc-4176	587	7	pmc9425566	pmc9425566	ADJ
dpc-4176	587	8	.	.	PUNCT
dpc-4176	588	1	30	30	NUM
dpc-4176	588	2	.	.	PUNCT
dpc-4176	589	1	pirro	pirro	PROPN
dpc-4176	589	2	f	f	PROPN
dpc-4176	589	3	,	,	PUNCT
dpc-4176	589	4	caldarola	caldarola	PROPN
dpc-4176	589	5	g	g	PROPN
dpc-4176	589	6	,	,	PUNCT
dpc-4176	589	7	chiricozzi	chiricozzi	NOUN
dpc-4176	589	8	a	a	NOUN
dpc-4176	589	9	,	,	PUNCT
dpc-4176	589	10	et	et	PROPN
dpc-4176	589	11	al	al	PROPN
dpc-4176	589	12	.	.	PROPN
dpc-4176	589	13	impact	impact	NOUN
dpc-4176	589	14	of	of	ADP
dpc-4176	589	15	body	body	NOUN
dpc-4176	589	16	mass	mass	NOUN
dpc-4176	589	17	index	index	NOUN
dpc-4176	589	18	on	on	ADP
dpc-4176	589	19	the	the	DET
dpc-4176	589	20	efficacy	efficacy	NOUN
dpc-4176	589	21	of	of	ADP
dpc-4176	589	22	biological	biological	ADJ
dpc-4176	589	23	therapies	therapy	NOUN
dpc-4176	589	24	in	in	ADP
dpc-4176	589	25	patients	patient	NOUN
dpc-4176	589	26	with	with	ADP
dpc-4176	589	27	psoriasis	psoriasis	NOUN
dpc-4176	589	28	:	:	PUNCT
dpc-4176	589	29	a	a	DET
dpc-4176	589	30	real	real	ADJ
dpc-4176	589	31	-	-	PUNCT
dpc-4176	589	32	world	world	NOUN
dpc-4176	589	33	study	study	NOUN
dpc-4176	589	34	.	.	PUNCT
dpc-4176	590	1	clin	clin	PROPN
dpc-4176	590	2	drug	drug	PROPN
dpc-4176	590	3	investig	investig	PROPN
dpc-4176	590	4	.	.	PUNCT
dpc-4176	591	1	2021;41:917–25	2021;41:917–25	X
dpc-4176	591	2	.	.	PUNCT
dpc-4176	591	3	doi	doi	NOUN
dpc-4176	591	4	:	:	PUNCT
dpc-4176	591	5	10.1007	10.1007	NUM
dpc-4176	591	6	/	/	SYM
dpc-4176	591	7	s40261	s40261	PROPN
dpc-4176	591	8	-	-	PUNCT
dpc-4176	591	9	021	021	NUM
dpc-4176	591	10	-	-	PUNCT
dpc-4176	591	11	01080	01080	NUM
dpc-4176	591	12	-	-	PUNCT
dpc-4176	591	13	z.	z.	PROPN
dpc-4176	591	14	pmid	pmid	PROPN
dpc-4176	591	15	:	:	PUNCT
dpc-4176	591	16	34537921	34537921	NUM
dpc-4176	591	17	;	;	PUNCT
dpc-4176	591	18	pmcid	pmcid	ADJ
dpc-4176	591	19	:	:	PUNCT
dpc-4176	591	20	pmc8481196	pmc8481196	NOUN
dpc-4176	591	21	.	.	PUNCT
dpc-4176	592	1	31	31	NUM
dpc-4176	592	2	.	.	PUNCT
dpc-4176	593	1	gerdes	gerdes	PROPN
dpc-4176	593	2	s	s	PROPN
dpc-4176	593	3	,	,	PUNCT
dpc-4176	593	4	bräu	bräu	NOUN
dpc-4176	593	5	b	b	PROPN
dpc-4176	593	6	,	,	PUNCT
dpc-4176	593	7	hoffmann	hoffmann	PROPN
dpc-4176	593	8	m	m	PROPN
dpc-4176	593	9	,	,	PUNCT
dpc-4176	593	10	et	et	PROPN
dpc-4176	593	11	al	al	PROPN
dpc-4176	593	12	.	.	PUNCT
dpc-4176	594	1	real	real	ADJ
dpc-4176	594	2	-	-	PUNCT
dpc-4176	594	3	world	world	NOUN
dpc-4176	594	4	effectiveness	effectiveness	NOUN
dpc-4176	594	5	of	of	ADP
dpc-4176	594	6	guselkumab	guselkumab	NOUN
dpc-4176	594	7	in	in	ADP
dpc-4176	594	8	patients	patient	NOUN
dpc-4176	594	9	with	with	ADP
dpc-4176	594	10	psoriasis	psoriasis	NOUN
dpc-4176	594	11	:	:	PUNCT
dpc-4176	594	12	health	health	NOUN
dpc-4176	594	13	-	-	PUNCT
dpc-4176	594	14	related	relate	VERB
dpc-4176	594	15	quality	quality	NOUN
dpc-4176	594	16	of	of	ADP
dpc-4176	594	17	life	life	NOUN
dpc-4176	594	18	and	and	CCONJ
dpc-4176	594	19	efficacy	efficacy	NOUN
dpc-4176	594	20	data	datum	NOUN
dpc-4176	594	21	from	from	ADP
dpc-4176	594	22	the	the	DET
dpc-4176	594	23	noninterventional	noninterventional	ADJ
dpc-4176	594	24	,	,	PUNCT
dpc-4176	594	25	prospective	prospective	ADJ
dpc-4176	594	26	,	,	PUNCT
dpc-4176	594	27	german	german	ADJ
dpc-4176	594	28	multicenter	multicenter	NOUN
dpc-4176	594	29	persist	persist	ADJ
dpc-4176	594	30	trial	trial	NOUN
dpc-4176	594	31	.	.	PUNCT
dpc-4176	595	1	j	j	PROPN
dpc-4176	595	2	dermatol	dermatol	NOUN
dpc-4176	595	3	.	.	PUNCT
dpc-4176	596	1	2021;48:1854–62	2021;48:1854–62	NUM
dpc-4176	596	2	.	.	X
dpc-4176	596	3	doi	doi	NOUN
dpc-4176	596	4	:	:	PUNCT
dpc-4176	596	5	10.1111/1346	10.1111/1346	NUM
dpc-4176	596	6	-	-	PUNCT
dpc-4176	596	7	8138.16128	8138.16128	NOUN
dpc-4176	596	8	.	.	PUNCT
dpc-4176	597	1	pmid	pmid	NOUN
dpc-4176	597	2	:	:	PUNCT
dpc-4176	597	3	34510527	34510527	NUM
dpc-4176	597	4	.	.	PUNCT
dpc-4176	598	1	32	32	NUM
dpc-4176	598	2	.	.	PUNCT
dpc-4176	599	1	foley	foley	PROPN
dpc-4176	599	2	p	p	PROPN
dpc-4176	599	3	,	,	PUNCT
dpc-4176	599	4	gordon	gordon	PROPN
dpc-4176	599	5	k	k	PROPN
dpc-4176	599	6	,	,	PUNCT
dpc-4176	599	7	griffiths	griffiths	PROPN
dpc-4176	599	8	cem	cem	PROPN
dpc-4176	599	9	,	,	PUNCT
dpc-4176	599	10	et	et	PROPN
dpc-4176	599	11	al	al	PROPN
dpc-4176	599	12	.	.	PROPN
dpc-4176	599	13	efficacy	efficacy	PROPN
dpc-4176	599	14	of	of	ADP
dpc-4176	599	15	guselkumab	guselkumab	NOUN
dpc-4176	599	16	compared	compare	VERB
dpc-4176	599	17	with	with	ADP
dpc-4176	599	18	adalimumab	adalimumab	NOUN
dpc-4176	599	19	and	and	CCONJ
dpc-4176	599	20	placebo	placebo	NOUN
dpc-4176	599	21	for	for	ADP
dpc-4176	599	22	psoriasis	psoriasis	NOUN
dpc-4176	599	23	in	in	ADP
dpc-4176	599	24	specific	specific	ADJ
dpc-4176	599	25	body	body	NOUN
dpc-4176	599	26	regions	region	NOUN
dpc-4176	599	27	:	:	PUNCT
dpc-4176	599	28	a	a	DET
dpc-4176	599	29	secondary	secondary	ADJ
dpc-4176	599	30	analysis	analysis	NOUN
dpc-4176	599	31	of	of	ADP
dpc-4176	599	32	2	2	NUM
dpc-4176	599	33	randomized	randomize	VERB
dpc-4176	599	34	clinical	clinical	ADJ
dpc-4176	599	35	trials	trial	NOUN
dpc-4176	599	36	.	.	PUNCT
dpc-4176	600	1	jama	jama	PROPN
dpc-4176	600	2	dermatol	dermatol	NOUN
dpc-4176	600	3	.	.	PUNCT
dpc-4176	601	1	2018;154:676	2018;154:676	X
dpc-4176	601	2	.	.	PUNCT
dpc-4176	601	3	doi	doi	NOUN
dpc-4176	601	4	:	:	PUNCT
dpc-4176	601	5	10.1001	10.1001	NUM
dpc-4176	601	6	/	/	SYM
dpc-4176	601	7	jamadermatol.2018.0793	jamadermatol.2018.0793	ADJ
dpc-4176	601	8	.	.	PUNCT
dpc-4176	602	1	pmid	pmid	NOUN
dpc-4176	602	2	:	:	PUNCT
dpc-4176	602	3	29799960	29799960	NUM
dpc-4176	602	4	;	;	PUNCT
dpc-4176	602	5	pmcid	pmcid	ADJ
dpc-4176	602	6	:	:	PUNCT
dpc-4176	602	7	pmc6145649	pmc6145649	NOUN
dpc-4176	602	8	.	.	PUNCT
dpc-4176	603	1	33	33	NUM
dpc-4176	603	2	.	.	PUNCT
dpc-4176	604	1	blauvelt	blauvelt	VERB
dpc-4176	604	2	a	a	PRON
dpc-4176	604	3	,	,	PUNCT
dpc-4176	604	4	leonardi	leonardi	PROPN
dpc-4176	604	5	c	c	PROPN
dpc-4176	604	6	,	,	PUNCT
dpc-4176	604	7	elewski	elewski	NOUN
dpc-4176	604	8	b	b	PROPN
dpc-4176	604	9	,	,	PUNCT
dpc-4176	604	10	et	et	PROPN
dpc-4176	604	11	al	al	PROPN
dpc-4176	604	12	.	.	PUNCT
dpc-4176	605	1	a	a	DET
dpc-4176	605	2	head	head	NOUN
dpc-4176	605	3	-	-	PUNCT
dpc-4176	605	4	to	to	ADP
dpc-4176	605	5	-	-	PUNCT
dpc-4176	605	6	head	head	NOUN
dpc-4176	605	7	comparison	comparison	NOUN
dpc-4176	605	8	of	of	ADP
dpc-4176	605	9	ixekizumab	ixekizumab	NOUN
dpc-4176	605	10	vs.	vs.	ADP
dpc-4176	605	11	guselkumab	guselkumab	NOUN
dpc-4176	605	12	in	in	ADP
dpc-4176	605	13	patients	patient	NOUN
dpc-4176	605	14	with	with	ADP
dpc-4176	605	15	moderate	moderate	ADJ
dpc-4176	605	16	-	-	PUNCT
dpc-4176	605	17	to	to	ADP
dpc-4176	605	18	-	-	PUNCT
dpc-4176	605	19	severe	severe	ADJ
dpc-4176	605	20	plaque	plaque	NOUN
dpc-4176	605	21	psoriasis	psoriasis	NOUN
dpc-4176	605	22	:	:	PUNCT
dpc-4176	605	23	24	24	NUM
dpc-4176	605	24	-	-	PUNCT
dpc-4176	605	25	week	week	NOUN
dpc-4176	605	26	efficacy	efficacy	NOUN
dpc-4176	605	27	and	and	CCONJ
dpc-4176	605	28	safety	safety	NOUN
dpc-4176	605	29	results	result	NOUN
dpc-4176	605	30	from	from	ADP
dpc-4176	605	31	a	a	DET
dpc-4176	605	32	randomized	randomized	ADJ
dpc-4176	605	33	,	,	PUNCT
dpc-4176	605	34	double	double	ADJ
dpc-4176	605	35	-	-	PUNCT
dpc-4176	605	36	blinded	blind	VERB
dpc-4176	605	37	trial	trial	NOUN
dpc-4176	605	38	.	.	PUNCT
dpc-4176	606	1	br	br	PROPN
dpc-4176	606	2	j	j	PROPN
dpc-4176	606	3	dermatol	dermatol	NOUN
dpc-4176	606	4	.	.	PUNCT
dpc-4176	607	1	2021;184:1047–58	2021;184:1047–58	ADJ
dpc-4176	607	2	.	.	PUNCT
dpc-4176	608	1	doi	doi	NOUN
dpc-4176	608	2	:	:	PUNCT
dpc-4176	608	3	10.1111	10.1111	NUM
dpc-4176	608	4	/	/	SYM
dpc-4176	608	5	bjd.19509	bjd.19509	NOUN
dpc-4176	608	6	.	.	PUNCT
dpc-4176	609	1	pmid	pmid	NOUN
dpc-4176	609	2	:	:	PUNCT
dpc-4176	609	3	32880909	32880909	NUM
dpc-4176	609	4	;	;	PUNCT
dpc-4176	609	5	pmcid	pmcid	NOUN
dpc-4176	609	6	:	:	PUNCT
dpc-4176	609	7	pmc8246960	pmc8246960	PROPN
dpc-4176	609	8	.	.	PUNCT
dpc-4176	610	1	34	34	NUM
dpc-4176	610	2	.	.	PUNCT
dpc-4176	611	1	gerdes	gerdes	PROPN
dpc-4176	611	2	s	s	PROPN
dpc-4176	611	3	,	,	PUNCT
dpc-4176	611	4	hoffman	hoffman	PROPN
dpc-4176	611	5	m	m	PROPN
dpc-4176	611	6	,	,	PUNCT
dpc-4176	611	7	asadullah	asadullah	PROPN
dpc-4176	611	8	k	k	PROPN
dpc-4176	611	9	,	,	PUNCT
dpc-4176	611	10	et	et	PROPN
dpc-4176	611	11	al	al	PROPN
dpc-4176	611	12	.	.	PROPN
dpc-4176	611	13	effectiveness	effectiveness	PROPN
dpc-4176	611	14	,	,	PUNCT
dpc-4176	611	15	safety	safety	NOUN
dpc-4176	611	16	and	and	CCONJ
dpc-4176	611	17	quality	quality	NOUN
dpc-4176	611	18	of	of	ADP
dpc-4176	611	19	life	life	NOUN
dpc-4176	611	20	effects	effect	NOUN
dpc-4176	611	21	of	of	ADP
dpc-4176	611	22	guselkumab	guselkumab	NOUN
dpc-4176	611	23	and	and	CCONJ
dpc-4176	611	24	ustekinumab	ustekinumab	NOUN
dpc-4176	611	25	in	in	ADP
dpc-4176	611	26	patients	patient	NOUN
dpc-4176	611	27	with	with	ADP
dpc-4176	611	28	psoriasis	psoriasis	NOUN
dpc-4176	611	29	:	:	PUNCT
dpc-4176	611	30	week	week	NOUN
dpc-4176	611	31	104	104	NUM
dpc-4176	611	32	results	result	NOUN
dpc-4176	611	33	from	from	ADP
dpc-4176	611	34	the	the	DET
dpc-4176	611	35	non	non	X
dpc-4176	611	36	interventional	interventional	ADJ
dpc-4176	611	37	,	,	PUNCT
dpc-4176	611	38	prospective	prospective	ADJ
dpc-4176	611	39	german	german	ADJ
dpc-4176	611	40	multicentre	multicentre	NOUN
dpc-4176	611	41	persist	persist	ADJ
dpc-4176	611	42	study	study	NOUN
dpc-4176	611	43	.	.	PUNCT
dpc-4176	612	1	j	j	PROPN
dpc-4176	612	2	eur	eur	PROPN
dpc-4176	612	3	acad	acad	PROPN
dpc-4176	612	4	dermatol	dermatol	NOUN
dpc-4176	612	5	venereol	venereol	NOUN
dpc-4176	612	6	.	.	PUNCT
dpc-4176	613	1	2023	2023	NUM
dpc-4176	613	2	.	.	PUNCT
dpc-4176	614	1	doi	doi	NOUN
dpc-4176	614	2	:	:	PUNCT
dpc-4176	614	3	10.1111	10.1111	NUM
dpc-4176	614	4	/	/	SYM
dpc-4176	614	5	jdv.19296	jdv.19296	PROPN
dpc-4176	614	6	.	.	PUNCT
dpc-4176	615	1	epub	epub	NOUN
dpc-4176	615	2	ahead	ahead	ADV
dpc-4176	615	3	of	of	ADP
dpc-4176	615	4	print	print	NOUN
dpc-4176	615	5	.	.	PUNCT
dpc-4176	616	1	pmid	pmid	NOUN
dpc-4176	616	2	:	:	PUNCT
dpc-4176	616	3	37462295	37462295	NUM
dpc-4176	616	4	.	.	X
dpc-4176	617	1	35	35	NUM
dpc-4176	617	2	.	.	PUNCT
dpc-4176	618	1	jo	jo	PROPN
dpc-4176	618	2	sj	sj	PROPN
dpc-4176	618	3	,	,	PUNCT
dpc-4176	618	4	huang	huang	PROPN
dpc-4176	618	5	y	y	PROPN
dpc-4176	618	6	,	,	PUNCT
dpc-4176	618	7	tsai	tsai	PROPN
dpc-4176	618	8	t	t	PROPN
dpc-4176	618	9	,	,	PUNCT
dpc-4176	618	10	et	et	PROPN
dpc-4176	618	11	al	al	PROPN
dpc-4176	618	12	.	.	PROPN
dpc-4176	618	13	efficacy	efficacy	NOUN
dpc-4176	618	14	of	of	ADP
dpc-4176	618	15	guselkumab	guselkumab	NOUN
dpc-4176	618	16	in	in	ADP
dpc-4176	618	17	difficult	difficult	ADJ
dpc-4176	618	18	-	-	PUNCT
dpc-4176	618	19	to	to	AUX
dpc-4176	618	20	-	-	PUNCT
dpc-4176	618	21	treat	treat	VERB
dpc-4176	618	22	psoriasis	psoriasis	NOUN
dpc-4176	618	23	regions	region	NOUN
dpc-4176	618	24	:	:	PUNCT
dpc-4176	618	25	data	datum	NOUN
dpc-4176	618	26	from	from	ADP
dpc-4176	618	27	voyage	voyage	NOUN
dpc-4176	618	28	1	1	NUM
dpc-4176	618	29	and	and	CCONJ
dpc-4176	618	30	voyage	voyage	NOUN
dpc-4176	618	31	2	2	NUM
dpc-4176	618	32	asian	asian	ADJ
dpc-4176	618	33	subpopulations	subpopulation	NOUN
dpc-4176	618	34	.	.	PUNCT
dpc-4176	619	1	j	j	PROPN
dpc-4176	619	2	dermatol	dermatol	NOUN
dpc-4176	619	3	.	.	PUNCT
dpc-4176	620	1	2023;50:1180–9	2023;50:1180–9	X
dpc-4176	620	2	.	.	PUNCT
dpc-4176	621	1	doi	doi	NOUN
dpc-4176	621	2	:	:	PUNCT
dpc-4176	621	3	10.1111/1346	10.1111/1346	NUM
dpc-4176	621	4	-	-	PUNCT
dpc-4176	621	5	8138.16865	8138.16865	VERB
dpc-4176	621	6	.	.	PUNCT
dpc-4176	622	1	pmid	pmid	NOUN
dpc-4176	622	2	:	:	PUNCT
dpc-4176	622	3	37341137	37341137	NUM
dpc-4176	622	4	.	.	PUNCT
dpc-4176	623	1	36	36	NUM
dpc-4176	623	2	.	.	PUNCT
dpc-4176	624	1	farley	farley	PROPN
dpc-4176	624	2	e	e	PROPN
dpc-4176	624	3	,	,	PUNCT
dpc-4176	624	4	masrour	masrour	PROPN
dpc-4176	624	5	s	s	PROPN
dpc-4176	624	6	,	,	PUNCT
dpc-4176	624	7	mckey	mckey	PROPN
dpc-4176	624	8	j	j	PROPN
dpc-4176	624	9	,	,	PUNCT
dpc-4176	624	10	et	et	PROPN
dpc-4176	624	11	al	al	PROPN
dpc-4176	624	12	.	.	PROPN
dpc-4176	624	13	palmoplantar	palmoplantar	PROPN
dpc-4176	624	14	psoriasis	psoriasis	NOUN
dpc-4176	624	15	:	:	PUNCT
dpc-4176	624	16	a	a	DET
dpc-4176	624	17	phenotypical	phenotypical	ADJ
dpc-4176	624	18	and	and	CCONJ
dpc-4176	624	19	clinical	clinical	ADJ
dpc-4176	624	20	review	review	NOUN
dpc-4176	624	21	with	with	ADP
dpc-4176	624	22	introduction	introduction	NOUN
dpc-4176	624	23	of	of	ADP
dpc-4176	624	24	a	a	DET
dpc-4176	624	25	new	new	ADJ
dpc-4176	624	26	quality	quality	NOUN
dpc-4176	624	27	-	-	PUNCT
dpc-4176	624	28	of	of	ADP
dpc-4176	624	29	-	-	PUNCT
dpc-4176	624	30	life	life	NOUN
dpc-4176	624	31	assessment	assessment	NOUN
dpc-4176	624	32	tool	tool	NOUN
dpc-4176	624	33	.	.	PUNCT
dpc-4176	625	1	j	j	PROPN
dpc-4176	625	2	am	be	AUX
dpc-4176	625	3	acad	acad	ADJ
dpc-4176	625	4	dermatol	dermatol	NOUN
dpc-4176	625	5	.	.	PUNCT
dpc-4176	626	1	2009;60:1024–31	2009;60:1024–31	X
dpc-4176	626	2	.	.	PUNCT
dpc-4176	626	3	doi	doi	NOUN
dpc-4176	626	4	:	:	PUNCT
dpc-4176	626	5	10.1016	10.1016	NUM
dpc-4176	626	6	/	/	SYM
dpc-4176	626	7	j.jaad.2008.11.910	j.jaad.2008.11.910	NOUN
dpc-4176	626	8	.	.	PUNCT
dpc-4176	627	1	pmid	pmid	NOUN
dpc-4176	627	2	:	:	PUNCT
dpc-4176	627	3	19467374	19467374	NUM
dpc-4176	627	4	.	.	PUNCT
dpc-4176	628	1	37	37	NUM
dpc-4176	628	2	.	.	X
dpc-4176	628	3	raposo	raposo	VERB
dpc-4176	628	4	i	i	PRON
dpc-4176	628	5	,	,	PUNCT
dpc-4176	628	6	torres	torre	VERB
dpc-4176	628	7	t.	t.	PROPN
dpc-4176	628	8	palmoplantar	palmoplantar	NOUN
dpc-4176	628	9	psoriasis	psoriasis	NOUN
dpc-4176	628	10	and	and	CCONJ
dpc-4176	628	11	palmoplantar	palmoplantar	NOUN
dpc-4176	628	12	pustulosis	pustulosis	NOUN
dpc-4176	628	13	:	:	PUNCT
dpc-4176	628	14	current	current	ADJ
dpc-4176	628	15	treatment	treatment	NOUN
dpc-4176	628	16	and	and	CCONJ
dpc-4176	628	17	future	future	ADJ
dpc-4176	628	18	prospects	prospect	NOUN
dpc-4176	628	19	.	.	PUNCT
dpc-4176	629	1	am	be	AUX
dpc-4176	629	2	j	j	PROPN
dpc-4176	629	3	clin	clin	PROPN
dpc-4176	629	4	dermatol	dermatol	NOUN
dpc-4176	629	5	.	.	PUNCT
dpc-4176	630	1	2016;17:349–58	2016;17:349–58	X
dpc-4176	630	2	.	.	PUNCT
dpc-4176	631	1	doi:10.1007	doi:10.1007	VERB
dpc-4176	631	2	/	/	SYM
dpc-4176	631	3	s40257	s40257	NOUN
dpc-4176	631	4	-	-	PUNCT
dpc-4176	631	5	016	016	NUM
dpc-4176	631	6	-	-	PUNCT
dpc-4176	631	7	0191	0191	NUM
dpc-4176	631	8	-	-	PUNCT
dpc-4176	631	9	7	7	NUM
dpc-4176	631	10	.	.	PUNCT
dpc-4176	631	11	pmid	pmid	NOUN
dpc-4176	631	12	:	:	PUNCT
dpc-4176	631	13	27113059	27113059	NUM
dpc-4176	631	14	.	.	PUNCT
dpc-4176	632	1	38	38	NUM
dpc-4176	632	2	.	.	PUNCT
dpc-4176	633	1	passeron	passeron	PROPN
dpc-4176	633	2	t	t	PROPN
dpc-4176	633	3	,	,	PUNCT
dpc-4176	633	4	carrascosa	carrascosa	PROPN
dpc-4176	633	5	jm	jm	PROPN
dpc-4176	633	6	,	,	PUNCT
dpc-4176	633	7	warren	warren	PROPN
dpc-4176	633	8	rb	rb	PROPN
dpc-4176	633	9	,	,	PUNCT
dpc-4176	633	10	et	et	PROPN
dpc-4176	633	11	al	al	PROPN
dpc-4176	633	12	.	.	PUNCT
dpc-4176	634	1	a	a	DET
dpc-4176	634	2	phase	phase	NOUN
dpc-4176	634	3	iiib	iiib	NOUN
dpc-4176	634	4	,	,	PUNCT
dpc-4176	634	5	multicentre	multicentre	NOUN
dpc-4176	634	6	,	,	PUNCT
dpc-4176	634	7	interventional	interventional	ADJ
dpc-4176	634	8	,	,	PUNCT
dpc-4176	634	9	randomised	randomise	VERB
dpc-4176	634	10	,	,	PUNCT
dpc-4176	634	11	placebo	placebo	NOUN
dpc-4176	634	12	-	-	PUNCT
dpc-4176	634	13	controlled	control	VERB
dpc-4176	634	14	clinical	clinical	ADJ
dpc-4176	634	15	trial	trial	NOUN
dpc-4176	634	16	investigating	investigate	VERB
dpc-4176	634	17	the	the	DET
dpc-4176	634	18	efficacy	efficacy	NOUN
dpc-4176	634	19	and	and	CCONJ
dpc-4176	634	20	safety	safety	NOUN
dpc-4176	634	21	of	of	ADP
dpc-4176	634	22	guselkumab	guselkumab	NOUN
dpc-4176	634	23	for	for	ADP
dpc-4176	634	24	the	the	DET
dpc-4176	634	25	treatment	treatment	NOUN
dpc-4176	634	26	of	of	ADP
dpc-4176	634	27	nonpustular	nonpustular	ADJ
dpc-4176	634	28	palmoplantar	palmoplantar	NOUN
dpc-4176	634	29	psoriasis	psoriasis	NOUN
dpc-4176	634	30	(	(	PUNCT
dpc-4176	634	31	g	g	NOUN
dpc-4176	634	32	-	-	PUNCT
dpc-4176	634	33	plus	plus	NOUN
dpc-4176	634	34	)	)	PUNCT
dpc-4176	634	35	.	.	PUNCT
dpc-4176	635	1	dermatol	dermatol	NOUN
dpc-4176	635	2	ther	ther	ADV
dpc-4176	635	3	.	.	PUNCT
dpc-4176	636	1	2023	2023	NUM
dpc-4176	636	2	;	;	PUNCT
dpc-4176	636	3	2023:1–14	2023:1–14	X
dpc-4176	636	4	.	.	PUNCT
dpc-4176	636	5	doi	doi	NOUN
dpc-4176	636	6	:	:	PUNCT
dpc-4176	636	7	10.1155/2023/9967747	10.1155/2023/9967747	NUM
dpc-4176	636	8	.	.	PUNCT
dpc-4176	637	1	review	review	NOUN
dpc-4176	637	2	|	|	ADV
dpc-4176	637	3	dermatol	dermatol	ADJ
dpc-4176	637	4	pract	pract	NOUN
dpc-4176	637	5	concept	concept	NOUN
dpc-4176	637	6	.	.	PUNCT
dpc-4176	638	1	2024;14(3):e2024181	2024;14(3):e2024181	NUM
dpc-4176	638	2	15	15	NUM
dpc-4176	638	3	treated	treat	VERB
dpc-4176	638	4	with	with	ADP
dpc-4176	638	5	guselkumab	guselkumab	NOUN
dpc-4176	638	6	.	.	PUNCT
dpc-4176	639	1	dermatol	dermatol	NOUN
dpc-4176	639	2	ther	ther	ADV
dpc-4176	639	3	.	.	PUNCT
dpc-4176	640	1	2020;33	2020;33	NUM
dpc-4176	640	2	:	:	PUNCT
dpc-4176	641	1	e14180	e14180	ADJ
dpc-4176	641	2	.	.	PUNCT
dpc-4176	641	3	doi:10.1111	doi:10.1111	ADJ
dpc-4176	641	4	/	/	SYM
dpc-4176	641	5	dth.14180	dth.14180	PROPN
dpc-4176	641	6	.	.	PUNCT
dpc-4176	642	1	pmid	pmid	NOUN
dpc-4176	642	2	:	:	PUNCT
dpc-4176	642	3	32790040	32790040	NUM
dpc-4176	642	4	.	.	PUNCT
dpc-4176	643	1	66	66	NUM
dpc-4176	643	2	.	.	PUNCT
dpc-4176	644	1	burzi	burzi	PROPN
dpc-4176	644	2	l	l	PROPN
dpc-4176	644	3	,	,	PUNCT
dpc-4176	644	4	repetto	repetto	PROPN
dpc-4176	644	5	f	f	PROPN
dpc-4176	644	6	,	,	PUNCT
dpc-4176	644	7	ramondetta	ramondetta	VERB
dpc-4176	644	8	a	a	DET
dpc-4176	644	9	,	,	PUNCT
dpc-4176	644	10	et	et	PROPN
dpc-4176	644	11	al	al	PROPN
dpc-4176	644	12	.	.	PROPN
dpc-4176	644	13	guselkumab	guselkumab	NOUN
dpc-4176	644	14	in	in	ADP
dpc-4176	644	15	the	the	DET
dpc-4176	644	16	treatment	treatment	NOUN
dpc-4176	644	17	of	of	ADP
dpc-4176	644	18	severe	severe	ADJ
dpc-4176	644	19	hidradenitis	hidradenitis	PROPN
dpc-4176	644	20	suppurativa	suppurativa	PROPN
dpc-4176	644	21	,	,	PUNCT
dpc-4176	644	22	a	a	DET
dpc-4176	644	23	promising	promising	ADJ
dpc-4176	644	24	role	role	NOUN
dpc-4176	644	25	?	?	PUNCT
dpc-4176	645	1	dermatol	dermatol	NOUN
dpc-4176	645	2	ther	ther	ADV
dpc-4176	645	3	.	.	PUNCT
dpc-4176	646	1	2021;34	2021;34	NOUN
dpc-4176	646	2	:	:	PUNCT
dpc-4176	646	3	e14930	e14930	NUM
dpc-4176	646	4	.	.	PUNCT
dpc-4176	647	1	doi	doi	NOUN
dpc-4176	647	2	:	:	PUNCT
dpc-4176	647	3	10.1111	10.1111	NUM
dpc-4176	647	4	/	/	SYM
dpc-4176	647	5	dth.14930	dth.14930	PROPN
dpc-4176	647	6	.	.	PUNCT
dpc-4176	648	1	pmid	pmid	NOUN
dpc-4176	648	2	:	:	PUNCT
dpc-4176	648	3	33665949	33665949	NUM
dpc-4176	648	4	.	.	PUNCT
dpc-4176	649	1	67	67	NUM
dpc-4176	649	2	.	.	PUNCT
dpc-4176	650	1	croitoru	croitoru	PROPN
dpc-4176	650	2	do	do	VERB
dpc-4176	650	3	,	,	PUNCT
dpc-4176	650	4	seigel	seigel	VERB
dpc-4176	650	5	k	k	PROPN
dpc-4176	650	6	,	,	PUNCT
dpc-4176	650	7	nathanielsz	nathanielsz	PROPN
dpc-4176	650	8	n	n	CCONJ
dpc-4176	650	9	,	,	PUNCT
dpc-4176	650	10	et	et	PROPN
dpc-4176	650	11	al	al	PROPN
dpc-4176	650	12	.	.	PUNCT
dpc-4176	651	1	treatment	treatment	NOUN
dpc-4176	651	2	of	of	ADP
dpc-4176	651	3	severe	severe	ADJ
dpc-4176	651	4	hidradenitis	hidradenitis	NOUN
dpc-4176	651	5	suppurativa	suppurativa	NOUN
dpc-4176	651	6	and	and	CCONJ
dpc-4176	651	7	fistulizing	fistulize	VERB
dpc-4176	651	8	crohn	crohn	PROPN
dpc-4176	651	9	’s	’s	PART
dpc-4176	651	10	disease	disease	NOUN
dpc-4176	651	11	with	with	ADP
dpc-4176	651	12	guselkumab	guselkumab	NOUN
dpc-4176	651	13	.	.	PUNCT
dpc-4176	652	1	j	j	PROPN
dpc-4176	652	2	eur	eur	PROPN
dpc-4176	652	3	acad	acad	PROPN
dpc-4176	652	4	dermatol	dermatol	NOUN
dpc-4176	652	5	venereol	venereol	NOUN
dpc-4176	652	6	.	.	PUNCT
dpc-4176	653	1	2022;36	2022;36	X
dpc-4176	653	2	:	:	PUNCT
dpc-4176	653	3	e563	e563	PROPN
dpc-4176	653	4	-	-	PUNCT
dpc-4176	653	5	65	65	PROPN
dpc-4176	653	6	.	.	PUNCT
dpc-4176	654	1	doi	doi	NOUN
dpc-4176	654	2	:	:	PUNCT
dpc-4176	654	3	10.1111	10.1111	NUM
dpc-4176	654	4	/	/	SYM
dpc-4176	654	5	jdv.18033	jdv.18033	PROPN
dpc-4176	654	6	.	.	PUNCT
dpc-4176	655	1	pmid	pmid	NOUN
dpc-4176	655	2	:	:	PUNCT
dpc-4176	655	3	35224787	35224787	NUM
dpc-4176	655	4	.	.	PUNCT
dpc-4176	656	1	68	68	NUM
dpc-4176	656	2	.	.	PUNCT
dpc-4176	657	1	berman	berman	PROPN
dpc-4176	657	2	hs	hs	PROPN
dpc-4176	657	3	,	,	PUNCT
dpc-4176	657	4	villa	villa	PROPN
dpc-4176	657	5	nm	nm	PROPN
dpc-4176	657	6	,	,	PUNCT
dpc-4176	657	7	shi	shi	PROPN
dpc-4176	657	8	vy	vy	PROPN
dpc-4176	657	9	,	,	PUNCT
dpc-4176	657	10	et	et	PROPN
dpc-4176	657	11	al	al	PROPN
dpc-4176	657	12	.	.	PROPN
dpc-4176	657	13	guselkumab	guselkumab	NOUN
dpc-4176	657	14	in	in	ADP
dpc-4176	657	15	the	the	DET
dpc-4176	657	16	treatment	treatment	NOUN
dpc-4176	657	17	of	of	ADP
dpc-4176	657	18	concomitant	concomitant	ADJ
dpc-4176	657	19	hidradenitis	hidradenitis	NOUN
dpc-4176	657	20	suppurativa	suppurativa	NOUN
dpc-4176	657	21	,	,	PUNCT
dpc-4176	657	22	psoriasis	psoriasis	NOUN
dpc-4176	657	23	,	,	PUNCT
dpc-4176	657	24	and	and	CCONJ
dpc-4176	657	25	crohn	crohn	PROPN
dpc-4176	657	26	’s	’s	PART
dpc-4176	657	27	disease	disease	NOUN
dpc-4176	657	28	.	.	PUNCT
dpc-4176	658	1	j	j	PROPN
dpc-4176	658	2	dermatol	dermatol	NOUN
dpc-4176	658	3	treat	treat	NOUN
dpc-4176	658	4	.	.	PUNCT
dpc-4176	659	1	2021;32:261–3	2021;32:261–3	NUM
dpc-4176	659	2	.	.	PUNCT
dpc-4176	659	3	doi:10.108	doi:10.108	VERB
dpc-4176	659	4	0/09546634.2019.1654067	0/09546634.2019.1654067	NOUN
dpc-4176	659	5	.	.	PUNCT
dpc-4176	660	1	pmid	pmid	NOUN
dpc-4176	660	2	:	:	PUNCT
dpc-4176	660	3	31389737	31389737	NUM
dpc-4176	660	4	.	.	PUNCT
dpc-4176	661	1	69	69	NUM
dpc-4176	661	2	.	.	PUNCT
dpc-4176	662	1	jørgensen	jørgensen	PROPN
dpc-4176	662	2	ar	ar	PROPN
dpc-4176	662	3	,	,	PUNCT
dpc-4176	662	4	holm	holm	PROPN
dpc-4176	662	5	jg	jg	PROPN
dpc-4176	662	6	,	,	PUNCT
dpc-4176	662	7	thomsen	thomsen	PROPN
dpc-4176	662	8	sf	sf	PROPN
dpc-4176	662	9	.	.	PROPN
dpc-4176	662	10	guselkumab	guselkumab	NOUN
dpc-4176	662	11	for	for	ADP
dpc-4176	662	12	hidradenitis	hidradenitis	PROPN
dpc-4176	662	13	suppurativa	suppurativa	NOUN
dpc-4176	662	14	in	in	ADP
dpc-4176	662	15	a	a	DET
dpc-4176	662	16	patient	patient	NOUN
dpc-4176	662	17	with	with	ADP
dpc-4176	662	18	concomitant	concomitant	PROPN
dpc-4176	662	19	crohn	crohn	PROPN
dpc-4176	662	20	’s	’s	PART
dpc-4176	662	21	disease	disease	NOUN
dpc-4176	662	22	:	:	PUNCT
dpc-4176	662	23	report	report	NOUN
dpc-4176	662	24	and	and	CCONJ
dpc-4176	662	25	systematic	systematic	ADJ
dpc-4176	662	26	literature	literature	NOUN
dpc-4176	662	27	review	review	PROPN
dpc-4176	662	28	of	of	ADP
dpc-4176	662	29	effectiveness	effectiveness	NOUN
dpc-4176	662	30	and	and	CCONJ
dpc-4176	662	31	safety	safety	NOUN
dpc-4176	662	32	.	.	PUNCT
dpc-4176	663	1	clin	clin	PROPN
dpc-4176	663	2	case	case	PROPN
dpc-4176	663	3	rep	rep	PROPN
dpc-4176	663	4	.	.	PROPN
dpc-4176	663	5	2020;8:2873–6	2020;8:2873–6	NUM
dpc-4176	663	6	.	.	PUNCT
dpc-4176	664	1	doi	doi	NOUN
dpc-4176	664	2	:	:	PUNCT
dpc-4176	664	3	10.1002	10.1002	NUM
dpc-4176	664	4	/ccr3.3090	/ccr3.3090	X
dpc-4176	664	5	.	.	PUNCT
dpc-4176	665	1	pmid	pmid	NOUN
dpc-4176	665	2	:	:	PUNCT
dpc-4176	665	3	33363841	33363841	NUM
dpc-4176	665	4	;	;	PUNCT
dpc-4176	665	5	pmcid	pmcid	ADJ
dpc-4176	665	6	:	:	PUNCT
dpc-4176	665	7	pmc7752321	pmc7752321	ADJ
dpc-4176	665	8	.	.	PUNCT
dpc-4176	666	1	70	70	NUM
dpc-4176	666	2	.	.	PUNCT
dpc-4176	667	1	george	george	PROPN
dpc-4176	667	2	c	c	PROPN
dpc-4176	667	3	,	,	PUNCT
dpc-4176	667	4	deroide	deroide	ADV
dpc-4176	667	5	f	f	X
dpc-4176	667	6	,	,	PUNCT
dpc-4176	667	7	rustin	rustin	NOUN
dpc-4176	667	8	m.	m.	NOUN
dpc-4176	667	9	pyoderma	pyoderma	PROPN
dpc-4176	667	10	gangrenosum	gangrenosum	VERB
dpc-4176	667	11	a	a	DET
dpc-4176	667	12	guide	guide	NOUN
dpc-4176	667	13	to	to	ADP
dpc-4176	667	14	diagnosis	diagnosis	NOUN
dpc-4176	667	15	and	and	CCONJ
dpc-4176	667	16	management	management	NOUN
dpc-4176	667	17	.	.	PUNCT
dpc-4176	668	1	clin	clin	PROPN
dpc-4176	668	2	med	med	PROPN
dpc-4176	668	3	(	(	PUNCT
dpc-4176	668	4	lond	lond	PROPN
dpc-4176	668	5	)	)	PUNCT
dpc-4176	668	6	.	.	PUNCT
dpc-4176	669	1	2019;19:224–8	2019;19:224–8	X
dpc-4176	669	2	.	.	PUNCT
dpc-4176	670	1	doi	doi	NOUN
dpc-4176	670	2	:	:	PUNCT
dpc-4176	670	3	10.7861	10.7861	NUM
dpc-4176	670	4	/	/	SYM
dpc-4176	670	5	clinmedicine.19	clinmedicine.19	PROPN
dpc-4176	670	6	-	-	PUNCT
dpc-4176	670	7	3	3	NUM
dpc-4176	670	8	-	-	NUM
dpc-4176	670	9	224	224	NUM
dpc-4176	670	10	.	.	PUNCT
dpc-4176	671	1	pmid	pmid	NOUN
dpc-4176	671	2	:	:	PUNCT
dpc-4176	671	3	31092515	31092515	NUM
dpc-4176	671	4	;	;	PUNCT
dpc-4176	671	5	pmcid	pmcid	ADJ
dpc-4176	671	6	:	:	PUNCT
dpc-4176	671	7	pmc6542232	pmc6542232	NOUN
dpc-4176	671	8	.	.	PUNCT
dpc-4176	672	1	71	71	NUM
dpc-4176	672	2	.	.	PUNCT
dpc-4176	673	1	yamanaka	yamanaka	PROPN
dpc-4176	673	2	k.	k.	PROPN
dpc-4176	674	1	new	new	ADJ
dpc-4176	674	2	treatment	treatment	NOUN
dpc-4176	674	3	of	of	ADP
dpc-4176	674	4	pyoderma	pyoderma	NOUN
dpc-4176	674	5	gangrenosum	gangrenosum	NOUN
dpc-4176	674	6	and	and	CCONJ
dpc-4176	674	7	hidradenitis	hidradenitis	PROPN
dpc-4176	674	8	suppurativa	suppurativa	PROPN
dpc-4176	674	9	:	:	PUNCT
dpc-4176	674	10	a	a	DET
dpc-4176	674	11	review	review	NOUN
dpc-4176	674	12	.	.	PUNCT
dpc-4176	675	1	j	j	PROPN
dpc-4176	675	2	dermatol	dermatol	NOUN
dpc-4176	675	3	.	.	PUNCT
dpc-4176	676	1	2023;1346	2023;1346	NUM
dpc-4176	676	2	-	-	PUNCT
dpc-4176	676	3	8138.17031	8138.17031	NOUN
dpc-4176	676	4	.	.	PUNCT
dpc-4176	677	1	doi	doi	NOUN
dpc-4176	677	2	:	:	PUNCT
dpc-4176	677	3	10.1111/1346	10.1111/1346	NUM
dpc-4176	677	4	-	-	SYM
dpc-4176	677	5	8138.17031	8138.17031	NOUN
dpc-4176	677	6	.	.	PUNCT
dpc-4176	678	1	pmid	pmid	NOUN
dpc-4176	678	2	:	:	PUNCT
dpc-4176	678	3	38009911	38009911	NUM
dpc-4176	678	4	.	.	PUNCT
dpc-4176	679	1	72	72	NUM
dpc-4176	679	2	.	.	PUNCT
dpc-4176	680	1	baier	baier	PROPN
dpc-4176	680	2	c	c	PROPN
dpc-4176	680	3	,	,	PUNCT
dpc-4176	680	4	barak	barak	PROPN
dpc-4176	680	5	o.	o.	PROPN
dpc-4176	680	6	guselkumab	guselkumab	NOUN
dpc-4176	680	7	as	as	ADP
dpc-4176	680	8	a	a	DET
dpc-4176	680	9	treatment	treatment	NOUN
dpc-4176	680	10	option	option	NOUN
dpc-4176	680	11	for	for	ADP
dpc-4176	680	12	recalcitrant	recalcitrant	ADJ
dpc-4176	680	13	pyoderma	pyoderma	NOUN
dpc-4176	680	14	gangrenosum	gangrenosum	NOUN
dpc-4176	680	15	.	.	PUNCT
dpc-4176	681	1	jaad	jaad	NOUN
dpc-4176	681	2	case	case	NOUN
dpc-4176	681	3	rep	rep	PROPN
dpc-4176	681	4	.	.	PROPN
dpc-4176	681	5	2021;8:43–6	2021;8:43–6	PROPN
dpc-4176	681	6	.	.	PUNCT
dpc-4176	682	1	doi	doi	NOUN
dpc-4176	682	2	:	:	PUNCT
dpc-4176	682	3	10.1016	10.1016	NUM
dpc-4176	682	4	/	/	SYM
dpc-4176	682	5	j.jdcr.2020.12.005	j.jdcr.2020.12.005	PROPN
dpc-4176	682	6	.	.	PUNCT
dpc-4176	683	1	pmid	pmid	NOUN
dpc-4176	683	2	:	:	PUNCT
dpc-4176	683	3	33490346	33490346	NUM
dpc-4176	683	4	;	;	PUNCT
dpc-4176	683	5	pmcid	pmcid	PROPN
dpc-4176	683	6	:	:	PUNCT
dpc-4176	683	7	pmc7810910	pmc7810910	NOUN
dpc-4176	683	8	.	.	PUNCT
dpc-4176	684	1	73	73	NUM
dpc-4176	684	2	.	.	PUNCT
dpc-4176	685	1	reese	reese	PROPN
dpc-4176	685	2	am	am	PROPN
dpc-4176	685	3	,	,	PUNCT
dpc-4176	685	4	erickson	erickson	PROPN
dpc-4176	685	5	k	k	PROPN
dpc-4176	685	6	,	,	PUNCT
dpc-4176	685	7	reed	reed	PROPN
dpc-4176	685	8	kb	kb	PROPN
dpc-4176	685	9	,	,	PUNCT
dpc-4176	685	10	et	et	PROPN
dpc-4176	685	11	al	al	PROPN
dpc-4176	685	12	.	.	PROPN
dpc-4176	685	13	modified	modified	PROPN
dpc-4176	685	14	dose	dose	PROPN
dpc-4176	685	15	of	of	ADP
dpc-4176	685	16	guselkumab	guselkumab	NOUN
dpc-4176	685	17	for	for	ADP
dpc-4176	685	18	treatment	treatment	NOUN
dpc-4176	685	19	of	of	ADP
dpc-4176	685	20	pyoderma	pyoderma	NOUN
dpc-4176	685	21	gangrenosum	gangrenosum	NOUN
dpc-4176	685	22	.	.	PUNCT
dpc-4176	686	1	jaad	jaad	NOUN
dpc-4176	686	2	case	case	NOUN
dpc-4176	686	3	rep	rep	PROPN
dpc-4176	686	4	.	.	PROPN
dpc-4176	686	5	2022;21:38–42	2022;21:38–42	NUM
dpc-4176	686	6	.	.	PUNCT
dpc-4176	686	7	doi:10.1016	doi:10.1016	PROPN
dpc-4176	686	8	/	/	SYM
dpc-4176	686	9	j.jdcr.2021.11.030	j.jdcr.2021.11.030	PROPN
dpc-4176	686	10	.	.	PUNCT
dpc-4176	687	1	pmid	pmid	NOUN
dpc-4176	687	2	:	:	PUNCT
dpc-4176	687	3	35146098	35146098	NUM
dpc-4176	687	4	;	;	PUNCT
dpc-4176	687	5	pmcid	pmcid	ADJ
dpc-4176	687	6	:	:	PUNCT
dpc-4176	687	7	pmc8818803	pmc8818803	NOUN
dpc-4176	687	8	.	.	PUNCT
dpc-4176	688	1	74	74	NUM
dpc-4176	688	2	.	.	NUM
dpc-4176	688	3	villaverde	villaverde	PROPN
dpc-4176	688	4	piñeiro	piñeiro	PROPN
dpc-4176	688	5	l	l	PROPN
dpc-4176	688	6	,	,	PUNCT
dpc-4176	688	7	loureiro	loureiro	PROPN
dpc-4176	688	8	martínez	martínez	PROPN
dpc-4176	688	9	m	m	PROPN
dpc-4176	688	10	,	,	PUNCT
dpc-4176	688	11	cachafeiro	cachafeiro	NOUN
dpc-4176	688	12	pin	pin	NOUN
dpc-4176	688	13	ai	ai	VERB
dpc-4176	688	14	.	.	PUNCT
dpc-4176	689	1	tratamiento	tratamiento	PROPN
dpc-4176	689	2	del	del	PROPN
dpc-4176	689	3	pioderma	pioderma	PROPN
dpc-4176	689	4	gangrenoso	gangrenoso	VERB
dpc-4176	689	5	con	con	PROPN
dpc-4176	689	6	guselkumab	guselkumab	NOUN
dpc-4176	689	7	en	en	PROPN
dpc-4176	689	8	condiciones	condicione	NOUN
dpc-4176	689	9	diferentes	diferente	VERB
dpc-4176	689	10	a	a	DET
dpc-4176	689	11	las	las	PROPN
dpc-4176	689	12	autorizadas	autorizadas	PROPN
dpc-4176	689	13	en	en	X
dpc-4176	689	14	la	la	PROPN
dpc-4176	689	15	ficha	ficha	PROPN
dpc-4176	689	16	técnica	técnica	PROPN
dpc-4176	689	17	.	.	PUNCT
dpc-4176	690	1	med	med	PROPN
dpc-4176	690	2	clín	clín	NOUN
dpc-4176	690	3	.	.	PUNCT
dpc-4176	691	1	2023;161:226–7	2023;161:226–7	X
dpc-4176	691	2	.	.	PUNCT
dpc-4176	691	3	doi	doi	NOUN
dpc-4176	691	4	:	:	PUNCT
dpc-4176	691	5	10.1016	10.1016	NUM
dpc-4176	691	6	/	/	SYM
dpc-4176	691	7	j.medcli.2023.04.029	j.medcli.2023.04.029	PROPN
dpc-4176	691	8	.	.	PUNCT
dpc-4176	692	1	pmid	pmid	NOUN
dpc-4176	692	2	:	:	PUNCT
dpc-4176	692	3	37271670	37271670	NUM
dpc-4176	692	4	.	.	PUNCT
dpc-4176	693	1	75	75	NUM
dpc-4176	693	2	.	.	PUNCT
dpc-4176	694	1	wang	wang	PROPN
dpc-4176	694	2	d	d	PROPN
dpc-4176	694	3	,	,	PUNCT
dpc-4176	694	4	chong	chong	PROPN
dpc-4176	694	5	vcl	vcl	PROPN
dpc-4176	694	6	,	,	PUNCT
dpc-4176	694	7	chong	chong	PROPN
dpc-4176	694	8	ws	ws	PROPN
dpc-4176	694	9	,	,	PUNCT
dpc-4176	694	10	et	et	PROPN
dpc-4176	694	11	al	al	PROPN
dpc-4176	694	12	.	.	PUNCT
dpc-4176	695	1	a	a	DET
dpc-4176	695	2	review	review	NOUN
dpc-4176	695	3	on	on	ADP
dpc-4176	695	4	pityriasis	pityriasis	NOUN
dpc-4176	695	5	rubra	rubra	NOUN
dpc-4176	695	6	pilaris	pilaris	NOUN
dpc-4176	695	7	.	.	PUNCT
dpc-4176	695	8	am	be	AUX
dpc-4176	695	9	j	j	PROPN
dpc-4176	695	10	clin	clin	PROPN
dpc-4176	695	11	dermatol	dermatol	NOUN
dpc-4176	695	12	.	.	PUNCT
dpc-4176	696	1	2018;19:377–90	2018;19:377–90	X
dpc-4176	696	2	.	.	PUNCT
dpc-4176	696	3	doi	doi	NOUN
dpc-4176	696	4	:	:	PUNCT
dpc-4176	696	5	10.1007	10.1007	NUM
dpc-4176	696	6	/	/	SYM
dpc-4176	696	7	s40257	s40257	NOUN
dpc-4176	696	8	-	-	PUNCT
dpc-4176	696	9	017	017	NUM
dpc-4176	696	10	-	-	PUNCT
dpc-4176	696	11	0338	0338	NUM
dpc-4176	696	12	-	-	PUNCT
dpc-4176	696	13	1	1	NUM
dpc-4176	696	14	.	.	PUNCT
dpc-4176	697	1	pmid	pmid	NOUN
dpc-4176	697	2	:	:	PUNCT
dpc-4176	697	3	29302927	29302927	NUM
dpc-4176	697	4	.	.	PUNCT
dpc-4176	698	1	76	76	NUM
dpc-4176	698	2	.	.	PUNCT
dpc-4176	699	1	feldmeyer	feldmeyer	PROPN
dpc-4176	699	2	l	l	PROPN
dpc-4176	699	3	,	,	PUNCT
dpc-4176	699	4	mylonas	mylonas	PROPN
dpc-4176	699	5	a	a	PRON
dpc-4176	699	6	,	,	PUNCT
dpc-4176	699	7	demaria	demaria	PROPN
dpc-4176	699	8	o	o	NOUN
dpc-4176	699	9	,	,	PUNCT
dpc-4176	699	10	et	et	PROPN
dpc-4176	699	11	al	al	PROPN
dpc-4176	699	12	.	.	PUNCT
dpc-4176	700	1	interleukin	interleukin	NOUN
dpc-4176	700	2	23	23	NUM
dpc-4176	700	3	–	–	PUNCT
dpc-4176	700	4	helper	helper	NOUN
dpc-4176	700	5	t	t	PROPN
dpc-4176	700	6	cell	cell	NOUN
dpc-4176	700	7	17	17	NUM
dpc-4176	700	8	axis	axis	NOUN
dpc-4176	700	9	as	as	ADP
dpc-4176	700	10	a	a	DET
dpc-4176	700	11	treatment	treatment	NOUN
dpc-4176	700	12	target	target	NOUN
dpc-4176	700	13	for	for	ADP
dpc-4176	700	14	pityriasis	pityriasis	NOUN
dpc-4176	700	15	rubra	rubra	NOUN
dpc-4176	700	16	pilaris	pilaris	NOUN
dpc-4176	700	17	.	.	PUNCT
dpc-4176	701	1	jama	jama	PROPN
dpc-4176	701	2	dermatol	dermatol	NOUN
dpc-4176	701	3	.	.	PUNCT
dpc-4176	702	1	2017;153:304	2017;153:304	NUM
dpc-4176	702	2	-	-	SYM
dpc-4176	702	3	308	308	NUM
dpc-4176	702	4	.	.	PUNCT
dpc-4176	703	1	doi	doi	NOUN
dpc-4176	703	2	:	:	PUNCT
dpc-4176	703	3	10.1001	10.1001	NUM
dpc-4176	703	4	/jamadermatol.2016.5384	/jamadermatol.2016.5384	NUM
dpc-4176	703	5	.	.	PUNCT
dpc-4176	704	1	pmid	pmid	NOUN
dpc-4176	704	2	:	:	PUNCT
dpc-4176	704	3	28122069	28122069	NUM
dpc-4176	704	4	.	.	PUNCT
dpc-4176	705	1	77	77	NUM
dpc-4176	705	2	.	.	PUNCT
dpc-4176	706	1	kannan	kannan	PROPN
dpc-4176	706	2	ak	ak	PROPN
dpc-4176	706	3	,	,	PUNCT
dpc-4176	706	4	su	su	PROPN
dpc-4176	706	5	z	z	PROPN
dpc-4176	706	6	,	,	PUNCT
dpc-4176	706	7	gauvin	gauvin	NOUN
dpc-4176	706	8	dm	dm	PROPN
dpc-4176	706	9	,	,	PUNCT
dpc-4176	706	10	et	et	PROPN
dpc-4176	706	11	al	al	PROPN
dpc-4176	706	12	.	.	PROPN
dpc-4176	706	13	il-23	il-23	NOUN
dpc-4176	706	14	induces	induce	VERB
dpc-4176	706	15	regulatory	regulatory	ADJ
dpc-4176	706	16	t	t	NOUN
dpc-4176	706	17	cell	cell	NOUN
dpc-4176	706	18	plasticity	plasticity	NOUN
dpc-4176	706	19	with	with	ADP
dpc-4176	706	20	implications	implication	NOUN
dpc-4176	706	21	for	for	ADP
dpc-4176	706	22	inflammatory	inflammatory	ADJ
dpc-4176	706	23	skin	skin	NOUN
dpc-4176	706	24	diseases	disease	NOUN
dpc-4176	706	25	.	.	PUNCT
dpc-4176	707	1	sci	sci	PROPN
dpc-4176	707	2	rep	rep	PROPN
dpc-4176	707	3	.	.	PROPN
dpc-4176	707	4	2019;9:17675	2019;9:17675	PROPN
dpc-4176	707	5	.	.	PUNCT
dpc-4176	708	1	doi:10.1038	doi:10.1038	NOUN
dpc-4176	708	2	/	/	SYM
dpc-4176	708	3	s41598	s41598	NOUN
dpc-4176	708	4	-	-	PUNCT
dpc-4176	708	5	019	019	NUM
dpc-4176	708	6	-	-	PUNCT
dpc-4176	708	7	53240	53240	NUM
dpc-4176	708	8	-	-	PUNCT
dpc-4176	708	9	z.	z.	PROPN
dpc-4176	708	10	pmid	pmid	PROPN
dpc-4176	708	11	:	:	PUNCT
dpc-4176	708	12	31776355	31776355	NUM
dpc-4176	708	13	;	;	PUNCT
dpc-4176	708	14	pmcid	pmcid	NOUN
dpc-4176	708	15	:	:	PUNCT
dpc-4176	708	16	pmc6881359	pmc6881359	VERB
dpc-4176	708	17	.	.	PUNCT
dpc-4176	709	1	78	78	NUM
dpc-4176	709	2	.	.	PUNCT
dpc-4176	710	1	pilz	pilz	PROPN
dpc-4176	710	2	ac	ac	PROPN
dpc-4176	710	3	,	,	PUNCT
dpc-4176	710	4	seiringer	seiringer	NOUN
dpc-4176	710	5	p	p	PROPN
dpc-4176	710	6	,	,	PUNCT
dpc-4176	710	7	biedermann	biedermann	PROPN
dpc-4176	710	8	t	t	PROPN
dpc-4176	710	9	,	,	PUNCT
dpc-4176	710	10	et	et	PROPN
dpc-4176	710	11	al	al	PROPN
dpc-4176	710	12	.	.	PUNCT
dpc-4176	710	13	treatment	treatment	NOUN
dpc-4176	710	14	of	of	ADP
dpc-4176	710	15	pityriasis	pityriasis	NOUN
dpc-4176	710	16	rubra	rubra	NOUN
dpc-4176	710	17	pilaris	pilaris	NOUN
dpc-4176	710	18	with	with	ADP
dpc-4176	710	19	guselkumab	guselkumab	NOUN
dpc-4176	710	20	.	.	PUNCT
dpc-4176	711	1	jama	jama	PROPN
dpc-4176	711	2	dermatol	dermatol	NOUN
dpc-4176	711	3	.	.	PUNCT
dpc-4176	712	1	2019;155:1424	2019;155:1424	NUM
dpc-4176	712	2	-	-	SYM
dpc-4176	712	3	1426	1426	NUM
dpc-4176	712	4	.	.	PUNCT
dpc-4176	713	1	doi	doi	NOUN
dpc-4176	713	2	:	:	PUNCT
dpc-4176	713	3	10.1001	10.1001	NUM
dpc-4176	713	4	/	/	SYM
dpc-4176	713	5	jamadermatol.2019.2774	jamadermatol.2019.2774	NOUN
dpc-4176	713	6	.	.	PUNCT
dpc-4176	714	1	pmid	pmid	NOUN
dpc-4176	714	2	:	:	PUNCT
dpc-4176	714	3	31577328	31577328	NUM
dpc-4176	714	4	.	.	PUNCT
dpc-4176	715	1	79	79	NUM
dpc-4176	715	2	.	.	PUNCT
dpc-4176	716	1	nagai	nagai	PROPN
dpc-4176	716	2	h	h	PROPN
dpc-4176	716	3	,	,	PUNCT
dpc-4176	716	4	jimbo	jimbo	PROPN
dpc-4176	716	5	h	h	PROPN
dpc-4176	716	6	,	,	PUNCT
dpc-4176	716	7	matsuura	matsuura	PROPN
dpc-4176	716	8	s	s	PROPN
dpc-4176	716	9	,	,	PUNCT
dpc-4176	716	10	et	et	PROPN
dpc-4176	716	11	al	al	PROPN
dpc-4176	716	12	.	.	PROPN
dpc-4176	717	1	successful	successful	ADJ
dpc-4176	717	2	treatment	treatment	NOUN
dpc-4176	717	3	of	of	ADP
dpc-4176	717	4	pityriasis	pityriasis	NOUN
dpc-4176	717	5	rubra	rubra	NOUN
dpc-4176	717	6	pilaris	pilaris	NOUN
dpc-4176	717	7	with	with	ADP
dpc-4176	717	8	guselkumab	guselkumab	NOUN
dpc-4176	717	9	:	:	PUNCT
dpc-4176	717	10	serum	serum	NOUN
dpc-4176	717	11	ccl20	ccl20	NOUN
dpc-4176	717	12	as	as	ADP
dpc-4176	717	13	a	a	DET
dpc-4176	717	14	potential	potential	ADJ
dpc-4176	717	15	marker	marker	NOUN
dpc-4176	717	16	for	for	ADP
dpc-4176	717	17	the	the	DET
dpc-4176	717	18	disease	disease	NOUN
dpc-4176	717	19	activity	activity	NOUN
dpc-4176	717	20	.	.	PUNCT
dpc-4176	718	1	dermatol	dermatol	NOUN
dpc-4176	718	2	ther	ther	ADV
dpc-4176	718	3	.	.	PUNCT
dpc-4176	719	1	2020;33	2020;33	NUM
dpc-4176	719	2	:	:	PUNCT
dpc-4176	719	3	e14403	e14403	PROPN
dpc-4176	719	4	.	.	PUNCT
dpc-4176	720	1	doi	doi	NOUN
dpc-4176	720	2	:	:	PUNCT
dpc-4176	720	3	10.1111	10.1111	NUM
dpc-4176	720	4	/	/	SYM
dpc-4176	720	5	dth.14403	dth.14403	PROPN
dpc-4176	720	6	.	.	PUNCT
dpc-4176	721	1	pmid	pmid	NOUN
dpc-4176	721	2	:	:	PUNCT
dpc-4176	721	3	33044038	33044038	NUM
dpc-4176	721	4	.	.	PUNCT
dpc-4176	722	1	80	80	NUM
dpc-4176	722	2	.	.	PUNCT
dpc-4176	723	1	nishimura	nishimura	PROPN
dpc-4176	723	2	m	m	PROPN
dpc-4176	723	3	,	,	PUNCT
dpc-4176	723	4	kondo	kondo	PROPN
dpc-4176	723	5	m	m	PROPN
dpc-4176	723	6	,	,	PUNCT
dpc-4176	723	7	habe	habe	PROPN
dpc-4176	723	8	k	k	PROPN
dpc-4176	723	9	,	,	PUNCT
dpc-4176	723	10	et	et	PROPN
dpc-4176	723	11	al	al	PROPN
dpc-4176	723	12	.	.	PROPN
dpc-4176	724	1	successful	successful	ADJ
dpc-4176	724	2	treatment	treatment	NOUN
dpc-4176	724	3	with	with	ADP
dpc-4176	724	4	cyclosporine	cyclosporine	NOUN
dpc-4176	724	5	and	and	CCONJ
dpc-4176	724	6	guselkumab	guselkumab	NOUN
dpc-4176	724	7	for	for	ADP
dpc-4176	724	8	pityriasis	pityriasis	NOUN
dpc-4176	724	9	rubra	rubra	NOUN
dpc-4176	724	10	pilaris	pilaris	NOUN
dpc-4176	724	11	.	.	PUNCT
dpc-4176	725	1	52	52	NUM
dpc-4176	725	2	.	.	PUNCT
dpc-4176	726	1	mease	mease	PROPN
dpc-4176	726	2	pj	pj	PROPN
dpc-4176	726	3	,	,	PUNCT
dpc-4176	726	4	rahman	rahman	PROPN
dpc-4176	726	5	p	p	PROPN
dpc-4176	726	6	,	,	PUNCT
dpc-4176	726	7	gottlieb	gottlieb	PROPN
dpc-4176	726	8	ab	ab	PROPN
dpc-4176	726	9	,	,	PUNCT
dpc-4176	726	10	et	et	PROPN
dpc-4176	726	11	al	al	PROPN
dpc-4176	726	12	.	.	PROPN
dpc-4176	726	13	guselkumab	guselkumab	NOUN
dpc-4176	726	14	in	in	ADP
dpc-4176	726	15	biologic	biologic	ADJ
dpc-4176	726	16	-	-	PUNCT
dpc-4176	726	17	naive	naive	ADJ
dpc-4176	726	18	patients	patient	NOUN
dpc-4176	726	19	with	with	ADP
dpc-4176	726	20	active	active	ADJ
dpc-4176	726	21	psoriatic	psoriatic	ADJ
dpc-4176	726	22	arthritis	arthritis	NOUN
dpc-4176	726	23	(	(	PUNCT
dpc-4176	726	24	discover-2	discover-2	PROPN
dpc-4176	726	25	):	):	PUNCT
dpc-4176	726	26	a	a	DET
dpc-4176	726	27	double	double	ADJ
dpc-4176	726	28	-	-	PUNCT
dpc-4176	726	29	blind	blind	ADJ
dpc-4176	726	30	,	,	PUNCT
dpc-4176	726	31	randomised	randomise	VERB
dpc-4176	726	32	,	,	PUNCT
dpc-4176	726	33	placebo	placebo	NOUN
dpc-4176	726	34	-	-	PUNCT
dpc-4176	726	35	controlled	control	VERB
dpc-4176	726	36	phase	phase	NOUN
dpc-4176	726	37	3	3	NUM
dpc-4176	726	38	trial	trial	NOUN
dpc-4176	726	39	.	.	PUNCT
dpc-4176	727	1	lancet	lancet	NOUN
dpc-4176	727	2	.	.	PUNCT
dpc-4176	728	1	2020;395:1126–36	2020;395:1126–36	X
dpc-4176	728	2	.	.	PUNCT
dpc-4176	729	1	doi	doi	NOUN
dpc-4176	729	2	:	:	PUNCT
dpc-4176	729	3	10.1016	10.1016	NUM
dpc-4176	729	4	/	/	SYM
dpc-4176	729	5	s0140	s0140	ADJ
dpc-4176	729	6	-6736(20)30263	-6736(20)30263	ADV
dpc-4176	729	7	-	-	PUNCT
dpc-4176	729	8	4	4	NUM
dpc-4176	729	9	.	.	PUNCT
dpc-4176	730	1	pmid	pmid	NOUN
dpc-4176	730	2	:	:	PUNCT
dpc-4176	730	3	32178766	32178766	NUM
dpc-4176	730	4	.	.	PUNCT
dpc-4176	731	1	53	53	NUM
dpc-4176	731	2	.	.	PUNCT
dpc-4176	732	1	deodhar	deodhar	PROPN
dpc-4176	732	2	a	a	DET
dpc-4176	732	3	,	,	PUNCT
dpc-4176	732	4	helliwell	helliwell	NOUN
dpc-4176	732	5	ps	ps	NOUN
dpc-4176	732	6	,	,	PUNCT
dpc-4176	732	7	boehncke	boehncke	PROPN
dpc-4176	732	8	wh	wh	PROPN
dpc-4176	732	9	,	,	PUNCT
dpc-4176	732	10	et	et	PROPN
dpc-4176	732	11	al	al	PROPN
dpc-4176	732	12	.	.	PROPN
dpc-4176	732	13	guselkumab	guselkumab	NOUN
dpc-4176	732	14	in	in	ADP
dpc-4176	732	15	patients	patient	NOUN
dpc-4176	732	16	with	with	ADP
dpc-4176	732	17	active	active	ADJ
dpc-4176	732	18	psoriatic	psoriatic	ADJ
dpc-4176	732	19	arthritis	arthritis	NOUN
dpc-4176	732	20	who	who	PRON
dpc-4176	732	21	were	be	AUX
dpc-4176	732	22	biologic	biologic	ADJ
dpc-4176	732	23	naive	naive	ADJ
dpc-4176	732	24	or	or	CCONJ
dpc-4176	732	25	had	have	AUX
dpc-4176	732	26	previously	previously	ADV
dpc-4176	732	27	received	receive	VERB
dpc-4176	732	28	tnfα	tnfα	NOUN
dpc-4176	732	29	inhibitor	inhibitor	NOUN
dpc-4176	732	30	treatment	treatment	NOUN
dpc-4176	732	31	(	(	PUNCT
dpc-4176	732	32	discover-1	discover-1	PROPN
dpc-4176	732	33	):	):	PUNCT
dpc-4176	732	34	a	a	DET
dpc-4176	732	35	double	double	ADJ
dpc-4176	732	36	-	-	PUNCT
dpc-4176	732	37	blind	blind	ADJ
dpc-4176	732	38	,	,	PUNCT
dpc-4176	732	39	randomised	randomise	VERB
dpc-4176	732	40	,	,	PUNCT
dpc-4176	732	41	placebo	placebo	NOUN
dpc-4176	732	42	-	-	PUNCT
dpc-4176	732	43	controlled	control	VERB
dpc-4176	732	44	phase	phase	NOUN
dpc-4176	732	45	3	3	NUM
dpc-4176	732	46	trial	trial	NOUN
dpc-4176	732	47	.	.	PUNCT
dpc-4176	733	1	lancet	lancet	PROPN
dpc-4176	733	2	.	.	PUNCT
dpc-4176	734	1	2020;395:1115–25	2020;395:1115–25	X
dpc-4176	734	2	.	.	PUNCT
dpc-4176	734	3	doi	doi	NOUN
dpc-4176	734	4	:	:	PUNCT
dpc-4176	734	5	10.1016	10.1016	NUM
dpc-4176	734	6	/	/	SYM
dpc-4176	734	7	s0140	s0140	ADJ
dpc-4176	734	8	-6736(20)30265	-6736(20)30265	NOUN
dpc-4176	734	9	-	-	PUNCT
dpc-4176	734	10	8	8	NUM
dpc-4176	734	11	.	.	PUNCT
dpc-4176	735	1	pmid	pmid	NOUN
dpc-4176	735	2	:	:	PUNCT
dpc-4176	735	3	32178765	32178765	NUM
dpc-4176	735	4	.	.	PUNCT
dpc-4176	736	1	54	54	NUM
dpc-4176	736	2	.	.	PUNCT
dpc-4176	737	1	kelly	kelly	PROPN
dpc-4176	737	2	g	g	PROPN
dpc-4176	737	3	,	,	PUNCT
dpc-4176	737	4	sweeney	sweeney	PROPN
dpc-4176	737	5	cm	cm	PROPN
dpc-4176	737	6	,	,	PUNCT
dpc-4176	737	7	tobin	tobin	PROPN
dpc-4176	737	8	a	a	X
dpc-4176	737	9	,	,	PUNCT
dpc-4176	737	10	et	et	PROPN
dpc-4176	737	11	al	al	PROPN
dpc-4176	737	12	.	.	PROPN
dpc-4176	737	13	hidradenitis	hidradenitis	PROPN
dpc-4176	737	14	suppurativa	suppurativa	PROPN
dpc-4176	737	15	:	:	PUNCT
dpc-4176	737	16	the	the	DET
dpc-4176	737	17	role	role	NOUN
dpc-4176	737	18	of	of	ADP
dpc-4176	737	19	immune	immune	ADJ
dpc-4176	737	20	dysregulation	dysregulation	NOUN
dpc-4176	737	21	.	.	PUNCT
dpc-4176	738	1	int	int	NOUN
dpc-4176	738	2	j	j	PROPN
dpc-4176	738	3	dermatol	dermatol	NOUN
dpc-4176	738	4	.	.	PUNCT
dpc-4176	739	1	2014;53:1186–96	2014;53:1186–96	NUM
dpc-4176	739	2	.	.	PUNCT
dpc-4176	739	3	doi:10.1111	doi:10.1111	PROPN
dpc-4176	739	4	/	/	SYM
dpc-4176	739	5	ijd.12550	ijd.12550	PROPN
dpc-4176	739	6	.	.	PUNCT
dpc-4176	740	1	pmid	pmid	NOUN
dpc-4176	740	2	:	:	PUNCT
dpc-4176	740	3	24961484	24961484	NUM
dpc-4176	740	4	.	.	PUNCT
dpc-4176	741	1	55	55	NUM
dpc-4176	741	2	.	.	PUNCT
dpc-4176	742	1	schlapbach	schlapbach	PRON
dpc-4176	742	2	c	c	NOUN
dpc-4176	742	3	,	,	PUNCT
dpc-4176	742	4	hänni	hänni	PROPN
dpc-4176	742	5	t	t	PROPN
dpc-4176	742	6	,	,	PUNCT
dpc-4176	742	7	yawalkar	yawalkar	NOUN
dpc-4176	742	8	n	n	CCONJ
dpc-4176	742	9	,	,	PUNCT
dpc-4176	742	10	et	et	PROPN
dpc-4176	742	11	al	al	PROPN
dpc-4176	742	12	.	.	PUNCT
dpc-4176	742	13	expression	expression	NOUN
dpc-4176	742	14	of	of	ADP
dpc-4176	742	15	the	the	DET
dpc-4176	742	16	il-23	il-23	NOUN
dpc-4176	742	17	/	/	SYM
dpc-4176	742	18	th17	th17	NOUN
dpc-4176	742	19	pathway	pathway	NOUN
dpc-4176	742	20	in	in	ADP
dpc-4176	742	21	lesions	lesion	NOUN
dpc-4176	742	22	of	of	ADP
dpc-4176	742	23	hidradenitis	hidradenitis	PROPN
dpc-4176	742	24	suppurativa	suppurativa	PROPN
dpc-4176	742	25	.	.	PUNCT
dpc-4176	743	1	j	j	PROPN
dpc-4176	743	2	am	be	AUX
dpc-4176	743	3	acad	acad	ADJ
dpc-4176	743	4	dermatol	dermatol	NOUN
dpc-4176	743	5	.	.	PUNCT
dpc-4176	744	1	2011;65:790–8	2011;65:790–8	NUM
dpc-4176	744	2	.	.	PUNCT
dpc-4176	745	1	doi	doi	NOUN
dpc-4176	745	2	:	:	PUNCT
dpc-4176	745	3	10.1016	10.1016	NUM
dpc-4176	745	4	/	/	SYM
dpc-4176	745	5	j.jaad.2010	j.jaad.2010	PROPN
dpc-4176	745	6	.07.010	.07.010	PROPN
dpc-4176	745	7	.	.	PUNCT
dpc-4176	746	1	pmid	pmid	NOUN
dpc-4176	746	2	:	:	PUNCT
dpc-4176	746	3	21641076	21641076	NUM
dpc-4176	746	4	.	.	PUNCT
dpc-4176	747	1	56	56	NUM
dpc-4176	747	2	.	.	PUNCT
dpc-4176	748	1	littman	littman	PROPN
dpc-4176	748	2	dr	dr	PROPN
dpc-4176	748	3	,	,	PUNCT
dpc-4176	748	4	rudensky	rudensky	PROPN
dpc-4176	748	5	ay	ay	NOUN
dpc-4176	748	6	.	.	PUNCT
dpc-4176	749	1	th17	th17	NOUN
dpc-4176	749	2	and	and	CCONJ
dpc-4176	749	3	regulatory	regulatory	ADJ
dpc-4176	749	4	t	t	NOUN
dpc-4176	749	5	cells	cell	NOUN
dpc-4176	749	6	in	in	ADP
dpc-4176	749	7	mediating	mediate	VERB
dpc-4176	749	8	and	and	CCONJ
dpc-4176	749	9	restraining	restrain	VERB
dpc-4176	749	10	inflammation	inflammation	NOUN
dpc-4176	749	11	.	.	PUNCT
dpc-4176	750	1	cell	cell	NOUN
dpc-4176	750	2	.	.	PUNCT
dpc-4176	751	1	2010;140:845–58	2010;140:845–58	PROPN
dpc-4176	751	2	.	.	PUNCT
dpc-4176	752	1	doi	doi	PROPN
dpc-4176	752	2	:	:	PUNCT
dpc-4176	752	3	10.1016	10.1016	NUM
dpc-4176	752	4	/	/	SYM
dpc-4176	752	5	j.cell.2010.02.021	j.cell.2010.02.021	PROPN
dpc-4176	752	6	.	.	PUNCT
dpc-4176	753	1	pmid	pmid	NOUN
dpc-4176	753	2	:	:	PUNCT
dpc-4176	753	3	20303875	20303875	NUM
dpc-4176	753	4	.	.	PUNCT
dpc-4176	754	1	57	57	NUM
dpc-4176	754	2	.	.	X
dpc-4176	755	1	cole	cole	PROPN
dpc-4176	755	2	s	s	PROPN
dpc-4176	755	3	,	,	PUNCT
dpc-4176	755	4	murray	murray	PROPN
dpc-4176	755	5	j	j	PROPN
dpc-4176	755	6	,	,	PUNCT
dpc-4176	755	7	simpson	simpson	PROPN
dpc-4176	755	8	c	c	PROPN
dpc-4176	755	9	,	,	PUNCT
dpc-4176	755	10	et	et	PROPN
dpc-4176	755	11	al	al	PROPN
dpc-4176	755	12	.	.	PUNCT
dpc-4176	756	1	interleukin	interleukin	NOUN
dpc-4176	756	2	(	(	PUNCT
dpc-4176	756	3	il)-12	il)-12	NOUN
dpc-4176	756	4	and	and	CCONJ
dpc-4176	756	5	il-18	il-18	ADP
dpc-4176	756	6	synergize	synergize	VERB
dpc-4176	756	7	to	to	PART
dpc-4176	756	8	promote	promote	VERB
dpc-4176	756	9	mait	mait	ADJ
dpc-4176	756	10	cell	cell	NOUN
dpc-4176	756	11	il-17a	il-17a	PROPN
dpc-4176	756	12	and	and	CCONJ
dpc-4176	756	13	il-17f	il-17f	ADP
dpc-4176	756	14	production	production	NOUN
dpc-4176	756	15	independently	independently	ADV
dpc-4176	756	16	of	of	ADP
dpc-4176	756	17	il-23	il-23	NOUN
dpc-4176	756	18	signaling	signal	VERB
dpc-4176	756	19	.	.	PUNCT
dpc-4176	757	1	front	front	ADJ
dpc-4176	757	2	immunol	immunol	NOUN
dpc-4176	757	3	.	.	PUNCT
dpc-4176	758	1	2020;11:585134	2020;11:585134	NUM
dpc-4176	758	2	.	.	X
dpc-4176	758	3	doi:10.3389	doi:10.3389	PROPN
dpc-4176	758	4	/	/	SYM
dpc-4176	758	5	fimmu.2020.585134	fimmu.2020.585134	PROPN
dpc-4176	758	6	.	.	PUNCT
dpc-4176	759	1	pmid	pmid	NOUN
dpc-4176	759	2	:	:	PUNCT
dpc-4176	759	3	33329560	33329560	NUM
dpc-4176	759	4	;	;	PUNCT
dpc-4176	759	5	pmcid	pmcid	ADJ
dpc-4176	759	6	:	:	PUNCT
dpc-4176	759	7	pmc7714946	pmc7714946	NOUN
dpc-4176	759	8	.	.	PUNCT
dpc-4176	760	1	58	58	NUM
dpc-4176	760	2	.	.	PUNCT
dpc-4176	761	1	dudink	dudink	PROPN
dpc-4176	761	2	k	k	PROPN
dpc-4176	761	3	,	,	PUNCT
dpc-4176	761	4	bouwman	bouwman	NOUN
dpc-4176	761	5	k	k	PROPN
dpc-4176	761	6	,	,	PUNCT
dpc-4176	761	7	chen	chen	PROPN
dpc-4176	761	8	y	y	PROPN
dpc-4176	761	9	,	,	PUNCT
dpc-4176	761	10	et	et	PROPN
dpc-4176	761	11	al	al	PROPN
dpc-4176	761	12	.	.	PROPN
dpc-4176	761	13	guselkumab	guselkumab	NOUN
dpc-4176	761	14	for	for	ADP
dpc-4176	761	15	hidradenitis	hidradenitis	PROPN
dpc-4176	761	16	suppurativa	suppurativa	PROPN
dpc-4176	761	17	:	:	PUNCT
dpc-4176	761	18	a	a	DET
dpc-4176	761	19	phase	phase	NOUN
dpc-4176	761	20	ii	ii	NOUN
dpc-4176	761	21	,	,	PUNCT
dpc-4176	761	22	open	open	ADJ
dpc-4176	761	23	-	-	PUNCT
dpc-4176	761	24	label	label	NOUN
dpc-4176	761	25	,	,	PUNCT
dpc-4176	761	26	mode	mode	NOUN
dpc-4176	761	27	-	-	PUNCT
dpc-4176	761	28	of	of	ADP
dpc-4176	761	29	-	-	PUNCT
dpc-4176	761	30	action	action	NOUN
dpc-4176	761	31	study	study	NOUN
dpc-4176	761	32	.	.	PUNCT
dpc-4176	762	1	br	br	PROPN
dpc-4176	762	2	j	j	PROPN
dpc-4176	762	3	dermatol	dermatol	NOUN
dpc-4176	762	4	.	.	PUNCT
dpc-4176	763	1	2023;188:601–9	2023;188:601–9	NUM
dpc-4176	763	2	.	.	PUNCT
dpc-4176	764	1	doi	doi	NOUN
dpc-4176	764	2	:	:	PUNCT
dpc-4176	764	3	10.1093	10.1093	NUM
dpc-4176	764	4	/	/	SYM
dpc-4176	764	5	bjd	bjd	PROPN
dpc-4176	764	6	/	/	SYM
dpc-4176	764	7	ljad010	ljad010	PROPN
dpc-4176	764	8	.	.	PUNCT
dpc-4176	765	1	pmid	pmid	NOUN
dpc-4176	765	2	:	:	PUNCT
dpc-4176	765	3	36811949	36811949	NUM
dpc-4176	765	4	.	.	PUNCT
dpc-4176	766	1	59	59	NUM
dpc-4176	766	2	.	.	PUNCT
dpc-4176	767	1	kimball	kimball	PROPN
dpc-4176	767	2	ab	ab	PROPN
dpc-4176	767	3	,	,	PUNCT
dpc-4176	767	4	podda	podda	PROPN
dpc-4176	767	5	m	m	PROPN
dpc-4176	767	6	,	,	PUNCT
dpc-4176	767	7	alavi	alavi	VERB
dpc-4176	767	8	a	a	DET
dpc-4176	767	9	,	,	PUNCT
dpc-4176	767	10	et	et	PROPN
dpc-4176	767	11	al	al	PROPN
dpc-4176	767	12	.	.	PROPN
dpc-4176	767	13	guselkumab	guselkumab	NOUN
dpc-4176	767	14	for	for	ADP
dpc-4176	767	15	the	the	DET
dpc-4176	767	16	treatment	treatment	NOUN
dpc-4176	767	17	of	of	ADP
dpc-4176	767	18	patients	patient	NOUN
dpc-4176	767	19	with	with	ADP
dpc-4176	767	20	moderate	moderate	ADJ
dpc-4176	767	21	-	-	PUNCT
dpc-4176	767	22	to	to	ADP
dpc-4176	767	23	-	-	PUNCT
dpc-4176	767	24	severe	severe	ADJ
dpc-4176	767	25	hidradenitis	hidradenitis	NOUN
dpc-4176	767	26	suppurativa	suppurativa	NOUN
dpc-4176	767	27	:	:	PUNCT
dpc-4176	767	28	a	a	DET
dpc-4176	767	29	phase	phase	NOUN
dpc-4176	767	30	2	2	NUM
dpc-4176	767	31	randomized	randomized	ADJ
dpc-4176	767	32	study	study	NOUN
dpc-4176	767	33	.	.	PUNCT
dpc-4176	768	1	j	j	PROPN
dpc-4176	768	2	eur	eur	PROPN
dpc-4176	768	3	acad	acad	PROPN
dpc-4176	768	4	dermatol	dermatol	NOUN
dpc-4176	768	5	venereol	venereol	NOUN
dpc-4176	768	6	.	.	PUNCT
dpc-4176	769	1	2023;37:2098–108	2023;37:2098–108	X
dpc-4176	769	2	.	.	PUNCT
dpc-4176	769	3	doi	doi	NOUN
dpc-4176	769	4	:	:	PUNCT
dpc-4176	769	5	10.1111	10.1111	NUM
dpc-4176	769	6	/	/	SYM
dpc-4176	769	7	jdv.19252	jdv.19252	PROPN
dpc-4176	769	8	.	.	PUNCT
dpc-4176	770	1	pmid	pmid	NOUN
dpc-4176	770	2	:	:	PUNCT
dpc-4176	770	3	37317022	37317022	NUM
dpc-4176	770	4	.	.	PUNCT
dpc-4176	771	1	60	60	NUM
dpc-4176	771	2	.	.	PUNCT
dpc-4176	772	1	casseres	cassere	NOUN
dpc-4176	772	2	rg	rg	PROPN
dpc-4176	772	3	,	,	PUNCT
dpc-4176	772	4	kahn	kahn	PROPN
dpc-4176	772	5	js	js	PROPN
dpc-4176	772	6	,	,	PUNCT
dpc-4176	772	7	her	her	PRON
dpc-4176	772	8	mj	mj	NOUN
dpc-4176	772	9	,	,	PUNCT
dpc-4176	772	10	et	et	PROPN
dpc-4176	772	11	al	al	PROPN
dpc-4176	772	12	.	.	PROPN
dpc-4176	772	13	guselkumab	guselkumab	NOUN
dpc-4176	772	14	in	in	ADP
dpc-4176	772	15	the	the	DET
dpc-4176	772	16	treatment	treatment	NOUN
dpc-4176	772	17	of	of	ADP
dpc-4176	772	18	hidradenitis	hidradenitis	PROPN
dpc-4176	772	19	suppurativa	suppurativa	PROPN
dpc-4176	772	20	:	:	PUNCT
dpc-4176	772	21	a	a	DET
dpc-4176	772	22	retrospective	retrospective	ADJ
dpc-4176	772	23	chart	chart	NOUN
dpc-4176	772	24	review	review	NOUN
dpc-4176	772	25	.	.	PUNCT
dpc-4176	773	1	j	j	PROPN
dpc-4176	773	2	am	be	AUX
dpc-4176	773	3	acad	acad	ADJ
dpc-4176	773	4	dermatol	dermatol	NOUN
dpc-4176	773	5	.	.	PUNCT
dpc-4176	774	1	2019;81:265–7	2019;81:265–7	NUM
dpc-4176	774	2	.	.	PUNCT
dpc-4176	775	1	doi:10.1016	doi:10.1016	PROPN
dpc-4176	775	2	/	/	SYM
dpc-4176	775	3	j	j	PROPN
dpc-4176	775	4	.jaad.2018.12.017	.jaad.2018.12.017	PUNCT
dpc-4176	775	5	.	.	PUNCT
dpc-4176	776	1	pmid	pmid	NOUN
dpc-4176	776	2	:	:	PUNCT
dpc-4176	776	3	30562567	30562567	NUM
dpc-4176	776	4	.	.	PUNCT
dpc-4176	777	1	61	61	NUM
dpc-4176	777	2	.	.	X
dpc-4176	777	3	montero	montero	PROPN
dpc-4176	777	4	-	-	PUNCT
dpc-4176	777	5	vilchez	vilchez	PROPN
dpc-4176	777	6	t	t	PROPN
dpc-4176	777	7	,	,	PUNCT
dpc-4176	777	8	martinez	martinez	PROPN
dpc-4176	777	9	-	-	PUNCT
dpc-4176	777	10	lopez	lopez	PROPN
dpc-4176	777	11	a	a	PRON
dpc-4176	777	12	,	,	PUNCT
dpc-4176	777	13	salvador	salvador	NOUN
dpc-4176	777	14	-	-	PUNCT
dpc-4176	777	15	rodriguez	rodriguez	NOUN
dpc-4176	777	16	l	l	NOUN
dpc-4176	777	17	,	,	PUNCT
dpc-4176	777	18	et	et	PROPN
dpc-4176	777	19	al	al	PROPN
dpc-4176	777	20	.	.	PUNCT
dpc-4176	778	1	the	the	DET
dpc-4176	778	2	use	use	NOUN
dpc-4176	778	3	of	of	ADP
dpc-4176	778	4	guselkumab	guselkumab	NOUN
dpc-4176	778	5	100	100	NUM
dpc-4176	778	6	mg	mg	NOUN
dpc-4176	778	7	every	every	DET
dpc-4176	778	8	4	4	NUM
dpc-4176	778	9	weeks	week	NOUN
dpc-4176	778	10	on	on	ADP
dpc-4176	778	11	patients	patient	NOUN
dpc-4176	778	12	with	with	ADP
dpc-4176	778	13	hidradenitis	hidradenitis	PROPN
dpc-4176	778	14	suppurativa	suppurativa	NOUN
dpc-4176	778	15	and	and	CCONJ
dpc-4176	778	16	a	a	DET
dpc-4176	778	17	literature	literature	NOUN
dpc-4176	778	18	review	review	NOUN
dpc-4176	778	19	.	.	PUNCT
dpc-4176	779	1	dermatol	dermatol	NOUN
dpc-4176	779	2	ther	ther	ADV
dpc-4176	779	3	.	.	PUNCT
dpc-4176	780	1	2020;33	2020;33	NUM
dpc-4176	780	2	:	:	PUNCT
dpc-4176	781	1	e13456	e13456	NOUN
dpc-4176	781	2	.	.	PUNCT
dpc-4176	782	1	doi	doi	NOUN
dpc-4176	782	2	:	:	PUNCT
dpc-4176	782	3	10.1111	10.1111	NUM
dpc-4176	782	4	/	/	SYM
dpc-4176	782	5	dth.13456	dth.13456	NOUN
dpc-4176	782	6	.	.	PUNCT
dpc-4176	783	1	pmid	pmid	NOUN
dpc-4176	783	2	:	:	PUNCT
dpc-4176	783	3	32319172	32319172	NUM
dpc-4176	783	4	.	.	PUNCT
dpc-4176	784	1	62	62	NUM
dpc-4176	784	2	.	.	PUNCT
dpc-4176	785	1	kearney	kearney	PROPN
dpc-4176	785	2	n	n	PROPN
dpc-4176	785	3	,	,	PUNCT
dpc-4176	785	4	byrne	byrne	PROPN
dpc-4176	785	5	n	n	CCONJ
dpc-4176	785	6	,	,	PUNCT
dpc-4176	785	7	kirby	kirby	PROPN
dpc-4176	785	8	b	b	PROPN
dpc-4176	785	9	,	,	PUNCT
dpc-4176	785	10	et	et	PROPN
dpc-4176	785	11	al	al	PROPN
dpc-4176	785	12	.	.	PROPN
dpc-4176	786	1	successful	successful	ADJ
dpc-4176	786	2	use	use	NOUN
dpc-4176	786	3	of	of	ADP
dpc-4176	786	4	guselkumab	guselkumab	NOUN
dpc-4176	786	5	in	in	ADP
dpc-4176	786	6	the	the	DET
dpc-4176	786	7	treatment	treatment	NOUN
dpc-4176	786	8	of	of	ADP
dpc-4176	786	9	severe	severe	ADJ
dpc-4176	786	10	hidradenitis	hidradenitis	PROPN
dpc-4176	786	11	suppurativa	suppurativa	PROPN
dpc-4176	786	12	.	.	PROPN
dpc-4176	787	1	clin	clin	PROPN
dpc-4176	787	2	exp	exp	NOUN
dpc-4176	787	3	dermatol	dermatol	NOUN
dpc-4176	787	4	.	.	PUNCT
dpc-4176	788	1	2020;45:618–9	2020;45:618–9	NUM
dpc-4176	788	2	.	.	PUNCT
dpc-4176	789	1	doi	doi	NOUN
dpc-4176	789	2	:	:	PUNCT
dpc-4176	789	3	10.1111	10.1111	NUM
dpc-4176	789	4	/	/	SYM
dpc-4176	789	5	ced.14199	ced.14199	NOUN
dpc-4176	789	6	.	.	PUNCT
dpc-4176	790	1	pmid	pmid	NOUN
dpc-4176	790	2	:	:	PUNCT
dpc-4176	790	3	32068912	32068912	NUM
dpc-4176	790	4	.	.	PUNCT
dpc-4176	791	1	63	63	NUM
dpc-4176	791	2	.	.	PUNCT
dpc-4176	792	1	kovacs	kovacs	PROPN
dpc-4176	792	2	m	m	PROPN
dpc-4176	792	3	,	,	PUNCT
dpc-4176	792	4	podda	podda	PROPN
dpc-4176	792	5	m.	m.	NOUN
dpc-4176	792	6	guselkumab	guselkumab	NOUN
dpc-4176	792	7	in	in	ADP
dpc-4176	792	8	the	the	DET
dpc-4176	792	9	treatment	treatment	NOUN
dpc-4176	792	10	of	of	ADP
dpc-4176	792	11	severe	severe	ADJ
dpc-4176	792	12	hidradenitis	hidradenitis	PROPN
dpc-4176	792	13	suppurativa	suppurativa	PROPN
dpc-4176	792	14	.	.	PUNCT
dpc-4176	793	1	j	j	PROPN
dpc-4176	793	2	eur	eur	PROPN
dpc-4176	793	3	acad	acad	PROPN
dpc-4176	793	4	dermatol	dermatol	NOUN
dpc-4176	793	5	venereol	venereol	NOUN
dpc-4176	793	6	.	.	PUNCT
dpc-4176	794	1	2019;33	2019;33	NUM
dpc-4176	794	2	:	:	PUNCT
dpc-4176	795	1	e140	e140	PROPN
dpc-4176	795	2	-	-	PUNCT
dpc-4176	795	3	e141	e141	PROPN
dpc-4176	795	4	.	.	PUNCT
dpc-4176	796	1	doi	doi	NOUN
dpc-4176	796	2	:	:	PUNCT
dpc-4176	796	3	10.1111	10.1111	NUM
dpc-4176	796	4	/	/	SYM
dpc-4176	796	5	jdv.15368	jdv.15368	PROPN
dpc-4176	796	6	.	.	PUNCT
dpc-4176	797	1	pmid	pmid	NOUN
dpc-4176	797	2	:	:	PUNCT
dpc-4176	797	3	30480844	30480844	NUM
dpc-4176	797	4	.	.	PUNCT
dpc-4176	798	1	64	64	NUM
dpc-4176	798	2	.	.	PUNCT
dpc-4176	799	1	martora	martora	PROPN
dpc-4176	800	1	f	f	X
dpc-4176	800	2	,	,	PUNCT
dpc-4176	800	3	fabbrocini	fabbrocini	NOUN
dpc-4176	800	4	g	g	PROPN
dpc-4176	800	5	,	,	PUNCT
dpc-4176	800	6	marasca	marasca	PROPN
dpc-4176	800	7	c	c	PROPN
dpc-4176	800	8	,	,	PUNCT
dpc-4176	800	9	et	et	PROPN
dpc-4176	800	10	al	al	PROPN
dpc-4176	800	11	.	.	PROPN
dpc-4176	800	12	paradoxical	paradoxical	ADJ
dpc-4176	800	13	hidradenitis	hidradenitis	PROPN
dpc-4176	800	14	suppurativa	suppurativa	NOUN
dpc-4176	800	15	induced	induce	VERB
dpc-4176	800	16	by	by	ADP
dpc-4176	800	17	adalimumab	adalimumab	NOUN
dpc-4176	800	18	biosimilar	biosimilar	PROPN
dpc-4176	800	19	successfully	successfully	ADV
dpc-4176	800	20	treated	treat	VERB
dpc-4176	800	21	with	with	ADP
dpc-4176	800	22	guselkumab	guselkumab	NOUN
dpc-4176	800	23	in	in	ADP
dpc-4176	800	24	a	a	DET
dpc-4176	800	25	patient	patient	NOUN
dpc-4176	800	26	with	with	ADP
dpc-4176	800	27	psoriasis	psoriasis	NOUN
dpc-4176	800	28	.	.	PUNCT
dpc-4176	801	1	comment	comment	NOUN
dpc-4176	801	2	on	on	ADP
dpc-4176	801	3	‘	'	PUNCT
dpc-4176	801	4	paradoxical	paradoxical	ADJ
dpc-4176	801	5	hidradenitis	hidradenitis	NOUN
dpc-4176	801	6	suppurativa	suppurativa	NOUN
dpc-4176	801	7	due	due	ADJ
dpc-4176	801	8	to	to	ADP
dpc-4176	801	9	anti	anti	ADJ
dpc-4176	801	10	-	-	ADJ
dpc-4176	801	11	interleukin-1	interleukin-1	ADJ
dpc-4176	801	12	agents	agent	NOUN
dpc-4176	801	13	for	for	ADP
dpc-4176	801	14	mevalonate	mevalonate	ADJ
dpc-4176	801	15	kinase	kinase	PROPN
dpc-4176	801	16	deficiency	deficiency	NOUN
dpc-4176	801	17	successfully	successfully	ADV
dpc-4176	801	18	treated	treat	VERB
dpc-4176	801	19	with	with	ADP
dpc-4176	801	20	the	the	DET
dpc-4176	801	21	addition	addition	NOUN
dpc-4176	801	22	of	of	ADP
dpc-4176	801	23	ustekinumab	ustekinumab	NOUN
dpc-4176	801	24	.	.	PUNCT
dpc-4176	801	25	’	'	PUNCT
dpc-4176	802	1	clin	clin	PROPN
dpc-4176	802	2	exp	exp	NOUN
dpc-4176	802	3	dermatol	dermatol	NOUN
dpc-4176	802	4	.	.	PUNCT
dpc-4176	803	1	2023;48:701–3	2023;48:701–3	NOUN
dpc-4176	803	2	.	.	PUNCT
dpc-4176	804	1	doi	doi	NOUN
dpc-4176	804	2	:	:	PUNCT
dpc-4176	804	3	10.1093	10.1093	NUM
dpc-4176	804	4	/	/	SYM
dpc-4176	804	5	ced	ced	PROPN
dpc-4176	804	6	/	/	SYM
dpc-4176	804	7	llad082	llad082	PROPN
dpc-4176	804	8	.	.	PUNCT
dpc-4176	805	1	pmid	pmid	NOUN
dpc-4176	805	2	:	:	PUNCT
dpc-4176	805	3	36883596	36883596	NUM
dpc-4176	805	4	.	.	PUNCT
dpc-4176	806	1	65	65	NUM
dpc-4176	806	2	.	.	PUNCT
dpc-4176	807	1	garcia	garcia	PROPN
dpc-4176	807	2	-	-	PUNCT
dpc-4176	807	3	melendo	melendo	PROPN
dpc-4176	807	4	c	c	NOUN
dpc-4176	807	5	,	,	PUNCT
dpc-4176	807	6	vilarrasa	vilarrasa	PROPN
dpc-4176	807	7	e	e	NOUN
dpc-4176	807	8	,	,	PUNCT
dpc-4176	807	9	cubiró	cubiró	PROPN
dpc-4176	807	10	x	x	PROPN
dpc-4176	807	11	,	,	PUNCT
dpc-4176	807	12	et	et	PROPN
dpc-4176	807	13	al	al	PROPN
dpc-4176	807	14	.	.	PROPN
dpc-4176	808	1	sequential	sequential	ADJ
dpc-4176	808	2	paradoxical	paradoxical	ADJ
dpc-4176	808	3	psoriasiform	psoriasiform	NOUN
dpc-4176	808	4	reaction	reaction	NOUN
dpc-4176	808	5	and	and	CCONJ
dpc-4176	808	6	sacroiliitis	sacroiliitis	ADV
dpc-4176	808	7	following	follow	VERB
dpc-4176	808	8	adalimumab	adalimumab	NOUN
dpc-4176	808	9	treatment	treatment	NOUN
dpc-4176	808	10	of	of	ADP
dpc-4176	808	11	hidradenitis	hidradenitis	PROPN
dpc-4176	808	12	suppurativa	suppurativa	PROPN
dpc-4176	808	13	,	,	PUNCT
dpc-4176	808	14	successfully	successfully	ADV
dpc-4176	808	15	16	16	NUM
dpc-4176	808	16	review	review	NOUN
dpc-4176	808	17	|	|	ADV
dpc-4176	808	18	dermatol	dermatol	ADJ
dpc-4176	808	19	pract	pract	NOUN
dpc-4176	808	20	concept	concept	NOUN
dpc-4176	808	21	.	.	PUNCT
dpc-4176	809	1	2024;14(3):e2024181	2024;14(3):e2024181	NUM
dpc-4176	809	2	90	90	NUM
dpc-4176	809	3	.	.	PUNCT
dpc-4176	810	1	product	product	NOUN
dpc-4176	810	2	information	information	NOUN
dpc-4176	810	3	:	:	PUNCT
dpc-4176	810	4	tremfya	tremfya	PROPN
dpc-4176	810	5	(	(	PUNCT
dpc-4176	810	6	guselkumab	guselkumab	NOUN
dpc-4176	810	7	)	)	PUNCT
dpc-4176	810	8	solution	solution	NOUN
dpc-4176	810	9	for	for	ADP
dpc-4176	810	10	injection	injection	NOUN
dpc-4176	810	11	.	.	PUNCT
dpc-4176	811	1	janssen	janssen	PROPN
dpc-4176	811	2	inc	inc	PROPN
dpc-4176	811	3	.	.	PROPN
dpc-4176	811	4	toronto	toronto	PROPN
dpc-4176	811	5	,	,	PUNCT
dpc-4176	811	6	on	on	ADV
dpc-4176	811	7	.	.	PUNCT
dpc-4176	812	1	accessed	access	VERB
dpc-4176	812	2	november	november	PROPN
dpc-4176	812	3	10	10	NUM
dpc-4176	812	4	,	,	PUNCT
dpc-4176	812	5	2017	2017	NUM
dpc-4176	812	6	.	.	PUNCT
dpc-4176	813	1	https://pdf.hres.ca/dpd_pm/00042101.pdf	https://pdf.hres.ca/dpd_pm/00042101.pdf	PROPN
dpc-4176	813	2	.	.	PUNCT
dpc-4176	814	1	91	91	NUM
dpc-4176	814	2	.	.	PUNCT
dpc-4176	815	1	burlando	burlando	PROPN
dpc-4176	815	2	m	m	PROPN
dpc-4176	815	3	,	,	PUNCT
dpc-4176	815	4	capurro	capurro	PROPN
dpc-4176	815	5	n	n	CCONJ
dpc-4176	815	6	,	,	PUNCT
dpc-4176	815	7	herzum	herzum	PROPN
dpc-4176	815	8	a	a	PROPN
dpc-4176	815	9	,	,	PUNCT
dpc-4176	815	10	et	et	PROPN
dpc-4176	815	11	al	al	PROPN
dpc-4176	815	12	.	.	PROPN
dpc-4176	815	13	guselkumabassociated	guselkumabassociate	VERB
dpc-4176	815	14	bullous	bullous	ADJ
dpc-4176	815	15	pemphigoid	pemphigoid	NOUN
dpc-4176	815	16	in	in	ADP
dpc-4176	815	17	a	a	DET
dpc-4176	815	18	psoriasis	psoriasis	NOUN
dpc-4176	815	19	patient	patient	NOUN
dpc-4176	815	20	:	:	PUNCT
dpc-4176	815	21	a	a	DET
dpc-4176	815	22	case	case	NOUN
dpc-4176	815	23	report	report	NOUN
dpc-4176	815	24	and	and	CCONJ
dpc-4176	815	25	review	review	NOUN
dpc-4176	815	26	of	of	ADP
dpc-4176	815	27	the	the	DET
dpc-4176	815	28	literature	literature	NOUN
dpc-4176	815	29	.	.	PUNCT
dpc-4176	816	1	dermatol	dermatol	NOUN
dpc-4176	816	2	ther	ther	ADV
dpc-4176	816	3	.	.	PUNCT
dpc-4176	817	1	2022;35	2022;35	NUM
dpc-4176	817	2	:	:	PUNCT
dpc-4176	817	3	e15207	e15207	PROPN
dpc-4176	817	4	.	.	PUNCT
dpc-4176	818	1	doi	doi	NOUN
dpc-4176	818	2	:	:	PUNCT
dpc-4176	818	3	10.1111	10.1111	NUM
dpc-4176	818	4	/	/	SYM
dpc-4176	818	5	dth.15207	dth.15207	PROPN
dpc-4176	818	6	.	.	PUNCT
dpc-4176	819	1	pmid	pmid	NOUN
dpc-4176	819	2	:	:	PUNCT
dpc-4176	819	3	34791777	34791777	NUM
dpc-4176	819	4	;	;	PUNCT
dpc-4176	819	5	pmcid	pmcid	PROPN
dpc-4176	819	6	:	:	PUNCT
dpc-4176	819	7	pmc9285773	pmc9285773	PROPN
dpc-4176	819	8	.	.	PUNCT
dpc-4176	820	1	92	92	NUM
dpc-4176	820	2	.	.	PUNCT
dpc-4176	821	1	martora	martora	PROPN
dpc-4176	821	2	f	f	X
dpc-4176	821	3	,	,	PUNCT
dpc-4176	821	4	annunziata	annunziata	PROPN
dpc-4176	821	5	mc	mc	PROPN
dpc-4176	821	6	,	,	PUNCT
dpc-4176	821	7	guerriero	guerriero	PROPN
dpc-4176	821	8	l	l	PROPN
dpc-4176	821	9	,	,	PUNCT
dpc-4176	821	10	et	et	PROPN
dpc-4176	821	11	al	al	PROPN
dpc-4176	821	12	.	.	PROPN
dpc-4176	821	13	guselkumab	guselkumab	PROPN
dpc-4176	821	14	induced	induce	VERB
dpc-4176	821	15	vitiligo	vitiligo	NOUN
dpc-4176	821	16	in	in	ADP
dpc-4176	821	17	a	a	DET
dpc-4176	821	18	patient	patient	NOUN
dpc-4176	821	19	with	with	ADP
dpc-4176	821	20	psoriatic	psoriatic	ADJ
dpc-4176	821	21	arthritis	arthritis	NOUN
dpc-4176	821	22	.	.	PUNCT
dpc-4176	822	1	jaad	jaad	NOUN
dpc-4176	822	2	case	case	NOUN
dpc-4176	822	3	rep	rep	PROPN
dpc-4176	822	4	.	.	PROPN
dpc-4176	822	5	2023;41:46–8	2023;41:46–8	PROPN
dpc-4176	822	6	.	.	PUNCT
dpc-4176	823	1	doi	doi	PROPN
dpc-4176	823	2	:	:	PUNCT
dpc-4176	823	3	10.1016	10.1016	NUM
dpc-4176	823	4	/	/	SYM
dpc-4176	823	5	j.jdcr.2023.08.043	j.jdcr.2023.08.043	PROPN
dpc-4176	823	6	.	.	PUNCT
dpc-4176	824	1	pmid	pmid	NOUN
dpc-4176	824	2	:	:	PUNCT
dpc-4176	824	3	37842149	37842149	NUM
dpc-4176	824	4	;	;	PUNCT
dpc-4176	824	5	pmcid	pmcid	ADJ
dpc-4176	824	6	:	:	PUNCT
dpc-4176	824	7	pmc10568222	pmc10568222	NOUN
dpc-4176	824	8	.	.	PUNCT
dpc-4176	825	1	93	93	NUM
dpc-4176	825	2	.	.	PUNCT
dpc-4176	826	1	le	le	PROPN
dpc-4176	826	2	guern	guern	PROPN
dpc-4176	826	3	a	a	PROPN
dpc-4176	826	4	,	,	PUNCT
dpc-4176	826	5	alkeraye	alkeraye	PROPN
dpc-4176	826	6	s	s	PROPN
dpc-4176	826	7	,	,	PUNCT
dpc-4176	826	8	vermersch	vermersch	PROPN
dpc-4176	826	9	-	-	PUNCT
dpc-4176	826	10	langlin	langlin	PROPN
dpc-4176	826	11	a	a	PROPN
dpc-4176	826	12	,	,	PUNCT
dpc-4176	826	13	et	et	PROPN
dpc-4176	826	14	al	al	PROPN
dpc-4176	826	15	.	.	PUNCT
dpc-4176	827	1	bullous	bullous	ADJ
dpc-4176	827	2	pemphigoid	pemphigoid	NOUN
dpc-4176	827	3	during	during	ADP
dpc-4176	827	4	ustekinumab	ustekinumab	NOUN
dpc-4176	827	5	therapy	therapy	NOUN
dpc-4176	827	6	.	.	PUNCT
dpc-4176	828	1	jaad	jaad	NOUN
dpc-4176	828	2	case	case	NOUN
dpc-4176	828	3	rep	rep	PROPN
dpc-4176	828	4	.	.	PROPN
dpc-4176	829	1	2015;1:359–60	2015;1:359–60	PROPN
dpc-4176	829	2	.	.	PROPN
dpc-4176	830	1	94	94	NUM
dpc-4176	830	2	.	.	PUNCT
dpc-4176	831	1	frisoli	frisoli	PROPN
dpc-4176	831	2	ml	ml	PROPN
dpc-4176	831	3	,	,	PUNCT
dpc-4176	831	4	essien	essien	PROPN
dpc-4176	831	5	k	k	PROPN
dpc-4176	831	6	,	,	PUNCT
dpc-4176	831	7	harris	harris	PROPN
dpc-4176	831	8	je	je	PROPN
dpc-4176	831	9	.	.	PROPN
dpc-4176	832	1	vitiligo	vitiligo	PROPN
dpc-4176	832	2	:	:	PUNCT
dpc-4176	832	3	mechanisms	mechanism	NOUN
dpc-4176	832	4	of	of	ADP
dpc-4176	832	5	pathogenesis	pathogenesis	NOUN
dpc-4176	832	6	and	and	CCONJ
dpc-4176	832	7	treatment	treatment	NOUN
dpc-4176	832	8	.	.	PUNCT
dpc-4176	833	1	ann	ann	PROPN
dpc-4176	833	2	rev	rev	PROPN
dpc-4176	833	3	immunol	immunol	NOUN
dpc-4176	833	4	.	.	PUNCT
dpc-4176	834	1	2020;38:621–48	2020;38:621–48	X
dpc-4176	834	2	.	.	PUNCT
dpc-4176	835	1	doi	doi	NOUN
dpc-4176	835	2	:	:	PUNCT
dpc-4176	835	3	10.1146	10.1146	NUM
dpc-4176	835	4	/	/	SYM
dpc-4176	835	5	annurev	annurev	NOUN
dpc-4176	835	6	-	-	PUNCT
dpc-4176	835	7	immunol-100919	immunol-100919	NOUN
dpc-4176	835	8	-	-	PUNCT
dpc-4176	835	9	023531	023531	NUM
dpc-4176	835	10	.	.	PUNCT
dpc-4176	836	1	pmid	pmid	NOUN
dpc-4176	836	2	:	:	PUNCT
dpc-4176	836	3	32017656	32017656	NUM
dpc-4176	836	4	.	.	PUNCT
dpc-4176	837	1	95	95	NUM
dpc-4176	837	2	.	.	PUNCT
dpc-4176	837	3	guselkumab	guselkumab	NOUN
dpc-4176	837	4	(	(	PUNCT
dpc-4176	837	5	tremfya	tremfya	PROPN
dpc-4176	837	6	®	®	PROPN
dpc-4176	837	7	)	)	PUNCT
dpc-4176	838	1	[	[	X
dpc-4176	838	2	internet	internet	NOUN
dpc-4176	838	3	]	]	PUNCT
dpc-4176	838	4	.	.	PUNCT
dpc-4176	839	1	in	in	ADP
dpc-4176	839	2	:	:	PUNCT
dpc-4176	839	3	mother	mother	NOUN
dpc-4176	839	4	to	to	ADP
dpc-4176	839	5	baby	baby	NOUN
dpc-4176	839	6	|	|	ADV
dpc-4176	839	7	fact	fact	NOUN
dpc-4176	839	8	sheets	sheet	NOUN
dpc-4176	839	9	.	.	PUNCT
dpc-4176	840	1	brentwood	brentwood	PROPN
dpc-4176	840	2	(	(	PUNCT
dpc-4176	840	3	tn	tn	PROPN
dpc-4176	840	4	):	):	PUNCT
dpc-4176	840	5	organization	organization	NOUN
dpc-4176	840	6	of	of	ADP
dpc-4176	840	7	teratology	teratology	NOUN
dpc-4176	840	8	information	information	NOUN
dpc-4176	840	9	specialists	specialist	NOUN
dpc-4176	840	10	(	(	PUNCT
dpc-4176	840	11	otis	otis	PROPN
dpc-4176	840	12	)	)	PUNCT
dpc-4176	840	13	;	;	PUNCT
dpc-4176	840	14	1994	1994	NUM
dpc-4176	840	15	[	[	X
dpc-4176	840	16	cited	cite	VERB
dpc-4176	840	17	2023	2023	NUM
dpc-4176	840	18	dec	dec	PROPN
dpc-4176	840	19	27	27	NUM
dpc-4176	840	20	]	]	PUNCT
dpc-4176	840	21	.	.	PUNCT
dpc-4176	841	1	available	available	ADJ
dpc-4176	841	2	from	from	ADP
dpc-4176	841	3	:	:	PUNCT
dpc-4176	841	4	http://www.ncbi.nlm.nih.gov/books/nbk582737/	http://www.ncbi.nlm.nih.gov/books/nbk582737/	PROPN
dpc-4176	841	5	96	96	NUM
dpc-4176	841	6	.	.	PUNCT
dpc-4176	842	1	stratigakis	stratigakis	PROPN
dpc-4176	842	2	a	a	PRON
dpc-4176	842	3	,	,	PUNCT
dpc-4176	842	4	paty	paty	NOUN
dpc-4176	842	5	d	d	PROPN
dpc-4176	842	6	,	,	PUNCT
dpc-4176	842	7	zou	zou	PROPN
dpc-4176	842	8	p	p	PROPN
dpc-4176	842	9	,	,	PUNCT
dpc-4176	842	10	et	et	PROPN
dpc-4176	842	11	al	al	PROPN
dpc-4176	842	12	.	.	PUNCT
dpc-4176	843	1	a	a	DET
dpc-4176	843	2	regression	regression	NOUN
dpc-4176	843	3	approach	approach	NOUN
dpc-4176	843	4	for	for	ADP
dpc-4176	843	5	assessing	assess	VERB
dpc-4176	843	6	large	large	ADJ
dpc-4176	843	7	molecular	molecular	ADJ
dpc-4176	843	8	drug	drug	NOUN
dpc-4176	843	9	concentration	concentration	NOUN
dpc-4176	843	10	in	in	ADP
dpc-4176	843	11	breast	breast	NOUN
dpc-4176	843	12	milk	milk	NOUN
dpc-4176	843	13	.	.	PUNCT
dpc-4176	844	1	reprod	reprod	PROPN
dpc-4176	844	2	breed	breed	PROPN
dpc-4176	844	3	.	.	PUNCT
dpc-4176	845	1	2023;3:199–207	2023;3:199–207	NUM
dpc-4176	845	2	.	.	PUNCT
dpc-4176	846	1	97	97	NUM
dpc-4176	846	2	.	.	PUNCT
dpc-4176	846	3	anderson	anderson	PROPN
dpc-4176	846	4	po	po	PROPN
dpc-4176	846	5	.	.	PROPN
dpc-4176	846	6	monoclonal	monoclonal	NOUN
dpc-4176	846	7	antibodies	antibody	NOUN
dpc-4176	846	8	during	during	ADP
dpc-4176	846	9	breastfeeding	breastfeeding	NOUN
dpc-4176	846	10	.	.	PUNCT
dpc-4176	847	1	breastfeed	breastfeed	AUX
dpc-4176	847	2	med	med	PROPN
dpc-4176	847	3	.	.	PUNCT
dpc-4176	848	1	2021;16:591–3	2021;16:591–3	NUM
dpc-4176	848	2	.	.	PUNCT
dpc-4176	849	1	doi	doi	NOUN
dpc-4176	849	2	:	:	PUNCT
dpc-4176	849	3	10.1089	10.1089	NUM
dpc-4176	849	4	/	/	SYM
dpc-4176	849	5	bfm.2021.0110	bfm.2021.0110	PROPN
dpc-4176	849	6	.	.	PUNCT
dpc-4176	850	1	pmid	pmid	NOUN
dpc-4176	850	2	:	:	PUNCT
dpc-4176	850	3	33956488	33956488	NUM
dpc-4176	850	4	.	.	PUNCT
dpc-4176	851	1	98	98	NUM
dpc-4176	851	2	.	.	PUNCT
dpc-4176	851	3	krysko	krysko	PROPN
dpc-4176	851	4	km	km	PROPN
dpc-4176	851	5	,	,	PUNCT
dpc-4176	851	6	dobson	dobson	PROPN
dpc-4176	851	7	r	r	PROPN
dpc-4176	851	8	,	,	PUNCT
dpc-4176	851	9	alroughani	alroughani	NOUN
dpc-4176	851	10	r	r	NOUN
dpc-4176	851	11	,	,	PUNCT
dpc-4176	851	12	et	et	PROPN
dpc-4176	851	13	al	al	PROPN
dpc-4176	851	14	.	.	PROPN
dpc-4176	852	1	family	family	NOUN
dpc-4176	852	2	planning	planning	NOUN
dpc-4176	852	3	considerations	consideration	NOUN
dpc-4176	852	4	in	in	ADP
dpc-4176	852	5	people	people	NOUN
dpc-4176	852	6	with	with	ADP
dpc-4176	852	7	multiple	multiple	ADJ
dpc-4176	852	8	sclerosis	sclerosis	NOUN
dpc-4176	852	9	.	.	PUNCT
dpc-4176	853	1	lancet	lancet	PROPN
dpc-4176	853	2	neurol	neurol	PROPN
dpc-4176	853	3	.	.	PUNCT
dpc-4176	854	1	2023;22:350–66	2023;22:350–66	X
dpc-4176	854	2	.	.	PUNCT
dpc-4176	854	3	doi:10.1016	doi:10.1016	PROPN
dpc-4176	854	4	/	/	SYM
dpc-4176	854	5	s1474	s1474	PROPN
dpc-4176	854	6	-	-	PROPN
dpc-4176	854	7	4422(22)00426	4422(22)00426	NOUN
dpc-4176	854	8	-	-	PUNCT
dpc-4176	854	9	4	4	NUM
dpc-4176	854	10	.	.	PUNCT
dpc-4176	855	1	pmid	pmid	NOUN
dpc-4176	855	2	:	:	PUNCT
dpc-4176	855	3	36931808	36931808	NUM
dpc-4176	855	4	.	.	PUNCT
dpc-4176	856	1	99	99	NUM
dpc-4176	856	2	.	.	PUNCT
dpc-4176	857	1	kim	kim	PROPN
dpc-4176	857	2	sr	sr	PROPN
dpc-4176	857	3	,	,	PUNCT
dpc-4176	857	4	kibbi	kibbi	NOUN
dpc-4176	857	5	n	n	CCONJ
dpc-4176	857	6	,	,	PUNCT
dpc-4176	857	7	craiglow	craiglow	PROPN
dpc-4176	857	8	bg	bg	PROPN
dpc-4176	857	9	.	.	PROPN
dpc-4176	857	10	guselkumab	guselkumab	NOUN
dpc-4176	857	11	for	for	ADP
dpc-4176	857	12	the	the	DET
dpc-4176	857	13	treatment	treatment	NOUN
dpc-4176	857	14	of	of	ADP
dpc-4176	857	15	severe	severe	ADJ
dpc-4176	857	16	refractory	refractory	NOUN
dpc-4176	857	17	psoriasis	psoriasis	NOUN
dpc-4176	857	18	in	in	ADP
dpc-4176	857	19	a	a	DET
dpc-4176	857	20	pediatric	pediatric	ADJ
dpc-4176	857	21	patient	patient	NOUN
dpc-4176	857	22	.	.	PUNCT
dpc-4176	858	1	jaad	jaad	NOUN
dpc-4176	858	2	case	case	NOUN
dpc-4176	858	3	rep	rep	PROPN
dpc-4176	858	4	.	.	PROPN
dpc-4176	858	5	2019;5:552–4	2019;5:552–4	PROPN
dpc-4176	858	6	.	.	PUNCT
dpc-4176	859	1	doi:10.1016	doi:10.1016	PROPN
dpc-4176	859	2	/	/	SYM
dpc-4176	859	3	j.jdcr.2019.04.014	j.jdcr.2019.04.014	PROPN
dpc-4176	859	4	.	.	PROPN
dpc-4176	859	5	100	100	NUM
dpc-4176	859	6	.	.	PUNCT
dpc-4176	860	1	song	song	PROPN
dpc-4176	860	2	ej	ej	PROPN
dpc-4176	860	3	,	,	PUNCT
dpc-4176	860	4	whitman	whitman	PROPN
dpc-4176	860	5	p	p	PROPN
dpc-4176	860	6	,	,	PUNCT
dpc-4176	860	7	samsel	samsel	NOUN
dpc-4176	860	8	j.	j.	PROPN
dpc-4176	860	9	the	the	DET
dpc-4176	860	10	use	use	NOUN
dpc-4176	860	11	of	of	ADP
dpc-4176	860	12	ustekinumab	ustekinumab	NOUN
dpc-4176	860	13	and	and	CCONJ
dpc-4176	860	14	guselkumab	guselkumab	NOUN
dpc-4176	860	15	in	in	ADP
dpc-4176	860	16	a	a	DET
dpc-4176	860	17	pediatric	pediatric	ADJ
dpc-4176	860	18	psoriasis	psoriasis	NOUN
dpc-4176	860	19	patient	patient	ADJ
dpc-4176	860	20	with	with	ADP
dpc-4176	860	21	active	active	ADJ
dpc-4176	860	22	hepatitis	hepatitis	NOUN
dpc-4176	860	23	b	b	NOUN
dpc-4176	860	24	infection	infection	NOUN
dpc-4176	860	25	.	.	PUNCT
dpc-4176	861	1	jaad	jaad	NOUN
dpc-4176	861	2	case	case	NOUN
dpc-4176	861	3	rep	rep	PROPN
dpc-4176	861	4	.	.	PROPN
dpc-4176	861	5	2021;8:37–9	2021;8:37–9	NUM
dpc-4176	861	6	.	.	PUNCT
dpc-4176	862	1	doi:10.1016	doi:10.1016	PROPN
dpc-4176	862	2	/	/	SYM
dpc-4176	862	3	j.jdcr	j.jdcr	PROPN
dpc-4176	862	4	.2020.12.006	.2020.12.006	PROPN
dpc-4176	862	5	.	.	PUNCT
dpc-4176	863	1	101	101	NUM
dpc-4176	863	2	.	.	PUNCT
dpc-4176	864	1	ruggiero	ruggiero	PROPN
dpc-4176	864	2	a	a	DET
dpc-4176	864	3	,	,	PUNCT
dpc-4176	864	4	fabbrocini	fabbrocini	NOUN
dpc-4176	864	5	g	g	NOUN
dpc-4176	864	6	,	,	PUNCT
dpc-4176	864	7	cinelli	cinelli	PROPN
dpc-4176	864	8	e	e	PROPN
dpc-4176	864	9	,	,	PUNCT
dpc-4176	864	10	et	et	PROPN
dpc-4176	864	11	al	al	PROPN
dpc-4176	864	12	.	.	PUNCT
dpc-4176	864	13	anti	anti	ADJ
dpc-4176	864	14	-	-	ADJ
dpc-4176	864	15	interleukin-23	interleukin-23	ADJ
dpc-4176	864	16	for	for	ADP
dpc-4176	864	17	psoriasis	psoriasis	NOUN
dpc-4176	864	18	in	in	ADP
dpc-4176	864	19	elderly	elderly	ADJ
dpc-4176	864	20	patients	patient	NOUN
dpc-4176	864	21	:	:	PUNCT
dpc-4176	864	22	guselkumab	guselkumab	NOUN
dpc-4176	864	23	,	,	PUNCT
dpc-4176	864	24	risankizumab	risankizumab	NOUN
dpc-4176	864	25	and	and	CCONJ
dpc-4176	864	26	tildrakizumab	tildrakizumab	NOUN
dpc-4176	864	27	in	in	ADP
dpc-4176	864	28	real	real	ADJ
dpc-4176	864	29	-	-	PUNCT
dpc-4176	864	30	world	world	NOUN
dpc-4176	864	31	practice	practice	NOUN
dpc-4176	864	32	.	.	PUNCT
dpc-4176	865	1	clin	clin	PROPN
dpc-4176	865	2	exp	exp	NOUN
dpc-4176	865	3	dermatol	dermatol	NOUN
dpc-4176	865	4	.	.	PUNCT
dpc-4176	866	1	2022;47:561–7	2022;47:561–7	NUM
dpc-4176	866	2	.	.	PUNCT
dpc-4176	867	1	doi:10.1111	doi:10.1111	ADJ
dpc-4176	867	2	/	/	SYM
dpc-4176	867	3	ced.14979	ced.14979	PROPN
dpc-4176	867	4	.	.	NOUN
dpc-4176	867	5	clin	clin	PROPN
dpc-4176	867	6	case	case	PROPN
dpc-4176	867	7	rep	rep	PROPN
dpc-4176	867	8	.	.	PROPN
dpc-4176	867	9	2022;10	2022;10	NUM
dpc-4176	867	10	:	:	PUNCT
dpc-4176	867	11	e6413	e6413	ADJ
dpc-4176	867	12	.	.	PUNCT
dpc-4176	868	1	doi:10.1002	doi:10.1002	NOUN
dpc-4176	868	2	/	/	SYM
dpc-4176	868	3	ccr3.6413	ccr3.6413	PROPN
dpc-4176	868	4	.	.	PUNCT
dpc-4176	869	1	pmid	pmid	NOUN
dpc-4176	869	2	:	:	PUNCT
dpc-4176	869	3	36245447	36245447	NUM
dpc-4176	869	4	;	;	PUNCT
dpc-4176	869	5	pmcid	pmcid	NOUN
dpc-4176	869	6	:	:	PUNCT
dpc-4176	869	7	pmc9540577	pmc9540577	ADJ
dpc-4176	869	8	.	.	PUNCT
dpc-4176	870	1	81	81	NUM
dpc-4176	870	2	.	.	PUNCT
dpc-4176	871	1	langrish	langrish	PROPN
dpc-4176	871	2	cl	cl	PROPN
dpc-4176	871	3	,	,	PUNCT
dpc-4176	871	4	chen	chen	PROPN
dpc-4176	871	5	y	y	PROPN
dpc-4176	871	6	,	,	PUNCT
dpc-4176	871	7	blumenschein	blumenschein	PROPN
dpc-4176	871	8	wm	wm	PROPN
dpc-4176	871	9	,	,	PUNCT
dpc-4176	871	10	et	et	PROPN
dpc-4176	871	11	al	al	PROPN
dpc-4176	871	12	.	.	PROPN
dpc-4176	871	13	il-23	il-23	NOUN
dpc-4176	872	1	drives	drive	VERB
dpc-4176	872	2	a	a	DET
dpc-4176	872	3	pathogenic	pathogenic	ADJ
dpc-4176	872	4	t	t	NOUN
dpc-4176	872	5	cell	cell	NOUN
dpc-4176	872	6	population	population	NOUN
dpc-4176	872	7	that	that	PRON
dpc-4176	872	8	induces	induce	VERB
dpc-4176	872	9	autoimmune	autoimmune	ADJ
dpc-4176	872	10	inflammation	inflammation	NOUN
dpc-4176	872	11	.	.	PUNCT
dpc-4176	873	1	j	j	PROPN
dpc-4176	873	2	exp	exp	NOUN
dpc-4176	873	3	med	med	PROPN
dpc-4176	873	4	.	.	PUNCT
dpc-4176	874	1	2005;201:233–40	2005;201:233–40	PROPN
dpc-4176	874	2	.	.	PUNCT
dpc-4176	875	1	doi:10.1084	doi:10.1084	PROPN
dpc-4176	875	2	/	/	SYM
dpc-4176	875	3	jem	jem	PROPN
dpc-4176	875	4	.20041257	.20041257	PROPN
dpc-4176	875	5	.	.	PUNCT
dpc-4176	876	1	pmid	pmid	NOUN
dpc-4176	876	2	:	:	PUNCT
dpc-4176	876	3	15657292	15657292	NUM
dpc-4176	876	4	;	;	PUNCT
dpc-4176	876	5	pmcid	pmcid	ADJ
dpc-4176	876	6	:	:	PUNCT
dpc-4176	876	7	pmc2212798	pmc2212798	ADJ
dpc-4176	876	8	.	.	PUNCT
dpc-4176	877	1	82	82	NUM
dpc-4176	877	2	.	.	PUNCT
dpc-4176	878	1	mcgeachy	mcgeachy	PROPN
dpc-4176	878	2	mj	mj	PROPN
dpc-4176	878	3	,	,	PUNCT
dpc-4176	878	4	chen	chen	PROPN
dpc-4176	878	5	y	y	PROPN
dpc-4176	878	6	,	,	PUNCT
dpc-4176	878	7	tato	tato	PROPN
dpc-4176	878	8	cm	cm	PROPN
dpc-4176	878	9	,	,	PUNCT
dpc-4176	878	10	et	et	PROPN
dpc-4176	878	11	al	al	PROPN
dpc-4176	878	12	.	.	PUNCT
dpc-4176	879	1	the	the	DET
dpc-4176	879	2	interleukin	interleukin	NOUN
dpc-4176	879	3	23	23	NUM
dpc-4176	879	4	receptor	receptor	NOUN
dpc-4176	879	5	is	be	AUX
dpc-4176	879	6	essential	essential	ADJ
dpc-4176	879	7	for	for	ADP
dpc-4176	879	8	the	the	DET
dpc-4176	879	9	terminal	terminal	ADJ
dpc-4176	879	10	differentiation	differentiation	NOUN
dpc-4176	879	11	of	of	ADP
dpc-4176	879	12	interleukin	interleukin	NOUN
dpc-4176	879	13	17	17	NUM
dpc-4176	879	14	–	–	PUNCT
dpc-4176	879	15	producing	produce	VERB
dpc-4176	879	16	effector	effector	NOUN
dpc-4176	879	17	t	t	NOUN
dpc-4176	879	18	helper	helper	NOUN
dpc-4176	879	19	cells	cell	NOUN
dpc-4176	879	20	in	in	ADP
dpc-4176	879	21	vivo	vivo	NOUN
dpc-4176	879	22	.	.	PUNCT
dpc-4176	880	1	nat	nat	PROPN
dpc-4176	880	2	immunol	immunol	NOUN
dpc-4176	880	3	.	.	PUNCT
dpc-4176	881	1	2009;10:314–24	2009;10:314–24	X
dpc-4176	881	2	.	.	PUNCT
dpc-4176	881	3	doi	doi	PROPN
dpc-4176	881	4	:	:	PUNCT
dpc-4176	881	5	10.1038	10.1038	NUM
dpc-4176	881	6	/	/	SYM
dpc-4176	881	7	ni.1698	ni.1698	PROPN
dpc-4176	881	8	.	.	PUNCT
dpc-4176	882	1	pmid	pmid	NOUN
dpc-4176	882	2	:	:	PUNCT
dpc-4176	882	3	19182808	19182808	NUM
dpc-4176	882	4	;	;	PUNCT
dpc-4176	882	5	pmcid	pmcid	ADJ
dpc-4176	882	6	:	:	PUNCT
dpc-4176	882	7	pmc2945605	pmc2945605	NOUN
dpc-4176	882	8	.	.	PUNCT
dpc-4176	883	1	83	83	NUM
dpc-4176	883	2	.	.	PUNCT
dpc-4176	884	1	wang	wang	PROPN
dpc-4176	884	2	r	r	PROPN
dpc-4176	884	3	,	,	PUNCT
dpc-4176	884	4	hasnain	hasnain	ADJ
dpc-4176	884	5	sz	sz	PROPN
dpc-4176	884	6	,	,	PUNCT
dpc-4176	884	7	tong	tong	PROPN
dpc-4176	884	8	h	h	NOUN
dpc-4176	884	9	,	,	PUNCT
dpc-4176	884	10	et	et	PROPN
dpc-4176	884	11	al	al	PROPN
dpc-4176	884	12	.	.	PUNCT
dpc-4176	884	13	neutralizing	neutralize	VERB
dpc-4176	884	14	il-23	il-23	NOUN
dpc-4176	884	15	is	be	AUX
dpc-4176	884	16	superior	superior	ADJ
dpc-4176	884	17	to	to	ADP
dpc-4176	884	18	blocking	block	VERB
dpc-4176	884	19	il-17	il-17	ADV
dpc-4176	884	20	in	in	ADP
dpc-4176	884	21	suppressing	suppress	VERB
dpc-4176	884	22	intestinal	intestinal	ADJ
dpc-4176	884	23	inflammation	inflammation	NOUN
dpc-4176	884	24	in	in	ADP
dpc-4176	884	25	a	a	DET
dpc-4176	884	26	spontaneous	spontaneous	ADJ
dpc-4176	884	27	murine	murine	ADJ
dpc-4176	884	28	colitis	colitis	NOUN
dpc-4176	884	29	model	model	NOUN
dpc-4176	884	30	.	.	PUNCT
dpc-4176	885	1	inflamm	inflamm	PROPN
dpc-4176	885	2	bowel	bowel	PROPN
dpc-4176	885	3	dis	dis	PROPN
dpc-4176	885	4	.	.	PUNCT
dpc-4176	886	1	2015;21:973–84	2015;21:973–84	X
dpc-4176	886	2	.	.	PUNCT
dpc-4176	887	1	doi	doi	NOUN
dpc-4176	887	2	:	:	PUNCT
dpc-4176	887	3	10.1097	10.1097	NUM
dpc-4176	887	4	/	/	SYM
dpc-4176	887	5	mib.0000000000000353	mib.0000000000000353	PROPN
dpc-4176	887	6	.	.	PUNCT
dpc-4176	888	1	pmid	pmid	NOUN
dpc-4176	888	2	:	:	PUNCT
dpc-4176	888	3	25803508	25803508	NUM
dpc-4176	888	4	.	.	PUNCT
dpc-4176	889	1	84	84	NUM
dpc-4176	889	2	.	.	PUNCT
dpc-4176	890	1	solimani	solimani	PROPN
dpc-4176	890	2	f	f	PROPN
dpc-4176	890	3	,	,	PUNCT
dpc-4176	890	4	pollmann	pollmann	ADJ
dpc-4176	890	5	r	r	NOUN
dpc-4176	890	6	,	,	PUNCT
dpc-4176	890	7	schmidt	schmidt	PROPN
dpc-4176	890	8	t	t	PROPN
dpc-4176	890	9	,	,	PUNCT
dpc-4176	890	10	et	et	PROPN
dpc-4176	890	11	al	al	PROPN
dpc-4176	890	12	.	.	PUNCT
dpc-4176	891	1	therapeutic	therapeutic	ADJ
dpc-4176	891	2	targeting	targeting	NOUN
dpc-4176	891	3	of	of	ADP
dpc-4176	891	4	th17	th17	PROPN
dpc-4176	891	5	/	/	SYM
dpc-4176	891	6	tc17	tc17	PROPN
dpc-4176	891	7	cells	cell	NOUN
dpc-4176	891	8	leads	lead	VERB
dpc-4176	891	9	to	to	ADP
dpc-4176	891	10	clinical	clinical	ADJ
dpc-4176	891	11	improvement	improvement	NOUN
dpc-4176	891	12	of	of	ADP
dpc-4176	891	13	lichen	lichen	NOUN
dpc-4176	891	14	planus	planus	NOUN
dpc-4176	891	15	.	.	PUNCT
dpc-4176	892	1	front	front	ADJ
dpc-4176	892	2	immunol	immunol	NOUN
dpc-4176	892	3	.	.	PUNCT
dpc-4176	893	1	2019;10:1808	2019;10:1808	NUM
dpc-4176	893	2	.	.	PUNCT
dpc-4176	893	3	doi:10.3389	doi:10.3389	PROPN
dpc-4176	893	4	/fimmu.2019.01808	/fimmu.2019.01808	PROPN
dpc-4176	893	5	.	.	PUNCT
dpc-4176	894	1	pmid	pmid	NOUN
dpc-4176	894	2	:	:	PUNCT
dpc-4176	894	3	31417572	31417572	NUM
dpc-4176	894	4	;	;	PUNCT
dpc-4176	894	5	pmcid	pmcid	NOUN
dpc-4176	894	6	:	:	PUNCT
dpc-4176	894	7	pmc6685396	pmc6685396	ADJ
dpc-4176	894	8	.	.	PUNCT
dpc-4176	895	1	85	85	NUM
dpc-4176	895	2	.	.	X
dpc-4176	895	3	murgia	murgia	PROPN
dpc-4176	895	4	rd	rd	PROPN
dpc-4176	895	5	,	,	PUNCT
dpc-4176	895	6	gross	gross	ADJ
dpc-4176	895	7	gp	gp	NOUN
dpc-4176	895	8	.	.	PUNCT
dpc-4176	895	9	stewart	stewart	PROPN
dpc-4176	895	10	-	-	PUNCT
dpc-4176	895	11	treves	treves	PROPN
dpc-4176	895	12	syndrome	syndrome	NOUN
dpc-4176	895	13	[	[	X
dpc-4176	895	14	internet	internet	NOUN
dpc-4176	895	15	]	]	PUNCT
dpc-4176	895	16	.	.	PUNCT
dpc-4176	896	1	in	in	ADP
dpc-4176	896	2	:	:	PUNCT
dpc-4176	896	3	statpearls	statpearl	NOUN
dpc-4176	896	4	.	.	PUNCT
dpc-4176	896	5	treasure	treasure	NOUN
dpc-4176	896	6	island	island	NOUN
dpc-4176	896	7	(	(	PUNCT
dpc-4176	896	8	fl	fl	PROPN
dpc-4176	896	9	):	):	PUNCT
dpc-4176	896	10	statpearls	statpearl	NOUN
dpc-4176	896	11	publishing	publishing	NOUN
dpc-4176	896	12	;	;	PUNCT
dpc-4176	896	13	2023	2023	NUM
dpc-4176	896	14	[	[	PUNCT
dpc-4176	896	15	cited	cite	VERB
dpc-4176	896	16	2023	2023	NUM
dpc-4176	896	17	dec	dec	PROPN
dpc-4176	896	18	27	27	NUM
dpc-4176	896	19	]	]	PUNCT
dpc-4176	896	20	.	.	PUNCT
dpc-4176	897	1	available	available	ADJ
dpc-4176	897	2	from	from	ADP
dpc-4176	897	3	:	:	PUNCT
dpc-4176	897	4	http://www.ncbi.nlm.nih	http://www.ncbi.nlm.nih	NUM
dpc-4176	897	5	.gov	.gov	ADJ
dpc-4176	897	6	/	/	SYM
dpc-4176	897	7	books	book	NOUN
dpc-4176	897	8	/	/	SYM
dpc-4176	897	9	nbk507833/	nbk507833/	PROPN
dpc-4176	897	10	86	86	NUM
dpc-4176	897	11	.	.	PUNCT
dpc-4176	898	1	nardinocchi	nardinocchi	PROPN
dpc-4176	898	2	l	l	PROPN
dpc-4176	898	3	,	,	PUNCT
dpc-4176	898	4	sonego	sonego	NOUN
dpc-4176	898	5	g	g	NOUN
dpc-4176	898	6	,	,	PUNCT
dpc-4176	898	7	passarelli	passarelli	X
dpc-4176	898	8	f	f	X
dpc-4176	898	9	,	,	PUNCT
dpc-4176	898	10	et	et	PROPN
dpc-4176	898	11	al	al	PROPN
dpc-4176	898	12	.	.	PUNCT
dpc-4176	899	1	interleukin-17	interleukin-17	PROPN
dpc-4176	899	2	and	and	CCONJ
dpc-4176	899	3	interleukin-22	interleukin-22	PROPN
dpc-4176	899	4	promote	promote	VERB
dpc-4176	899	5	tumor	tumor	NOUN
dpc-4176	899	6	progression	progression	NOUN
dpc-4176	899	7	in	in	ADP
dpc-4176	899	8	human	human	PROPN
dpc-4176	899	9	nonmelanoma	nonmelanoma	PROPN
dpc-4176	899	10	skin	skin	NOUN
dpc-4176	899	11	cancer	cancer	NOUN
dpc-4176	899	12	.	.	PUNCT
dpc-4176	900	1	eur	eur	PROPN
dpc-4176	900	2	j	j	PROPN
dpc-4176	900	3	immunol	immunol	NOUN
dpc-4176	900	4	.	.	PUNCT
dpc-4176	901	1	2015;45(3):922–31	2015;45(3):922–31	NUM
dpc-4176	901	2	.	.	PUNCT
dpc-4176	901	3	doi:10.1002	doi:10.1002	NOUN
dpc-4176	901	4	/	/	SYM
dpc-4176	901	5	eji.201445052	eji.201445052	PROPN
dpc-4176	901	6	.	.	PUNCT
dpc-4176	902	1	pmid	pmid	NOUN
dpc-4176	902	2	:	:	PUNCT
dpc-4176	902	3	25487261	25487261	NUM
dpc-4176	902	4	.	.	PUNCT
dpc-4176	903	1	87	87	NUM
dpc-4176	903	2	.	.	PUNCT
dpc-4176	904	1	sheng	sheng	PROPN
dpc-4176	904	2	s	s	PROPN
dpc-4176	904	3	,	,	PUNCT
dpc-4176	904	4	zhang	zhang	PROPN
dpc-4176	904	5	j	j	PROPN
dpc-4176	904	6	,	,	PUNCT
dpc-4176	904	7	ai	ai	VERB
dpc-4176	904	8	j	j	PROPN
dpc-4176	904	9	,	,	PUNCT
dpc-4176	904	10	et	et	PROPN
dpc-4176	904	11	al	al	PROPN
dpc-4176	904	12	.	.	PROPN
dpc-4176	904	13	aberrant	aberrant	ADJ
dpc-4176	904	14	expression	expression	NOUN
dpc-4176	904	15	of	of	ADP
dpc-4176	904	16	il-23	il-23	NOUN
dpc-4176	904	17	/	/	SYM
dpc-4176	904	18	il-23r	il-23r	NOUN
dpc-4176	904	19	in	in	ADP
dpc-4176	904	20	patients	patient	NOUN
dpc-4176	904	21	with	with	ADP
dpc-4176	904	22	breast	breast	NOUN
dpc-4176	904	23	cancer	cancer	NOUN
dpc-4176	904	24	and	and	CCONJ
dpc-4176	904	25	its	its	PRON
dpc-4176	904	26	clinical	clinical	ADJ
dpc-4176	904	27	significance	significance	NOUN
dpc-4176	904	28	.	.	PUNCT
dpc-4176	905	1	mol	mol	ADP
dpc-4176	905	2	med	med	PROPN
dpc-4176	905	3	rep	rep	PROPN
dpc-4176	905	4	.	.	PROPN
dpc-4176	905	5	2018;17:4639	2018;17:4639	PROPN
dpc-4176	905	6	-	-	SYM
dpc-4176	905	7	4644	4644	NUM
dpc-4176	905	8	.	.	PUNCT
dpc-4176	906	1	doi	doi	NOUN
dpc-4176	906	2	:	:	PUNCT
dpc-4176	906	3	10.3892	10.3892	NUM
dpc-4176	906	4	/	/	SYM
dpc-4176	906	5	mmr.2018.8427	mmr.2018.8427	PROPN
dpc-4176	906	6	.	.	PUNCT
dpc-4176	906	7	pmid	pmid	NOUN
dpc-4176	906	8	:	:	PUNCT
dpc-4176	906	9	29328397	29328397	NUM
dpc-4176	906	10	.	.	PUNCT
dpc-4176	907	1	88	88	NUM
dpc-4176	907	2	.	.	PUNCT
dpc-4176	907	3	nie	nie	PROPN
dpc-4176	907	4	w	w	PROPN
dpc-4176	907	5	,	,	PUNCT
dpc-4176	907	6	yu	yu	PROPN
dpc-4176	907	7	t	t	PROPN
dpc-4176	907	8	,	,	PUNCT
dpc-4176	907	9	sang	sing	VERB
dpc-4176	907	10	y	y	PROPN
dpc-4176	907	11	,	,	PUNCT
dpc-4176	907	12	et	et	PROPN
dpc-4176	907	13	al	al	PROPN
dpc-4176	907	14	.	.	PUNCT
dpc-4176	908	1	tumor	tumor	NOUN
dpc-4176	908	2	-	-	PUNCT
dpc-4176	908	3	promoting	promote	VERB
dpc-4176	908	4	effect	effect	NOUN
dpc-4176	908	5	of	of	ADP
dpc-4176	908	6	il-23	il-23	NOUN
dpc-4176	908	7	in	in	ADP
dpc-4176	908	8	mammary	mammary	ADJ
dpc-4176	908	9	cancer	cancer	NOUN
dpc-4176	908	10	mediated	mediate	VERB
dpc-4176	908	11	by	by	ADP
dpc-4176	908	12	infiltration	infiltration	NOUN
dpc-4176	908	13	of	of	ADP
dpc-4176	908	14	m2	m2	PROPN
dpc-4176	908	15	macrophages	macrophage	NOUN
dpc-4176	908	16	and	and	CCONJ
dpc-4176	908	17	neutrophils	neutrophil	NOUN
dpc-4176	908	18	in	in	ADP
dpc-4176	908	19	tumor	tumor	NOUN
dpc-4176	908	20	microenvironment	microenvironment	NOUN
dpc-4176	908	21	.	.	PUNCT
dpc-4176	909	1	biochem	biochem	PROPN
dpc-4176	909	2	biophys	biophys	PROPN
dpc-4176	909	3	res	re	NOUN
dpc-4176	909	4	commun	commun	PROPN
dpc-4176	909	5	.	.	PUNCT
dpc-4176	910	1	2017;482:1400–6	2017;482:1400–6	NOUN
dpc-4176	910	2	.	.	PUNCT
dpc-4176	911	1	doi:10.1016	doi:10.1016	PROPN
dpc-4176	911	2	/	/	SYM
dpc-4176	911	3	j.bbrc	j.bbrc	PROPN
dpc-4176	911	4	.2016.12.048	.2016.12.048	PROPN
dpc-4176	911	5	.	.	PUNCT
dpc-4176	912	1	pmid	pmid	NOUN
dpc-4176	912	2	:	:	PUNCT
dpc-4176	912	3	27956175	27956175	NUM
dpc-4176	912	4	.	.	PUNCT
dpc-4176	913	1	89	89	NUM
dpc-4176	913	2	.	.	PUNCT
dpc-4176	914	1	van	van	PROPN
dpc-4176	914	2	esbeen	esbeen	PROPN
dpc-4176	914	3	l	l	PROPN
dpc-4176	914	4	,	,	PUNCT
dpc-4176	914	5	roquet	roquet	NOUN
dpc-4176	914	6	-	-	PUNCT
dpc-4176	914	7	gravy	gravy	NOUN
dpc-4176	914	8	pp	pp	NOUN
dpc-4176	914	9	.	.	PUNCT
dpc-4176	915	1	improvement	improvement	NOUN
dpc-4176	915	2	of	of	ADP
dpc-4176	915	3	stewart	stewart	NOUN
dpc-4176	915	4	-	-	PUNCT
dpc-4176	915	5	treves	treve	NOUN
dpc-4176	915	6	angiosarcoma	angiosarcoma	VERB
dpc-4176	915	7	through	through	ADP
dpc-4176	915	8	interleukin	interleukin	NOUN
dpc-4176	915	9	23p19	23p19	NUM
dpc-4176	915	10	inhibition	inhibition	NOUN
dpc-4176	915	11	.	.	PUNCT
dpc-4176	916	1	jaad	jaad	NOUN
dpc-4176	916	2	case	case	NOUN
dpc-4176	916	3	rep	rep	PROPN
dpc-4176	916	4	.	.	PROPN
dpc-4176	916	5	2021;17:84–6	2021;17:84–6	PROPN
dpc-4176	916	6	.	.	PUNCT
dpc-4176	917	1	doi	doi	PROPN
dpc-4176	917	2	:	:	PUNCT
dpc-4176	917	3	10.1016	10.1016	NUM
dpc-4176	917	4	/	/	SYM
dpc-4176	917	5	j.jdcr.2021.09.035	j.jdcr.2021.09.035	PROPN
dpc-4176	917	6	.	.	PUNCT
dpc-4176	918	1	pmid	pmid	NOUN
dpc-4176	918	2	:	:	PUNCT
dpc-4176	918	3	34712764	34712764	NUM
dpc-4176	918	4	;	;	PUNCT
dpc-4176	918	5	pmcid	pmcid	ADJ
dpc-4176	918	6	:	:	PUNCT
dpc-4176	918	7	pmc8531457	pmc8531457	NOUN
dpc-4176	918	8	.	.	PUNCT